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by Laura Chiecchio 
 
Multiple myeloma (MM) is a malignancy of clonal plasma cells (PC) which develops as a 
consequence of a multistep process of transformation from a normal PC to an asymptomatic 
stage known as monoclonal gammopathy of undetermined significance (MGUS) to MM to the 
more aggressive plasma cell leukaemia (PCL). MGUS is the most common PC disorder and the 
majority of cases never progress to MM requiring treatment, as progression only occurs in ~1% 
of patients per year. From a genetic point of view, specific abnormalities represent initiating 
events (i.e. IgH translocations or hyperdiploidy) of this multistep process while others occur at 
later stages. In this study, interphase-FISH showed that initiating events are present in MGUS 
(n=187) and asymptomatic MM (SMM, n=128) at similar frequencies as found in MM (n=400) 
(the only exception was t(4;14)) and showed that these abnormalities alone, regardless of their 
biological impact in MM, cannot drive progression to overt disease. The time of occurrence of 
deletion/monosomy of chromosome 13 (∆13) was found to depend on the presence of specific 
concurrent abnormalities. ∆13 was extremely rare in MGUS and SMM with translocations 
directly involving CCND1 and CCND3 suggesting a possible role of ∆13 in the progression of 
disease specifically in these genetic sub-groups. However, it was clear that, excluding ∆13 in 
these sub-groups, standard interphase-FISH abnormalities are insufficient to predict progression 
of MGUS and SMM. 
High resolution array CGH showed an increasing level of genomic complexity from 
MGUS (n=25) to SMM (n=15) to MM (n=47) to PCL (n=11). In MGUS, the number of copy 
number changes per case was highly associated with progression (P=0.003). The simplest 
profiles belonged to MGUS cases with t(11;14) and t(14;20); surprisingly, none of these 
patients had progressed to MM by the end of this study (median follow-up=72 months).  
The integration of results from interphase-FISH, array CGH and metaphase analysis 
suggested that there were various abnormalities (corresponding to distinct molecular pathways) 
responsible for disease progression. A number of chromosomal changes were found to be 
strongly associated with progression (del(1)(p22.3-p23); del(6)(q25), MYC changes, 
del(12)(p13), ∆13 in t(11;14), abnormalities involving members of the NF-κB pathway, 
del(17)(p13)). Such associations were not only suggested by the fact that these abnormalities 
were rare in MGUS/SMM compared to MM, but also by the observation that all pre-malignant 
patients positive for these changes progressed to overt disease. However, among patients who 
did progress and carried the same abnormalities, time to progression was found to be highly 
variable from case to case. This suggested that other factors (genetic or otherwise) must be 
interacting with chromosomal abnormalities in order to lead to progression. Other changes, e.g. 
1q21 gain, despite being rare in pre-malignant cases compared to MM and despite some being 
associated with a dismal prognosis in MM, did not appear to be linked to rapid progression.  
This study has made significant progress towards understanding the progression from 
pre-malignant disease to MM, which will provide information towards potential novel targets 
for therapy to prevent progression or prolong the pre-malignant phase of a highly aggressive 
disease.   iii 
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1  INTRODUCTION 
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1.1  Cancer 
Cancer is the final stage of a multi-step process characterized by a number of somatic mutations 
that allow a normal cell to originate a population of proliferating and invasive cells 
1. 
Mammalian cells have multiple measures of defence to protect them against the effects of 
cancer gene mutations and only when several genes are defective does an invasive cancer 
develop 
2. Some mutations enhance cell proliferation, creating an expanded target population of 
cells; other mutations affect the stability of the entire genome, at either the chromosomal or the 
deoxyribonucleic acid (DNA) level, increasing the overall mutation rate.  
Three types of genes have been recognized to be the main targets of mutations promoting 
tumourigenesis: oncogenes, tumour suppressor genes and stability genes. Proto-oncogenes 
promote cell proliferation through gain of function mutations which lead to forms that are 
excessively or inappropriately active; a single mutant allele may affect the phenotype of the cell. 
Among the tumour suppressor genes some prevent inappropriate cell cycle progression, while 
others push deviant cells into apoptosis. Mutations in both the maternal and the paternal alleles 
of a tumour suppressor gene are generally required to confer a selective advantage to a cell 
3. 
However, some tumour suppressor genes have been reported to exert a selective advantage on a 
cell when only one allele is inactivated while the other remains functional. This is known as 
haploinsufficiency 
4. Stability genes monitor genome integrity and coordinate cell cycle 
progression with DNA repair. When stability genes are mutated they promote tumourigenesis 
by loss of control of the incidence of genetic alterations. Other stability genes control mitotic 
recombination and chromosomal segregation 
3. 
Many different mechanisms can lead to aberrant functions of these genes and include 
polymorphisms, changes in genome copy number and structure, point mutations and epigenetic 
modifications. 
 
1.2  Cancer cytogenetics 
In 1960, Nowell and Hungerford discovered the first chromosomal abnormality associated with 
cancer using cytogenetics 
5. Specifically, they identified an abnormal minute chromosome that 
was present in cultured bone marrow (BM) cells of patients with chronic myeloid leukaemia, a 
form of cancer that causes unrestricted growth of myeloid cells in the BM. This minute 
chromosome was named the Philadelphia chromosome; later Rowley, using new cytogenetic Introduction 
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techniques namely quinacrine fluorescence and G-banding, discovered that the Philadelphia 
chromosome was formed from a specific translocation between chromosomes 9 and 22 
6. In 
1985, Heisterkamp et al. showed that the translocation led to the formation of an abnormal, 
fused gene called bcr-abl (breakpoint cluster region and V-abl Abelson murine leukemia 
oncogene homolog 1) 
7; this gene codes for an aberrant tyrosine kinase protein which is 
constitutively activated, interfering with normal cell regulation and allowing cells that express 
the aberrant protein to divide more rapidly 
8. 
Since the discovery of this chromosomal aberration, many abnormalities have been 
demonstrated to be associated with cancer as shown by the catalogue of recurrent abnormalities 
in a wide range of cancers compiled by Mitelman and colleagues (Mitelman Database of 
Chromosome Aberrations in Cancer, see URL in Appendix 1). These findings established the 
clinical associations of cytogenetics and malignancies. 
 
1.2.1  Types of chromosomal changes 
Chromosomal changes are highly variable and include altered ploidy, gain or loss of individual 
chromosomes or portions of them and structural rearrangements (Figure 1-1). The structural 
changes may involve balanced exchange of material between two chromosomal regions (i.e. 
Philadelphia chromosome) or may be non-reciprocal, such that portions of the genome are lost 
or gained. Restricted regions of the genome may be amplified and the amplified sequences may 
present in small acentric fragments (double minutes, DM), incorporated into chromosomes in 
nearly contiguous homogeneously staining regions (HSR) or spread throughout the genome 
1. 
There is considerable variability in the degree to which tumour genomes are aberrant at the 
chromosomal level; some tumours have few chromosomal aberrations whereas others may 
contain dozens 
9. Moreover, cancer cells generally gain multiple types of chromosomal 
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Figure 1- 1  Schematic illustration of mechanisms by which chromosomal aberrations 
arise leading to aneuploidy (a) or leaving the chromosome apparently intact (b) 
Modified from Albertson et al., 2003 
1 
 
1.3  Haematopoiesis 
The process of blood cell production and homeostasis is termed haematopoiesis. All mature 
blood cells are generated from a relatively small number of hematopoietic stem cells (HSC) 
10,11. 
HSC generate the multiple hematopoietic lineages through a successive series of intermediate 
progenitors. These include common lymphoid progenitors, which generate lymphocytes B, T 
and Natural Killer cells, and common myeloid progenitors, which generate red cells, platelets, 
granulocytes and monocytes (Figure 1-2) 
12,13.  
Downstream of the common lymphoid and myeloid progenitors are more mature progenitors 
that are further restricted in the number and type of lineages they generate 
13. Terminally 
differentiated cells cannot divide and undergo apoptosis after a period of time ranging from 
hours (for neutrophils) to decades (for some lymphocytes).  
A complex interaction between the genetic processes of blood cells and their microenvironment 
determines whether HSC, progenitors and mature blood cells remain quiescent, proliferate, 
differentiate, self-renew or undergo apoptosis 
14. Cytokines, extracellular matrix components 
and chemokines are important environmental regulators of haematopoiesis.  
 Introduction 
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Figure 1- 2  The developmental stages of haematopoiesis 
 
1.3.1  Lymphopoiesis 
B cell development is a highly regulated process of ordered events; mature B cells, as well as 
mature T cells, express antigen receptors, each with different antigen specificity. B cells 
primarily originate and differentiate in the BM where the ‘pre B cell’ arises from the progenitor 
‘(Pro) B cell’ following rearrangement of the immunoglobulin (Ig) heavy chain (IgH) gene, 
resulting in cytoplasmic expression of the µ heavy chain. Subsequently, rearrangement of the 
light chain genes occurs. This results in the expression of a complete IgM molecule on the cell 
surface, consisting of two µ chains and two light chains. During this progression a pool of B 
cells is generated in which each B cell expresses one specific Ig with an appropriate affinity to a 
particular antigen. This ‘immature B cell’ is unable to initiate an immune response, but acquires 
this ability on leaving the BM and entering the peripheral lymphoid tissue. Here B cells migrate 
to the outer region of the lymph node within the primary follicles and later to the follicle 
mantles. This differentiation step is associated with the additional expression of IgD, as a result 
of an alternative splicing of IgH messenger ribonucleic acid (mRNA). These IgM+/IgD+ B 
cells, known as ‘naive mature B cells’, populate the blood and the peripheral lymphoid organs, 
where in response to the binding of foreign antigens, they transform into proliferating extra-
follicular B blasts. The daughter cells either differentiate into short-lived, IgM-producing 
plasma cells (PC) or B cells that acquire the capacity to initiate a germinal centre reaction. 
These so-called ‘primed B cells’ proliferate and differentiate into centroblasts forming an early 
germinal centre 
15,16. During the mitotic proliferation and differentiation of centroblasts into Introduction 
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centrocytes, a randomized introduction of mutations in the variable region of the Ig genes 
(somatic hypermutation) leads to the production of Ig with high affinity for the antigens. Those 
centrocytes with advantageous mutations are positively selected and undergo several rounds of 
proliferation, mutation and selection before they finally differentiate into ‘memory’ B cells or 
long-lived PC. The presence of mutations in the variable (V) region of the Ig is considered to be 
a reliable marker for cells that have been exposed to the germinal centre. The affinity maturation 
process is associated with a switch in the IgH chain class from IgM to IgG, IgA or less 
commonly to IgE. The post-germinal centre B cells generate plasmablasts, which typically 
migrate to the BM microenvironment where they interact with stromal cells and differentiate 
into long-lived PC that survive for about 30 days 
17. 
 
1.4  The Ig loci 
Immunoglobulins are either produced at the membrane of the B cell or they are secreted. They 
consist of two identical light chains (L) and two identical heavy chains (H). At the three-
dimensional level, an Ig consists of one N-terminal variable domain and one (for an L) or 
several (for an H chain) C-terminal constant domain(s) (Figure 1-3). 
The heavy chain variable region gene, located at chromosome 14q32.32, is split into arrays of 
gene segments, the V (variable), D (diversity), and J (junctional) segments. Light chain genes 
are similarly organised on different chromosomes (Igκ genes at chromosome band 2p11; Igλ on 
chromosome band 22q11) although they have no D gene segments. To express functional Ig, B 
cells undergo extensive genomic rearrangements within their Ig loci 
18: V(D)J recombination, 
somatic hyper mutation and class switch recombination. 
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i.   V(D)J recombination 
There are 87 VH segments, of which at least 32 are pseudogenes and, so far, 30 germline DH and 
six JH segments have been identified. In order to increase diversity, the D region may be read in 
three different reading frames without generating stop codons and more than one D segment 
may join to form an enlarged D region.  
Of the 76 Vk genes, 16 have minor defects and 25 are pseudogenes, leaving 35 potentially 
functional genes. While there are 5 Jk segments, there is only one constant-region gene. The 
number of possible ĸ chain variable regions that may be produced in this way is approximately 
150. The Igλ gene contains a set of V genes, and each of the seven C genes is accompanied by 
one J gene 
19. 
The recombination of gene segments is a key feature in the generation of a functional 
immunoglobulin, for both light and heavy chain variable regions (Figure 1-4). Specific base 
sequences that act as recombination signal sequences have been identified. A signal sequence is 
found downstream (3') of each V and D segment, and immediately upstream (5') of all germ line 
D and J segments. The recombination signal sequences (RSS) following a Vk, Vλ, VH or D 
segment are complementary to those preceding the Jk, Jλ, D or JH segments with which they 
recombine. The recombination process is controlled at least in part by two lymphocyte-specific 
endonucleases, the recombination-activating genes (RAG-1 and RAG-2). These proteins cut the 
rearranging gene segments at RSS. 
 
        
Figure 1- 4  Molecular processes modifying Ig genes 
 
At the DNA level during the V(D)J recombination of the heavy chains, one of the DH segments 
is joined to one of the JH segments, with deletion of the intermediary DNA, to create a 
rearranged DH-JH segment. The rearranged DH-JH segment is then joined to one of the VH 
segments. Small variations in the positions at which recombination takes place can generate 
additional diversity. Also, nucleotides of variable length and composition are randomly inserted 
between the rearranged V, D and J segments. Introduction 
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In the pre-B lymphocyte, the µ chain is synthesized first because the constant IgHM gene 
segment is located close to the VH-DH-JH rearrangement. This µ chain is associated with the 
pseudo-light chain. The first kappa, if productive, leads to inhibition of the other allele of Igκ 
and Igλ genes. If kappa is unproductive, or cannot pair with the heavy chain, the lambda 
combines to constitute the pre-B receptor.  
 
ii.  Somatic hypermutation 
The process of somatic hypermutation introduces mainly nucleotide substitutions; deletions and 
duplications account for only about 5% of the mutation events. Although the mechanism is still 
obscure, it has been demonstrated that hypermutation is associated with double-strand DNA 
breaks and that an error-prone DNA polymerase is involved in the introduction of mutations in 
the proximity of the DNA breaks 
20,21. 
 
iii.  Class switch recombination 
During class switch recombination, DNA strand breaks are introduced into both the switch µ 
region and the switch region associated with one of the downstream CH genes. The DNA 
fragment between the switch regions is removed from the chromosome and the gene segments 
surrounding the deleted portion are rejoined to retain a functional antibody gene that produces 
an antibody of a different isotype 
19,22. 
All cells which arise from progenitor B cells possess two Ig gene rearrangement products, VH-
DH-JH and VL-JL, which are unique to that cell. Given the number of possible combinations in 
originating an Ig product, individual B cells differ from each other in their differently 
rearranged IgH and IgL genes; this diversity is termed ‘polyclonality’. In contrast, tumour cells 
of B cell neoplasms possess identical VH-DH-JH and VL-JL sequences, indicating that they have 




1.4.1  Activation of proto-oncogenes by chromosomal translocation in 
B cell malignancies 
Chromosomal translocations represent one of the main mechanisms of proto-oncogene 
activation in B cell malignancies 
24. In neoplasms originating from precursor lymphoid or 
myeloid cells, these translocations generally lead to the fusion of two genes originating a new Introduction 
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transcript with acquired oncogenic potential. One example is the translocation t(1;19)(q23;p13) 
found in childhood B cell acute lymphoblastic leukaemia (ALL) which gives rise to the 
E2A/PBX1 fusion gene 
25; the product of the chimaeric gene can drive cell division, inhibit 
DNA repair and cause genomic instability.  
 
In mature B and T cell malignancies, chromosomal translocations usually juxtapose the proto-
oncogene to heterologous regulatory sequences of genes which are expressed at sustained levels 
in normal cells 
23; as a consequence of such translocations the oncogene expression is 
constitutively upregulated. Most of these translocations have one of the breakpoints involving 
either the Ig (B cells) or the T cell receptor (Tcr; T cells) loci. The specific location of these 
breakpoints indicates that  double –stranded breaks naturally occurring during V(D)J 
recombination (Ig or Tcr loci), class-switch recombination (IgH locus) or somatic 
hypermutation (Ig loci) are implicated in the generation of these chromosomal rearrangements 
26. For example in lymphomas, errors in the V(D)J recombination result in the translocations 
t(11;14)(q13;q32) CCND1-IgH, in mantle cell lymphoma and t(14;18)(q32;q21) BCL2-IgH, in 
follicular lymphoma 
27,28.  
Somatic hypermutation is probably involved in the translocation t(8;14)(q24;q32) MYC-IgH in 
Burkitt’s lymphoma: in fact MYC is often joined to the IgH locus within a rearranged and 
somatically mutated IgH variable region 
29,30. 
Chromosomal translocations originating from errors in class-switch recombination have been 
detected mainly in multiple myeloma (MM) and in sporadic Burkitt’s lymphoma 
31. In such 
cases, the location of the breakpoints on chromosome 14 is within the switch regions 
32. It is 
thought that during the switch–region remodelling process, DNA double strand breaks are 
introduced into the switch regions of the recombining CH genes and switch-like regions on other 
chromosomes, sometimes resulting in the translocation of oncogenes to the derivative 
chromosome 14 (der(14)) 
33. These oncogenes are juxtaposed to the potent IgH enhancers, 
resulting in their dysregulated expression. 
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1.5  Plasma cell neoplasms 
PC neoplasms result from the expansion of a clone of Ig-secreting, heavy-chain class-switched, 
terminally differentiated B cells (Figure 1-5A). These cells are phenotypically similar to long-
lived PC, including a strong dependence on the BM microenvironment for survival and growth 
34. They typically secrete a single electrophoretically homogeneous Ig product, known as the 
monoclonal (M) component (Figure 1-5B) 
35.  
A  B   
Figure 1- 5  A) Giemsa-stained BM smear of a MM case; B) Electrophoretic pattern of 
a normal person (green) and of a MM patient (red) 
 
1.5.1  Classification of PC neoplasms 
PC neoplasms have been classified into distinct groups by the World Health Organization 
(WHO) 
36. The WHO recognizes monoclonal gammopathy of undetermined significance 
(MGUS), MM, plasmacytoma (solitary plasmacytoma of the bone and 
extraosseous/extramedullary plasmacytoma), immunoglobulin deposition diseases (primary 
amyloidosis; systemic light and heavy chain deposition diseases) and osteosclerotic MM 
(POEMS syndrome). The diagnostic criteria of the PC neoplasms are summarized in Table 1-1. 
MGUS and MM are the two most common PC disorders. Within the MM group, three variants 
are also defined: asymptomatic/smouldering MM (SMM); non-secretory MM (affecting 3% of 
MM patients) characterized by no detectable M-protein in the serum or in the urine but only in 
the BM PC; and plasma cell leukemia (PCL). The diagnosis of the specific entities within this 
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￿  M-protein in serum <30 g/L 
￿  BM clonal PC <10% and low level of PC infiltration in the trephine biopsy (if done) 
￿  No evidence of other B cell proliferative disorders 
￿  No MM-related organ or tissue impairment (no end organ damage, including bone lesions) 
SMM 
￿  M-protein in serum >30 g/L and/or BM clonal PC >10% 
￿  No evidence of other B cell proliferative disorders 
￿  No MM-related organ or tissue impairment (no end organ damage) or symptoms 
MM 
￿  M-protein in serum and/or urine* 
￿  BM clonal PC or plasmacytoma
# 
￿  No evidence of other B-cell proliferative disorders 
￿  Related organ or tissue impairment (no end organ damage, including bone lesions)  
 
* M-protein in most cases is >30 g/L (>25g/L sometimes used for IgA) and >1g/24 hr of urine light 
chain but some patients with symptomatic MM have levels lower than these 
#  Monoclonal PC usually exceed 10% of nucleated cells in the BM but no minimal level is designated 
because about 5% of patients with symptomatic MM have <10% BM PC 
Plamacytoma  
     • Solitary plasmacytoma of the bone 
￿  No M-protein in the serum and/or urine (a small M-component may sometimes be present) 
￿  Single area of bone destruction due to clonal PC 
￿  BM not consistent with MM 
￿  Normal skeletal survey (and magnetic resonance imaging (MRI) of spine and pelvis if done) 
￿  No MM-related organ or tissue impairment (no end organ damage other than solitary bone 
lesions)  
    • Extramedullary plasmacytoma 
￿  No M-protein in serum and/or urine (a small M-component may sometimes be present) 
￿  Extramedullary tumour of clonal PC 
￿  Normal BM 
￿  Normal skeletal survey 
￿  No MM-related organ or tissue impairment (no end organ damage other than solitary bone 
lesions) 
Non-secretory MM 
￿  No M-protein in serum and/or urine with immunofixation 
￿  BM clonal plasmacytosis >10% or plasmacytoma 
￿  Related organ or tissue impairment (end organ damage, including bone lesions) 
Plasma cell leukaemia 
￿  Absolute PC count in peripheral blood >2.0 x 10
9/l 
￿  Peripheral blood differential white cell count with >20% PC 
Amyloidosis 
￿  Presence of an amyloid-related systemic syndrome 
￿  Positive amyloid staining by Congo red in any tissue (e.g. fat aspirate, BM, organ biopsy) 
￿  Evidence that amyloid is light chain-related established by direct examination of the amyloid 
￿  Presence of a monoclonal PC disorder 
 
Myeloma related organ or tissue impairment (CRAB) 
Hypercalcemia (serum calcium >11.5mg/dl) (C), renal insufficiency (serum creatinine >177µmol/L) 
(R), anaemia (haemoglobin <10g/dl) (A); bone lesions: lytic lesions or oteoporosis with compression 
fractures (MRI may clarify) (B). Other: symptomatic hyperviscosity, amyloidosis, recurrent bacterial 
infections (> two episodes in 12 months) 
37.  Introduction 
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1.5.2  Pre-malignant conditions 
MGUS and SMM are asymptomatic, pre-malignant disorders. They are characterized by clonal 
expansion of PC within the BM, which is responsible for the presence of an M-protein in the 
serum, but with no evidence of end-organ impairment 
35. Patients with MGUS and SMM are 
often diagnosed by chance, as M-proteins are frequently identified during investigation of 
unrelated symptoms or during health screening. These patients are associated with an increased 
risk of developing MM or related malignancy and require lifelong observation in order to detect 
signs of transformation. The purpose of  monitoring is to try to identify transformation to a 
malignant disorder at an early stage, when there is no significant irreversible lytic bone disease, 
renal failure or other disabling symptoms and at a stage when the patient is fit enough to benefit 
from increasingly effective treatments. In line with the British Committee for Standards in 
Haematology Guidelines on the Diagnosis and Management of Multiple Myeloma 2005 
38, 
patients with MGUS or SMM are not treated unless progression occurs.  
SMM needs to be differentiated from MGUS in the clinical setting as its rate of transformation 




From Kyle et al.(2007) 
39 
Figure 1- 6  Probability of progression to active MM or primary amyloidosis in patients 
with SMM or MGUS 
Vertical bars denote 95% confidence intervals 
 
The rate of progression of MGUS is ~1% per year vs 10% per year for SMM 
40,41. Moreover, 
while in MGUS this risk of progression remains constant over time 
40, in SMM it is influenced 
by the time elapsed since diagnosis, being approximately 10% per year in the first 5 years, 3% 
in the next 5 years with a decrease to 1% per year thereafter 
39. Since the risk of progression to Introduction 
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MM is much higher in SMM compared to MGUS, SMM patients should be managed differently 
in terms of frequency of follow-up.  
 
1.5.2.1  Monoclonal gammopathy of undetermined significance (MGUS) 
MGUS is the most common PC disorder; its incidence increases with age, affecting 
approximately 3.2% and 5.3% of adults older than 50 and 70 years, respectively 
42. The median 
age at diagnosis is around 70 years; less than 2% of patients with MGUS are under 40 years of 
age 
42. For MGUS as well as for SMM and MM, the incidence is two fold higher in American 
blacks than whites and significantly higher in males 
43.  
Diagnostic criteria for MGUS are listed in Table 1-1. It has been suggested that the best test for 
an accurate diagnosis of MGUS (as compared with MM) is disease stability over a period of 
time of 6 to 12 months after diagnosis 
40,44,45. By applying this criterion, only a very small 
percentage of true MGUS with progression to MM would be missed, but most cases of early 
MM would be identified 
46; the problem is that this approach can only be applied 
retrospectively. 
Different studies have followed the clinical course of MGUS patients. The original Mayo Clinic 
series of 241 MGUS patients was followed for more than 35 years. The study showed that the 
interval from the time of diagnosis of MGUS to the detection of a neoplastic condition ranged 
from 2 to 29 years (median, 10 years) 
47, indicating that MGUS patients are biologically very 
heterogeneous and also that they must be monitored throughout their lives for evidence of 
progressive disease. 
The constant rate of progression suggests a minimal two-hit genetic model of malignancy and, 
given that the risk of progression does not depend on the known duration of the antecedent 
MGUS phase, the second-hit responsible for progression appears to be a random event and not 
cumulative damage 
40. 
Risk factors for transformation of MGUS to a malignant condition have been addressed in 
several studies. A major shortcoming of most of these studies has been their relative small size. 
Kyle and colleagues studied a large group of MGUS patients in order to investigate whether 
specific clinical parameters were predictive of progressive disease 
40. Results showed that, 
although none of the markers could conclusively identify those patients who evolved, the 
presence of three adverse risk factors, namely a high serum M-protein level (>15 g/L), an 
abnormal serum free light chain ratio and non-IgG MGUS was associated with a risk of 
progression at 20 years of 58% (high-risk MGUS). Any two of these factors present together 
(high-intermediate-risk MGUS) were associated with a risk of 37%; the risk was 21% with one Introduction 
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of the factors (low-intermediate risk MGUS) and 5% when none of the risk factors were present 
40,48. The type and level of M-protein as risk factors for transformation have consistently been 
confirmed by a number of other studies 
49-52.  
 
1.5.2.2  Smouldering myeloma (SMM) 
SMM is an uncommon form of MM accounting for slightly less than 10% of patients with this 
disease 
53,54. Diagnostic criteria of SMM are listed in Table 1-1. The distinction between SMM 
and MM cannot be made by histopathologic examination of the BM, but is determined by those 
clinical findings indicative of end-organ damage (CRAB), which are absent from SMM 
patients. The combination of serum M-protein level and the extent of BM involvement emerged 
as the most important independent risk factor of disease progression. The presence of IgA M-
protein, urinary light chain, reduction in the levels of polyclonal Ig and the pattern of PC 
involvement in BM (sheets of cells vs singly distributed cells or small clusters) also emerged as 
significant markers of progression on univariate analysis 
39. Most patients with SMM eventually 
progress to symptomatic disease; however, some patients can remain progression free for a 




The pattern of disease progression seems to be variable. Rosinol et al. recognized two types of 
SMM: ‘evolving’ and ‘non-evolving’ 
54. The evolving variant was characterized by a 
progressive increase in the serum M-protein level until the development of symptomatic MM, a 
shorter time to progression and a previously recognized MGUS phase in most patients. The non-
evolving type was characterized by a long-lasting stable M-protein until the onset of 
symptomatic disease, longer time to progression and no previous MGUS. Interestingly, the 
evolving type could be identified after the first two follow-up assessments, as most patients with 
evolving SMM had an increase in M-protein of >10% during the first 6 months of follow-up.  
The same evolution patterns recognized in SMM were identified in MGUS. Blade and 
colleagues found that the behaviour of about 10% of MGUS patients resembled that of the 
‘evolving variant’, defined by a slow but progressive increase in the M-protein size during the 
first 3 years of follow-up 
55. The ‘evolving MGUS’ may be considered as an early MM, whereas 
the non-evolving type might be considered a true stable MGUS, requiring a second hit for 
malignant transformation. 
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1.5.3  Symptomatic multiple myeloma (MM) 
MM is a devastating incurable malignancy which constitutes 1% of all cancers. It represents the 
second most common blood cancer after lymphomas accounting for 10% of all haematological 
malignancies 
56. The median age at diagnosis is 60-65 years, with fewer than 2% of patients 
younger than 40 years. 
The malignant PC are located at multiple sites within the BM, in close association with stromal 
cells. The interaction between tumour and stromal cells, through cytokines and adhesion 
molecules, activates the stromal cells that further support the growth and survival of the MM 
cells, which leads to the complications associated with the condition 
57.  
MM PC have a minimal proliferative activity, their labelling index is very low with less than 
1% of tumour cells synthesizing DNA until late disease. At this time MM cells are found 
outside the BM, including blood, pleural fluid and skin 
58. 
Diagnostic criteria for MM are shown in Table 1-1. The minimal level of clonal BM PC has 
been indicated to be 10%. However, approximately 5% of patients with symptomatic MM have 
a PC content <10%. This is usually due to an inadequate specimen or to the possibility of 
unevenly distributed PC within the BM. An IgG M-protein is found in about half of patients, 
one fifth have an IgA and monoclonal light chain only is found in almost 20% 
35.  
The outcome for MM patients is highly variable. Although the median overall survival (OS) is 3 
to 4 years, the range is from less than 6 months to greater than 10 years. This variability is 
thought to derive from heterogeneity in both MM cell biology and multiple host factors 
59. 
Several prognostic factors have been used over the years in order to stratify patients into 
prognostic sub-groups (i.e. age, β2-microglobulin (β2M), albumin, lactate dehydrogenase, C-
reactive protein, platelet count, abnormal karyotype and PC labelling index) 
60-62. More recently 
a worldwide collaboration defined an International Staging System (ISS), which is based on two 
readily available variables: β2M and albumin. These two parameters can separate patients into 
three stages with different outcome 
59.  
 
1.5.4  Plasma cell leukemia (PCL) 
Primary or de novo plasma cell leukemia (pPCL) arises from the expansion of a clonal 
population of PC, diagnosed during the leukemic phase without a preceding diagnosis of MM. 
Secondary PCL (sPCL) arises from leukemic transformation of MM 
35,63-65. Approximately 60% 
of patients with PCL have the primary type. Diagnostic criteria are listed in Table 1-1 
63. PCL is 
a rare disorder, representing less than 5% of malignant PC neoplasia. Most patients have a poor Introduction 
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prognosis with a reported median survival of 6 to 8 months 
66,67. Compared to MM, pPCL shows 
more extensive disease 
67.  
Despite showing some degree of overlap in the antigenic expression of CD38 and CD138, PC 
from PCL appear to have a more immature phenotype than PC from MM. This is suggested by 
the expression of CD20 antigen, usually absent in MM 
68. Moreover PC from PCL frequently 
lack the antigens CD9, CD117, HLA-DR (Human leukocyte antigen DR-1) and CD56. The 
latter is considered to be important in anchoring PC to the BM stroma 
69,70. However, these 
phenotypic differences do not provide a complete discrimination between PCL and MM 
71.  
 
1.5.5  Plasmacytoma 
Solitary plasmacytoma of the bone is a localized bone tumour consisting of monoclonal PC and 
represents 3%-5% of PC neoplasms. Complete skeletal radiographs show no other lesions; there 
are no clinical features of MM and no evidence of BM plasmacytosis, except for the solitary 
lesion. This lesion is usually found in BM sites where haematopoiesis is most active, such as the 
vertebrae, ribs, skull, pelvis, femur, clavicle and scapula. An M-protein is found in the serum or 
urine in 24%-72% of patients. Local control is achieved by radiotherapy in most cases, but up to 
two thirds of patients eventually evolve to MM or additional solitary or multiple 
plasmacytomas. 
Extraosseous/extramedullary plasmacytomas are localized PC tumours that arise in tissues other 
than bone. They have a similar frequency to the solitary plasmacytomas of the bone. The 
majority (80%) occur in the upper respiratory tract but they may be found in the gastrointestinal 
tract, lymph nodes, bladder, breast, thyroid, testis, parotid and skin. In most cases these lesions 
are eradicated with localized radiation therapy. Progression to MM is infrequent, although 25% 




1.5.6  Multistep transformation process 
Until recently it was not clear whether all MM were preceded by an MGUS phase. Two studies 
published at the beginning of 2009 offered important clues about MGUS and its relationship to 
MM 
74,75. (i) Landgren and colleagues reported that among 77476 healthy adults enrolled in a 
prospective Cancer Screening Trial, 71 individuals developed MM. For all 71 patients there 
were stored serum samples obtained from 2 to 10 years prior to the diagnosis of MM. All MM Introduction 
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patients showed evidence of having gone through a preceding MGUS, with 75% of them 
showing a detectable M-protein 8 or more years prior to transformation to MM. In about half of 
the patients, the serum M-protein showed a year-by-year increase before the diagnosis of MM 
74. (ii) Weiss and colleagues reported on the prevalence of MGUS in 30 MM patients for whom 
there was available serum stored by the US department of Defence Serum Repository and 
collected 2 to 15 years prior to the diagnosis of MM. A preceding MGUS was detected in 27 of 
the 30 patients 
75. These two studies indicated that virtually all MM cases were preceded by an 
MGUS phase. They also showed that in 30%-50% of MGUS patients who evolved to MM, the 
M-protein remained stable until progression occurred, while in 50%-70% of patients the M-
protein showed a gradual and progressive increase.  
These with other studies led to the generation of disease models of MM based on the multistep 
progression of normal to MGUS through to myelomatous PC. In these models, the initiating 
event is thought to be an immortalization episode in PC, which initiates the formation of a 
clone. It has been suggested that such clones may remain quiescent and non-accumulating 
without producing end organ damage (MGUS/SMM stage). If transformation occurs, and so far 
the mechanisms leading to progression remain unknown, PC accumulate within the BM leading 
to organ and tissue impairment. This disease usually enters a quiescent phase of variable 
duration, followed by a late stage of drug resistance with resistance to apoptosis and 
independence from the BM microenvironment 
76. 
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1.6  Genetic abnormalities in MM and related disorders 
The acquisition of recurrent chromosomal abnormalities is an early event in MM development, 
as many of the genetic changes identified in the PC of MM patients have also been found in 
MGUS and SMM. Although the mechanisms responsible for the acquisition of these changes is 
not well understood, current evidence suggests that in many cases an abnormal response to 
antigenic stimulation may be a key factor 
77-79.  
Although several genetic abnormalities found in the neoplastic clone have been suggested to be 
associated with the transition from MGUS/SMM to MM, no definite genetic markers of 
progression have been identified. Specific genetic abnormalities are probably ‘driver’ events 
contributing critically to clonal selection and disease evolution. However, because of the 
asymptomatic nature of MGUS and SMM, at the time of MM diagnosis the developmental 
timing of these changes is buried in the MM’s covert natural history. Furthermore, it remains 
unclear how much the genetic or epigenetic changes within the clonal PC affect disease 
progression compared to extrinsic changes in the non-tumour cells of the BM 
microenvironment. The BM microenvironment has been shown to undergo marked 
modifications during progression, including induction of angiogenesis and abnormal paracrine 




1.6.1  Methodological approaches: cytogenetic analysis and 
fluorescence in situ hybridization (FISH) 
The initial approach to study genetic abnormalities of PC disorders has been cytogenetic 
analysis of metaphases. As previously mentioned, although MM is more proliferative than 
MGUS or SMM, all conditions are characterized by an extremely low proliferation rate. This 
aspect, together with the often poor quality of the BM samples due to the scattered and variable 
degree of BM infiltration, has made cytogenetic studies difficult. When cytogenetic analysis 
reveals only normal metaphases, they usually originate from the myeloid elements and not from 
the clonal PC 
46. For these reasons, metaphase analysis grossly underestimates the incidence of 
chromosomal changes in these conditions. Clonal abnormalities are almost never found in 
MGUS and SMM, while they are found in ~40% of MM cases, 20%-35% at diagnosis and 
about 60%-80% of patients in stage III (ISS staging system) or with an extramedullary tumour Introduction 
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(PCL) 
81,82. As a consequence most changes described by metaphase analysis mostly relate to 
the late stages of the disease, relapsing cases or PCL.  
Culture parameters, such as addition of IL-6 or granulocyte colony stimulating factor and length 
of time in culture, appeared to increase the detection rate of chromosomal abnormalities 
83,84. 
Other aspects of cytogenetic analysis which make the interpretation of the karyotype difficult 
and often inaccurate include: the telomeric location of some translocation partners and the high 
level of complexity of most abnormal cases. In most patients, the karyotype resembles that of 
solid tumours: a multitude of complex chromosomal aberrations where it is difficult to 
understand which ones are responsible for tumour initiation and which for tumour progression. 
Despite these problems, metaphase analysis has identified a number of structural and numerical 
abnormalities. The latter, in particular, have subdivided patients into specific ploidy categories.  
 
A technique that to a certain extent has overcome the limitations of metaphase analysis is 
interphase FISH (iFISH). The basis of this technique is the detection of specific sequences of 
genomic DNA in cytological material fixed to a microscope slide through the hybridization of a 
labelled DNA or RNA probe.  
The development of FISH has permitted the study of chromosomal rearrangements at a 
resolution significantly higher than that of conventional cytogenetics. Furthermore, because 
iFISH does not need dividing cells, it has provided the opportunity of studying numerical and 
structural abnormalities in all patients at all disease stages 
85. Given the low PC infiltration 
characterizing most BM samples from cases with PC disorders, iFISH is preferentially done on 
purified cells (e.g. CD138
+ microbead selection, see Section 2.2.5) or using simultaneous 
immunofluorescence to identify the PC 
46.  
Interphase-FISH studies have shown that using probes for five to ten different chromosomes, 
more than 90% of cases (including both MM and MGUS) had at least one abnormality and 
confirmed that most MGUS PC were aneuploid 
45,86.  
A major limitation of this technique is that it is highly specific, requiring prior knowledge of the 
type and location of the genetic abnormality under investigation with no possibility to detect 
other changes.  
 
Metaphase analysis, although uninformative in many cases, seems to have the advantage over 
iFISH of playing a major role in the prediction of outcome in MM (see Section 1.6.4). The 
detection of an abnormal clone, at any time in the disease or treatment course, is associated with 
an inferior outcome. The detection of chromosomal abnormalities in metaphase not only seems 
to reflect high proliferative activity, but also stroma-cell independence of in vitro cell division 
of malignant PC 
87,88. 
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1.6.2  Disease stages and timing of oncogenic events 
In MM two distinct pathways of pathogenesis have been recognized (Figure 1-7): a non-
hyperdiploid (nonHRD) pathway (black triangle) that usually includes one of seven recurrent 
IgH translocations as an early event and a hyperdiploid (HRD) pathway (white triangle) which 
















Adapted from Chng et al., 2007 
89 
 
Figure 1- 7  Disease stages and timing of oncogenic events 
IgH tx, primary Ig translocations; DEL13, monosomy/deletion 13; * the partner at 8q24 refers here 
to MAFA as MYC is also located on 8q24; MYC-translocations are usually secondary events 
 
 
Monosomy/deletion of chromosome 13 (∆13) (grey triangle) has also been suggested to be an 
early abnormality shared by MGUS and MM tumours. IgH translocations, HRD and ∆13 are all 
early and partially overlapping events; however, the relative timing of their occurrence is not yet 
completely understood. Secondary chromosomal rearrangements and other abnormalities can 
occur at any time during tumourigenesis. Mutually exclusive activating mutations of K- or N-
RAS (rat sarcoma viral oncogene homolog) or FGFR3 (fibroblast growth factor receptor 3), 
when there is a t(4;14) translocation are rare in MGUS. Their prevalence is 30% to 40% in early 
MM with a small increase during tumour progression. 
Late oncogenic events that occur at a time when tumours are becoming more aggressive include 
MYC (v-MYC avian myelocytomatosis viral oncogene homologue) dysregulation, promiscuous Introduction 
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mutations that constitutively activate the NF-κB (nuclear factor kappa-light-chain enhancer of 
activated B cells) pathway, additional inactivation of the retinoblastoma pathway, such as bi-
allelic deletion of p18/CDKN2C (cyclin-dependent kinase inhibitor 2C), loss or mutation of 
TP53 (tumour protein 53) and methylation of the p16INK4A/CDKN2A (cyclin-dependent kinase 
inhibitor 2A) promoter 
89,90. 
 
1.6.3  Aneuploidy 
Numerical chromosomal abnormalities are present in virtually all MM and in most, if not all, 
cases of MGUS and SMM 
85,91. There is non random involvement of different chromosomes: 
the most common trisomies are 3, 5, 7, 9, 11, 15, 19 and 21, while the most common 
monosomies are 13, 14, 16, and 22. No specific numerical chromosomal change is constant or 
predictive of disease progression. In cases showing multiple gains, it is unknown if the extra 
chromosomes are accumulated one at a time, in sequential steps or as a single event.  
Global aneuploidy analysis segregates patients into four sub-categories: hypodiploid (<45 
chromosomes), pseudodiploid (46 - 47 chromosomes), HRD (>48 chromosomes), and near-
tetraploid (>75 chromosomes). Near-tetraploidy usually represents the doubling of hypodiploid 
or pseudodiploid chromosomal complements, as the majority of the cases with a near-tetraploid 
population also have cells with a pseudodiploid or hypodiploid karyotype 
92-94.  
It is agreed that there are specific patterns of association among these four classes: hypodiploid 
cases are classified with pseudodiploid and near-tetraploid as nonHRD 
92-94; half of MM cases 
fall in this ploidy category. Compared to the HRD group, nonHRD MM is characterized by a 
higher prevalence of IgH translocations, ∆13 and structural chromosomal abnormalities. Two 
studies have shown that  HRD and nonHRD are not only established early in disease 
development but are maintained over time or during progression from pre-malignant stages to 
MM, although the relative percentages of cells carrying different chromosomal abnormalities 
may change 
95,96. As extramedullary MM and human myeloma cell lines (HMCL) almost always 




1.6.4  Chromosome 13 abnormalities (∆13) 
∆13 is highly prevalent in PC disorders. In most cases, ∆13 represents a whole-chromosome 
monosomy 
46,85,98; only a subset of tumours show interstitial deletions, with a common deleted Introduction 
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region located at 13q14 
99,100. Although the genes targeted by this abnormality remain unclear, 
the retinoblastoma (RB1) gene falls within the minimal common deleted region. RB1 was the 
first tumour suppressor gene to be cloned. It is a negative regulator of the cell cycle through its 
ability to bind the transcription factor E2F and repress the transcription of genes required for 
entry to the synthesis (S) phase of the cell cycle 
101. Studies on other types of cancer showed that 
both copies of RB1 must be inactivated to eliminate its tumour-suppressor function 
34. In MM, 
apart from rare cases of biallelic deletion, inactivating mutations of the remaining allele are not 
commonly seen. RB protein levels correlate with mRNA levels and DNA copy number, 
suggesting that mono-allelic loss of RB1 might be tumourigenic through a haploinsufficiency 
mechanism. However, currently the role of RB1 remains unclear 
34,102. 
 
∆13 was originally detected in ~50% of patients with abnormal karyotypes, equivalent to 10-
20% of all patients. Initially it was not described in MGUS or SMM, probably due to the 
difficulty in obtaining metaphases in these disease types 
46. Since the use of iFISH, it became 
clear that ∆13 occurred at all stages of PC neoplasms. However, conflicting reports have been 
published on the actual prevalence of this abnormality in MGUS and MM. Some studies 
reported a substantially lower incidence in MGUS (~25%) as compared to MM (50%–60%) 
85, 
whereas others showed an almost identical prevalence 
44,103. The lower incidence in MGUS 
implied that ∆13 may be involved in the transition from pre-malignant conditions to MM, 
whereas the latter suggested that ∆13 was associated with initiation of the disease and was not 
an event linked to progression. A recent study suggested that, while in MM ∆13 is the hallmark 
of hypodiploidy, in MGUS the abnormality is associated with HRD. Therefore discrepancies in 
the incidence of ∆13 found in different series might be related to the relative proportions of 
HRD and hypodiploid patients tested 
104. Further studies are needed to resolve these 
discrepancies.  
 
The presence of ∆13 has been associated with an adverse prognosis, but its clinical relevance 
appears to depend on the detection method used 
46. Metaphase analysis detects the abnormality 
in considerably fewer patients than iFISH (~20% vs ~50%), but when ∆13 is detected in 
metaphase it has been shown to confer a significantly shorter OS than when detected by iFISH. 
These findings indicated that ∆13 detected by iFISH is an inadequate independent prognostic 
marker and that the prognostic value of ∆13 depends on the ability of the PC clone to divide in 
vitro. As a confirmation of these results, PC with ∆13 in metaphase have been shown to have a 
distinct gene expression profile 
102. By iFISH, ∆13 was found to be predictive of inferior 
survival only when associated with other poor prognostic markers (i.e. t(4;14), 17p13 deletion). Introduction 
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In patients with ∆13 in the absence of other poor prognostic markers, ∆13 by iFISH was not 
significantly associated with an inferior survival 
87,102,105. 
 
1.6.5  Ig translocations are present in a majority of PC tumours 
Like other post-germinal centre B cell tumours, translocations involving the IgH locus (14q32) 
or one of the IgL loci (κ, 2p12 or λ, 22q11) are common  in PC neoplasms 
22. These 
translocations may be primary/initiating events during tumour pathogenesis or secondary, 
occurring during disease progression.  
 
As previously described, primary translocations seem to originate from errors in one of the three 
B cell specific DNA modification mechanisms, specifically class switch recombination and 
somatic hypermutation. These translocations usually juxtapose an oncogene close to one or 
more of the potent Ig enhancers (Eµ, Eα1, Eα2) on the der(14) originated from the translocation 
106. Since there is no evidence that somatic hypermutation and class switch recombination are 
active in normal or neoplastic PC, presumably these translocations represent very early if not 
initiating oncogenic events arising as normal B cells pass through the germinal centre. 
Studies from different groups have shown that the prevalence of primary IgH translocations 
increases with disease stage: about 50% in MGUS or SMM, 55%-70% in intramedullary MM, 
85% in PCL, and >90% in HMCL 
107-109. Limited studies indicated that Igλ translocations are 
present in about 10% of MGUS/SMM and 15%-20% of intramedullary MM. Translocations 
involving an Igκ locus are rare, occurring in only 1%-2% of MM 
34. 
Secondary translocations appear to be very late events which do not always involve Ig loci and 
usually do not arise from B cell specific recombination mechanisms 
110. Typical examples of 
secondary translocations are those involving MYC. The breakpoints on both chromosomes 8 and 
14 can be highly variable and therefore it is unlikely that Ig remodelling events are responsible 
for these translocations 
111,112. All of these translocations are readily detected by iFISH analysis 
in the majority of cases. 
 
1.6.5.1  Seven recurrent IgH translocations represent primary oncogenic events 
The seven recurrent chromosomal partners (oncogenes) involved in primary IgH translocations 
(listed in Figure 1-7) represent three recurrent IgH translocation groups 
113-118: 
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￿  Cyclin D: 11q13 (Cyclin D1, CCND1), 15%; 12p13 (Cyclin D2, CCND2), <1%; 6p21 
(Cyclin D3, CCND3), 2% 
￿  MAF  (v-MAF avian musculoaponeurotic fibrosarcoma oncogene): 16q23 (c-MAF), 
5%; 20q12 (MAFB), 2%; 8q24.3 (MAFA), <1% 
￿  MMSET/FGFR3 (multiple myeloma SET domain/ fibroblast growth factor receptor 3): 
4p16 (MMSET and usually FGFR3), 15% 
 
IgH translocations involving CCND2 and MAFA have recently been reported 
89 and are 
extremely rare. The combined prevalence of these seven rearrangements is about 40% and they 
occur predominantly in nonHRD tumours; less than 10% of HRD cases have one of these 
rearrangements 
34. One of the striking features of IgH translocations in MM is the fact that some 
oncogenes are dysregulated even when they are located more than 1 Mb from the breakpoint on 
the der(14).  
 
i.  t(4;14)(p16.3;q32) 
The translocation t(4;14) is cytogenetically cryptic and was first identified from cloning 
experiments in HMCL. It can be detected by iFISH or by reverse transcriptase polymerase chain 
reaction (RT-PCR) specific for the IgH-MMSET hybrid transcript. The translocation is seen in 
15-20% of primary MM samples and in 25% of HMCL 
46. It is the second most common IgH 
translocation after t(11;14) 
119. Patients with t(4;14) often have an IgA isotype. 
In the majority of cases, t(4;14) originates from illegitimate switch recombination. As a 
consequence of the translocation, FGFR3 becomes associated with the 3'α enhancer(s) on the 
der(14). The 4p16 breakpoints cluster within a 60 kb region, within the 5' exons of the MMSET 
gene, 50-100 kb centromeric of FGFR3. FGFR3 is one of the four high-affinity tyrosine kinase 
receptors for the fibroblast growth factor (FGF) family of ligands. It is normally expressed in 
lung, kidney and at high levels in the developing central nervous system and cartilage. Its level 
of expression in mononuclear cells isolated from the BM is almost undetectable. On ligand 
stimulation, FGFR3 undergoes dimerization and tyrosine autophosphorylation resulting in cell 
proliferation or differentiation, depending on the cell context, through the mitogen-activated 
protein kinase (MAPK) and phospholipase Cγ signal transduction pathways 
120,121.  
The MMSET gene encodes four different protein products originating from two alternative 
splicing events and an alternative transcription site. Very little is known about the function of 
the various protein isoforms. Based on homology to other SET domain containing proteins, the 
full length isoform, MMSET II, is predicted to act as regulator of gene expression by 
methylating specific lysine residues on histones H3 and H4 
119. MMSET is dysregulated in all 
cases by its association with the intronic enhancer (Eµ) on the der(4). Nearly one third of Introduction 
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patients with the translocation do not express FGFR3; FGFR3 lack of expression is mainly due 
to the loss of the der(14). In some cases the der(14) is present, thus other mechanisms must be 
responsible for the loss of gene expression.  
It is unclear whether loss of FGFR3 expression is a primary or a secondary event and whether 
FGFR3 dysregulation is critical for MM pathogenesis. Kinase-activating mutations of the 
dysregulated FGFR3 are seen late in tumourigenesis, and it seems that the proliferation of these 
MM tumours is dependent on the mutated FGFR3 
116. Other t(4;14) tumours acquire K- or N-
RAS mutations that appear to be mutually exclusive of FGFR3 mutations 
122. The consistent 
persistence of MMSET dysregulation suggests that this gene might be the critical oncogene in 
the initiation of these tumours. However, it remains unclear how MMSET contributes to the 
pathogenesis of MM. The t(4;14) almost always coexists with ∆13 and is highly associated with 
nonHRD in both MM and MGUS. 
The t(4;14) is associated with an unfavourable prognosis in MM patients treated with either 
conventional or high-dose therapy (HDT) with stem cell transplantion. The adverse outcome 
manifests as early relapse; the presence or absence of the der(14) does not appear to have an 
influence on survival 
123. FGFR3 inhibitors are available: PD173074 is a compound that has 
been shown to block proliferation and induce apoptosis in some HMCL with the translocation 
49. Recently, several studies have suggested that treatment with bortezomib overcomes the poor 
prognosis associated with t(4;14) in both newly diagnosed and relapsed patients 
124-126. 
 
ii.  t(11;14)(q13;q32), t(6;14)(p21;q32) & t(12;14)(p13;q32) 
The t(11;14) is easily detectable by metaphase analysis. It is found in 15-20% of MM patients, 
with approximately the same prevalence in MGUS and SMM 
44,109,127, although its frequency is 
higher in primary amyloidosis (50%) 
44,85,128.  
The translocation results in ectopic expression of CCND1, which promotes the progression of 
cells from G1 growth arrest phase into the S phase. CCND1 is the regulatory subunit of a 
holoenzyme that phosphorylates and inactivates the RB1 protein and promotes progression 
through the G1-S phase of the cell cycle in a manner dependent on cyclin-dependent kinases 
(CDK). In addition, CCND1 has a number of cell cycle- and CDK-independent functions. It 
associates with and regulates transcription factors, co-activators and co-repressors that govern 
histone acetylation and chromatin remodelling proteins. Amplification or overexpression of 
CCND1 play pivotal roles in the development of several human cancers, including parathyroid 
adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer 
129-131. Normal 
B cells express CCND2 and CCND3 but not CCND1.  
The breakpoints in 14q32 are within either the JH region or the switch regions, while the 
breakpoints at 11q13 are dispersed over 300 kb centromeric of CCND1 
106,107. Following the Introduction 
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translocation, IgH enhancers become located to the der(11). This may lead to dysregulation of 
the myeloma overexpressed (MYEOV) gene, which was found to be upregulated in three of 
seven HMCL with t(11;14) 
132. 
This translocation is usually associated with a diploid or pseudodiploid karyotype and it appears 
to have an intermediate prognosis. However, its overrepresentation in HMCL and PCL suggests 
that, at least in some cases, the t(11;14) results in aggressive clonal growth which might be due 
to the coexistence or acquisition of secondary genetic changes 
113. 
The t(6;14) and t(12;14) lead to dysregulation of CCND3 and CCND2, respectively. The 
frequency of t(6;14) is ~3% in MM, although the frequency in pre-malignant conditions is 
unclear 
117; the t(12;14) is rare. Patients with t(6;14) or t(11;14) seem to follow a similar clinical 
course. 
 
iii.  t(14;16)(q32;q23) 
The t(14;16) translocation has been identified in 5% of MM patients and leads to dysregulation 
of the c-MAF proto-oncogene. Despite the large distance between the translocated IgH 
enhancers and the c-MAF locus, the gene is highly up-regulated in these tumours, indicating that 
c-MAF is the targeted gene. Interestingly, a recent study using immunohistochemistry reported 
that in MM c-MAF protein is exclusively expressed in cases positive for c-MAF rearrangements 
133.  
Five of the breakpoints cloned on 16q23 occur over a region 550-1350 kb centromeric of c-
MAF and all but one are located within the 800 kb intron of the WWOX (WW domain-
containing oxidoreductase) gene. This region is a common fragile site, FRA16D. Deletions of 
this region have been found in adenocarcinoma of the stomach, lung, colon and ovary, 
suggesting a possible role of WWOX as a tumour suppressor gene 
134,135. c-MAF is a leucine-
zipper transcription factor that heterodimerizes with jun (v-jun avian sarcoma virus 17 oncogene 
homolog) and fos (Finkel-Biskis-Jinkins (FBJ) murine osteosarcoma virus). It has been 
proposed that c-MAF transforms PC by stimulating cell cycle progression and altering BM 
stromal interactions 
136. From gene expression profiling, three c-MAF target genes have been 
identified which were all shown to be over-expressed: CCND2, integrin β7 and CCR1 
(chemokine CC motif receptor 1).  
The translocation is readily detected by iFISH, while its detection by metaphase analysis can be 
challenging, depending on the quality of the metaphase preparations. The prognostic 
significance of t(14;16) is less well established than t(4;14) as numbers are small. However, 
there is a suggestion that t(14;16) is associated with poor prognosis 
108. As seen with t(4;14), 80-
90% of tumours with this translocation have ∆13. Introduction 
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Avet-Loiseau and colleagues found a decreased prevalence of IgH translocations involving 
4p16 and 16q23 in MGUS as compared to MM 
109. Similar data were reported in two other 
studies 
44,137. Collectively, these findings suggested that these translocations may be associated 
with rapid progression from MGUS to MM, so that the pre-malignant stages are rarely 
recognized. However, in a number of MGUS or SMM cases positive for one of these two 
translocations, it appeared that the presence of the abnormality alone was insufficient to lead to 
progression to MM, with some patients remaining stable for years 
44,137,138. Given the overall 
low incidence of the t(14;16), such observations need to be confirmed in larger patient series. 
 
iv.  t(14;20)(q32;q12) 
The translocation t(14;20) has been reported in 1-2% of primary MM. It leads to ectopic 
expression of MAFB (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B). On 
chromosome 20, the breakpoint is located within a gene sparse region, with the closest 
oncogene, MAFB, located 1100 kb telomeric of the breakpoint 
139.  
The MAFB gene belongs to the MAF family of basic region/leucine zipper transcription factors 
140. Like other large MAF proteins, such as c-MAF, it has both a carboxy-terminal region/leucin 
zipper domain, which mediates DNA binding and dimer formation, and an amino-terminal 
acidic domain associated with transactivating capability. MAFB proteins have dual functions in 
the transcription of downstream genes and whether they function as transactivators or 
transrepressors depends on the target sequences and the interacting proteins. In hematopoietic 
cells, MAFB expression appears to be restricted to the myelomonocytic lineage and 
macrophages. MAFB plays a role in the proliferation of myelomonocytic progenitors, their 
differentiation into the monocytic lineage and in the prevention of erythroid differentiation 
118.  
This translocation seems to have a very poor prognosis in MM, although the information on its 
clinical associations is very limited. The prevalence of the translocation in MGUS/SMM has not 
been fully investigated 
46. 
 
1.6.5.2  Secondary Ig translocations 
Among the secondary translocations, approximately 10-20% in MGUS and MM do not involve 
one of the seven recurrent partners or MYC. The partner loci have rarely been identified and 
many of those have been found in single cases only. These IgH translocations share many 
similarities with MYC translocations with breakpoints outside or close to IgH switch or VDJ 
regions, the presence of unbalanced or complex structural rearrangements and a similar 
prevalence in HRD and nonHRD tumours. Introduction 
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1.6.5.2.1  MYC rearrangements 
The MYC transcription factor has been implicated in the control of many aspects of tumour cell 
biology. It promotes cell proliferation and restrains differentiation controlling the transcription 
of multiple genes involved in cell growth and metabolism, vasculogenesis, cell adhesion and 
genomic stability
141. MYC is a basic helix-loop-helix-leucine zipper transcription factor that 
dimerizes with the related protein MAX. MYC/MAX heterodimers bind to specific DNA 
elements, designated as E-boxes, located in the promoter regions of target genes mediating 
either activation or repression of transcription 
142. In MM, rearrangements that involve the MYC 
proto-oncogenes are thought to represent a very late event, occurring at the time when MM 
tumours are becoming less stromal-cell-dependent and more proliferative. These rearrangements 
have been reported to be rare or absent in MGUS/SMM, while they have been found in 15% of 
primary MM tumours, 44% of advanced tumours and nearly 90% of HMCL 
111. MYC, located at 
the chromosomal band 8q24.21, is the gene most frequently involved. However, 2% of primary 
tumours ectopically express N-MYC and an L-MYC translocation has been identified in one cell-
line (U-266 cell line, L-MYC, translocation and inversion). These rearrangements are usually 
complex translocations or insertions, sometimes involving three different chromosomes 
34,109,110 
and an Ig locus is involved in 25%-60% of cases 
89. Given the complexity and the multiple 
breakpoints identified in MYC rearrangements, FISH tests which only map some of the 
breakpoints, using relatively large bacterial artificial chromosome (BAC) probes cannot provide 
a full picture of MYC abnormalities. Therefore, survival analyses based on FISH results are not 
fully reliable. In support of this, Avet-Loiseau et al. found no difference in prognosis between 
patients with and without MYC abnormalities tested by FISH 
143. In contrast, an analysis of 596 
patients based on gene expression profiling showed that patients with N-MYC expression, or 
very high levels of MYC expression had a significantly poorer survival (unpublished data 
revised by Chng et al. 
89). 
 
1.6.6  Deletions of 17p13 
Deletions of 17p13 detected by iFISH have been found in ~10% of MM patients and 
approximately 40% of PCL and HMCL 
144,145. The abnormality occurs with a similar prevalence 
in HRD and nonHRD tumours and has been associated with a poor prognosis (on uni- and 
multivariate analysis) in different studies 
87,105,143. Despite the often small size of these deletions, 
there is no definitive evidence to prove which is the critical gene targeted by the abnormality. 
Certainly, TP53 is contained within the minimal deleted region reported by different groups and 
probes targeting this gene are the ones used to assess 17p status by iFISH. Almost all 17p13 Introduction 
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deletions are mono-allelic. Chng et al. performed mutational analysis of TP53 on 268 newly 
diagnosed MM patients and detected 3% of patients with mutations 
146. The spectrum of these 
mutations was broad and not typical of other malignancies, in fact two mutations were found in 
exons 4 and 11 which are rarely involved in mutations. The presence of TP53 mutations was 
significantly associated with the presence of TP53 deletions as five of the nine patients with 
mutation also had 17p13.1 hemizygous loss 
146. However, only five of 31 (16%) patients with 
17p13 deletion had mutation of the remaining TP53 allele. Also, the use of whole BM DNA 
may have resulted in a markedly reduced sensitivity of the study. In a smaller study (24 newly 
diagnosed MM patients) using CD138
+ PC, no TP53 mutations were detected, but it is unclear 
whether these samples also had 17p13 deletion 
147. Although current evidence does not exclude 
TP53 as the critical gene deleted on 17p13, more studies are needed. The p53 protein is a DNA 
binding protein, which acts as a tumour suppressor in response to DNA damage. It is part of the 
complex pathways which ensure the maintenance of the genome, allowing DNA repair or 
alternatively activating cellular apoptosis. The expression of p53 was found to correlate with 
17p13 status defined by FISH and low expression of p53 was an independent factor associated 
with poor prognosis 
147. The frequency of TP53 mutations appears to increase with disease stage 
and is about 3%-5% at MM diagnosis, 20%-40% in advanced MM or PCL and 65% in HMCL 
146,148-150. Deletions of TP53 in MGUS or SMM are rare 
46. 
 
1.6.7  Gain of chromosome 1q21 
Gain of the long arm of chromosome 1 (1q) is one of the most common genetic abnormalities in 
MM 
151. Although in most cases it is the whole arm that is gained, the band 1q21 seems to be 
consistently involved. The term ‘amplification’ has been widely used to indicate the presence of 
extra copies of this region without discriminating between amplification defined by >6 copies 
and low or high level gain (four-five copies). 
By cytogenetic analysis it was noted that extra copies of 1q resulted from a number of different 
chromosomal rearrangements, such as unbalanced translocations, duplications and triplications, 
isochromosomes and ‘jumping translocations’ involving all or part of the chromosome arm 
152. 
Gene expression profiling studies found elevated expression levels of genes mapping to 1q21 in 
cases with gain of this region 
151,153,154. Among the genes found to be over-expressed, MUC1 
(Mucin-1 Precursor), MCL1(Induced myeloid leukaemia cell differentiation protein ), PDZK1 
(PDZ domain containing 1), IL6R (Interleukin 6 receptor), BCL9 (B cell CLL/lymphoma 9), 
CKS1B (CDC28 protein kinase regulatory subunit 1B), PSMD4 (26S Proteaosomenon-ATPase 
regulatory subunit 4) and RAB25 (member RAS oncogene family) have been suggested as Introduction 
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possible targets of the abnormality 
155-158. Different studies focused on CKS1B as the targeted 
gene and CKS1B probes are usually used to assess 1q status by iFISH 
157,159. CKS1B is a 
member of the highly conserved CKS1 protein family that interacts with CDK, playing a critical 
role in cell cycle progression while regulating the proteolysis of CDKN1B (cyclin-dependent 
kinase inhibitor B). If CKS1B is responsible for increased proliferation, it might be expected 
that other mechanisms involved in the dysregulation of this gene would be found, such as 
translocations. However, there has been no evidence of other mechanisms. 
Gain of 1q21 is rare or absent in pre-malignant conditions and a few studies performed showed 
that when present in SMM it seems to be associated with progressive disease 
160-164. However, 
such findings were based on limited patient numbers and relatively short follow-up, therefore 
larger studies are needed in order to assess whether 1q gain is a reliable marker of disease 
progression in MGUS and SMM. 
 
1q abnormalities are found at a higher incidence in cases with dysregulated expression of c-
MAF or FGFR3/MMSET and those with a high proliferation expression index 
162. Hanamura 
and colleagues showed for the first time that 1q21 gain detected by FISH is a significant and 
independent poor prognostic factor 
162. However, another study from the Mayo Clinic showed 
that, while significantly associated with poor prognosis on univariate analysis, 1q21 gain was 
not an independent prognostic factor on multivariate analysis when PC labelling index and 
t(4;14) were included 
165. To confirm these findings, the French Intergroupe Francophone du 
Myelome (IFM) trials investigated 1q21 copy number by FISH on 365 patients and did not find 
1q gain to be an independent marker of adverse prognosis 
166. The same group recently 
published a single-nucleotide polymorphism (SNP) array study of 192 newly diagnosed and 
uniformly treated MM patients younger than 66 years. Using uni- and multivariate analysis, 
they found three independent markers of prognosis: two associated with a poor prognosis: 
1q23.3 gain and 12p13.31 loss; and one with a favourable prognosis: 5q31.3 gain. However, 
when these markers were adjusted to the established prognostic variables (i.e., t(4;14), loss of 
17p13, β2M), 1q gain lost its significance 
167.  Introduction 
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1.7  Gene expression profiling in PC disorders 
Different technological approaches have resulted in the ability to assess genomic aberrations at 
both the DNA and RNA levels in a global fashion. 
 
1.7.1  Use of gene expression profiling to classify MM 
1.7.1.1  Translocation and cyclin D (TC) classification 
Cyclin D genes are expressed at low levels in quiescent cells, while in response to growth 
factors they are transcriptionally up-regulated and expressed in all proliferating cells. Despite 
the very low proliferative activity observed in PC from MGUS/SMM and MM patients, the 
level of CCND1, CCND2 or CCND3 mRNA in all these tumours was found to be relatively 
high compared with the level of CCND2 mRNA expression in healthy proliferating PC 
168. This 
upregulation of Cyclin D genes is caused by either IgH translocations or other, unknown 
mechanisms.  
Gene expression profiling can detect the expression levels of CCND1, CCND2, and CCND3 and 
simultaneously identify spiked expression of genes deregulated by primary IgH translocations. 
Supervised analysis of gene expression profiles provided the basis for a molecular classification 
of MM: the translocation and cyclin D (TC) classification (Figure 1-8).  
Eight groups of tumours were identified: (1) 4p16 tumours (15%) expressing high levels of 
CCND2 and MMSET (and in most cases FGFR3) as a result of the translocation t(4;14); (2) 
MAF tumours (7%) expressing the highest levels of CCND2 and showing high levels of either 
c-MAF or MAFB, consistent with the possibility that both MAF transcription factors upregulate 
the expression of CCND2; (3) 11q13 (16%) and (4) 6p21 (3%) tumours expressing high levels 
of either CCND1 or CCND3 as a result of an IgH translocation; (5) D1 tumours (34%) 
ectopically expressing low to moderate levels of CCND1 despite the absence of a t(11;14) 
translocation; (6) D1+D2 (6%) expressing both CCND1 and CCND2. (7) D2 tumours (17%) 
were a mixture of tumours expressing CCND2; (8) none (1%) expressed no D-type cyclins. The 
TC classification did not clearly identify patients with HRD MM. HRD tumours were mainly 
found in the D1 and D1+D2 groups. D1 and D2 HRD MM appeared to have a higher incidence 
of proliferative disease compared to D1 HRD MM characterized by a low proliferative index. 
However, no differences in survival were noted between the two groups 
168. Introduction 
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Adapted from Bergsagel et al., 2005 
90 
 
Figure 1- 8  Translocation and cyclin D (TC) classification 
Dysregulation of one of the three cyclin D can be a consequence of an Ig translocations (solid 
arrow) or by an unknown mechanism (dashed arrow) 
 
1.7.1.2  UAMS (University of Arkansas for Medical Science) molecular 
classification of MM 
An alternative molecular classification was based on unsupervised clustering of tumours by 
gene expression profiling. This identified seven molecular groups, which were similar although 
not identical to the TC groups. These clusters identified tumours with t(4;14), MAF 
translocations, t(11;14) and t(6;14), corresponding to MS (MMSET), MF (MAF/MAFB) and 
CD (CCND) -1 or CD-2 groups, respectively. According to this classification, the t(11;14) and 
t(6;14) might belong to either the CD-1 or CD-2 group, depending on expression of CD20 and 
other B-related genes. In contrast to the TC classification, the UAMS identified HRD MM as a 
distinct HY (HYperdiploid) group. This group, however, included only about 60% of HRD 
tumours. The remaining HRD tumours were distributed between the other six groups. The PR 
(PRoliferation) group included MM with increased expression of proliferation-related genes, 
while the LB (Low Bone disease) group defined tumours with low bone disease and lower 
expression of genes associated with bone disease. 
The PR, MS, and MF groups identified patients with a poor prognosis. The PR group comprised 
patients with t(4;14), t(11;14) and HRD with more proliferative disease and an associated 
inferior outcome. Introduction 
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The advantage of the UAMS classification is its close clinical relevance. It is also interesting 
that an unsupervised analysis of gene expression profiling data essentially identified the main 
genetic subtypes of MM, suggesting that the predominant transcriptional heterogeneity seen in 
MM is driven by these pivotal primary genetic events 
124. 
 
1.7.2  Use of gene expression profiling to define a high-risk molecular 
signature 
Although many of the genetic and molecular lesions associated with disease initiation are 
known, those lesions that promote an aggressive clinical course among MM patients have 
remained unclear. Gene expression profiling has been used to define the molecular signature for 
high-risk disease. Shaughnessy and colleagues found 70 genes to be linked to early disease-
related death (51 up-regulated and 19 down-regulated) 
154. Interestingly, 30% of these genes 
mapped to chromosome 1, with the majority of those up-regulated mapping to 1q and the down-
regulated ones to 1p. The up-regulated genes were highly enriched for proliferation-related 
genes. Multivariate discriminant analysis revealed that a 17-gene subset (12 up-regulated) could 
predict outcome as efficiently as the 70-gene model. This 17-gene signature was validated in 
two additional datasets of newly diagnosed and relapsed patients. In both settings it was 
significantly associated with inferior outcome. It was also found that the presence of t(4;14) 
further dissected the high-risk group, with those having both t(4;14) and the high-risk 17-gene 
score displaying shorter survival. 
The IFM group also used gene expression profiling to identify a 15-gene signature defining a 
high-risk group of patients. This group was significantly associated with ∆13, deletion of 17p, 
gain of 1q and t(4;14). The IFM 15-gene model also improved the ISS prognostication 
169. 
 
1.7.3  Use of gene expression profiling to differentiate MGUS from 
MM 
Microarray studies have been applied to define global patterns of gene expression relevant to the 
biology of normal PC and PC from MGUS and MM patients. In initial studies, normal PC were 
differentiated from PC of MGUS and MM, but PC from MGUS could not be distinguished from 
PC from MM 
170. The main feature separating normal and malignant PC was the decreased level 
of expression of a large number of genes, while the list of up-regulated genes was more limited. Introduction 
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The similarity of the transcriptome between PC from MGUS patients and PC from MM was 
surprising, given the very different clinical behaviour of the two entities 
171.  
Using a third-generation microarray on a greater number of samples, Zhan et al. identified 52 
genes to be differentially expressed in PC of healthy individuals, those with MGUS and patients 
with MM. In contrast to previous reports, among the 52 genes, 41 exhibited a progressive 
increase in expression levels along the transition from normal PC to MGUS to MM, while only 
four genes exhibited a progressive reduction in expression. Among the MM patients, they 
detected a group of MM (MGUS-like MM) with more benign clinical features and longer 
survival who showed a gene expression signature similar to the one characterizing MGUS 
patients. However, the existence of an MGUS-like MM is still unclear as, when the MGUS 
signature was applied to an independent cohort of MM patients from the Mayo Clinic none of 
them expressed the signature (unpublished data revised by Chng et al. 
89); furthermore Zhan and 
colleagues did not specify how they excluded from their analysis the effect of contamination 
from non-malignant cells in cases with minimal plasmacytosis such as MGUS. Within the 
MGUS group no significant differences were noted, making it impossible to distinguish 
between cases more likely to progress and those which would remain completely stable 
172.  
As previously mentioned, more recent gene expression profiling studies have suggested that 
MYC activation, as the result of different mechanisms, might be a unifying pathological event in 
the transition from MGUS to MM 
173,174. 
 
1.8  Whole-genome approaches for the analysis of copy 
number changes 
The application of DNA probes to microarrays has emerged as a powerful technology in genetic 
studies. Microarray based comparative genomic hybridisation (CGH) enables the detection of 
copy number changes by competitively hybridising differentially labelled test and reference 
DNA to arrays of spotted and mapped clones. Thus, the technique allows the rapid screening of 
the whole genome at a resolution determined by the density of the markers spotted onto the 
array. This technique evolved from metaphase CGH 
175 with the replacement of metaphase 
chromosomes by spotted clones as the hybridisation target 
176,177.  
Different studies have used CGH, array CGH or SNP GeneChip mapping arrays to characterize 
MM patients, in order to find distinct biological patterns of genomic alterations 
155,178-182. The 
results have revealed a high level of molecular heterogeneity not previously appreciated. In the 
paper by Carrasco and colleagues, unsupervised clustering of array CGH results allowed the Introduction 
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identification of two distinct groups of HRD patients, while FISH can only define HRD as a 
single group 
178. These two groups displayed a significantly different event free survival (EFS) 
and minor differences in their OS. The group with improved survival was characterized by the 
presence of 11q gain and the absence of 1q gain and ∆13. This classification was further 
confirmed by gene expression profiling of the same patients, analysed with gene set enrichment 
analysis of the transcriptomes, which revealed perturbation of distinct cancer-relevant pathways 
in each subclass. While TP53 and K-RAS were altered in both subgroups, dysregulation of 
additional cancer-relevant pathways was observed in only one group. Particular attention was 
given to homozygously deleted and amplified chromosomal regions because they were more 
likely to involve those genes critical to the pathogenesis of the disease.  
 
Two different studies using array CGH found a number of abnormalities involving genes coding 
for proteins belonging to the NF-κB pathway, confirming the presence of heterogeneous genetic 
abnormalities leading to the dysregulation of a common pathway 
181,182.  
Few studies have been performed on MGUS or SMM, the main reason being the limited 
number of PC that can be isolated from BM samples of these patients. One study used CGH on 
MGUS and MM patients and identified loss of 6q and gains of 3p and 1p to be associated with 
progression from MGUS to MM 
183.  
 
1.9  Aims of the study 
A review of the literature, as presented in the preceding sections, shows that multiple and 
complex chromosomal and genetic abnormalities characterize PC of MGUS, SMM, MM and 
PCL patients. Some of these abnormalities are thought to be important in disease initiation 
while others seem to be responsible for disease progression. With the recent recognition that 
essentially all MM cases have a pre-existing asymptomatic phase, it becomes even more 
important to recognize those abnormalities that are associated with progression. The 
identification of these markers may allow for early detection of high-risk patients and for the 
development of primary prevention strategies in the future. 
A number of disease models have been generated. These models attempted to correlate the 
multistep process of transformation from a normal PC to MGUS to MM to PCL with the 
progressive acquisition of genetic abnormalities. However, because karyotypes are almost 
impossible to obtain at the MGUS/SMM stage, most of our understanding of this process is 
derived from iFISH studies focused on relatively few, specific loci reported to be frequently 
abnormal in MM. From these studies, alterations found to be rare or absent in MGUS/SMM Introduction 
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were thought to be associated with disease progression while changes found with a similar 
frequency at all stages were thought to be initiating events. 
 
The specific aim of this project is to identify molecular cytogenetic markers responsible for 
disease evolution from MGUS and SMM to MM and PCL. The study will initially focus on the 
genetic characterization of MGUS, SMM, MM and PCL using an extended panel of iFISH tests 
specific for baseline chromosomal abnormalities performed on large groups of patients with 
these diagnoses (also at the time of disease progression, whenever possible). This part of the 
study is intended to clarify the time of appearance of individual abnormalities and to identify 
whether specific changes are associated with evolving disease. Towards this aim, the 
availability of a detailed clinical history of the patients tested will be crucial for the 
interpretation of the findings.  
The second phase of the study will involve the assembly of a comprehensive genome-wide 
profile of regional gains and losses in MGUS, SMM, MM and PCL in order to identify 
candidate loci relevant to genesis and progression. For this purpose high-density oligonucleotide 
array CGH will be undertaken. As it has been hypothesized that distinct mechanisms might be 
responsible for disease progression depending on the nature of the primary initiating events (i.e. 
presence/type of IgH translocations), all the patients selected for array analysis will be 
previously tested by FISH for the baseline genetic abnormalities. The array CGH data will then 
be correlated with the patients’ clinical annotations. The incidence and clinical relevance of 
potential candidate genes or chromosomal regions, identified by array, will be validated by 
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2.1  Patient samples 
This study includes diagnostic BM samples from patients sent to the Leukaemia Research Fund 
UK Myeloma Forum Cytogenetic Database at the Wessex Regional Genetics Laboratory 
(WRGL) with a known or suspected diagnosis of a monoclonal gammopathy; samples were sent 
from more than 30 different centres throughout the UK with informed consent for 
cytogenetic/FISH analysis. The diagnoses included: MGUS, SMM, MM and PCL; patients were 
classified according to standard criteria 
35,184,185 and patients with MGUS or SMM were required 
to have no evidence of organ damage indicative of MM.  
Almost half of the MM samples received were from patients entered into the Medical Research 
Council (MRC) Myeloma IX Trial. This Trial, whose main purpose was to investigate the 
impact of thalidomide, was structured into two main treatment pathways: intensive for 
younger/fitter patients and non-intensive for those older and less fit. Non-trial MM patients 
were treated with a number of different therapies. However, almost all of them received 
thalidomide at one point of their treatment. 
As previously mentioned, most of the BM samples from patients with PC neoplasms (excluding 
PCL) are characterized by a low degree of plasmocytosis which hampers the interpretation of 
FISH and array CGH results. For this reason, PC were routinely purified in order to perform the 
various analyses on highly enriched material; for those samples where the proportion of PC, 
assessed at the beginning of the process, was greater than 50%, purification was not carried out. 
A poor PC recovery almost always limited the experiments to a minimum number of FISH tests 
(presence of ∆13, any IgH rearrangement, 17p13.1 deletion (TP53) and ploidy status).  
 
Reagents marked with an asterix are described in Appendix 2. 
 
2.2  Processing of BM samples 
2.2.1  Cell count 
The number of cells in the BM samples was counted at the beginning of the process. 
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2.2.1.1  Automatic count 
The count was performed on 0.25ml of BM, using the Sysmex cell counter according to the 
machine instructions. 
 
2.2.1.2  Manual count 
A manual count was performed on very particulate samples, because of the risk of blocking the 
Sysmex counter.  
 
1.  A same amount of cell suspension and Zap-o-globin* (Beckman Coulter, UK) were mixed; 
the appropriate quantity was placed under a haemocytometer (BDH, UK) coverslip.  
2.  At least 100 cells were counted from the central square (defined by 3 perimeter lines). If 
more than 250 cells were counted in the top row, the specimen needed to be diluted 
appropriately. The number of cells in the central square was then multiplied by two, to allow 
for the dilution with Zap-o-globin and by 10
4 to give the number of cells/ml.  
 
2.2.2  Red cell lysis 
If the sample had a high red blood count, red cell lysis (RCL) was conducted.   
     
1.  The sample was spun at 1500 rpm for 10 minutes (min) and the supernatant was removed; 
a volume of pre-warmed RCL buffer* (37˚C) equal to 10-15 times the volume of the cell 
pellet was added, and the tube incubated for 10 min at 37ºC. 
2.  The tube was spun at 1400 rpm for 10 min and the supernatant was carefully removed. 
PC collect at the interface just above the white cell pellet, so it was important to retain 
this layer. After adding 5-10ml of wash medium*, the cell suspension was spun at 1400 
rpm for 10 min and resuspended in 6ml of wash medium. 
 
2.2.3  Lymphoprep method 
Density gradient centrifugation was carried out on all samples after their count (or after RCL, if 
performed). This procedure separates the red cells and neutrophils from the remainder of the     Materials and Methods 
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mononuclear cells, removing cells incapable of dividing and increasing the mitotic index; it also 
improves the quality of the mitoses by removing the neutrophil granules from the cultures.  
No more than 5x10
7 cells were usually placed in any one tube. 
 
1.  After transferring 3ml Lymphoprep (Nycomed, UK) into an appropriate tube, 6ml of 
marrow resuspended in wash medium was gently layered on the top and spun at 2000 rpm 
for 20 min without breaking (red cells, because enucleated, have the greatest density and fall 
to the bottom of the tube; mononucleated cells remain suspended in a layer between the 
lymphoprep and the plasma). 
2.  The interface and the wash medium above it were carefully transferred into a new tube. 
When particles were present, they were transferred into a separate bijou, mixed with ~1ml of 
wash medium and disaggregated using a 2ml syringe with a blunt-end needle; these smaller 
particles were then added to the remainder of the cells from the interface. 
3.  The recovered cells were washed twice with 10ml of wash medium and the final cell pellet 
was resuspended in 5ml of medium. 
 
2.2.4  Assessment of the PC percentage 
The separated sample was counted for the second time. On average, half of the total number of 
white cells was lost.  
 
1.  A statspin slide was made with 4x10
4 cells using a cytofuge machine. The cells, 
resuspended in 200µl of wash medium, were concentrated into a 13mm spot on an X-tra 
slide (Surgipath, UK) coated on one side to allow the cells to stick; the medium was dried 
onto a filter paper placed on the top of the slide. The cytofuge was set for 6 min at 7000 
rpm. 
2.  The slide was left to dry, and then stained with Leishman’s stain (Sigma-Aldrich, UK): 
1ml stain was dropped onto the slide and left for 1.5 min; then 2ml of Sorensen’s 
phosphate buffer (Mercia Diagnostics, UK) was added for further 1.5 min. The slide was 
then rinsed with buffer and dried.  
3.  At least 300 cells were counted under the microscope in order to assess the PC percentage 
and the proportion of PC in the sample. Based on the total cell count and the PC 
percentage, it was decided whether there were enough cells for cytogenetic analysis 
and/or purification. Priority was given to the purification because purified cells can be 
used for techniques which don’t rely on the capacity of the PC to divide in vitro.     Materials and Methods 
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Therefore, purification was carried out on almost all the samples, while only a proportion 
of them was set up for chromosomal analysis. The estimated 50% PC recovery after 
purification was then calculated. If the recovery was greater then 5x10
5 cells, cultures for 
cytogenetic analysis were also set up.
  If the PC percentage was <20%, a 3DIS (3 day 
culture with IL-6; the letter ‘S’ indicates separated sample) and a 6 day (6DIS) cultures 
were set up; if the PC percentage was >20%, a 24 hour syncronized culture with IL-6 
(F1IS) was also set up.  
 
2.2.5  PC purification with CD138
+ magnetic micro-beads (Miltenyi 
Biotec, CA, USA) 
CD138 or syndecan-1 is a cell surface glycoprotein constitutively expressed by epithelial cells 
and human PC, either normal or malignant. The protein is therefore a good marker for the 
identification and isolation of PC from BM samples. Magnetic microbeads are conjugated with 
a monoclonal antiboby specific for CD138 to which cells bind; when cells are passed through a 
magnetic column, the PC conjugated to the beads are retained, while the non-PC fraction is 
eluted. Limitations of this strategy are: (i) the method does not distinguish between normal and 
tumour PC; (ii) in a very small percentage of cases, PC subpopulations may be negative for the 
surface marker (i.e. its expression is lost on PC which undergo apoptosis) and therefore eluted 
with the non-PC fraction. However, the positive sort fraction is usually highly representative of 
the clone.  
For each purification, no more than 2x10
8 cells could be process through each individual column 
if the PC percentage was <50%; 1x10
8 if the PC percentage was >50%.  
All solutions were maintained at low temperature.  
 
1.  Cells were centrifuged at 1400 rpm for 10 min; the supernatant was removed completely 
and the tube was flicked to resuspend the pellet in phosphate buffered saline
+ (PBS
+) 
buffer* (ice-cold and de-gassed throughout the entire process). The volume of PBS
+ used 
was 80µl for every 10
7 cells if the PC percentage was <25%; 60µl for every 10
7 cells if 
PC percentage was >25% (if the PBS
+ volume was >900µl, it was evenly divided 
between two or more tubes). 
2.  The MACS CD138 microbeads were then added (bead volume = 20µl for every 10
7 cells, 
if PC percentage <25%, 40µl for every 10
7 cells, if PC percentage >25%; minimum 
volume=10µl). After gentle mixing, the tube was incubated at 4˚C for 15 min.     Materials and Methods 
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3.  A volume of PBS
+, 10 to 15 times the volume of the cellular suspension, was added and 
the tube was spun at 1400 rpm for 10 min. After completely removing the supernatant, 
the pellet was resuspended in PBS
+ (100µl for every 10
7 cells). 
4.  After washing the column in the magnetic field with 3ml PBS
+, the cells were applied to 
the column and washed three times with 3ml PBS
+ in order to elute the non-PC fraction. 
PC were eluted with 5ml PBS
+ in the absence of the magnetic field.  
5.  The tube was centrifuged at 1400 rpm for 10 min and the pellet resuspended in 1-2ml of 
wash medium; a new count was performed and a new statspin was made with 1x10
4 cells; 
the final PC percentage was then calculated. 
6.  The allocation of the PC depended on both the purity and total cell number as shown in 
Table 2-1. 
 
Number of cells recovered 
after purification, % PC 









 PC%: 0%-80%  Fixed cells for FISH (~1x10
6)





  PC%: 80%-100%  Fixed cells for FISH (1x10
6), dry pellet for DNA 
extraction, Trizol pellet for RNA extraction 
 
          Table 2- 1  Use of the isolated PC based on their number and purity 
 
7.  PC selected for FISH analysis were spun for 10 min at 1400 rpm and, after removing the 
supernatant, incubated for 10 min at 37˚C with 5ml of warm hypotonic solution*. PC 
were then spun for 10 min at 1400 rpm and, after removing the hypotonic, 5ml of 
Carnoy’s fixative* was added dropwise until the cells were fully resuspended; PC were 
then kept at -20˚C. Fixed PC stored at -20˚C were primarily used for iFISH. For a number 
of samples, where no PC were stored as a dry pellet for DNA extraction, fixed cells were 
used to extract DNA for array CGH. 
8.  For dry pellets, PC were placed in a screw cap eppendorf and centrifuged in a microfuge 
for 12 min at 3000 rpm. The supernatant was removed carefully. Dry pellets for DNA 
extraction were stored at -80˚C. 
9.  For RNA extraction, every 1x10
6 cells were resuspended in 200µl Trizol (Invitrogen, 
UK) by pipetting up and down, under a ventilated hood. The tube was left at room 
temperature for 10 min and then transferred to -80°C.  
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2.3  Metaphase analysis 
2.3.1  Cytogenetic cultures of fresh BM samples 
RPMI-1640 medium, developed at the Roswell Park Memorial Institute (hence the acronym 
RPMI), is used as a basal medium for culturing BM samples. Such medium is a buffered salt 
solution containing amino acids, sugars, polysaccharides and nutrients. Basal medium alone 
cannot support optimal cell growth. Fetal calf serum (FCS) made up to 5-30% of the complete 
medium contains proteins including growth factors essential for cellular proliferation. It also 
helps to maintain an optimum pH (7.2-7.4). L-Glutamine provides an essential amino acid.  
IL-6 is a cytokine which encourages the proliferation of PC within the marrow; in vivo it is 
released by the stromal cells 
17,186. IL-6* (First Link, UK) was added to cytogenetic cultures to 
promote PC division in vitro.  
 
All culturing was carried out in a laminar flow hood using aseptic techniques. A standard 
culture was made of ~5x10
6 cells
 per 5ml of RPMI culture medium*. However cultures of 
smaller samples, for example of 2.5x10
6 cells, were regularly set up with 1ml of medium per 
1x10
6 cells (this being considered the optimum cell density for BM culture). Cultures were set 
up in Nunclon polystyrene flat-sided tubes (Scientific Laboratory Supplies Ltd, UK) which 
provide a larger surface area for the cells to grow. Cells were incubated at 37˚C for 24 hours, 3 
or 6 days; only the 24 hour cultures were synchronized.  
Cell division can be blocked at various points in the cell cycle and subsequently released at a 
controlled time, producing synchronization of cell division. This enables colcemid exposure to 
be greatly reduced, consequently producing longer chromosomes. Fluorodeoxyuridine* (FdU; 
Sigma-Aldrich, UK) is an effective blocking agent as it integrates into the DNA and blocks 
DNA synthesis. Uridine* (Sigma-Aldrich, UK) is added at the same time to prevent blockage of 
RNA synthesis. Release of the block is achieved by adding excess thymidine* (Sigma-Aldrich, 
UK). Optimal harvest time for BM samples is about 6 hours after release. 
 
1.  0.05ml FdU and 0.05ml uridine were added to cultures between 2 and 6pm on the day 
prior to the one of the harvest; cultures were then returned to 37
oC. 
2.  At 9am of the following day, 0.05ml thymidine was added to each culture; cultures were 
returned to the incubator for 5 hours and 45 min before starting the standard harvest 
procedure. 
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2.3.2  Tissue cultures from cryopreserved cells 
Tissue culturing is a technique to promote the in vitro proliferation of animal cells in a nutrient 
medium for extended periods of time. It provides an inexhaustible supply of heterogeneous 
material such as DNA, RNA and proteins and the cells can easily be manipulated, i.e. by adding 
drugs to the media. 
 
1.  RPMI-1640 culture medium, supplemented with filtered FCS (20%), L-glutamine and 
penicillin/streptomycin, was warmed to 37˚C. 
2.  Liquid nitrogen stored cell pellet was defrosted at room temperature and 5ml medium was 
added (the first 3ml dropwise). The cell suspension was then transferred to a 15ml Falcon 
tube which was spun for 5 min at 4000 rpm. 
3.  After being washed twice, the pellet was resuspended in 10ml of fresh medium, which 
was transferred to a 10ml tissue culture flask. The flask was placed, with the lid loosely 
fastened, in the incubator at 37˚C with CO2 levels at 5%.  
4.  According to the specific requirements of different cell lines, cells were supplemented 
with appropriate volumes of fresh medium at approximately 3 day intervals. The cell 
cultures were split and transferred into larger flasks as the volume increased. Cells were 
counted manually with Zap-o-globin, while trypan blue (Sigma-Aldrich, UK) was used to 
differentiate live from dead cells. Trypan blue is a negatively charged chromopore which 
interacts with damaged cell membranes: viable cells will exclude the dye while dead cells 
are stained blue.  
5.  Cultured cells were harvested to obtain metaphases for conventional analysis, and/or 
processed for DNA extraction. 
6.  For long term storage of cell pellets, cells were counted and resuspended in a universal 
container (Sterilin Ltd., UK) in complete medium at a concentration of 2–6x10
7/ml. 
7.  In a separate universal container, the cryopreserving solution was prepared: complete 
medium (20%), FCS (60%), dimethyl-sulfoxide (DMSO, Koch Light Ltd., UK) (20%). 
DMSO is an organic solvent that maintains the cells intact as they freeze. 
8.  Both containers were placed in the refrigerator for approximately 30 min. During this 
interval, 2ml plastic ampoules, screw top, for liquid nitrogen (Sterilin Ltd., UK) were 
labelled and placed in a rubber rack, which was then stored at -20˚C, until required. 
9.  The containers were removed from the refrigerator and put into an ice bath. The 
cryopreserving solution was added dropwise unto the container with the cell suspension 
which was agitated continuously. 
10.  The mixture of cell suspension and cryopreserving solution was aliquoted into the pre-
cooled plastic ampoules which were then tightly capped and slowly cooled: 40 min at -    Materials and Methods 
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20˚C inside the rubber rack; 30 min at -80˚C inside the rubber rack; overnight at -80˚C 
inside metal-trays; -180˚C in liquid nitrogen. 
 
2.3.3  Harvesting 
1.  15 min before the end of the culture period, 0.05ml of colcemid* (Sigma-Aldrich, UK) 
was added to each culture; cultures were then returned to the incubator for 15 min. 
Colcemid is a colchicine-analogue which inhibits the formation of the mitotic spindle. 
The mitotic index is proportional to the length of exposure to colcemid. However, 
prolonged exposures result in condensed chromosomes. 
2.  The cultures were centrifuged for 5 min at 1600 rpm. After removing the supernatant, the 
cells were resuspended in 6ml of hypotonic solution* at 37
oC. The hypotonic solution has 
a lower salt concentration than the cell cytoplasm, allowing water to move into the cell by 
osmosis. This swells the cells and is critical for adequate spreading of the chromosomes 
on the slide. Timing is crucial, as too long an exposure will cause the cells to burst, while 
too short an exposure will not swell the cells sufficiently, resulting in poor spreading. 
3.  The tubes were then spun for 5 min at 1600 rpm and the supernatant was removed; after 
flicking the tube to disaggregate the pellet, 5ml of Carnoy’s fixative was added with the 
first ml in a dropwise manner, while flicking the tube. Fixation kills the cells and 
preserves chromosomal morphology while removing nuclear and cytoplasmic proteins. 
Methanol fixes the chromosomes by replacing the water; acetic acid softens the cell 
membrane. 
4.  6ml fixative was added to each tube; the tubes were stored at –20
oC for a minimum of 1 
hour, but usually overnight. 
 
2.3.4  Slide preparation for metaphase analysis 
During slide preparation, the fixed cells are dropped onto glass slides for subsequent staining 
and analysis. In optimal preparations for cytogenetic analysis, metaphases must be well spread 
without any random chromosomal loss and with minimal overlapping of the chromosomes. 
 
1.  The fixed suspensions were removed from the freezer and spun at 1400 rpm for 10 min; 
the supernatant was removed and the pellet resuspended in fresh fixative; this stage was 
repeated four times. The pellet was then resuspended into a small quantity of fixative, to     Materials and Methods 
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provide the optimum cell density for slide making. The fixed cell suspension was usually 
dropped on dry slides at room temperature and slides were checked with a phase contrast 
microscope for metaphase quality and number. 
2.  Slides were aged by placing them in a 60
oC oven for 1 hour in order to enhance 
chromosome banding. 
 
2.3.5  Banding 
In this study, chromosome preparations were stained using the Giemsa banding (G-banding) 
method. These banding patterns are thought to reflect both the structural and functional 
composition of the chromosomes. Dark bands replicate their DNA late in S-phase, contain A+T-
rich DNA, appear to include relatively few active genes and may differ from light bands in 
protein composition. 
 
1.  After being aged under a UV source for 30 seconds, slides were treated with H2O2 for 1 
min and 30 seconds, washed under tap water and shaken to dry. 
2.  3ml Wright’s buffer* (Mercia Diagnostics, UK) and 1ml Wright’s stain* (Sigma-Aldrich, 
UK) were mixed rapidly and used to treat the slides for 2 - 5 min. 
3.  The slides were rinsed in gently running tap water for 5 seconds and shaken to dry. The 
quality of the banding was examined under a dry lens; the staining was adjusted if 
necessary by rinsing again or destaining in methanol and restaining for a shorter time.  
 
2.3.6  Cytogenetic analysis 
Slides were analyzed under a bright-field microscope. As in PC disorders the detection of an 
abnormal clone is rare, the analysis was carried out on 1 to 200 metaphases, depending on the 
cell availability.  
A clone is defined as a cell population derived from a single progenitor. The general rule in 
tumour cytogenetics is that only the clonal chromosomal abnormalities found in a tumour 
should be reported 
187. This means two or more cells having the same structural abnormality, or 
having gained the same chromosome; if the abnormality is loss of chromosome, the same 
change must be present in at least three cells to be accepted as clonal. In this study a single 
abnormal metaphase with typical myeloma abnormalities was considered to be representative of     Materials and Methods 
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the abnormal clone when supported by the iFISH results. Karyotypes were described using the 
International System for Human Cytogenetic Nomenclature (ISCN) 
187. 
 
2.4  Fluorescence in situ hybridization (FISH) analysis 
As discussed in Section 1.6.1, chromosomal analysis in cancer cytogenetics is sometimes 
hampered by failure in culture, paucity or complete absence of abnormal metaphases and by the 
presence of cryptic abnormalities not visible under the microscope. As FISH is applicable to 
non-dividing cells, it overcame many of the limitations intrinsic to conventional cytogenetics.  
The principle of FISH is the hybridization of a fluorochrome-labelled DNA ‘probe’ with a 
complementary target DNA sequence in nuclei, tissue sections or metaphase spreads. 
Radioactive isotopic labels were used initially, but were later replaced with fluorochromes, 
rendering the technique safer and easier to use 
188-190. Fluorochromes can be used to label the 
DNA directly; alternatively, the DNA can be labelled indirectly with haptens (digoxigenin and 
biotin are widely used) which are then detected by antibodies (anti-digoxigenin to detect 
digoxigenin and avidin for detection of biotin) conjugated to fluorochromes. The availability of 
a range of fluorochromes of different colours also gave the possibility of testing more than one 
probe simultaneously. 
In this study, FISH analysis was performed on interphase cells (usually purified PC) and on 
metaphases from cytogenetic cultures.  
 
2.4.1  Slide preparation for metaphase analysis 
Slides with visible metaphases were first stained for G-banding analysis. After capturing the 
metaphases and recording the coordinates of their specific locations, the slides were then 
distained (10 min in Carnoy’s fixative) and used for FISH analysis. 
 
2.4.2  Slide preparation for interphase FISH 
In order to maximize the number of tests for each sample, Dr. A. Vilain-Holmes developed a 
simple yet effective micro-technique in this laboratory that allowed multiple FISH tests to be     Materials and Methods 
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carried out even when as few as 2x10
5 PC were recovered. This technique permitted the analysis 
of eight different patients on the same slide 
191.  
Slides were prepared in a temperature and humidity controlled ‘harvester’ room. 
   
1.  Fixed suspensions of purified PC were stored at -20˚C for at least 16 hours before being 
centrifuged for 10 min at 1400 rpm and resuspended in fresh fixative for slide making. 
The cell density was adjusted to approximately 2500 cell/µl by making a trial 0.2µl spot 
and concentrating or diluting as necessary.  
2.  While adjusting the PC density, prewashed slides (stored in fixative at -20˚C overnight) 
were removed from the fixative and left to drain. 
3.  The slide was positioned on a template (Figure 2-1) indicating the exact position of nine 
spots located under a 22x22 mm coverslip. The nine spots corresponded to eight patients 
and one control (PC from normal bone marrow donors or peripheral blood lymphocytes). 
4.  0.2µl spots containing 100-500 cells were placed on the slide. This cell density ensured 
wide separation between each spot, preventing cross contamination.  
5.  Slides were checked under a phase contrast microscope. If the density was too low, 
multiple ejections were done onto the same spot, allowing each time the slide to dry 
before adding new cells. 
6.  When the slides were fully dry, they were washed with fixative and left at room 
temperature for several hours; they were then stored vertically at -20˚C, until required.
         
 
Figure 2- 1  Nine spot template for iFISH slides 
 
2.4.3  Probes 
The probes used in this study were commercial probes from Vysis (Abbott Diagnostic, UK) and 
those grown and labelled in the laboratory. 
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2.4.3.1  The Human Genome Project: resources for molecular cytogenetics 
The hierarchical shotgun sequencing approach adopted by the International Human Genome 
Sequencing Consortium involved in initially fragmenting the genome into large segments which 
were subsequently cloned into various types of vectors for downstream applications. Different 
cloning vectors have been developed for cloning different DNA inserts. Cosmids were one of 
the first types of vectors available which are suitable to clone inserts of up to 45 kb 
192. 
However, the resulting clones may become unstable, with loss of inserts during replication. 
Yeast artificial chromosomes (YAC) 
193 can support inserts of up to 1 Mb. However, YAC 
clones are difficult to construct and tend to undergo rearrangements leading to chimaerism. P1-
derived artificial chromosomes (PAC; artificial chromosome based on bacteriophage P1), 
bacterial artificial chromosomes (BAC; artificial chromosome based on E.coli F factor) and 
fosmids (plasmid-phage hybrid based on E.coli F factor) are more efficient vectors. The average 
insert size cloned into a PAC is 120 kb and the resulting clones proved easy to purify. They 
presented low or non existent chimaerism and insert instability 
194. These same advantages were 
shared by BAC, which accept an insert with an average size of 170 kb 
195 and fosmids, with an 
average insert size of 40 kb 
196. As a result of these developments, libraries of BAC, PAC and 
fosmids covering the entire human genome have been created. These individual clones can be 
utilised as DNA probes for FISH studies. 
However, the major contribution of the Human Genome Project has been the assembly of the 
sequence of the human genome and the mapping and identification of human genes. These have 
been deposited in publicly available databases and can be accessed via human genome 
browsers. Ensembl, hosted by the Welcome Trust Sanger Institute, and the University of 
California Santa Cruz (UCSC) browser, are two of the main browsers available (URL in 
Appendix 1). These browsers integrate sequence data from the reference human genome and 
provide annotation for known and predicted genes alongside numerous other features, e.g. 
expression data, comparative genomics, human variation and repeat elements. They are 
invaluable data for the study of chromosome rearrangements. 
In this study, home-made BAC/PAC clones mapping in the regions of interest were selected 
mainly from the Ensembl browser. Fosmid clones were used to detect deletions that array CGH 
results showed to be too small to be detected by BAC/PAC clones. They were selected from the 
UCSC browser and provided by the Children’s Hospital Oakland Research Institute (CHORI, 
Oakland, California, USA; see URL in Appendix 1). BAC/PAC clones from the Ensembl clone 
sets were grown from glycerol stocks stored at the WRGL, which were originally kindly 
provided by the Welcome Trust Sanger Institute. The probe mapping of the RB1 gene was 
kindly supplied by Prof. Mariano Rocchi from the Department of Genetics and Microbiology, 
University of Bari. Details of all probes used in this study are listed in Appendix 3.     Materials and Methods 
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2.4.3.2  Processing of in-house probes 
2.4.3.2.1  Growing the probes 
Bacteria were grown in Luria-Bertani (LB) broth* (Gibco, UK) overnight, prior to DNA 
extraction.  
 
1.  Bacteria were inoculated into 30ml of fresh LB broth in a sterile 30ml cell culture flask 
with the appropriate antibiotic*; the flask was incubated overnight at 37˚C with vigorous 
shaking (i.e. a 37˚C shaking incubator at ~220 rpm). 
2.  The freshly grown culture was used to inoculate LB agar (Dibco, UK) plates*. The 
culture was spread over the plate with an inoculation loop gradually reducing the 
concentration of the culture to obtain well spread colonies. The plate was incubated 
overnight at 37˚C.  
3.  Individual colonies were isolated and used to inoculate fresh LB broth of 30ml or 100ml 
with the appropriate antibiotic to obtain a purified colony culture. Thus culture was 
placed overnight in a 37ºC shaking incubator.  
4.  The culture was decanted into 30 ml centrifugation tubes and spun at 4ºC for 10 min at 
3000rpm. The pellet was stored at -20ºC until required. 
 
2.4.3.2.2  Extraction protocol (Rapid Alkaline Lysis) 
1.  1.5ml eppendorf tubes were filled with 800µl ice-cold isopropanol (Sigma-Aldrich, UK) 
and stored at -20˚C until required. 
2.  1.8ml P1 solution* was added to each 30ml pellet and the tubes were vortexed thoroughly 
to resuspend. Suspensions were then transferred to new centrifuge tubes. 
3.  1.8ml P2 solution* was added to each tube and tubes were gently shaken and left at room 
temperature for 5 min (the suspension changed from very turbid to almost translucent). 
4.  1.8ml P3 solution* was slowly added and the suspension was gently shaken. The tubes 
were placed on ice for 5 min (a thick white precipitate formed). 
5.  The tubes were spun at 10,000 rpm for 10 min (4˚C); the supernatant was transferred 
(avoiding the white precipitate) to the pre-prepared eppendorf tubes containing 800µl ice-
cold isopropanol (Sigma-Aldrich, UK). 
6.  The tubes were left overnight at -20ºC (or for a minimum of 2 hours at -70ºC) and then 
spun at 14,000 rpm for 15 min. After discarding the supernatant, the pellets were washed 
twice with 500µl of 70% ethanol (BDH, UK).     Materials and Methods 
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7.  After removing the ethanol, pellets were dried in a centrifuge dryer and after they turned 
from white to translucent in appearance (most of the ethanol had evaporated), they were 
resupended in 10µl TE* (Tris-EDTA) and left at room temperature overnight. 
 
2.4.3.2.3  DNA quantification  
DNA was then quantified using a Dyna Quant 200 Fluorometer (Hoefer Scientific Instruments, 
UK) which measures the amounts of DNA bound to a DNA-specific dye, compared with known 
standards. 
 
1.  For the Standard Assay*, the reference standard was prepared as follows: 10ml 10x TNE 
buffer*, 90ml dH20 and 10µl Hoechst Buffer (Hoefer Scientific Instruments, UK). 
2.  2ml Assay solution was transferred into the G cuvette (assay blank). 
3.  2µl of the appropriate DNA reference standard (i.e. low range calf thymus DNA, 1 
mg/ml) (Pharmacia Biotec, UK) was added to the 2ml assay solution. After calibration, 
2ml of fresh Standard Assay were dispensed into a clean cuvette and placed in the well; 
2µl of test sample were added to the Assay.   
 
2.4.3.2.4  Agarose gel electrophoresis 
Gel electrophoresis allows separation of DNA molecules by differential migration through the 
agarose according to their size. It was routinely used to assess the size and quantity of DNA. 
The agarose gel is a semi-permeable gel; if placed in a tank of buffer, it provides the ions to 
carry a current. DNA has a negative charge imparted by the phosphate backbone, therefore 
when applied at the cathode it migrates through the gel toward the anode. The smaller molecules 
are able to move more quickly through the polymer than the larger molecules. Ethidium 
bromide is added to the gel to visualise the DNA, as the positively charged ethidium ion 
intercalates between the bases of the DNA and fluoresces under ultra violet (UV) light. 
 
1.  Agarose gels used in this study ranged from 0.8%* to 3% agarose, and were prepared by 
dissolving the agarose (Bioline, UK) in 1x tris-borate (TBE) Buffer*. The gel was 
prepared by heating the suspension in a microwave for 1 min and 35 seconds twice, until 
the agarose had dissolved; the solution was cooled under running tap water until reaching 
~50˚C. 0.4µg/ml ethidium bromide (Sigma-Aldrich, UK) was added. 
2.  The solution was poured into a tank with an appropriately sized comb and left for 30 min 
to set. When solid, the gel was transferred to the tank, which was then filled with 1x TBE.      Materials and Methods 
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Although 1.5% gels were used most often, smaller polymerase chain reaction (PCR) products 
were resolved on 2% to 3% gels. Typically, 5 to 10µl of a PCR reaction was mixed with 2µl of 
6x loading buffer* before loading onto the gel, as this makes the PCR solution more visible and 
sink into the well. Gels were run at 80V for approximately 30 min, and viewed over a UV 
transilluminator. A 1 kb plus Ladder (100bp to 12 kb, Invitrogen, UK) was run alongside 
samples. 
 
2.4.3.2.5  Restriction digestion 
Running a restriction digest is a good indicator of the purity of the DNA: if it fails to cut on a 
restriction digest the probe should be re-purified. Restriction enzymes recognise specific 
nucleotide sequences that are usually 4bp to 8bp long; they then cleave the DNA at these sites. 
Eco RI with Buffer H, Bam HI or Hind III with Buffer B (Roche, UK) were used to obtain a 
digestion picture. 
 
1.  A total of 20µl reaction was prepared: 2µl enzyme (enzyme concentration: 10 units (U)/ 
µl; one U of enzyme is defined as the amount required to digest 1µg of wild-type 
bacteriophage DNA in 1 hour), 5µl DNA (~ 500-1000ng), 2µl of appropriate Buffer, 1µl 
Spermidine and 10µl dH2O. The reaction was vortex gently, pulsed (<4000 rpm) and 
incubated at 37˚C for 1 hour.  
2.  The digested sample was then loaded on the gel; 18µl dH2O was mixed with 2µl lambda 
HindIII marker (Invitrogen, UK) in the track adjacent to the cut DNA as a size marker. 
The gel was run at 112V for ~ 1 hour and then placed on the UV transilluminator to 
observe the restriction pattern.  
 
2.4.3.2.6  Direct labelling of DNA probes - Nick translation 
The purified DNA is labelled by using a suitable enzyme to incorporate labelled nucleotides. 
Nick translation was the labelling method used for labelling FISH probes. This procedure 
involves the random nicking of single-strand DNA by DNase I generating a 5' phosphate group 
and a 3' hydroxyl terminus. The Kornberg DNA polymerase I holoenzyme contributes two 
enzyme activities: (i) a 5'￿3' exonuclease attacks the exposed 5' termini of a nick and 
sequentially removes nucleotides in the 5'￿3' direction; (ii) a DNA polymerase adds new 
nucleotides to the exposed 3' hydroxyl group, continuing in the 5'￿3' direction, thereby     Materials and Methods 
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replacing nucleotides removed by the exonuclease and causing lateral displacement of the nick. 
The length of the labelled fragments is proportional to the concentration of DNase I. 
 
1.  For approximately 1µg of DNA probe, 25µl of labelling reaction was set up. The 
following reagents were added to a dark brown tube on ice in this order: 2.5µl 10x nick 
translation buffer*, 1.9µl of deoxyribonucleotide triphosphate (dNTPs, Pharmacia, UK) 
*, 0.7µl Cy3-dUTP (deoxyuridine triphosphate, Amersham Biosciences, UK), or 1.4µl 
Spectrum Green dUTP* (Vysis, Abbott Laboratories, UK) or DEAC-dUTP (NEN Life 
Science NEL 455, UK), 0.5µl DNase I working solution (Sigma-Aldrich, UK)* (the 
volume was determined by titration), 0.5µl DNA polymerase (5 units) (Gibco, UK), 1µg 
of DNA, and sterile dH2O to a  volume of 25µl. 
2.  The tube was flicked, pulse centrifuged at 3500 rpm, and incubated at 15˚C for the time 
previously determined by titration (usually 1 hour and 30 min – 1 hour and 50 min); the 
tube was then transferred to ice to pause the reaction. 
3.  8µl sterile dH2O was mixed with 2µl of labelled sample and the size of the smear was 
checked on a 0.8% agarose gel. If the fragment sizes were around 500bp, the reaction 
could be stopped (if not the reaction was replaced at 15˚C for a longer time). 
4.  1/10th of the volume (2.5µl) of 0.5M EDTA (ethylenediaminetetraacetic acid) was added 
to the reaction to inactivate the enzymes; 1/10th of the new volume (2.75µl) of 3M 
sodium acetate* (pH 7), and 2x the new volume (61µl) of ice-cold 100% ethanol were 
added to precipitate the DNA; the tube was incubated overnight at -20˚C (or for a 
minimum of 2 hours at -70˚C). 
5.  The tube was centrifuged at 14000 rpm for 10 min and the supernatant discarded. 
6.  61µl ice-cold 80% ethanol was added without disturbing the pellet and the tube was 
centrifuged at 14000 rpm for 10 min. The supernatant was discarded, leaving the pellet as 
dry as possible; the pellet was dried at 37˚C, taking care not to over-dry. 
7.  The pellet was resuspended in 10µl/µg TE buffer (pH 7.5) for 1 hour minimum at 37˚C. 
8.  The probe was stored at -20˚C, until required. 
 
2.4.3.2.7  Preparation of home-made probes 
1.  The tube of labelled DNA was thawed at 37˚C for 5 to 10 min. In general approximately 
200-500ng of individual probe DNA was required for one slide, depending on the 
fluorochrome used and the probe combination. 
2.  The following reagents were required for preparing the amount of probe for 1 slide: 200–
500ng of probe DNA, 4µl Cot 1 DNA* (working concentration 0.1µg/µl, GibcoBRL, 
UK), 4µl Carrier DNA (herring sperm DNA, working concentration 10mg/ml, Sigma-    Materials and Methods 
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Aldrich, UK). To this reaction, a quantity of 100% ethanol equal to 2 x the volume of the 
reaction was added. 
3.  The above reagents were vortexed and pulsed down; then the probe mixture was dried 
down in a speed Vacuum (temperature: 43˚C). 
4.  If the probe was not to be mixed with a commercial probe, after drying down, the DNA 
mixture was resuspended in 11µl complete hybridization mix*; the mixture was vortexed 
and pulsed down and incubated for 1 hour at 74˚C. 
5.  When probe preparations included an array of probes (CCND3, MAFB, etc), Cot-1 and 
carrier DNA volumes remained 4µl each per slide, but the ethanol was increased in 
proportion to the volume of DNA. 
 
2.4.4  Preparation of commercial probes 
1.  Both the probe and the complete hybridization buffer (Vysis, Abbott Laboratories, UK) 
were thawed at 37˚C for approximately 5 to 10 min before mixing and pulsing down. 
2.  1µl Vysis probe DNA, 8µl complete hybridization buffer and 2µl dH2O were mixed in a 
dark brown PCR tube to constitute the working probe stock. 
3.  In a clear PCR tube, for each slide, 2.5µl working probe stock was mixed with 8µl 
complete hybridization buffer. 
 
2.4.5  Slide pre-treatment 
Slides of both metaphase and interphase preparations were pre-treated in order to remove 
proteinaceous material which might interfere with the hybridization.  
 
1.  The eight spot slides were removed from the freezer and immersed in fixative as soon as 
possible for 30 min; the slides were left to air dry. Metaphase slides were usually freshly 
made and kept for few days at room temperature; for these slides no treatment with 
fixative was required. 
2.  900µl 2x SSC* was pre-warmed to 37˚C; 50µl aliquots of RNase* (working 
concentration 1mg/ml, Sigma-Aldrich, UK) and pepsin* (working concentration 
50mg/ml, Sigma-Aldrich, UK) were defrosted, vortexed, pulsed down and added to the 
2x SSC. The total mix was incubated at 37˚C for 10 min.     Materials and Methods 
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3.  Each slide was treated with 200µl RNase/pepsin/2x SSC and covered with a parafilm 
coverslip for 3 min; the slides were then immersed in 2x SSC for 2 min, dehydrated for 2 
min each in 70%, 90% and 100% industrial methylated spirit (IMS) (Genetics Store, UK), 
and left to dry. 
 
2.4.6  Slide denaturation and hybridization 
1.  10µl probe was placed onto a 22x22 mm coverslip and the slide was inverted over the 
coverslip. Air-bubbles were removed and the coverslip was sealed with vulcanising 
rubber solution (Weldtite, UK) and left to dry. 
2.  Slides were incubated in the Hybrite machine (Thermobrite, Abbott Diagnostic, UK). In 
the Hybrite chamber, tissues were moistened with water in order to ensure a high 
humidity. The metal slide surface was wiped with a damp tissue to create complete 
contact between the metal surface and the slides. 
3.  After having positioned all the slides and having lowered the cover, the Hybrite was set to 
reach a temperature of 75˚C for 5 min, followed by an overnight incubation at 37˚C. 
 
2.4.7  Hybridization washes 
Washes remove excess and loosely bound probe. The counterstain is used to provide overall 
staining of the chromosomes or cells. 
 
1.  A slide holder with 0.4x SSC/0.3% NP40* (Sigma-Aldrich, UK) was preheated to 74˚C, 
in a water-bath. 
2.  The glue sealant from the glass coverslip was removed and the slide was placed in a 
coplin jar with 4x SSC/0.05% NP40* at room temperature. The slide was agitated in 
order to gently release the coverslip from the slide without scratching the surface. 
3.  The slide was immersed for 1 min in 2x SSC/0.1% NP40* and then transferred to the 
0.4x SSC/0.3% NP40 stringent wash at 74˚C for: 1 x 3 min for the Vysis probe 5/9/15; 2x 
2 min for the Vysis probe TP53 and MYC; 1 x 2 min for all other probes. 
4.  After immersing the slide in fresh 2x SSC/0.1% NP40 for 1 min, the excess solution was 
drained, without allowing the slide to dry, it was mounted with Vectorshield containing 
full strength 4′,6-diamidino-2-phenylindol (DAPI) (Vector Laboratories Inc, California,     Materials and Methods 
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USA) or half strength when probes were labelled with DEAC-dUTP. The coverslip was 
sealed with nail varnish. 
 
2.4.8  Re-hybridization of FISH slides 
A number of slides were re-hybridized when no further cell suspension was available to make 
new slides for additional tests. The slides previously hybridized were treated to remove the 
original probe, following the method described above. 
  
1.  After removing the coverslip, the slide was immersed in 4x SSC for 3 min, followed by 2 
min in 2x SSC. The excess solution was then drained. 
2.  The slide was incubated with 10µl of complete hybridization buffer on a hot plate at 75˚C 
for 5 min and then immersed in fresh 2x SSC/0.1% NP40 for 2 min, followed by 2 min in 
2x SSC. The slide was dehydrated for 2 min each in 70%, 90% and 100% IMS. 
 
2.4.9  FISH scoring 
A minimum of 100 nuclei were analyzed for each probe, for each patient. Knowing the 
proportion of PC present in the cell suspension, the percentage of abnormal PC carrying a 
specific abnormality was then calculated. 
 
2.5  DNA extraction 
The genomic DNA used in this study was derived from: purified PC stored at -80˚C as a dried 
pellet; purified PC stored in fixative; non-purified fixed cells after lymphoprep separation (when 
the sample percentage of PC was > 70%) and non-purified cells derived from 24 hour and 3 day 
cytogenetic cultures (all fixed suspensions were stored at -20˚C). 
In order to extract DNA from fixed cells, cell suspensions were centrifuged at 4000 rpm for 12 
min, the supernatant removed and the pellet washed four times with 1x PBS. The pellet was 
then re-suspended in 200µl 1x PBS. 
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2.5.1  Salt extraction (> 1.5 x 10
6 cells) 
1.  Cells were centrifuged for 12 min at 4000 rpm and the supernatant discarded. 
2.  After washing the cells with 500µl resuspension buffer (RSB*), the pellet was re-
suspended and incubated overnight at 37˚C in 500µl RBS, 10µl sodium dodecyl sulphate 
(Sigma-Aldrich, UK) and 3µl proteinase K solution* (100mg/ml, Roche, UK) to remove 
cell lipids and digest cell proteins. 
3.  After checking that the cells were properly digested (if not 2µl proteinase K were added 
and left for as long as necessary), 150µl 6M NaCl (Sigma-Aldrich, UK) was added to 
precipitate the non-DNA components; the tube was shaken vigorously for 20 seconds and 
centrifuged at room temperature at 14000 rpm for 20 min. 
4.  The supernatant was transferred to a small sterilin tube (Sarstedt, UK) and approximately 
1.5x volume of 100% ethanol was added to precipitate the DNA. The sterilin tube was 
inverted until the DNA visibly collected as a ‘hair ball’. This DNA was removed using a 
sterile needle. (If no hairball was visible, the ethanol was frozen for at least 2 hours at -
20˚C and then centrifuged for 20 min at 14000rpm. The supernatant was removed and the 
pellet resupended in 50µl of dH2O). 
5.  The DNA was taken with the tip of a needle, washed in 70% ethanol in order to remove 
residual salts which might affect future manipulations and resupended in dH2O. DNA 
samples were stored at 4˚C whilst being studied. 
 
2.5.2  DNA extraction using DNeasy blood and tissue kit (Qiagen, UK) 
(<1.5 x 10
6 cells) 
1.  The AW1 and AW2 concentrates were made up with 25ml and 30ml 100% ethanol, 
respectively. 
2.  Cells for DNA extraction (maximum of 5x10
6 cells per column) were resuspended in 
200µl PBS, 20µl proteinase K and 200µl buffer AL. Tubes were then mixed by vortexing 
and incubated at 56˚C for 10 min. 200µl of 100% ethanol was then added and mixed.  
3.  The reaction mixture was pipetted into a DNeasy mini spin column placed in a 2ml 
collection tube and centrifuged for 1 min at 6000g. The flow through was discharged and 
the column was placed in a new collection tube. 
4.  500µl buffer AW1 was added and the column was centrifuged as above. The flow 
through was discharged and the column was placed in a new collection tube. 
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5.  500µl buffer AW2 was added and the column was centrifuged for 3 min at 20000 g to dry 
the membrane. The column was carefully removed from the collection tube to prevent 
any ethanol carryover and placed in a new one; 35-50µl dH2O was added directly to the 
membrane, left to incubate for 1 min at room temperature and then centrifuged for 1 min 
at 6000 g.  
 
2.5.3  DNA quantification using the NanoDrop ND-1000 (Thermo 
Scientific, UK) 
NanoDrop-1000 is a spectrophotometer which determines the concentration and purity of DNA 
by measuring the amount of light that a sample absorbs. The sample is pipetted onto the end of a 
fiber optic surface (the receiving cable). An upper second fiber optic surface (the source cable) 
automatically engages the sample, using surface tension to form a liquid bridge that bridges the 
gap between the two fiber optic ends. A pulse of light originating in the source cable is passed 
through the sample. When a photon encounters a DNA molecule it is absorbed and the intensity 
of light reaching the receiving cable is reduced and measured. DNA absorbs UV light at a 
wavelength of 260nm, proteins absorb light at 280nm and 230nm. Other contaminates such as 
carbohydrates also absorb at 230nm. Absorbance is measured at these three wavelengths 
allowing the concentration and purity of the DNA sample to be determined. 
 
1.  With the sampling arm in the down position, the NanoDrop-1000 software was started 
and the ‘nucleic acid application’ was selected. 
2.  To calibrate NanoDrop-1000, the sampling arm was lifted and 1.5µl dH2O was pipetted 
onto the lower measurement pedestal. The arm was lowered and ‘blank’ was selected. 
3.  The sampling arm was lifted and the water was wiped from both pedestals. 1.5µl dH2O or 
TE was pipetted onto the lower measurement pedestal, the arm was lowered and 
‘measure’ was selected. A flat base-line was returned. Both pedestals were wiped. 
4.  This last step was repeated for each DNA sample to be measured. The software provided 
a concentration in ng/µl which was calculated in the following way: 
 
Optical density (absorbance reading at 260nm) x 50 (1 absorbance 
 unit at 260 nm = 50 µg/µl DNA) 
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5.  To calculate DNA purity the absorbance at 260nm was divided by the absorbance at 
280nm and at 230nm. This ratio should fall between 1.5 and 2.0. A ratio below 1.5 
indicated a high level of contamination. 
 
2.5.4  DNA quality assessment 
The DNA quality was assessed by agarose gel electrophoresis (1%) as previously described. 
Genomic DNA comprises large molecules that do not migrate far along the gel, creating a 
discrete band. A smear indicates DNA degradation. 
In case of contamination, two methods were attempted to clean the DNA: ethanol precipitation 
(for small quantities of DNA) or the ‘Cleanup of genomic DNA’ protocol from the QIAmp 
DNA Qiagen kit (for larger amounts of DNA). 
 
2.5.5  Ethanol precipitation 
1.  A volume of 100% ice cold ethanol corresponding to 2-3x the volume of the sample and a 
volume of Na-Acetate corresponding to 1/10 the volume of the sample were added to the 
sample. The tube was stored at -20˚C for at least 2 hours (but usually overnight) and then 
centrifuged for 30 min at 13500 rpm at 4˚C. 
2.  The pellet was washed with 80% ice cold ethanol and centrifuged for 10 min at 13000 
rpm, at 4˚C. This step was repeated twice. 
3.  The pellet was air dried and resuspended in an appropriate volume of nuclease-free water. 
 
2.5.6  Clean-up of genomic DNA from the QIAmp DNA Micro Kit 
(Qiagen, UK) 
1.  The AW1 and AW2 concentrates were made up with 25ml and 30ml 100% ethanol, 
respectively. 
2.  The DNA was made up to 100µl with dH2O into a 1.5 ml micro-centrifuge tube; 10µl 
buffer AW1 and 250µl buffer AW2 were added; the cell suspension was mixed by pulse-
vortexing for 10 seconds and the sample was transferred to the QIAmp MinElute     Materials and Methods 
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Column. The column was centrifuged at 6000 g for 1 min and placed into a new 
collection tube. 
3.  500µl buffer AW2 was added to the column. The column was then centrifuged at 6000g 
for 1 min and placed in a clean 2ml collection tube which was then centrifuged at 
14000rpm for 3 min to dry the membrane completely.  
4.  The DNA was eluted with 35-50µl dH2O applied to the centre of the membrane and left 
to incubate at room temperature for 1 min; the column was centrifuged at 14000rpm for 1 
min. 
5.  The DNA quantity and purity were re-assessed. 
 
2.5.7  DNA amplification using REPLI-g kit (Qiagen, UK) 
A number of genetic analyses, including array CGH, require large quantities of template for 
testing and much effort has been invested in developing methods for whole genome 
amplification. The rolling circle amplification 
197 method was developed for amplifying large 
circular DNA templates such as plasmid and bacteriophage DNA 
198 using φ29 DNA 
polymerase and random exonuclease-resistant primers. The kit from Qiagen uses the 
bacteriophage φ29 DNA polymerase and random hexamer primers to exponentially amplify 
genomic DNA in a cascading, strand displacement reaction termed multiple displacement 
amplification (MDA). This method should provide a highly uniform representation across the 
genome. The φ29 enzyme has strand displacement activity, which displaces the 5' end of each 
strand by another upstream strand growing in the same direction. Displaced strands, which are 
single-stranded, are now targeted by new random priming events and these new strands are 
elongated in the opposite direction. Such a mechanism produces microgram amounts of DNA 
from nanogram amounts of initial template. The template DNA had to be >2 kb in length with 
some fragments > 10 kb. 
 
1.  DLB Buffer was prepared by adding 500µl nuclease-free water to the tube. Buffer D1 
(denaturation buffer) was prepared by mixing 35µl nuclease-free water with 5µl DLB 
Buffer; Buffer N1 (neutralization buffer) was prepared by mixing 72µl nuclease-free 
water with 8µl ‘stop solution’. 
2.  Equal amounts of patient and control DNA (100ng) were adjusted to 2.5µl with nuclease-
free water. 
3.  2.5µl Buffer D1 was added to the DNA, mixed by vortexing, centrifuged briefly and left 
at room temperature for 3 min. 
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4.  5µl Buffer N1 was added to each sample and mixed.  
5.  The REPLI-g Polymerase was thawed on ice; a 40µl mix reaction was prepared with 10µl 
nuclease-free water, 29µl Reaction Buffer and1µl DNA Polymerase, this was mixed with 
the denatured DNA. 
6.  The reaction mix was incubated at 30˚C for 2-4-6-8-16 hours then the enzyme was heat 
inactivated at 65˚C for 3 min. 
7.  After cooling on ice the samples were stored at 4˚C until required. 
8.  The QIAprep Spin Miniprep Kit was used for the clean-up of amplified-digested DNA 
(Buffer PE was prepared adding 100% ethanol to the Buffer PE bottle). 
9.  500µl Buffer PB was added to each 100µl sample which was then applied to a QIAprep 
Spin Miniprep column and spinned for 60 seconds at 17900 g. 
10.  After discarding the flow-through, 750µl Buffer PE was added and the column was 
spinned for 60 seconds at 17900 g. The flow-through was discarded and the column was 
spinned at the same conditions. 
11.  The DNA was eluted in 50µl Buffer EB and incubated for 60 seconds. The purified DNA 
was collected spinning the column for 60 seconds at 17900 g. 
12.  5µg of amplified DNA from the patient and the control samples were used to set up the 
array. 
 
2.6  Array-based Comparative Genomic Hybridisation  
Array-based comparative genomic hybridization is a sophisticated molecular technique that is 
used to identify and characterize DNA copy number alterations at the genomic level. Genomic 
DNA from two cell populations, test and reference, are differentially labelled with fluorescent 
dyes and competitively hybridised to a glass slide spotted with short sequences of DNA 
complementary to sequences which represent a normal genome 
199,200. Lasers scan the surface of 
the slide, exciting the dyes to fluorescence. The intensity of the different fluorochromes is 
measured and an array CGH profile of each chromosome generated from the log2 fluorescent 
ratios. Regions in which there is no deviation from the normal will have a ratio of 0, whilst 
those regions with duplications will have positive ratio values, conversely those with deletions 
will have negative ratio values (Figure 2-2).  
Prior to analysis, the data is normalized. This compensates for systematic experimental 
variation, such as unequal dye incorporation, detection inefficiencies and background 
fluorescence. The signal intensities are not a direct measure of copy number, rather an arbitrary     Materials and Methods 
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value, thus an alternative method (e.g. FISH) is required to confirm the actual DNA copy 
number. Copy number alterations are mapped directly onto the human genome sequence. 
The resolution of the array platform is variable depending upon the design. Array-based CGH 
platforms have been produced using large-insert DNA clones, such as BAC, complementary 
DNA (cDNA) 
201 and oligonucleotides as probe templates. Initial designs were based on BAC 
clones. These clones are approximately 200 kb long and usually each platform contains on 
average 3000 clones, spaced approximately 1Mb apart. Although they provide precise 
identification of the chromosome regions involved in the copy number change, their resolution 
is insufficient to identify specific gene aberrations; furthermore BAC clones are difficult to 
propagate 
202. BAC arrays have the advantages of providing more intense signals than arrays 
made from shorter sequences of DNA, and the clones can be used as FISH probes for 
confirmation of results. The optimization of oligonucleotide array CGH (oligo array CGH) has 
dramatically superseded the resolution of BAC approaches, providing a resolution to the 
magnitude of 6 kb.  
Limitations of array CGH include: inability to identify balanced structural rearrangements that 
do not result in copy number alterations; inability to identify the nature of unbalanced structural 
rearrangements; difficulties in detecting ploidy changes. 
When array CGH is applied to neoplastic samples or constitutional mosaic samples, the 
contamination with non-tumour cells, or the presence of different clones, can make the array 
CGH analysis difficult to analyze as the final result is an average of the specific abnormalities 
present in each clone 
203. Another problem is the presence of copy number 
variations/polymorphisms (CNV), which are abundant in the human genome, and have the 
potential to confound the identification of genuine somatic alterations. This problem can be 
solved by normalizing the DNA derived from the patient tumour with the patient’s normal 
germline DNA 
204; unfortunately both DNA samples are not always available. 
The Human Genome CGH 244k Microarray platform (Agilent Technologies, Palo Alto, USA) 
was used in this study. The platform consists of more than 236,000 60-mer oligonucleotide 
probes that span the human genome covering coding and non-coding sequences with emphasis 
on well-known genes, promoters, miRNAs and telomeric regions. It provides an average 
resolution of less than 6.5 kb. Patient DNA was hybridised against a sex-matched reference 
DNA extracted from peripheral blood of ten healthy donors (Promega, UK). Normal germline 
DNA from patients was not available in this study. 




Figure 2- 2  Representation of array CGH technique 
 
2.6.1  Restriction digestion of genomic DNA 
1.  The same amount (0.3-1.5µg) of genomic test DNA and reference DNA were made up to 
20.2µl with nuclease free water in separate tubes. 
2.  2µl nuclease free water, 2.6µl 10x Buffer C (Promega, UK), 0.2µl acetylated bovine 
serum albumin (BSA, Promega, UK) and 0.2µl of the restriction enzymes Alu I and Rsa I 
(Promega, UK) (digestion master mix) were added to both tubes, on ice. Samples were 
incubated in a water-bath at 37˚C for 2 hours. The enzymes were then inactivated by 
incubation at 65˚C for 20 min. 
 
2.6.2  DNA labelling 
1.  5µl 10x Random Primers (Agilent, USA) was added to each sample. The tubes were 
transferred to a hot plate at 95˚C for 3 min, and then transferred to ice for 5 min. 
2.  10µl 5x buffer, 5µl 10x dNTP, 3µl Cy3-dUTP or Cy5-dUTP and 1µl exo-klenov (a 
genetically engineered enzyme in which the 3′ to 5′ exonuclease activity has been 
removed) (Agilent, USA) were added to each sample. They were incubated in a water-    Materials and Methods 
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bath at 37˚C for 2 hours. The enzyme was then inactivated by incubation at 65˚C for 10 
min. Following incubation samples were transferred to ice. 
 
2.6.3  Clean-up of labelled DNA 
1.  430µl 1x TE buffer was added to each sample. A Microcon YM-3- filter (Millipore, 
Chemicon/ Upstate/ Linco, UK) was placed in a 1.5ml microfuge tube and the sample 
loaded onto the filter. It was centrifuged for 10 min at 8000 g. The flow-through was 
discarded. 
2.  480µl 1x TE was applied to the filter. The tube was centrifuged as before and the flow-
through was discarded; the filter was then inverted into a fresh collection tube which was 
centrifuged for 1 min at 8000 g. 
3.  If the sample volume exceeded 80.5µl, the sample was returned to its filter and 
centrifuged for 1 min at 8000 g, as previously described. The flow-through was 
discarded. The filter was inverted into a fresh collection tube and it was centrifuged for 1 
min at 8000 g. 
4.  The labelling index of each DNA sample was evaluated with the NanoDrop-1000. From 
the main menu, ‘Microarray Measurement’ was selected; 1.5µl 1x TE was used to blank 
the instrument. 1.5µl purified labelled genomic DNA was used to measure the absorbance 
at A260nm (DNA), A550nm (cyanine 3), and A650nm (cyanine 5). The specific activity 
of the labelled genomic DNA was obtained by dividing ‘pmol per µl dye/µg per µl 
genomic DNA’. The expected specific activity of cyanine-3 labelled samples was 25 to 
40; of cyanine-5, 35 to 55. If the values were within the acceptable range, the test and 
reference DNA were combined and the volume was brought to 157µl with nuclease-free 
water. 
 
2.6.4  Hybridisation 
1.  1350µl nuclease-free water was added to the lyophilized 10x blocking agent (Agilent, 
USA) and incubated for 60 min at room temperature to reconstitute it. 
2.  50µl Human Cot-1 DNA (Invitrogen, UK), 52µl 10x blocking agent and 260µl 2x 
hybridisation buffer (Agilent, USA) were added to the 157µl of combined sample. It was 
pipette mixed and centrifuged briefly to collect. The sample was incubated in a heat block 
at 95˚C for 3 min, then immediately transferred to a water bath at 37˚C for 30 min.     Materials and Methods 
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3.  The sample was centrifuged for 1 min at 17900 g to collect. 
4.  A clean gasket slide was loaded into the Agilent SureHyb chamber base with the label 
facing up and aligned with the rectangular section of the chamber base. 
5.  490µl hybridisation sample was slowly dispensed into the gasket well. An array was 
placed onto the gasket slide, so the numeric barcode side was facing up and the ‘Agilent’ 
barcode was facing down; the chamber cover was placed onto the sandwiched slides and 
the clamp was hand-tightened. 
6.  The assembled chamber was vertically rotated to wet the slides and assess the mobility of 
the bubbles. The assembly was tapped on a hard surface to move stationary bubbles; it 
was then placed into the hybridisation oven at 65˚C and rotated at 20 rpm for 40 hours. 
 
2.6.5  Washes and drying 
Excess unbound test and reference genomic DNA was removed by post hybridisation washes. 
At the same time it was important to stabilise and dry the hybridised array slide. As Cyanine 5 is 
sensitive to ozone degradation, stabilisation and drying solutions have been designed to 
minimize ozone induced degradation. 
 
1.  The required volume of Wash buffer 2 (Agilent, USA) was pre warmed in a 37˚C water 
bath, overnight. If the stabilization and drying solution showed a visible precipitation, this 
too required pre warming at 37˚C overnight. 
2.  Five slide staining tanks were filled with the following solutions: wash buffer 1 (Agilent, 
USA) (tank 1); wash buffer 1 filled to a sufficient level to cover a slide rack (tank 2); 
wash buffer 2 at 37˚C (tank 3); Acetonitrile (Sigma-Aldrich, UK) (tank 4); Stabilization 
and Drying solution (Agilent, USA) (tank 5). In addition to the solutions tank 2-5 
contained a magnetic flea and all four tanks were placed on a magnetic stir plate which 
was set at speed level 3. 
3.  The slide was removed from the hybchamber and placed in tank 1. Whilst submerged in 
the wash, the slides forming the ‘sandwich’ were gently prised apart, and placed into the 
slide rack and quickly transferred to tank 2. The slides were left for 5 min before being 
transferred to tank 3, where they were left for 1 min. The rack was transferred to tank 4 
and left for 1 min.  
4.  Finally the rack was transferred to tank 5 for 30 seconds. Very slowly the slides were 
removed from the tank, taking care to ensure that no droplets remained on the slide.      Materials and Methods 
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5.  The slides were then scanned on an Agilent scanner using the default scan setting. The 
scan resolution was set to 5µm as recommended for 244k density array. 
 
2.6.6  Data extraction 
The feature extraction software version 9.5.3.1 (Agilent, USA) converts the TIF images 
obtained from the scanner into a reduced representative set of features, which are required to 
describe a large set of data accurately. The arrays were then analyzed using the Agilent CGH 
Analytics 3.5.40 and 4.0 softwares, which is based on the UCSC March 2006 assembly (Hg18). 
The ratio of the fluorescent intensity of the test gDNA compared to the reference gDNA was 
calculated and averaged for each replicate before being converted to a log2 ratio, which was then 
normalized using z-scoring or Aberration Detection Method-2 (ADM-2). Aberrant regions were 
identified for each point in the data by calculating the moving average within 0.5 Mb window. 
Outliers were classified using a cut off +/- 0.25. Five consecutive aberrant spots were required 
for an aberrant call. 
 
2.7  RNA extraction (Qiagen RNEasy method) and cDNA 
synthesis 
RNA was extracted using the Qiagen RNeasy kit (Qiagen, UK). At the beginning, four volumes 
of 100% ethanol were added to buffer RPE (included in the kit) to obtain the working 
concentration. 
 
1.  Equal amounts of Trizol (Invitrogen, UK) sample and chloroform (Sigma-Aldrich, UK) 
were combined (usually 350-500µl of each). The tube was shaken vigorously for 15 
seconds and centrifuged at 14000 rpm for 5 min. 
2.  After centrifugation, the RNA remained in the upper colourless aqueous phase. This layer 
was transferred to a new eppendorf, being careful not to aspirate the interface. 
3.  The same amount of chloroform used in step 1 was added to the eppendorf; the tube was 
vortexed for 15 seconds and centrifuged for 5 min at 14000 rpm, at room temperature. 
4.  The top layer was carefully transferred into a new eppendorf and 70% ethanol was added 
in the same amount used for the chloroform.     Materials and Methods 
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5.  At this point, because of the low number of cells usually present in the sample, 20ng 
carrier RNA (Polyadenylic acid, Amersham, UK; working concentration of 10ng/µl) was 
added to the cell lysate before loading it onto the RNeasy membrane. The carrier RNA 
was co-purified with the cellular RNA, as the small amount used for each extraction did 
not interfere with subsequent PCR reactions.  
6.  The cellular lysate and the RNA carrier were applied to the RNeasy column which was 
then centrifuged for 15 seconds at 10000 rpm and the flow through was discarded. 
7.  650µl RW1 was added to the column and the tube was centrifuged for 15 seconds at 
10000 rpm; the flow through was discarded. 500µl RPE was added to the column and the 
tube was centrifuged for 15 seconds at 10000 rpm; the flow through was discarded. 
8.  500µl RPE was added to the column, and the column centrifuged for 2 min at 14000 rpm; 
the flow through was discarded and the column placed into a new 1.5ml eppendorf. 
9.  The cap of the column was left open for 3-5 min under the hood and then 25µl RNeasy 
free water was added at the centre of the filter, in the column. 
10.  The column was centrifuged for 1 min at 14000 rpm to elute the RNA and immediately 
placed on ice. After elution, the RNA was heated to 65˚C for 5 min and placed on ice, 
then immediately reverse transcribed into cDNA. 
11.  1-5µg RNA was incubated for 2 hours at 37˚C in a final reaction volume of 40µl 
containing 50mM Tris (pH 8.3), 75mM KCl, 3mM MgCl2, 1mM dithiothreitol (DTT, 
Sigma-Aldrich, UK), 1mM deoxyadenosine triphosphate (dATP), 1mM deoxycytidine 
triphosphate (dCTP), 1mM deoxythymidine triphosphate (dTTP), and 1mM 
deoxyguanosine triphosphate (dGTP), together with 100µg/µl of random pd(N)6 
hexamers (Amersham Pharmacia, Amersham, UK), 14,000U of Murine Molony 
Leukaemia Virus (MMLV) reverse transcriptase (Invitrogen, UK) and 1400U/ml RNase 
inhibitor (Promega, UK). Enzyme denaturation by heating to 65˚C for 10 min terminated 
cDNA synthesis. The cDNA was stored at -20˚C. 
 
2.7.1  cDNA quality assessment 
The quality of the cDNA was assessed by PCR with the BCR-ABL1 multiplex mix, used for 
detection of the translocation t(9;22)(q34;q11), which leads to fusion of the genes BCR and 
ABL1 
205. The PCR is a technique for the in vitro amplification of specific DNA sequences by 
the simultaneous primer extension of complementary strands of DNA 
206. A thermostable DNA 
polymerase synthesizes a DNA sequence using two primers, each complementary to opposite 
stands of the region of DNA, which has been denaturated by heating. This results in the de novo     Materials and Methods 
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synthesis of the region of DNA flanked by the two primers. The reaction requires 
deoxynucleotides, DNA polymerase, primers, template and buffer containing magnesium. A 
typical PCR programme of heating and cooling facilitates the exponential accumulation of DNA 
product which can be visualized by staining with ethidium bromide and electrophoresis on an 
agarose gel. The PCR programme used was as follow:  
 
      initial denaturation   95˚C for 10 min 
      denaturation phase    95˚C for 1 min 
      primer annealing   60˚C for 1 min              29 cycles 
      synthesis phase    72˚C for 1 min  
      extension phase   72˚C for 10 min  
      hold      15˚C 
 
PCR were performed in a volume of 21µl. All amplification reactions were performed in a MJ 
Research Tetrad thermocycler with heated lid, in sterile 200µl microtubes. The multiplex PCR 
mix contained 0.2µM primers (0,5µM for single PCR reactions), 0.2mM each of dCTP, dTTP, 
dATP, and dGTP, 1.5mM MgCl2, 1x buffer (10mM Tris-HCl (pH 8.3), 50mM KCl, 0.1% 
gelatine), 0.05 U/µl HotStar Taq polymerase (Qiagen, UK). The primer mix included: one 
reverse primer for exon 11 of the ABL gene (CA3-: tgt tga ctg gcg tga tgt agt tgc ttg g); one 
reverse primer for exon 21 of the BCR gene (C5e-: ata gga tcc ttt gca acc ggg tct gaa); one 
forward primer for exon 13 of the BCR gene (B2B: aca gaa ttc cgc tga cca tca ata ag); one 
forward primer for exon 1 for the BCR gene (BCR-C: acc gca tgt tcc ggg aca aaa g). 
As positive control, 1µl of cDNA from one of the two cell-lines (SD1 or K562) was used. 
 
2.8  Quantitative reverse transcription PCR (qRT-PCR) 
This technique is used for RNA quantitation or determination of gene expression levels. It can 
also be used for DNA and cDNA quantitation. Real-Time PCR is identical to a simple PCR 
except that the progress of the reaction is monitored by a camera in ‘real-time’. 
The taqman system uses a primer and a probe complementary to the gene of interest. The probe 
is labelled with a fluorescent reporter dye on the 5' end and a quencher molecule (capable of 
quenching the fluorescence of the reporter) on the 3' end. While the probe is intact, the 
proximity of the quencher molecule greatly reduces the fluorescence emitted by the reporter 
dye. The probe anneals to a target sequence downstream of the primer site and as the primer is 
extended by Taq DNA polymerase its 5' nuclease activity cleaves the reporter dye from the     Materials and Methods 
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quencher, which allows the fluorescence of the reporter to increase. Each cycle of denaturation, 
primer annealing and primer extension cleaves another probe. Reactions are characterized by 
the point in time during cycling when the fluorescence exceeds the threshold. The more RNA 
present the sooner this happens. The Taqman software generates a Ct value for each of the 
reactions. These refer to the cycle number needed to generate a defined amount of fluorescence 
when the PCR is in its linear phase. Therefore the higher the Ct value the less RNA is present in 
the sample. The comparative Ct method is used for quantitation of gene expression relative to 
an endogenous control gene. A housekeeping gene such as GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) is typically used as the reference gene. 
In this study MYC mRNA expression levels were investigated in a number of patients. RNA 
was obtained from purified PC of PCL and MM patients. Normal PC are characterized by a low 
level of MYC expression, as the gene is silenced during PC differentiation 
207; therefore RNA 
from purified BM PC (85%) from a patient with myelodysplasia was used in this study as 
calibrator sample. The RNA from the human promyelocytic leukemia cell line, HL-60, was 
used as positive control for MYC overexpression 
208. 
 
Real-time quantitative PCR was performed with the Corbett Rotor Gene 6000 (Corbett Life 
Science, Sydney, Australia). The 10µL qRT-PCR contained 2µL cDNA, 1x TaqMan Universal 
PCR Master Mix (Applied Biosystems, UK), 300nM forward and reverse primers and 200nM 
probe. Cycling conditions were 50˚C for 2 min, 95˚C for 10 min followed by 45 cycles of 95˚C 
for 15 seconds and 60˚C for 1 min.  Probes and primers used for MYC were: sense primer, 5'-





The level of MYC mRNA was determined by normalization to the level of the GUSB (beta-
glucuronidase) and BCR genes, used as endogenous controls, which showed little variability in 
expression across the patient samples. Probes and primers for GUSB were as described by the 
European against Cancer group 
210, and probes and primers for BCR were as described by 
Branford et al. 
211. The relative expression of MYC, compared to GUSB and BCR, was 
calculated using the Pfaffl method 
212. The myelodysplastic sample was measured in the same 
analytical run to exclude between-run variation. 
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2.9  Sequencing by dideoxynucleotide chain termination 
The dideoxynucleotide chain termination is a PCR based technique for sequencing that utilises 
the addition of all four fluorescently labelled dideoxynucleotides (ddNTP) to homogeneous, 
single stranded template DNA with the correct primer, DNA polymerase and dNTP. The ddNTP 
lack the 3' hydroxyl group, necessary for the formation of 3' - 5' phosphodiester bond and 
therefore halts chain elongation at random when incorporated into the synthesised template 
DNA. The resultant mixture is a series of DNA molecules at different lengths which, when run 
through the capillary gel electrophoresis separate on the basis of size and are detected when a 
laser excites the fluorescent dye attached to the ddNTP. 
 
2.9.1  ExoSAP 
For fluorescent-based sequencing of PCR products, removal of unused primers was performed 
by incubating 3µl of the PCR product with 2µl of exonuclease I (New England Biolabs, UK) 
and shrimp alkaline phosphatase (SAP, Roche Diagnostics Ltd, UK) mix at 37˚C for 15 min and 
then denatured by heating to 80˚C for 15 min. Exonuclease I degrades any residual single 
stranded primers and extragenous single-stranded DNA, whilst the SAP hydrolyses the 
remaining dNTPs from the PCR reaction. The exonuclease I/ SAP mix was prepared combining 
the enzymes in a ratio 1:4, respectively. The PCR product was then diluted in 5µl of water. 
 
2.9.2  Sequencing reaction 
Exonuclease I/ SAP purified PCR products were sequenced in a reaction containing 1µl PCR 
product, 0.5µl of a single primer (either forward or reverse), 0.5µl of v1.1 or 3.1 Big Dye 
Terminator, 1.5µl of 5x sequencing buffer and made up to 10µl with deionised water (Applied 
Biosystems, Foster City, CA, USA). The sequencing reaction was made up on ice and the 
sequencing programme was as follows: 
 
96°C    30 sec 
50°C    15 sec    25 cycles 
60°C    2 min   
4°C    hold 
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2.9.3  Removal of unincorporated dye terminators 
Unincorporated dye terminators were removed from the sequencing reaction using the montage 
SEQ96 sequencing reaction clean up kits (Millipore, UK). 25µl of Injection Solution was added 
to every tube with the sequencing products and the entire mix was transferred into the wells. At 
this point the vacuum was activated (for 3-4 min) until the wells were empty in order to filter 
the small contaminants present in the mix. After adding 25µl of Injection Solution, the vacuum 
was re-activated for a second time until the wells were dried. Deionised formamide (Sigma-
Aldrich, UK) or deionised water (20µl) was added to each well and used to resuspend the 
cleaned sequencing reactions, which were then loaded onto an Applied Biosystem 3100 or 3130 
sequencing machine. 
 
2.10   Multiplex Ligation-dependent Probe Amplification 
(MLPA) 
MLPA is a method to establish the copy number of multiple nucleic acid sequences in one 
single reaction by yielding amplification products of unique size per target 
213.  Products are 
separated by automated fluorescence-based sequence electrophoresis and the copy number of 
each target is determined from the relative intensities of the products compared to those 
obtained from controls. Genomic deletions and amplifications of a gene (or part of) will usually 
not be detected by sequence analysis of PCR amplified gene fragments if a normal copy is still 
present. With MLPA, only one pair of PCR primers is used and therefore MLPA reactions result 
in a very reproducible gel pattern with fragments ranging from 130 to 490bp (Figure 2-3).  
Each MLPA probe consists of a target-specific sequence and one phage M13 derived sequence. 
Two such probes are designed to hybridize immediately adjacent to each other and are joined by 
the action of a thermostable ligase. The outer phage-derived portions of the primer pair allow 
simultaneous amplification of all sequences in the reaction by FAM-labelled M13 primers, and 
contain a random ‘stuffer’ sequence designed to vary in length to aid separation of the 
individual targets. Each probe pair therefore gives rise to an amplification product of unique 
size, which can be quantified by capillary electrophoresis. The relative amounts of the probe 
amplification products reflect the relative copy number of the target sequences.  






















Figure 2- 3  Outline of the MLPA reaction 
Genomic DNA is denatured and hybridised with a probe mixture. For MLPA on mRNA, an initial 
cDNA synthesis step using reverse transcriptase and target specific probes is required. From then 
on the DNA and mRNA MLPA strategies are the same. Adapted from Schouten et al. 
213 
 
The amplification product of each probe has a unique length to allow amplified products to be 
separated by capillary electrophoresis. For MLPA on genomic DNA, relative amounts of probe 
amplification products reflect the relative copy number of target sequences. For MLPA 
performed on cDNA (RT-MLPA) the amounts of probe amplification product reflect the level 
of mRNA expression. 
 
2.10.1    Methodology (MRC Holland, the Netherlands) 
1.  1µl (50ng) DNA was added to 4µl of Tris-EDTA buffer in a 0.2ml PCR tube and overlaid 
with oil (to prevent evaporation overnight) before running on a MJ thermocycler tetrad 
‘Denature’ programme (heat at 98˚C for 7 min; cool to 25˚C).  
Each MLPA probe consists of 
two oligonucleotides, one 




The M13 derived probes have a 
different stuffer sequence length 
The two parts of each 
probe hybridise to 
adjacent target 
sequences 
The two parts of 
hybridised probes are 
ligated by a 
thermostable ligase 
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All probe ligation products are amplified by PCR using only one primer 
pair, which is fluorescently labelled 
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2.  To each denatured sample was then added a mixture of 1.5µl relevant probe mix and 
1.5µl MLPA buffer.  
3.  After mixing gently, samples were incubated for 1 min at 95˚C and then the probes were 
let to bound overnight at 60˚C. 
4.  The following morning, 3µl of Ligase buffer A, 3µl of Ligase buffer B, 25µl of water and 
1µl of Ligase were combined (Ligase mix) for each sample less than one hour before use 
and stored in ice.  
5.  After stopping the 60˚C overnight run, samples were held at 54˚C for at least 2 min 
before adding 32µl of the above Ligase mix. Samples were then incubated for 15 min at 
54˚C and at 98˚C for 5 min. 
6.  After the ligation was completed 1µl SALSA PCR-primers, 2µl SALSA Enzyme Dilution 
buffer, 15.75µl water, 0.25µl SALSA Polymerase and 5µl of Polymerase were added to 
each sample and the PCR reaction was started (PCR conditions, 35 cycles: 30 seconds 
95˚C; 30 seconds 60˚C; 60 seconds 72˚C. The reaction was ended with 20 min incubation 
at 72˚C. 
7.  The PCR samples were then analyzed on an ABI3130 by mixing 1µl PCR product to 9µl 
of formamide and 0.1µl of ROX500 size standard (Applied Biosystems, USA). 
 
Analysis of the samples was performed using Applied Biosystems Genescan
 software using a 
GS500 size standard. Following this, Applied Biosystem Genotyper software was used. Based 
on the number of probes in the MLPA kit the software can be manipulated. MLPA analysis 
sheets for each MLPA probe kit were set up in Microsoft Excel. The data from the genotyper 
table was imported into the Excel sheet and samples were compared to controls (genomic DNA 
from two healthy individuals). The peak height of each probe is compared against every other 
probe and against the control. This gives a data sheet of numbers (peak ratios) where 1 is 
normal, a horizontal row of 0.5 indicates a deletion and horizontal row of 1.5 a duplication.  
A variety of MLPA probemixes are available from MRC-Holland. Alternatively, it is now 
possible to add some probes of specific interest to a commercial kit or to have purchased a 
completely new and personal MLPA kit. For this study, Mark Townsend with the help of Dr 
Dave Bunyan, enriched the commercial kit ‘SALSA MLPA kit P088 Glioma 1’ with six new 
probes mapping at 1p32.3 the genes CDKN2C/p18 (Cyclin-dependent kinase 4 inhibitor C) and 
FAF1 (Fas (TNFRSF6) associated factor 1) (description and location of the probes included in 
the commercial kit can be found on the MRC-Holland Website, see URL in Appendix 1; 
sequence, size and location of the six customized probes are described in Appendix 4). MLPA 
was used to detect the exact breakpoint of deletions occurring at this chromosomal band.  
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2.11  Statistical analysis 
The frequencies of chromosomal abnormalities in different patient groups were compared by 
Fishers’ exact test or Kruskall-Wallis test as appropriate.  
Differences between survival curves in MM and differences between progression curves in 
MGUS were analysed using the Log-rank test. Kaplan-Meier curves were calculated using 
MINITAB 14. 
Fishers’ exact test was used to compare the frequencies of chromosomal abnormalities in PCL 
and MM patients (Section 3.6.4.9). The Mann-Whitney
 test was used to evaluate differences in 
MYC expression levels in MM and PCL between cases with and without evidence of 8q24 
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3.1  Characterization of MGUS and SMM by iFISH 
 
3.1.1  Introduction 
The paucity of PC within the bone marrow of MGUS and SMM patients, associated with the 
low proliferative capacity of these cells, has precluded meaningful karyotypic studies in these 
patients. Interphase-FISH provides an alternative approach to investigate chromosomal 
abnormalities (CA) in tumour cells from which metaphases are difficult to obtain. In MGUS, 
the interpretation of CA detected by iFISH has been complicated by the inferior PC purity due 
to a lower level of BM plasmocytosis 
85. However, CA have been consistently detected by 
iFISH in a high proportion of patients, with roughly 50% of them carrying one of the primary 
IgH translocations (IgHt) and the remaining patients displaying an HRD karyotype. These 
findings suggested that ploidy status and IgH rearrangements were early events delineating 
different pathogenetic pathways 
44,214,215.  
 
Conflicting results have been reported on the prevalence of ∆13 in MGUS. Avet-Loiseau et al. 
reported a substantially lower frequency (~25%) compared to MM (~50%) 
85,109 while others 
reported a similar incidence in both conditions 
44,103. Fonseca et al. also indicated that when ∆13 
was detected in MGUS it occurred in the majority of clonal PC 
44, consistent with that normally 
observed in MM 
98,99, while others reported a greater heterogeneity in MGUS 
98. 
 
Here iFISH was used (i) to assess the incidence and the association of ∆13 with IgH 
translocations, ploidy status, deletions of 16q23 and TP53 in a large series of MGUS and SMM 
patients; (ii) to compare these frequencies with those found in a group of newly diagnosed MM 
patients in order to determine whether the patterns of CA differ within the different diagnostic 
groups; (iii) to explore the reported clonal heterogeneity of MGUS by comparing the 
frequencies of the different CA detected in individual patients 
85.  
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3.1.2  Patients 
A consecutive series of 715 patients with PC disorders sent to the Myeloma Cytogenetic 
Database were evaluated. The cohort consisted of 187 MGUS (median age: 69 years, range 36-
92 years) and 128 SMM patients (median age: 69 years, range 31-89 years) not requiring 
therapy, and 400 newly diagnosed MM patients entered into the MRC Myeloma IX Trial 
(median age: 64 years, range 30-89 years). Patients with an IgM heavy chain subtype were not 
eligible for this study, given their different biology 
46. Age was statistically similarly distributed 
within the patient groups. All but four SMM and eight MGUS patients were studied at the time 
of diagnosis.  
 
3.1.3  Cytogenetic testing 
Mononuclear cells were separated after density gradient centrifugation of BM aspirates over 
Lymphoprep (Section 2.2.3) and CD138
+ PC were isolated by magnetic-activated cell sorting 
(Section 2.2.5). Interphase-FISH was performed on PC using a panel of commercial and in-
house probes (Appendix 3) as described in Sections 2.4.6 to 2.4.9. Results were available for 
∆13 (two probes in 13q14: RB1 and D13S319), IgH break-apart (14q32.33) (Figure 3-1), 
t(4;14)(p16;q32), CCND3 break-apart (6p21), t(11;14)(q13;q32), t(14;16)(q32;q23), MAFB 
break-apart (20q11), deletion of 16q23, interstitial deletion of TP53 (17p13) or monosomy 17 
(centromere 17) and ploidy status. The multi-colour probe set from Abbott, specific for the 
locus 5p15.2 and centromeres (CEP) 9 and 15, was used to assess ploidy. Break-apart patterns 
for the CCND3 or the MAFB probes, in cases with a concomitant break-apart of the IgH probe, 
were suggestive of t(6;14)(p21;q32) and t(14;20)(q32;q11), respectively. In these cases the 
presence of the suspected translocation was confirmed by re-hybridizing the same cells with the 
t(4;14)(p16;q32) probe (already found to be negative) with single colour probes for CCND3 or 
MAFB; the finding of fusion signals proved the suspected translocation. 
A FISH result was considered to be abnormal when above the cut-off levels recommended by 
the European Myeloma Network (EMN) FISH workshop: a level of 10% for fusion and break-
apart probes, 20% for numerical abnormalities. 




Figure 3- 1  Vysis IgH Dual Colour, break-apart probe  
A) Map of the probe; B) IgH probe hybridized to a nucleus exhibiting a split at 14q32 
corresponding to the signal pattern: 1G1R1F; this pattern is indicative of an IgH rearrangement. 
(G, green signal; R, red signal; F, fusion signal) 
 
3.1.4  Results 
3.1.4.1  Ploidy classification 
Only conventional cytogenetics can provide an accurate ploidy classification because all 
chromosomes can be visualized and counted at the same time. Given the lack of availability of 
abnormal metaphases in most MM or related monoclonal gammopathies the estimation of 
ploidy was attempted using a panel of FISH probes mapping multiple loci on different 
chromosomes. The FISH method used here to assess ploidy was designed and validated on MM 
patients, using a modification of the method of Wuilleme et al. 
216. According to this system, all 
patients with gain of signals for any two of the chromosomes 5, 9 or 15 were defined as HRD. 
Cases not meeting these criteria, and showing only loss of signals were defined as nonHRD, 
along with those having >four copies of >four probes (near-tetraploidy, these were considered 
as nonHRD) 
92. All other cases, in particular those with gain of a single probe, had their full 
iFISH pattern compared with the hypothetical result that would have been obtained for the same 
probes on all complete myeloma karyotypes in the Mitelman Database of Chromosomes in 
Cancer (URL in Appendix 1) and our own cytogenetic results. Where the majority (>75%) of 
comparable cases were HRD or nonHRD, then the appropriate category was assigned. If no 
clear pattern emerged or the comparable cases were equally divided between HRD and 
nonHRD, the case remained unassigned for ploidy 
87.  
Patients with MGUS and SMM were classified as being HRD or nonHRD using this method. 
In this series of pre-malignant patients, seven MGUS and 17 SMM patients had abnormal 
cytogenetics. For these cases the ploidy status defined by iFISH was compared with the actual 
karyotype (karyotypes and ploidy defined by iFISH are listed in Appendix 5): all but two cases 
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(one MGUS and one SMM) were correctly classified by iFISH. The first discrepant case 
(MGUS) had 47 chromosomes and the karyotype showed: one extra copy of chromosome X, 
trisomies of chromosomes 9 and 11 (detected by iFISH), trisomy 19 and losses of chromosomes 
13, 14 and 16 (detected by iFISH). Since trisomies of chromosomes 9 and 11 are usually 
associated with HRD and deletions of 14q32 and 16q23 detected by iFISH usually represent 
interstitial deletions the case was classified as HRD. The karyotype of the second discrepant 
case (SMM) had 48 chromosomes with a missing Y, one extra copy of chromosome 9 (detected 
by iFISH) and two extra copies of differently rearranged chromosomes 1. This is a very unusual 
karyotype and because iFISH only detected trisomy 9 with no other CA, the case has been 
classified as nonHRD. 
 
3.1.4.2  Frequencies of chromosomal abnormalities 
FISH analysis was performed according to availability of patient material: a minimum of eight 
loci were tested on all patients (4p16, 5p15.2, CEP 9, 11q13, 13q14 (two loci), 14q32 and CEP 
15). In more than 80% of patients, 13 different loci were analysed. Copy number changes or 
structural alterations were observed for at least one of the chromosomal regions tested in 
168/187 (90%) MGUS, 125/128 (98%) SMM and 396/400 (99%) MM.  
 
Table 3-1 summarizes the frequencies of the specific CA within each diagnostic group. The 
incidence of ∆13 was substantially lower in MGUS (25%) and SMM (35%) than in MM (47%); 
the difference across the three groups was statistically highly significant (Kruskall-Wallis test, 
MGUS vs SMM vs MM, P <0.001). 
Rearrangements involving the IgH heavy chain locus located at 14q32 were detected with 
similar frequencies in MGUS and MM (41% vs 46%, respectively); the incidence in SMM 
(36%) was lower, but this difference was not statistically significant. When the individual 
chromosomal partners of the primary translocations were considered, similar frequencies of 
t(6;14), t(11;14) and t(14;16) were observed among the three groups; t(4;14) was rare in MGUS 
(3%), while SMM and MM showed almost the same incidence (13% vs 12%, respectively) 
(MGUS vs MM, P<0.001). The frequency of t(14;20) was higher in MGUS (5%) than in either 
SMM (<1%) or MM (2%). The difference in the incidence of this translocation was not 
statistically significant in this analysis, but it reached significance when the same MGUS group 
was compared to a larger population of MM patients (MM, n=1830; frequency of the 
translocation, 1.5%). Deletion of 16q23 was found to have a lower incidence in MGUS (6%)      Results 
  80
and SMM (8%) than in MM (21%) (MGUS vs MM, P<0.001). Deletion of TP53 was also very 























patients (%)       
∆13
†  45/183 (25%)  43/124 (35%)  186/395 (47%)  0.07  <0.001  0.017 
IgH 
rearrangement 
76/187 (41%)  45/126 (36%)  183/398 (46%)  0.41  0.25  0.05 
t(4;14)  6/182 (3%)  16/123 (13%)  49/400 (12%)  0.003  <0.001  0.87 
t(6;14)  2/174 (1%)  1
††/119 (~1%)  6/393 (2%)  1  1  1 
t(11;14)  29/184 (16%)  13/123 (11%)  55/399 (14%)
§  0.24  0.53  0.44 
t(14;16)  6/178 (3%)  4/120 (3%)  15/396 (4%)  1  1  1 
Deletion 16q23  8/139 (6%)  7/84 (8%)  75/365 (21%)  0.58  <0.001  0.008 
t(14;20)  8/176 (5%)  1/119 (~1%)  9/394 (2%)  0.09  0.18
#  0.47 
Deletion TP53  5/175 (3%)  1/117 (~1%)  38/388 (10%)  0.41  0.003  <0.001 





(38%)**  165/388 (43%) 
0.002  <0.001  0.45 
 
Table 3- 1  Incidence of specific chromosomal abnormalities (CA) in the three 
diagnostic groups (statistically significant P values are in red) 
† Near-tetraploid cases with only two copies of 13q14 were counted as ∆13. 
†† The locus 6p21 was involved in a t(6;22)(p21;q11) with the IgL locus. 
* 19/171 patients (11%) belonging to the nonHRD group were found to be normal for all the iFISH 
tests performed and were classified as diploid (nonHRD). 
** 2/113 patients (~2%) were found to be normal for all the iFISH tests performed. 
§ 2/55 (4%) patients showed amplification of CCND1, in absence of t(11;14); given that both 
abnormalities result in over-expression of CCND1, they were analysed as a single group. 
# When the frequency of t(14;20) in MGUS was compared to that found in a larger group of MM 
(1830 patients; frequency of 1.5%), the difference was highly significant. 
 
 
The patient distribution in the two ploidy classes differed between the diagnostic groups. While 
a HRD karyotype was indicated in 62% of SMM and 57% of MM patients, only 42% of MGUS 
cases were assigned to this category. The nonHRD MGUS group also included those patients 
found to be negative for all the interphase FISH markers; in MGUS, 19 of 171 patients with 
ploidy results belonged to this group and accounted for most of the difference between the      Results 
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groups. This result was not surprising as there probably are MGUS cases who are genuinely 
normal from a cytogenetic point of view. 
 
IgH rearrangements involving the five recurrent loci (4p16, 6p21, 11q13, 16q23 and 20q11) 
were highly associated with a nonHRD karyotype in all three diagnostic groups: 93% of MGUS 
cases, 82% of SMM cases and 73% of MM cases with one of these IgH translocations were 
found in the context of nonHRD (P<0.001 for all groups). In contrast 35 of 49 MM cases with 
an IgH rearrangement not involving one of these loci were found in association with HRD 
(P=0.043). In the SMM group the six unidentified IgH rearrangements were equally distributed 
between the two ploidy groups. In MGUS, twelve of 16 unidentified IgH rearrangements were 
found in the context of a nonHRD karyotype but the association was not statistically significant. 
 
3.1.4.3  Percentage of PC in patients with ∆13 














Figure 3- 2  Distribution of the percentages of abnormal PC with ∆13 in patients found 
positive for the abnormality, among the three groups of patients 
 
As an exception, cases showing ∆13 in 10% to 20% PC were included in the assessment of the 
distribution of the percentages of abnormal PC with ∆13 in patients positive for the abnormality. 
Despite the fact that such cases were considered to be normal using the EMN criteria, some 
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indicating that, they did not represent technical artefacts (see patient 949, Section 3.2.4 and 
patient 259, Section 3.5.4.2). 
 
The median percentage of abnormal PC carrying the abnormality was 65% in MGUS, 88.5% in 
SMM and 95% in MM. Illegitimate IgH rearrangements showed no variation between disease 
types: in MGUS the median percentage of cells displaying a 14q32 translocation was 91.5% 
(range, 24%-100%).  
The level of PC involvement of different CA was compared for all MGUS patients who 
exhibited ∆13 with at least one other abnormality (Table 3-2). Because of the differences in 
false positive rates between probes (fusion probes vs break-apart probes vs probes used to detect 
deletions), unequivocal evidence of heterogeneity within the neoplastic clone was only accepted 
when the difference in the proportions of cells affected by distinct CA was >30%. In 15 of 45 
patients with ∆13, the abnormality was present in <60% PC (highlighted area of Table 3-2); of 
these 15 cases, 12 had other CA for comparison. All but four of these 12 showed the non-∆13 
abnormality to have a PC involvement at least 30% greater than the one shown by ∆13.  
 
Interestingly four of five (80%) MGUS cases positive for both t(4;14) and ∆13 showed the same 
proportion (± 5%) of PC with the two abnormalities. In contrast, three of four (75%) t(14;20) 
MGUS with ∆13, showed at least 30% fewer ∆13-positive PC (median, 45%) compared with 
those with t(14;20) (median, 100%) (∆13 vs t(14;20) for the four cases: 30% vs 100%; 45% vs 
90%; 56% vs 100%). The only t(14;20) SMM case of this cohort also showed ∆13; while the 
translocation was present in 90% of PC, ∆13 was present in 60%. In MM seven of nine (78%) 
t(14;20) cases were associated with ∆13 and the median difference in PC involvement of ∆13 
and the translocation was 10% (range, 0-27%). 
 
In MGUS, 16q23 deletions were often present in a sub-clone of the PC population (median, 
63%; range, 23%-100%), while in MM the median percentage of PC with the abnormality was 
87% (range, 21%-100%). Those MGUS cases showing low level PC involvement of 16q 
deletion displayed at least one of the other CA in the majority of clonal PC (deletion 16q23 vs 
other CA: 23% vs 82% IgH split; 33% vs 93% deletion of 14q32; 44% vs 92% IgH split; 47% vs 
99% IgH split).      Results 
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Table 3- 2  List of 45 MGUS patients with ∆13 ordered on the basis of the percentage of PC involvement of the abnormality 
For each case, concomitant numerical or structural CA are specified with the percentage of PC involvement; blank cells represent cases with ∆13 only with no other 
CA among the ones tested. Highlighted cells represent cases where ∆13 was present in <60% PC. (UIP, unidentified partner)
Case 
% of PC 
with ∆13  Other abnormalities (%)  Case 
% of PC 
with ∆13  Other abnormalities (%) 
1  20%  3 x ‘CCND3’ (36%); IgH split (32%) (UIP)  24  75%  Trisomies 5, 9 & 15 (99%); c-MYC split (47%) 
2  30%  t(14;20) (100%)  25  76%  t(14;16) (96%) 
3  36%  IgH split (30%) (UIP)  26  77%  t(6;14) (100%); trisomy 9 (35%); 3 x ‘CCND1’ (55%) 
4  38%  Trisomy & tetrasomy 9 (80%)  27  79%  Trisomy 5 (79%) 
5  40%     28  80%  Unbalanced IgH split (80%) (UIP) 
6  41%     29  81%  Unbalanced IgH split (100%) (UIP); deletion 16q23 (97%); deletion TP53 (50%) 
7  45%     30  82%    
8  45%  t(14;20) (90%)  31  83%  Trisomies 5, 11 & 15 (98%) 
9  48%  t(11;14) (100%)  32  83%  Deletion 14q32 (79%) 
10  52%  Trisomies 5, 6, 9 & 15 (>90%)   33  84%  t(4;14) (85%) 
11  53%  Trisomies 5, 15 (>90%); deletion 16q (95%)  34  88%  3 x ‘CCND3’ (75%); trisomy & tetrasomy 9 (100%); trisomy 15 (75%) 
12  56%  t(14;20) (100%)  35  90%  Deletion 14q32 (79%) 
13  56%  IgH split (89%) (UIP); deletion 16q (23%)  36  90% 
Trisomies 5 & 9 (99%); tetrasomy 15 (88%); 3 x ‘CCND1’ (76%); 3 x ‘IgH’ 
(94%) 
14  58%  Deletion 14q (67%)  37  94%  t(4;14) (89%) 
15  58%  3 x ‘CCND3’ (85%); trisomy 9 (89%); IgH split (76%) (UIP)  38  95%  t (14;16) (100%) 
16  61%  t(14;20) (75%)  39  96%  Trisomies 5 & 15 (95%) 
17  62%  t(14;16) (60%)  40  97%  Deletion 14q32 (93%); deletion 16q23 (33%) 
18  62%  Trisomies 9 (52%) & 15 (60%)  41  97%  t(4;14) (94%) 
19  63%  Trisomies & tetrasomies 5, 9 & 15 (79%)  42  100%    
20  65%  t(4;14) (70%)  43  100%  Trisomy 5 (94%); tetrasomy 9 & 15 (96%); 3 x ‘CCND1’ (60%) 
21  72%  t(14;16) (95%)  44  100%  Deletion 14q32 (88%) 
22  72%  Unbalanced IgH split (96%) (UIP)  45  100%  IgH split (100%) (UIP) 
23  74%  t(4;14) (100%)       Results 
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3.1.4.4  Association of ∆13 with other abnormalities 
Table 3-3 shows the association between ∆13 and other CA.  
 
                                    ∆13      Significant  P values 
CA  MGUS  SMM  MM   
IgHr  24/74 (32%)  23/44 (52%)  110/182 (60%)  MGUS vs SMM, P=0.05 
MGUS vs MM  P<0.001 
t(4;14)  5/6 (83%)  13/16 (81%)  45/48 (94%)   
t(6;14)  1/2 (50%)  0/1  4/6 (67%)   
t(11;14)  1/28 (3.6%)  2/13 (15%)  21/53 (40%)  MGUS vs MM,  P<0.001 
t(14;16)  4/6 (67%)  3/4 (75%)  11/15 (73%)   
t(14;20)  4/8 (50%)  1/1  7/9 (78%)   
HRD  11/71 (15%)  14/68 (21%)  74/219 (34%)  MGUS vs MM, P=0.003 
SMM vs MM, P=0.05 
nonHRD  30/99 (30%)  23/43 (53%)  109/164 (66%)  MGUS vs MM,  P<0.001 
MGUS vs SMM, P=0.01 
 
Table 3- 3  Association between ∆13 and the different CA 
(IgHr, IgH rearrangements) 
 
The ∆13 was less frequently associated with any of the IgH rearrangements in MGUS than in 
MM (MGUS vs MM, 32% vs 60%; P<0.001). However, when the individual translocations 
were examined, no significant differences were found in the frequencies of association of 
t(4;14), t(14;16), or t(14;20) with ∆13, among the three diagnostic groups.  
In MM, ∆13 was found in 40% of t(11;14) cases with a very high PC involvement (>85%) 
while only one of 28 (3.6%) MGUS cases with t(11;14) had ∆13 (P<0.001). In this case, only 
48% PC had ∆13 while the translocation was present in all cells. In SMM only two of t(11;14) 
cases had ∆13 (15%), but this was not significantly different from the percentage found in MM. 
Both SMM patients had ∆13 in 70% PC and the translocation in 100% PC.  
In this study, the presence of t(6;14) was detected in only 1-2% of patients, in agreement with 
other reported series 
46. Despite the small number of cases, it was notable that ∆13 was present 
in four of the six (67%) MM cases; in MGUS one of the two t(6;14) cases was negative for the 
abnormality (12% PC were found with the deletion), the other (patient 355) was positive for 
∆13. In this patient (M-protein type, IgGk; M-protein level, 26 g/L) iFISH analysis showed the 
presence of a t(6;14) in all PC, ∆13 in 77% of PC and three copies of chromosomes 9 
centromere and CCND1 in 35% and 55% of PC, respectively. Cytogenetic analysis done at the 
time of MGUS diagnosis revealed one abnormal metaphase out of 48; the karyotype confirmed Results 
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the t(6;14), the monosomy 13 and the trisomies 9 and 11 detected by iFISH as well as showing 
additional abnormalities (one extra copy of chromosome X, trisomy 19 and monosomies 14 and 
16). A second BM sample was received 21 months later; at this time the patient progressed to 
SMM (M-protein level, 40.9 g/L; array CGH done on this sample, see Section 3.3) and ∆13 was 
found to be present in 90% PC. The patient transformed to MM 20 months after the second 
sample. Interestingly, the array CGH profile obtained at the stage of SMM not only confirmed 
the presence of all the CA detected by iFISH and by conventional cytogenetics but also showed 
no additional changes. All together these findings suggest that, despite the relatively slow 
progression, the genetic background characterizing the PC at the MGUS stage was probably 
able to drive the evolution to overt disease without the need of further events. Of note was that 
cytogenetic analysis performed on the sample taken during the MGUS stage, revealed the 
presence of one abnormal metaphase. This in itself was an interesting finding, indicative of an 
already acquired capacity of the malignant clone to divide in vitro.  
Among the other three pre-malignant patients with either t(11;14) or t(6;14) and ∆13 (Table 3-
3), the only MGUS case (999) was still stable after 75 months from diagnosis. However, it has 
to be noted that ∆13 was only present in 48% of his PC. One SMM patient (805) died within 2 
years from diagnosis and no detailed information about his follow-up was available; the second 
SMM patient (2906), who had a recognized MGUS phase for more than 10 years prior to 
evolution to SMM, rapidly progressed to MM within 5 months from SMM diagnosis. In this 
patient, at the time of progression to SMM, ∆13 was present in 70% of PC while, at the time of 
MM diagnosis, the abnormality was present in all cells. Unfortunately, no material was 
available from the period corresponding to the MGUS stage, therefore it is impossible to know 
when ∆13 was acquired by the neoplastic clone.  
 
Interestingly, the ∆13 was found to be less frequent in MGUS and SMM with an HRD 
karyotype compared with MM HRD (MGUS vs MM, P=0.003; SMM vs MM, P=0.05). The 
lower incidence of this CA in nonHRD MGUS and SMM patients compared with MM patients 
reflects the fact that almost all t(11;14) patients belong to this ploidy group. 
 
3.1.5  Overall summary of the results and discussion 
The examination of a range of numerical and structural chromosomal changes in MGUS, SMM 
and MM patients showed that none of the CA tested were exclusive to any one diagnostic 
group. However, statistically significant differences were observed in the incidence of specific 
abnormalities between the three conditions. A significantly lower frequency of ∆13 was found Results 
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in MGUS and SMM as compared with MM. This is in accordance with the findings reported by 
Avet-Loiseau et al. 
85. The frequency of ∆13 progressively increased from MGUS to SMM to 
MM, suggesting a possible role of this abnormality in disease progression. The incidence of 
16q23 and TP53 deletions also showed a progressive increase from MGUS to MM (P<0.001 
and P=0.003, respectively). In contrast, a similar frequency of IgH rearrangements was 
observed in the three groups. When the individual incidences of the specific translocations were 
compared, only t(4;14) was significantly less frequent in MGUS, in agreement with other 
reports 
44,85. The t(14;20) showed a higher incidence in MGUS compared to SMM and MM; 
Chng et al. 
89 reported a high prevalence of this translocation in MGUS (7%) compared to MM 
(2%), although the number of cases studied was not documented. 
 
Interphase FISH was used to classify patients according to their ploidy status in HRD and 
nonHRD. The ∆13 was found more frequently in nonHRD patients than in HRD in all three 
groups (MGUS, 15% vs 30%; SMM, 21% vs 53%; MM, 34% vs 66%), suggesting that the 
specific association between ∆13 and nonHRD, extensively reported in MM 
46,89, is already 
established at the MGUS stage. These findings differ from those reported by Brousseau et al. 
104. In MGUS, they found ∆13 more frequently in HRD patients (11/29, 38%) than in nonHRD 
(3/27, 11%), although the reverse association was seen in MM. They defined ploidy by 
measuring the PC DNA content using Feulgen reaction and image cytometry, they detected ∆13 
by iFISH and observed a nonHRD DNA content (composed by hypodiploid and diploid cases) 
in 46% of their MGUS patients (34.5% were diploid). It is impossible to explain this 
discrepancy. However, the fact that ploidy was evaluated by two different methods may be 
partially responsible. Pseudodiploidy and low chromosome count HRD (48 – 49 chromosomes) 
are potentially difficult to identify by iFISH, compared to true hypodiploidy or high 
chromosome count HRD. However, comparison of ploidy determined by iFISH with the actual 
karyotypes for those patients with abnormal cytogenetics showed that all cases but two were 
accurately classified. Thus iFISH misclassification of ploidy is unlikely to account for the 
significant difference in results between the two series. 
 
Abnormalities of 14q32 were observed in the majority of clonal PC, independently of the stage 
of the disease, whereas the percentage of PC carrying ∆13 or 16q23 deletion varied significantly 
between MGUS, SMM and MM, with MGUS patients showing the greatest heterogeneity. In 
MGUS, ∆13 was often present in a sub-clone of the abnormal PC. Although low level clones in 
MGUS may be due to only a small proportion of the CD138 positive PC being part of the 
neoplastic clone, the results of this study indicate that, in these cases, the ∆13 is a later change 
following IgH translocations or multiple trisomies. Similar findings were observed for most low 
level 16q23 deletions in which the cells were found to be 100% positive for other CA. Results 
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The results reported here clearly show that the time of occurrence of specific abnormalities is 
crucially dependent on genetic context. The t(4;14), t(14;16) and t(14;20) are highly associated 
with ∆13 in MM 
46,87,89. The same association was observed in MGUS and SMM patients. 
Moreover in t(4;14) and t(14;16) cases, IgH rearrangement and ∆13 were found in a similar 
proportion of abnormal cells in the three diagnostic groups, suggesting that ∆13 occurred early 
in their pathogenesis. However, a different time of occurrence of ∆13 was observed in relation 
to t(14;20). In MGUS, four of eight cases with t(14;20) also had ∆13. In three of four cases, the 
proportion of cells with ∆13 was at least 30% lower than those with the translocation. The only 
SMM case with t(14;20) showed the IgH translocation in all PC and the ∆13 in only 60% of 
cells.  In MM, seven of nine t(14;20) had ∆13, and the deletion was present in the same 
proportion of cells carrying the translocation. In MGUS, ∆13 appeared to originate later than 
t(14;20).  
A striking difference between MGUS and MM was seen regarding the association of ∆13 with 
t(11;14). While in MM 21/53 t(11;14) cases also showed ∆13, in MGUS only 1/28 cases with 
the translocation were associated with ∆13 (P<0.001). In MM the median percentage of PC with 
∆13 in t(11;14) patients was 98% while the only MGUS with both t(11;14) and ∆13 showed all 
PC positive for t(11;14) but only 48% PC with ∆13. The ∆13 occurred less frequently also in 
SMM cases with t(11;14) (two of 13); one of them progressed to MM within 5 months from the 
diagnosis of SMM.  
The translocation t(11;14) has been related to t(6;14) on the basis of a similar biological and 
clinical behaviour 
90. Both translocations activate a cyclin D family member (CCND1 and 
CCND3, respectively) and gene expression profiling studies demonstrated that cases carrying 
either one or the other translocation exhibited dysregulation of similar transcriptional 
programmes showing overlapping gene expression profiles 
90,124. The ∆13 was found in 67% of 
MM cases with t(6;14); interestingly in MGUS, ∆13 was present in one of the two cases with 
this translocation and the patient evolved to MM after 41 months from the initial diagnosis.  
These findings are consistent with those reported by Bochtler et al. 
217, who used clustering 
analysis on patients with amyloid light chain amyloidosis, MGUS and MM, in order to detect 
clustering of the chromosomal abnormalities t(11;14), t(4;14), gains of 11q23 and 1q21, and 
∆13. Patients with amyloidosis and MGUS showed the t(11;14) branch independent of ∆13, 
while t(4;14), and gain of 1q21 were grouped together with ∆13. 
 
It is clear that MM includes a number of conditions which, despite being morphologically 
similar, have different underlying genetic backgrounds which are thought to dictate the clinical 
heterogeneity of MM. The increasing understanding of how the different CA relate to each other 
can contribute to explain the unique pathogenesis of the different subtypes and their dissimilar 
outcome.    Results 
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3.2  Biological significance of IgH translocations associated 
with a poor prognosis in MM and TP53 deletion in the 
context of pre-malignant conditions 
 
3.2.1  Introduction 
In MM, genetic testing has become important in diagnostic evaluation to identify patient 
subgroups with different prognoses. Among the five recurrent chromosomal partners involved 
in primary IgH translocations, rearrangements involving the loci 4p16 (FGFR3/MMSET), 16q23 
(c-MAF) and 20q12 (MAFB) have been associated with a poor prognosis, while rearrangements 
involving the loci 11q13 (CCND1) and 6p21 (CCND3) have been associated with an 
intermediate risk 
46,218.  
As shown in Section 3.1.4.2 (Table 3-1), overall, IgH rearrangements have been identified at 
similar incidences in MGUS, SMM and MM, with the only exception being t(4;14) found less 
frequently in MGUS. These findings support the hypothesis that IgH translocations represent 
early cytogenetic events in PC dyscrasias. The rarity of t(4;14) in MGUS suggests that it might 
result in a more aggressive disease characterized by a very short MGUS stage (hardly ever 
detectable), rapidly evolving to overt MM. However, different groups have reported long 
periods of stability after diagnosis (with translocation present) in patients with t(4;14) and 
t(14;16), suggesting that these abnormalities alone, at least in some cases, were not sufficient for 
progression from MGUS/SMM to MM 
44,109,137,138. 
 
Deletions of 17p13 are rare in MM and even rarer in MGUS or SMM, as shown in Section 




In this section the outcome of the individual MGUS and SMM patients with t(4;14), t(14;16), 
t(14;20) and 17p13 deletion was followed in order to better understand the clinical significance 
of these CA associated with a poor outcome in MM, in the context of the pre-malignant 
conditions. Results 
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3.2.2  Outcome of t(4;14), t(14;16) and t(14;20) in MM 
The MM Cytogenetics Database investigated the outcome of the three poor prognosis IgH 
rearrangements in a large group of MM patients (n=1830, 1695 were diagnostic samples) 
ranging in age from 27 to 93 years (median 65, with 33% over the age of 70 and 18% over the 
age of 75 years). These patients were treated with a variety of standard therapies within UK 
hospitals; 1020 patients were entered into the MRC Myeloma IX Trial and the majority of the 
remaining younger patients received at least one autologous transplant. 
The median follow-up was 31.7 months. As it is accepted that primary IgH translocations are 
early events occurring at the beginning of the neoplastic transformation, survival (in MM) or 
follow-up time (in pre-malignant cases) were calculated from the time of diagnosis, regardless 
of the time of FISH analysis. 
The incidence of t(4;14) and t(14;16) were 11% and 3%, respectively. The t(14;20) was 
confirmed to be rare, with an incidence of 1.5%. All three translocations resulted in short OS in 
MM patients (Figure 3-3) and among the three translocations, patients with t(14;20) showed the 








Figure 3- 3  Kaplan Meier survival curves of OS for patients with t(4;14) (A), t(14;16) 
(B) and t(14;20) (C) 
 
3.2.3  Results 
3.2.3.1  Characteristics of MGUS and SMM patients with the poor prognosis 
translocations 
The outcome of 21 MGUS patients (age range: 39-84 years; median, 58 years) and 24 SMM 
(age range: 30-78 years; median, 60 years) positive for one of the poor prognosis translocations 
was examined. Table 3-4 shows the genetic characteristics (IgH rearrangements, ∆13 and 
ploidy status) and the outcome of each patient. 
A B CResults 
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   Pt  Age  PP  Diagnosis  IgHt    ∆13  HRD  Stable 
Time to 
progression/length of FU 
(months) 
1230  56  IgAκ  MGUS  t(4;14)  √  -  Lost  - 
2715  65  IgGκ  MGUS  t(4;14)  √  -  √  39 
2664  42  IgGκ  MGUS  t(4;14)  √  -  √  44 
1390  39  IgGλ  MGUS  t(4;14)  √  -  √  57 
58  62  IgGλ  MGUS  t(4;14)  √  -  √  98 
1275  58  IgAκ  MGUS  t(4;14)  -  √  No  36 (SMM), 44 (MM) 
1494  39  IgGλ  MGUS  t(14;16)  √  -  √  17 
2941  53  IgAλ  MGUS  t(14;16)  -  -  √  23 
2190  66  IgGκ  MGUS  t(14;16)  √  -  √  45 
1189  63  IgGκ  MGUS  t(14;16)  -  -  √  120* 
837  47  IgGλ  MGUS  t(14;16)  √  -  No  44 (MM) 
551  57  IgGλ  MGUS  t(14;16)  √  -  No  76* (MM) 
2285  69  IgGκ  MGUS  t(14;20)  √  -  √  43 
1862  43  IgGλ  MGUS  t(14;20)  -  -  √  53 
1655  50  IgG  MGUS  t(14;20)  -  -  √  46 
823  74  Free λ  MGUS  t(14;20)  -  -  √  54 
976  78  IgGκ  MGUS  t(14;20)  √  -  √**  67 
842  75  IgGλ  MGUS  t(14;20)  -  -  √  60 
367  46  IgGλ  MGUS  t(14;20)  √  -  √  77 
630  58  IgGκ  MGUS  t(14;20)  -  -  √  78 
417  84  IgGλ  MGUS  t(14;20)  √  -  √  74 
1252  56  IgGκ  SMM  t(4;14)  √  -  √  24 
1342  65  IgGλ  SMM  t(4;14)  √  -  √**  9 
508  61  IgGκ  SMM  t(4;14)  √  √  √  14 
2849  69  IgGκ  SMM  t(4;14)  √  -  No  21 
1516  77  IgGκ  SMM  t(4;14)  √  √  √  32 
1925  60  IgG  SMM  t(4;14)  √  -  No  33 
1107  50  IgGκ  SMM  t(4;14)  √  √  √  67 
1134  37  IgGκ  SMM  t(4;14)  √  -  √  60 
1385  63  IgAκ  SMM  t(4;14)  √  -  √  60 
1509  46  IgAλ  SMM  t(4;14)  √  -  No  6
§ 
105  68  IgGκ  SMM  t(4;14)  √  -  No  7 
2295  42  IgAκ  SMM  t(4;14)  √  √  No  8 
1597  63  IgGκ  SMM  t(4;14)  √  √  No  11
§ 
2543  58  IgGλ  SMM  t(4;14)  √  -  No  15 
1836  60  IgAκ  SMM  t(4;14)
¤  √  -  No  16 
3269  36  IgGλ  SMM  t(4;14)  √  -  No  34 
331  71  IgGκ  SMM  t(4;14)  √  √  No  33 
259  30  IgAκ  SMM  t(4;14)  -  -  No  53 
579  78  IgGκ  SMM  t(4;14)  √  -  No  78* 
1073  67  IgG  SMM  t(14;16)  √  -  √  55 
2198  60  IgGλ  SMM  t(14;16)  √  -  No  124* 
582  56  IgAκ  SMM  t(14;16)  -  √  No  15 
1315  60  IgGλ  SMM  t(14;16)  √  -  No  49 
866  44  IgG  SMM  t(14;20)  √  -  √  71 
           
Table 3- 4  Disease course of MGUS (area in gray) and SMM patients with t(4;14), 
t(14;16) and t(14;20) (The outcome of patients who progressed is in bold) 
(Pt, patient; PP, paraprotein; IgHt, IgH translocation; HRD, Hyperdiploid; FU, follow-up; √, 
presence of CA and disease stability; -, absence of CA).  Results 
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Previous page, Table 3-4 
* Patients 1189, 2198, 551 and 579 studied at 86, 74, 66 and 27 months after diagnosis, respectively. 
§ Patients 1509 and 1597 also had deletion of 17p. 
¤ Patient 1836 also had a t(8;14)(q24;q32).  
** Patients 1342 and 976 died of unrelated causes. 
 
3.2.3.2  Outcome of MGUS and SMM patients with t(4;14), t(14;16) and t(14;20) 
The majority of MGUS patients (17 of 20, 85%) had stable disease throughout the study, with a 
median follow-up of 54 months (range, 17–120 months). Three MGUS patients (one with 
t(4;14) and two with t(14;16)) progressed to MM after 44, 44 and 142 months from diagnosis, 
respectively. None of the nine MGUS patients with t(14;20) progressed to MM, showing what 
appeared to be truly stable disease with no rise in paraprotein level after a period ranging from 
43 to 78 months (median follow-up, 60 months). The presence of ∆13 in association with any of 
these translocations did not appear to have an effect on progression (P=1). 
As expected, SMM cases showed a higher rate of progression 
39, with 15 of 24 (63%) evolving 
to MM within a median period of 21 months (range, 6–124 months); the median follow-up for 
those nine patients who did not progress was 55 months (range, 9–71 months). Twelve of the 15 
cases who progressed had t(4;14) and three had t(14;16); four patients (all t(4;14)) progressed 
within one year from initial presentation; four within the second year (three t(4;14) and one 
t(14;16)), while seven patients evolved to overt MM after a longer period of indolent disease, 
ranging from 33 to 124 months. As observed in MGUS, in SMM ∆13 did not appear to be a 
factor associated with progressive disease (P=0.51). 
A sample from patient 2198 was received by the Database (August 2005) and tested by FISH 
after 74 months from initial diagnosis of SMM. After 50 months from the time of analysis (124 
months from diagnosis), he progressed to MM. His serum paraprotein level did not show a 
constant increase but fluctuated substantially during the follow-up period (June 2002, 24 g/L; 
June 2005, 50 g/L; April 2007, 36 g/L). FISH results showed an IgH rearrangement involving c-
MAF and loss of one copy of 22q11.22 in all cells, suggesting an early acquisition of these CA; 
∆13 was also detected but only in 50% of PC, indicative of a later event. Moreover, a proportion 
of PC (~30%) was clearly near-tetraploid as in these cells all the CA detected in the hypodiploid 
state were found to be doubled-up. In this patient, the presence of the t(14;16) clearly did not 
lead to a more aggressive disease course as the patient experienced a period of stability with no 
MM-related symptoms for longer than 10 years. 
The only SMM case with t(14;20) (866) retained a stable disease state until the end of this 
study, 71 months after diagnosis. This female patient was diagnosed with SMM at the age of 44 
years, in May 2003. At that time, her IgG paraprotein level was 44.3 g/L; her BM aspirate 
showed a high level of infiltration with ~45% PC, while a ‘squashed’ trephine preparation Results 
  92
showed 7% PC. No Bence-Jones protein was detected and white blood cell (WBC) count, β2M 
and creatinin levels were normal. The magnetic resonance imaging (MRI) scan was also normal 
and the patient was totally asymptomatic. FISH results showed a t(14;20) in all PC and ∆13 in 
only a proportion of them (60%). Multiple CA were tested by iFISH (gain of 1q, deletion of 
1p32.3, numerical abnormalities of chromosomes 3, 5, 7, 9, 15, MYC abnormalities and 17p13 
deletion; probes are described in Appendix 3); they were all found to be negative. Conventional 
cytogenetics was also attempted but only 18 normal metaphases were found. At the last follow-
up visit (April 2009) the patient was still totally asymptomatic: the PC percentage within the 
BM remained constant reaching 50% (5% greater compared with the time of diagnosis) at the 
last examination, by this time the paraprotein level, which fluctuated slightly during the follow-
up time, lowered down to 34 g/L.  
 
3.2.3.3  Outcome of MGUS patients with 17p13 deletion  
Five MGUS patients showed deletion of 17p13. Among the four patients with available follow-
up information, three progressed to MM; the fourth patient (684) died of an unrelated cause 2 
months after diagnosis (Table 3-5). 
 
Pt  Age  PP  Diagnosis  IgHt  ∆13  HRD  Stable  Time to progression/length  
of FU (months) 
684
¤  84  IgGκ  MGUS  -  -  yes  √  2* 
2683
§  54  IgG  MGUS  -  -  yes  No  24 
949  75  IgAλ  MGUS  t(11;14)  -†  no  No  32 
1960
§  72  IgG  MGUS  UIP  √  no  No  15 
 
Table 3- 5  Disease course of MGUS with 17p13 deletion   
(Pt, patient; UIP, IgHt with unidentified partner; PP, paraprotein; HRD, Hyperdiploid; FU, follow-
up; -, absence of CA) 
*Patient 684 died for MM-unrelated causes (age 84 years) 2 months after MGUS diagnosis; 
¤ Patient 684 was found with ~60% PC carrying a bi-allelic 17p13 deletion. 
† patient 949 showed ∆13 in 9% PC at time of presentation and 15% in a sample analyzed a year 
later; TP53 deletion was present in 86% PC of the diagnostic sample. 
§ Patients 2683 and 1960 had 17p13 deletion in only a sub-population of PC: 42% and 50%, 
respectively.  
 
Two SMM patients had 17p13 loss (1509 and 1597) in association with t(4;14) and ∆13. Both 
patients evolved to MM 6 and 12 months after diagnosis, respectively. In both patients, the 17p 
deletion was detected in the majority of PC. However, it has to be noted that the initial diagnosis 
of the SMM case 1509 can be debated as he progressed to MM after only 6 months, suggesting Results 
  93
that the disease was fully unstable and probably more likely to be an early-MM instead of a 
SMM.  
 
3.2.4  Overall summary of the results and discussion 
Translocations associated with a poor prognosis in MM do not inevitably lead to aggressive 
disease when present in pre-malignant conditions. This is particularly true in the context of 
MGUS and of t(14;20) cases. In MGUS, not only a very small proportion of patients (15%) 
progressed, but in these patients progression occurred after more than 3 years from diagnosis. A 
higher proportion (63%) of SMM patients progressed to MM as compared with MGUS patients. 
However, those SMM cases who did not progress showed a median follow-up period almost 
three times longer than the median time to progression of those SMM patients who progressed. 
Moreover, among those SMM patients who progressed, the time to progression varied 
considerably. All together these observations suggest that the effect of these translocations is 
modulated by other factors and that these translocations alone cannot cause the establishment of 
a malignant phenotype. 
 
Deletion of 17p13 is a high-risk feature in MM and presumably leads to loss of heterozygosity 
of TP53 
146. The rarity of 17p13 deletions in pre-malignant conditions is suggestive that this 
change is associated with the clinical manifestation of the disease. Ignoring MGUS patient 684 
who died after 2 months from diagnosis from MM-unrelated causes, all MGUS and SMM cases 
positive for this abnormality progressed to MM. This strongly reinforces the role of 17p13 loss 
in the progression of these patients. However, progression was not rapid in all cases (patient 949 
progressed after 32 months) and variations in time to progression were not dependent on the 
percentage of PC carrying the abnormality. Patient 949 had 17p13 loss in 86% of PC, while 
patient 1960, who progressed after 15 months, had 17p13 deletion in only 50% of PC. 
Interestingly, patient 949 was found with a 17p13 deletion in 86% of PC, t(11;14) in all cells 
and ∆13 in 9% of PC (reported as negative based on the EMN cut-off levels). A second sample 
sent to the Database a year later (when the patient was still MGUS) was found with 17p13.1 
deletion in all cells and ∆13 in 15% of PC. This finding confirmed that ∆13 was not a technical 
artefact in the first sample and reinforces the idea that, in t(11;14) cases, ∆13 is a late event (in 
this case also slowly spreading within the neoplastic clone) and that its acquisition might be 
associated with disease progression.  Results 
  94
3.3  Array CGH analysis of PC neoplasms 
 
3.3.1  Introduction 
The primary IgHt observed in MGUS and SMM seem to be in themselves insufficient to initiate 
overt MM, suggesting a minimal two ‘hit’ model for molecular pathogenesis and aetiology. 
Data initially derived from conventional cytogenetics 
81,107,219,220 and later from high resolution 
SNP array and array CGH experiments 
155,167,178,181,182 showed that MM cases usually have, in 
addition to the IgHt or HRD, multiple DNA aberrations or copy number abnormalities (CNA). 
It is very important to understand when, in relation to IgH rearrangements or HRD, these 
multiple CNA arise in the multi-step molecular pathogenesis and how they affect the course of 
the disease.  
Interphase FISH, while useful to compare the frequencies of specific CA between different 
diagnostic groups, requires prior knowledge of the relevant abnormalities and can only test a 
few markers simultaneously. Whole genome approaches of investigations can overcome the 
limitations of FISH. However, the small amounts of material available from MGUS and SMM 
patients have restricted the number of meaningful studies. There are only a small number of 
reports using metaphase CGH to detect CA in these diagnostic groups 
164,183, thus the global 
picture of the PC genome in MGUS and SMM remains almost unexplored.  
 
Here, high-resolution array CGH has been used to identify the genetic changes associated with 
progression of MGUS and SMM to MM. Given the high genetic heterogeneity of PC neoplasms 
it is unclear whether different mechanisms are responsible for disease evolution dependent on 
the nature of the primary initiating events. To address this question within each diagnostic 
group, patients with different primary changes identified by iFISH were selected. Subsequently 
the CNA in MGUS, SMM and MM were compared and the minimally deleted/gained regions 
were mapped to localize potential genes involved in MM tumourigenesis.  
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3.3.2  Patients 
Array CGH was performed on 87 samples (25 MGUS, 15 SMM and 47 MM) from 85 patients 
acquired through the Myeloma Cytogenetic Database (the characteristics of the patients are 
described in Appendices 6 and 7). Few patients within the Database had sequential BM samples 
taken at the time of MGUS or SMM diagnosis and at the time of progression to MM; patients 
989 and 1581 were the only ones with enough material to perform array CGH at both time 
points. Patients were selected on the basis of material availability and their genetic profile 
previously defined by iFISH for a number of CA, including the presence of an IgH 
rearrangement and ploidy status. For each genetic group, patients at different stages of the 
disease were selected as shown in Table 3-6.  
Array CGH was also used to characterize the MM cell line KMS-11.  
 
 
Table 3- 6  Distribution of patients from the three diagnostic groups divided into 
different genetic classes on the basis of their iFISH profile 
Patients 989 (*) and 1581 (
§) are included in the table twice as different BM specimens were 
analyzed at different stages of the disease. 
(Unid, unidentified; HRD, hyperdiploid; IgHr, IgH rearrangement). 
 
 
Follow-up data was available for all MGUS and SMM and for 46 of the 47 MM patients; three 
MGUS, four SMM and five MM were not studied at diagnosis, for these patients follow-up was 
calculated from the time of analysis as it was impossible to know the exact time of acquisition 
of the different CNA detected by array CGH. Eight of 25 (32%) MGUS patients progressed to 
MM with a median follow-up of 60 months; the follow-up period for those patients who did not 
progress ranged between 17 and 84 months (median, 67 months). Nine of 15 (60%) SMM 
patients progressed to MM (time to progression: range, 7–50 months; median, 20 months); the 
follow-up period for those who did not progress ranged between 14 and 74 months (median, 
55.5 months). For MM patients the median follow-up was 28 months; 29 of 46 (64%) died 
(median time, 18.5 months). 
 
  Cytogenetic groups 




t(14;16)  t(14;20) 
HRD       
no IgHr or 







nonHRD          
 unid IgHr or 
with t(8;14) 
MGUS  3  6  3  3  8*  0  2  0
§ 
SMM  7  1  3  1  2  0  0  1 
MM  11  8  8  2  12*  1  1  4
§ Results 
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An independent group of consecutive patients (n=233) was tested by iFISH in order to define 
the frequencies and the eventual prognostic significance of five loci which were highlighted by 
array CGH analysis. The patient cohort consisted of 37 MGUS (median age: 73 years, range 50-
90 years), 13 SMM patients (median age: 65 years, range 30-85 years) and 183 MM patients 
(median age: 64 years, range 35-88 years). Of the 183 MM patients, 135 (74%) were studied at 
diagnosis. In MM, median survival was 34 months (range, 0-84 months) when calculated from 
the time of cytogenetic analysis and 46 months (range, 0-136 months) when calculated from 
time of diagnosis.  
 
3.3.3  Methods 
3.3.3.1  Conventional cytogenetics 
Cytogenetic studies were performed after density gradient separation of BM samples and PC 
percentage assessment as described in Sections 2.2.3 and 2.2.4. Cytogenetic cultures were set 
up on samples from 15 MGUS, 11 SMM and 39 MM patients as described in Section 2.3. 
 
3.3.3.2  Array CGH 
3.3.3.2.1  Genomic DNA 
Patient genomic DNA. Genomic DNA was extracted from purified PC stored as a dried pellet 
(seven patients), purified PC stored in Carnoy’s fixative (78 patients) and non-purified fixed 
cells derived from cytogenetic cultures of 24 hours (patient 2314) or 3 days (patient 1890) as 
described in Section 2.5. For the two latter MM patients, the PC percentage was deduced by 
testing the cell suspension by iFISH for a marker known to be abnormal in these cases; both 
patients were tested for the t(14;20). The percentage of PC carrying the translocation was 35% 
in patient 2314 and 38% in patient 1890. For the other cases tested, the percentage of PC after 
purification was >80%. DNA from the MM cell line was extracted from a dried pellet. 
 
Control genomic DNA. Pooled DNA extracted from the peripheral blood of ten healthy donors, 




3.3.3.2.2  Array CGH platform 
Human genome CGH 244k microarrays (Agilent Technologies, USA) were used as described in 
Section 2.6. A minimum quantity of DNA recommended for each test is 500ng. 
 
3.3.3.2.3  Strategies for handling samples with small amount of DNA 
For some MGUS and SMM patients, the amount of DNA recovered after purification ranged 
from 150ng to 500ng, which is below the minimum recommended amount. In order to be able 
to use the material from these patients, array CGH of amplified-DNA was attempted. To assess 
this approach, whole-genome amplification (WGA) was performed on good quality DNA 
extracted from a MM patient (342) previously tested by array CGH on non-amplified material.  
 
Whole-genome amplification. WGA non-PCR-based, using φ29 DNA polymerase and random 
hexamer primers, was performed on DNA from patient 342 and a sex-matched control 
following the protocol described in Section 2.5.7; this method suggested amplification of the 
DNA for 16 hours in order to obtain maximum yields.   
After the amplification reaction and before DNA labelling, 100ng of amplified DNA, measured 
by optical density at 260/280 nm, was analysed by multiplex PCR. The PCR reaction was 
performed with five primer sets which produce 100, 200, 300, 400 and 600 bp fragments from 
non overlapping target sites in the genes TBXAS1 (exon 9; chr 7q33-34), RAG1 (exon 2; chr 
11q13), PLZF (exon 1; chr 11q23) and AF4 (exons 3 and 11; chr 4q21) (primers are described 
in Appendix 2) 
221. Reagents were added to a 50µl total reaction with final concentrations: 1x 
Buffer II (Applied Biosystems, UK), 0.2mM dNTPs (Pharmacia, UK), 2.0mM MgCl2 (Applied 
Biosystems, UK), 1U AmpliTaq Gold (Applied Biosystems, UK), 2.5pmol each primer of 
primer mix A, 5pmol each primer of primer mix B, 100ng DNA. The cycling conditions were: 7 
min 94˚C, 35 cycles each of 1 min 94˚C, 1 min 60˚C and 1 min 72˚C, followed by 7 min 72˚C 
ending at 4˚C. 10µl of each sample was analyzed on 1.5% TBE agarose ethidium bromide-
stained gel, as described in Section 2.4.3.2.4. 
 
Array CGH using <500ng non-amplified DNA. 200ng non-amplified DNA from patient 342 
was used to set up array CGH; the same amount of control DNA was used. The array profile 





3.3.3.2.4  Array CGH analysis 
The quality of the array hybridizations was expressed as a derivative log ratio spread (DLRS) 
calculated by the Agilent CGH Analytics software; this parameter reflects the spread of log2 
ratio differences between consecutive probes along all chromosomes. The analysis of the array 
CGH data was performed as described in Section 2.6.6. Gains and losses were defined using a 
500 kb weighted moving-average window and the ADM-2 algorithm of the CGH Analytics 
software with a threshold of 6.0. An abnormality was defined as recurrent when detected in 
more than three patients. CNV were identified with a database integrated into the Agilent CGH 
Analytic software, with the Database of the Genomic Variants and with Ensembl (URL in 
Appendix 1) and excluded from further analysis.  
 
3.3.3.3  FISH 
In order to confirm the presence of selected CNA detected by array CGH, FISH was performed 
on interphase or metaphase preparations using specific commercial and home-made probes. 
Interphase-FISH was also performed on a large and independent patient cohort, as described in 
Sections 2.4.4 to 2.4.9, in order to define the frequencies and prognostic significance of five 
loci highlighted by array CGH. Three loci encompassed genes involved in the NF-κB pathway: 
BIRC2/3 (11q22.1), TRAF3 (14q32.32) and NIK (17q21.31); the other two loci encompassed 
CDKN2A/2B (9p21.3) and CDKN1B (12p13.1). For 9p deletions, a BAC for CDKN2A/2B was 
combined with a BAC mapping PAX5 at 9p13.2. The detection of BIRC2/3 and TRAF3 
deletions was performed with a combination of BAC and fosmid clones selected in order to 
distinguish small and larger deletions. NIK abnormalities were detected using a fusion strategy 
involving four different BAC clones mapping 17q21.31. CDKN1B abnormalities were detected 
with the use of a single fosmid (all probes are described in Appendix 3).  
 
3.3.4  Results 
3.3.4.1  Array CGH Comparison between non-amplified DNA (standard vs small 
quantity) and amplified DNA 
100ng DNA at high integrity from the patient and the control were amplified for 2, 4, 6, 8, 16 
hours and purified. The amplified genomic DNA was analysed by 2% agarose gel Results 
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electrophoresis to visualize the DNA size distribution; the majority of fragments showed a size 
ranging between 200bp and 500bp, as recommended by the company.   
The DNA quantification using the NanoDrop ND-1000 UV-VIS Spectrophotometer (see 
Section 2.5.3) showed a progressive increase in the amount of amplified DNA corresponding to 
longer incubation reactions. The amplification yields for the patient and the control were 
respectively: 0.5µg and 2.6µg at 2 hours, 1.2µg and 4.6µg at 4 hours, 2.7µg and 5.3µg at 6 
hours, 2.3µg and 6.3µg at 8 hours, 4.9 and 7.4 at 16 hours. 
Multiplex-PCR was used to test the quality of the amplified DNA. All DNA except the 600bp 
fragment from the 16-hour reaction of the patient showed all five PCR products (Figure 3-4).  
After 8 hours, more than 2µg amplified-purified DNA was generated for both the patient and the 
control. In order to minimize amplification bias, the 8-hour-amplified DNA samples from the 












Figure 3- 4  Multiplex-PCR reveals whether the 100, 200, 300, 400 or 600bp fragments 
were amplified from 100 ng total genomic DNA (patient and control); for the 16-hour 
patient sample, the 600bp fragment was not visible 
 
The array-profile obtained using 200ng non-amplified DNA was highly comparable to the one 
set up with 1.5µg non-amplified DNA (Figure 3-5). The two array CGH experiments were 
analyzed independently: an identical number of CNA and breakpoints were detected. In 
contrast, the array profile obtained using 8-hour amplified DNA was of poor quality (DLRS: 
0.9), characterized by a high level of noise which made the accurate detection of CNA almost 
impossible. This was probably due to a large variation in the extent of amplification occurring 
between different genomic regions 
222; this amplification bias seemed to totally alter the 




































































































































































































































































































































































































































































































As a consequence of these findings, for all samples with <500ng DNA, array CGH was set up 
using non-amplified material.  
CNA, detected by array CGH, were compared with the karyotype (if informative) or with the 
FISH results obtained using an extensive panel of probes. No discrepancies were found when 
array CGH was compared with FISH. Apparent discrepancies found when comparing array 
CGH and karyotype appeared to arise from misinterpretation of the conventional cytogenetics 




Figure 3- 5  G-banded idiogram and array CGH profiles of chromosome 8 obtained 
from hybridization of amplified and non-amplified DNA (standard amount vs 200ng) of 
patient 342. The plot of calls for every nucleotide of the region 8q23.2-q23.3 is shown for 
each array experiment; note the ‘noisy’ profile of amplified compared to non-amplified 
DNA 
 
3.3.4.2  Conventional cytogenetics 
Conventional cytogenetics revealed an abnormal karyotype in two of 15 MGUS, two of 11 
SMM and 31 of 39 MM patients (karyotypes are described in Appendices 6 and 7); one MM 
case failed to show metaphases and the remaining cases had a normal karyotype. 
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3.3.4.3  Array CGH 
3.3.4.3.1  Overall abnormalities 
Array CGH detected CNA in all but one MM sample (patient 1890); metaphase analysis for this 
patient showed the presence of two balanced rearrangements and no CNA (see karyotype in 
Appendix 7). Overall a total of 1327 CNA, defined as discrete segments showing copy number 
variation consistent with loss or gain, were detected with a median of 8 per case (range, 1-24) in 
MGUS, 11 per case in SMM (range, 5-19) and 19 per case in MM (range, 0-63) (array CGH 
results for each patient are described in Appendix 8; a graphical representation of CNA of all 









Total number of 
gains  
(Average) 






8  31 (3.9)  52 (6.5) 
t(14;20)  3  1 (0.3)  13 (4.3) 
t(6;14) & 
t(11;14)  6  5 (0.8)  6 (1) 
MGUS 




11  58 (5.3)  60 (5.5) 
t(14;20)  1  1  4 
t(6;14) & 
t(11;14)  1  3  3 
SMM 




24  143 (6)  373 (15.6) 
t(14;20)  2  5 (2.5)  6 (3) 
t(6;14) & 
t(11;14)  8  83 (10.4)  85 (10.6) 
MM 
HRD  13  178 (13.7)  93 (7.2) 
 
Table 3- 7  Number of CNA found in MGUS, SMM and MM by array CGH 
 
Table 3-7 shows that, for all diagnostic groups the number of CNA progressively increased 
from MGUS to MM. The greatest difference was noted in patients with t(6;14) and t(11;14): in 
MGUS they showed an average of  gains and losses of 0.8 and 1, respectively, while in MM 
these averages increased to 10.4 and 10.6, respectively. MGUS and SMM patients with t(14;20) 
also showed a relatively low number of CNA. One (1890) of the two MM patients with this 
translocation showed no CNA (confirmed by metaphase analysis); the second case showed six 
losses and five gains. Unfortunately no material from other MM cases with this translocation 




cytogenetics were found: the majority of them showed complex karyotypes with multiple 
structural and numerical changes (karyotypes are described in Appendix 10); therefore it is 
possible that the number of CNA detected by array CGH for these two patients was not entirely 
representative of MM patients with this translocation.  
In all diagnostic groups, patients characterized by one of the poor prognosis IgH translocations 
or by a hypodiploid karyotype showed a higher average number of losses compared to gains, 
while in the HRD groups the opposite was true. Patients with t(11;14) showed a similar average 
of gains and losses in the three diagnostic groups. 
 
In MGUS, there was a clear association between a high number of CNA (defined as >5) and 
disease progression to MM (Figure 3-6): none of the 11 MGUS patients with <5 CNA, 
regardless of the genetic group, progressed to MM while eight of 14 patients with >5 CNA 
evolved. The only SMM case (866) with <5 CNA (with t(14;20)) also showed no evidence of 















Figure 3- 6  Kaplan-Meier analysis of progression in MGUS displayed in relation to the 
number of CNA (<5 or >5) per case detected by array CGH  
(Follow-up was calculated from the time of analysis) 
 
Homozygous deletions (HD) and amplifications (defined as >6 copies) were very rare in pre-
malignant patients. One HD but no amplified regions were detected in MGUS; one HD and one 
amplification were found in two SMM patients, while 25 HD and 19 amplifications were found 
in 20 MM patients; two HD were detected in the cell-line KMS-11. Five HD were found in 
more than one patient, while the only recurrent amplified region was located at 8q24.21 and 
P=0.003
Progressed/N        Median time 
to progression
Number of CNA <5 0/11                           *
Number of CNA >5 8/14                            75
P=0.003
Progressed/N        Median time 
to progression
Number of CNA <5 0/11                           *
Number of CNA >5 8/14                            75
Progressed/N        Median time 
to progression
Number of CNA <5 0/11                           *
Number of CNA >5 8/14                            75Results 
  103
involved the MYC gene (Table 3-8). As HD and amplifications may be secondary events, they 
often involve only a sub-clone of the tumour population. In these cases, it may be difficult to 
detect them by array CGH as the log2 ratio for each locus represents the average of the number 
of copies for all cells, resulting in an overall dilution of the chromosome aberration calls. 
Therefore it is important to verify cases with suspicious high level gains or borderline HD by 
iFISH as they may hide sub-clonal amplifications or HD. One example was the amplification 
found at 22q13.1 in the SMM patient 1252. This CNA was initially interpreted as high level 
gain but iFISH showed amplification of this region in less than 50% of PC, with four to six 
copies of the cosmid probe for PDGFβ and >seven copies of the BAC probe centromeric to 
PDGFβ (probes are described in Appendix 3).  Results 
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Patient  HD  Amplification 
  Chromosomal 
region  Mb position  Chromosomal 
region  Mb position 
2715 (MGUS)  13q21.32   66239860 -66369533  -  - 
1252 (SMM)  -  -  22q12.3-q13.2
§  35160638 - 38954220 
582 (SMM)  14q32.32
§  102295758 - 102628399  -  - 




45018886 – 46076516 
66562569 – 68358572 
69016058 – 69409552 
69753919 - 70471343 




89279518 - 90847519 
-  - 
719 (MM)  13q14.2 
Xp22.11 
Xq21.32 
47791842 – 47995068 
21341117 – 21372735 
91645681 - 91688206 
-  - 




34837268 – 34974263 
91404795 - 91632202  -  - 
374 (MM)  1p32.3
§  51121283 - 51254925  -  - 
1148 (MM)  13q34  63162766 – 63242385 * 
 
17p13.2
§  4735005 - 5683523 




49905463 - 51755900 
101061854 - 103024486 
-  - 
282 (MM)  16q23.1  77227769 - 77263523  17p12-p11.2
§  15796976 - 17105002 
309 (MM)  11q22.3
§  97013770-103605664  -  - 
619 (MM)  13q14.2 
16q12.2 
22q13.1 
47817280 – 47928395 
52181870 – 52500340 
37683612 - 37709985 
-  - 
2906 (MM)  9p13.2  21998596 - 22007894  -  - 
666 (MM)  -  -  20q13.33
§  60474168 - 61929664 
3325 (MM)  -  -  8q24.21
§  128132928 - 130339406 
1524 (MM)  -  -  8q24.21
§  127508344 - 128892972 





177442074 – 179423743 
116673147 – 116710377 
55200444 – 55365810 * 
44678212 – 44827435 
79721622 - 79876033 
-  - 
1776 (MM)  -  -  7p15.2  26931500 - 26987201 










75628165 - 76191463 
79745146 – 81155223 
87369697 - 87865857 
128767860 -  129988129 
60447455 – 61203003 
68972488 – 70439619 
62778502 - 64490079 
14294323 – 14489561 
491 (MM)  14q32.32
§  102408026 - 102592287  -  - 






47928974 – 51949445 
76737934 - 77794243 
-  - 
 
Table 3- 8  List of all HD and amplifications detected by array CGH 
Recurrent  HD  are  highlighted  using  the  same  colour.  The  only  recurrent  amplified  region  at 
8q24.21 is indicated in red  
* no genes involved in the CNA. 
§ CNA validated by FISH. Results 
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Comparing the array CGH profiles among the three diagnostic groups, significantly higher 
frequencies of loss of 1p, 6q, 8p, 9p, 12p, 16q, 17p, 18p and gains/rearrangements of 8q24.21 
were found in MM compared with MGUS and SMM. In Table 3-9, for each pre-malignant 
patient, the presence or absence of specific CNA is shown. CNA that were found to be totally 
absent in MGUS/SMM (i.e. 9p21.3 and 12p13.1 deletions) were not considered in this table. 
 
 
Table 3- 9  For each pre-malignant patient the disease course, follow-up time and 
presence of specific CNA is shown (patients who progressed are highlighted in blue) Results 
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Previous page, Table 3-9 
(√, presence of CNA; blank cell, absence of CNA; Progr, progressed; FU, follow-up; Diagn, 
diagnosis; HRD, hyperdiploid; nonHRD, non-hyperdiploid).  CNA that were not detected in any of 
the MGUS/SMM have not been included in the table. * The CNA was present in a sub-population 
of PC. 
¤ Patient 3318 died after 17 months from diagnosis for MM-unrelated causes. However, her 
paraprotein was beginning to rise and atypical PC were detected in her BM.  # Patient 1252 moved 
to USA 24 months after diagnosis; although he remained asymptomatic, his paraprotein was rising 
considerably. 
 
3.3.4.3.2  Chromosome 1 abnormalities 
Chromosome 1 was one of the most highly rearranged chromosomes, usually characterized by 
gain of 1q and loss of 1p (Figure 3-7). On 1q, a minimal region of gain was identified at 1q12-
q23.2 (141465960Mb – 157108464Mb). Gains of this region were detected in seven of 25 


















Figure 3- 7  Graphical representation of CNA of chromosome 1 for all patient groups 
The 850-band idiogram of the G-banding pattern of the chromosome is shown on the left. Vertical 
blue lines correspond to each patient; red bars = gains; thicker red bars = gains of two extra copies; 
green bars = mono-allelic losses; black areas circled in red = HD; yellow and light blue areas = 
CNV, respectively losses and gains. Black bars divide the different genetic groups. Black vertical 
lines separate the different genetic groups. Two common minimally deleted regions on 1p are 
defined by grey dotted rectangles. 
 Results 
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Even though the frequency of 1q21-q23.2 gain increased from MGUS to MM, this difference 
was not statistically significant (MGUS vs MM, P=0.21). In MGUS/SMM, 1q21-q23.2 gain was 
rare in HRD (1/10, 10%), while it was frequently detected in the t(4;14) group (7/10, 70%). The 
same association was found in MM patients with t(4;14) (7/11, 64%), with five patients 
showing two extra copies of the whole arm or part of it.  
No statistically significant correlation was found between gain of 1q21-q23.2 and progression to 
MM, either in MGUS or in SMM. Three of the eight MGUS patients who progressed and four 
of the 17 patients who did not progress showed gain of 1q21-q23.2 (P=0.64). Within the SMM 
group, five of the nine patients who progressed and one of the six who did not progress had the 
abnormality (P=0.29). Among the five patients with 1q21-q23.2 gain and no evidence of 
progression, four had a follow-up of more than 3 years. 
 
Deletions of 1p were highly complex in this patient cohort with some patients showing multiple 
interstitial losses. Eighteen of 47 (38%) MM patients were found with 1p deletions compared to 
three of 25 (12%) MGUS and one of 15 (7%) SMM patients (MGUS vs MM, P=0.028). These 
deletions were variable in size and had different breakpoints; in only one MM case was the 
whole arm deleted. In MM, three HD encompassed the same chromosomal region at 1p32.3-p33 
(highlighted by the upper blue rectangle in Figure 3-7 and in more detail in Figure 3-8): patient 
374 (51121283Mb – 51254925Mb), patient 665 (50131470Mb – 51875603Mb) and patient 
1336 (49905463Mb – 51755900Mb). All three HD encompassed the genes CDKN2C/p18 and 
FAF1. The cell line KMS-11 also showed HD at this locus (47928974Mb – 51949445Mb). 
Three MM patients had hemizygous deletions involving this region, while no deletions were 
found in the pre-malignant cases. 
 
Figure 3- 8  Array CGH profile of the chromosomal region 1p32.3-p33 of patients 374, 
665 and 1336 
 Results 
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Previous page, Figure 3-8 
The G-banded idiogram of chromosome 1 (on the left) and the plot of ‘calls’ for every 
oligonucleotide (on the right) of the selected chromosomal region are shown for the three patients 
 
 
A second region of 1p was found to be deleted in 16 of 47 (34%) MM cases. It involved the 
chromosomal bands 1p21.3-p22.1 (93524365Mb – 95160822Mb) (highlighted by the bottom 
blue rectangle in Figure 3-7) and included the genes: DR1, FNBP1L, BCAR3, DNTTIP2, 
GCLM, ABCA4, ARHGAP29, ABCD3, F3, SLC44A3, CNN3 and has-mir-760. No HD were 
detected. Within the pre-malignant group, all four cases (MGUS patients: 698, 989, 3318; SMM 
patient: 1252) with 1p losses encompassed this region. Two MGUS patients progressed to MM 
after 74 (989) and 75 (698) months; the MGUS patient 3318 died of MM-unrelated causes 17 
months after diagnosis; however, her paraprotein level was steadily increasing. Patient 1252, 
despite lacking any clinical manifestation after 24 months (at this time he moved to the USA), 
showed a notable rise in paraprotein: in January 2004 (time of diagnosis), 16g/L; in January 
2006, 25g/L (Table 3-9).  
 
3.3.4.3.3  Chromosome 6 abnormalities 
Chromosome 6 abnormalities were mainly characterized by gains of the short arm and deletions 
of the long arm (Figure 3-9). Deletions of 6q were observed in 20 of 47 (43%) MM patients; no 
specific association was seen between this abnormality and the genetic groups. Most deletions 
were large, with different break-points. Four common minimally deleted regions were found 
(highlighted by blue rectangles in Figure 3-9): 6q16.1 (97117200Mb – 97207730Mb, n=10); 
6q16.3 (102293569Mb – 102493547Mb, n=10); 6q22.31 (124201765Mb – 124957157Mb, 
n=11); and 6q25.1-q25.2 (151458397Mb – 154443800Mb; n=16). The latter region contained 
15 genes between MTHFD1L and OPRM1, including MYCT1, FBXO5 and MTRF1L. 
Deletions of 6q were detected in two MGUS (3318 and 989) and two SMM (1836 and 1581) 
patients and involved either both or only one (6q25.1-q25.2) of the two most telomeric common 
minimally deleted regions identified in MM. For the region 6q25.1-q25.2, the difference in 
frequency between MGUS and MM was statistically significant (P=0.020). Patients 989, 1836 
and 1581 progressed to MM after 74, 16 and 15 months, respectively; patient 3318 (MGUS; 85 
years old), as stated in Table 3-9, died of MM-unrelated causes 17 months after diagnosis 























Figure 3- 9  Graphical representation of CNA for chromosome 6 for all patient groups 
The 850-band idiogram of the G-banding pattern of the chromosome is shown on the left. Vertical 
blue lines correspond to each patient; red bars = gains; thicker red bars = gains of two extra copies; 
green bars = mono-allelic losses; black areas circled in red = HD; yellow and light blue areas = 
CNV, respectively losses and gains. Common minimally deleted chromosomal regions on 6q are 
defined by grey dotted rectangles. Black vertical lines separate the different genetic groups. 
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3.3.4.3.4  Chromosome 8 abnormalities 
Deletions on 8p were large and shared a common minimally deleted region defined by the 
chromosomal bands 8p22-p21.2 (17652178Mb – 26788320Mb). Losses of this region were 
detected in two MGUS (8%), three SMM (20%) and 15 MM (32%) patients (MGUS vs MM, 
P=0.022). The three SMM patients showed this CNA to be present in only a sub-population of 
PC. One of the two MGUS patients with this CNA progressed to MM after 74 months, while the 
other (3318, see Table 3-9) died of MM-unrelated causes after only 17 months. Among the 
three SMM patients: one progressed to MM after 21 months, one remained stable after 55 
months and the third (1252) despite lacking any clinical manifestation after 24 months (at this 
time he moved to the USA), showed a notable rise in paraprotein (Table 3-9).  
 
CNA involving 8q were mainly represented by abnormalities involving the band 8q24.21 where 
the MYC gene is located. In the MM group a total of 12 CNA involved this locus (Figure 3-
10A): small interstitial duplications were found in five patients (Figure 3-10 B-C-D) 
(minimally gained region, 128822396Mb – 128847262Mb; all were confirmed by FISH with 
the BAC RPI-80K22 described in Appendix 3). FISH using the MYC break-apart and the LSI 
IgH/MYC probes was carried out on all samples; one of the patients with small interstitial gains 
was also found to be positive for a t(8;14)(q24;q32); another patient gave a positive result with 
the MYC break-apart . Larger gains involving this region were found in three cases (297, 756, 
2458) and amplifications in another three cases (1524, 3325, 1512). Patient 1037 was found to 
have a large deletion involving almost the entire chromosome 8 (8pter-q24.21; 61327Mb – 
128470644Mb) terminating just proximal of the MYC locus. FISH confirmed the presence of a 
structural rearrangement at 8q24.21, resulting in an unbalanced t(8;14) translocation. Patient 
314 was found to be positive for a MYC rearrangement by iFISH in the absence of CNA 
involving its locus. In total, 13 MM patients (28%) displayed MYC abnormalities either by 
FISH and/or array CGH; interestingly seven of these 13 (54%) cases were HRD (P=0.026). 
Only one MGUS patient was found with MYC abnormalities (MGUS vs MM, P=0.003). This 
MGUS case (528) showed an interstitial deletion involving the bands 8q24.13-q24.21 
(125794416Mb – 128611131Mb) in a sub-population of PC. The deletion was immediately 
proximal of MYC and a MYC break-apart was confirmed by iFISH in 40% of PC. This case was 
HRD and had no IgH rearrangements; he progressed to MM after 45 months. The SMM patient 
1836 (with a t(4;14)) was found to be positive for a t(8;14) by iFISH in all PC, with no CNA 





















Figure 3- 10  Graphical representation of CNA for chromosome 8q for all MM patients 
(A); diagram showing the megabase positions of copy number gains involving MYC at 
8q24.21, identified in six MM patients by array CGH (patients from left to right: 666, 506, 
375, 756, 830, 1213) (B); Patient 666 in detail (C); Patient 506 in detail (D) 
In Figure 3-10 (A) Vertical blue lines correspond to each patient; red bars = gains; thicker red bars 
= gains of two or more extra copies; green bars = mono-allelic losses; bright blue areas circled in 
black = amplifications.  Yellow areas = CNV, losses. The common minimally gained region at 8q24 
is indicated by the blue dotted rectangle.  
 
 
Two of the three MM cases with amplification at 8q24.21 had t(11;14) (1524 and 3325); the 
third (1512) was HRD with no IgH rearrangements but with multiple other amplified regions 
including 11q13, where the CCND1 gene is located. Both the t(11;14) and the 11q13 
amplification resulted in CCND1 overexpression; therefore in this patient cohort all cases with 







































Figure 3- 11  Array CGH profile of the chromosomal region 8q24 in three patients 
carrying the amplification 
The G-banded idiogram of chromosome 8 and the plot of ‘calls’ for each oligonucleotide of the 
selected chromosomal region are shown for the three patients on the left. On the right, images of 
metaphase and iFISH MYC amplification detected using the LSI IgH/MYC probe combination 
(MYC in sp red, IgH in sp green). 
 
In the three cases, the level of MYC amplification by array CGH was remarkably different, as 
shown in Figure 3-11. Patient 3325 was found to have a 2.2 Mb amplicon containing only MYC 
and TMEM75 (the smallest amplicon); the level of amplification was represented by a log2 ratio 
= +4. FISH showed typical amplification in the form of DM with 2 to ~100 copies of MYC in 
80–100% of PC. Patient 1512 showed a complex pattern of gains and losses along 8q, with two 
main areas of amplification at 8q21.1 and 8q24 (128767860Mb – 129988129Mb); the level of 














signals localized in two main clusters of amplification, suggestive of HSR; in this case iFISH 
and array CGH showed a similar level and pattern of amplification for CCND1. In patient 1524, 
array CGH showed a large region (8q23.2-q24.23) of variable high level gain, with part of 
8q24.21 (127408340Mb – 128892972Mb) showing the highest level of gain represented by a 
log2 ratio = +1.5. The level of gain detected by array CGH was not suggestive of amplification; 
however, FISH for MYC detected the presence of seven - ten DM in 32% of PC. The presence 
of DM in a minority of PC resulted in an overall dilution of the chromosome aberration calls. 
 
3.3.4.3.5  Chromosome 9 abnormalities 
Eight MM patients showed deletions of 9p (with one showing entire monosomy 9): in seven, the 
commonly deleted region encompassed 9p21.3 (21853204Mb – 22018332Mb) and included the 
genes CDKN2A (cyclin-dependent kinase inhibitor 2A) and CDKN2B.  Interestingly four of 
these seven cases had t(14;16), resulting in 50% of t(14;16) cases having this CNA; the other 
three cases were one each of: t(4;14), t(11;14) and HRD. The latter case, despite being classified 
as HRD, showed an IgH rearrangement with an unidentified partner, confirming that 
CDKN2A/2B loss preferentially arises in IgH-translocated MM. No chromosomal losses 
involving chromosome 9 were found in pre-malignant cases (MGUS/SMM vs MM, P=0.007). 
 
iFISH was performed on the independent patient cohort for the genes CDKN2A/2B and PAX5 
(paired box gene 5; 9p13.2). Deletions of CDKN2A/2B were detected in four of 34 MGUS 
(12%) and ten of 174 MM (6%); none of the SMM patients showed deletions of this locus. In 
MGUS, the median percentage of PC with the deletion was 57% (range, 25%–64%); in MM, 
65% (range, 24%-100%). These findings indicated that the deletion was as a secondary/later 
event. No deletions of PAX5 were detected, confirming the interstitial nature of CDKN2A/2B 
deletions. In three MGUS and four MM, the FISH signal pattern for CDKN2A/2B included one 
signal of normal size (non-deleted allele) and one diminished signal (deleted allele) suggesting a 
partial deletion of the locus with one of the break-points falling within the gene.  
In MM, CDKN2A/2B deletion was associated with nonHRD (P=0.04) (Table 3-10). 
 
 
Table 3- 10  Table of associations between CDKN2A/2B deletion and other CA in 
MGUS and MM (statistically significant associations are highlighted in blue) 
N, normal; T, translocated; Del, deletion Results 
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Array CGH showed that in MM this deletion was particularly frequent in patients with t(14;16); 
in this cohort no such association was found but it must be noted that only four t(14;16) cases 
were included. More cases, particularly those with t(14;16), need to be tested in order to 
investigate this possible association.  
MM patients with CDKN2A/2B deletion showed significantly inferior OS compared to patients 
with normal 9p (11 months vs 41 months, P=0.006). This significance was found when survival 
was calculated from the time of analysis but not when the initial time point was time of 
diagnosis (26 months vs 53 months, P=0.07).  
In MGUS, among the four patients positive for the deletion, two evolved to MM after 40 and 75 
months from diagnosis; the other two patients were stable after 38 and 79 months. 
 
3.3.4.3.6  Chromosome 12 abnormalities 
Chromosome 12 was mainly characterized by deletions, with only one MM case showing entire 
monosomy. Deletions of 12p were found only in MM patients (n=11) and two distinct common 
minimally deleted regions were defined: 12p13.1 (12720245Mb – 12778201Mb; n=9) and 
12p13.1-p12.3 (12904980Mb – 17188748Mb; n=9). The first region included only three genes: 
GPR19, CDKN1B (cyclin-dependent kinase inhibitor 1B, also known as p27 or Kip1) and 
APOLD1. This deletion was confirmed by FISH using a fosmid probe for CDKN1B (Appendix 
3). Decreased CDKN1B levels are a poor prognostic factor in many malignancies 
223,224 and it 
has been proposed that CKS1B gain on 1q21 enhances CDKN1B degradation 
157. Thus the 
CDKN1B probe was used to test the independent cohort of patients: one of 34 (3%) MGUS, two 
of 13 SMM (15%) and 29 of 171 (17%) MM patients were found to be positive for this deletion 
(MGUS vs MM, P=0.033); all deletions were hemizygous. The relatively high frequency of this 
CA in MM, considering the genetic heterogeneity of the disease, was surprising. No significant 
associations were found between CDKN1B deletions and any of the other CA tested; there was 
only a non significant enrichment in t(4;14) (P=0.076) and nonHRD (P =0.061) noted (Table 3-
11 ).  
 
 
Table 3- 11  Table of associations between CDKN1B deletion and other CA in MM 
N, normal; T, translocated; Del, deletion 
 Results 
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In order to improve the definition of the size of these deletions, iFISH was performed on those 
cases found to be deleted with the fosmid probe, using BAC probes located 0.5Mb proximally 
and distally of CDKN1B (bA515B12 at 12p13.1 and bA388F6 at 12p13.32, Appendix 3). One 
case showed a diminished FISH signal for the CDKN1B probe suggesting that the breakpoint of 
the deletion was located within CDKN1B. In the remaining cases, at least one of the flanking 
markers was lost, indicating that the deletions were variable in size and rather large, suggesting 
the possible importance of other genes within the deleted region. 
 
The Kaplan-Meier curve for OS showed no difference between MM patients with and without 
the deletion, either calculating the survival time from the time of analysis (39 months vs 39 
months; P=0.754) or from the time of diagnosis (41 months vs 56 months; P=0.632).  
The only MGUS patient (871) found to be positive for the deletion showed a HRD karyotype 
and normal IgH; the CDKN1B deletion was present in all PC. The patient was 85 years old 
when diagnosed with MGUS and died 9 months later for MM-unrelated causes. In both SMM 
patients (651 and 925), the CDKN1B deletion was detected in only a sub-population of PC (39% 
and 26%), while other CA detected by iFISH showed complete PC involvement. This suggested 
that, in these patients, this CNA represented a later event. Both patients had a HRD karyotype 
with no IgH rearrangements. Patient 651 was tested after 4.5 years from the initial diagnosis of 
SMM. Interestingly, at this time, ∆13 was also found in 19% PC, suggesting that, as for 12p 
deletion, some CA originated later when compared to trisomies 9 and 15 which were found in 
the majority of PC (76%). Both patients progressed to MM: patient 925, after 2 years from 
diagnosis and patient 651 after a period ranging between 6 and 30 months from cytogenetic 
analysis (uncertain follow-up information). 
 
3.3.4.3.7  Chromosome 16 abnormalities 
Chromosome 16 was mainly characterized by losses of chromosomal material. Deletions of 16p 
were detected in eight MM patients; they shared a common minimally deleted region at 16p13.3 
defined by the positions 3603589Mb – 3883030Mb and encompassing the genes DNASE1, 
TRAP1 and CREBBP. One MGUS (695) and one SMM (259) had loss of 16p (16p13.13-pter); 
the MGUS patient remained stable after 6 years from the detection of the CNA, the SMM 
patient progressed to MM after 53 months. 
 
Deletions of 16q were found in 14 of 47 (30%) MM patients; eight were whole arm losses. Four 
deletions were found in t(14;16) patients, while there were none found in the t(4;14) group. The 
two most commonly deleted chromosomal regions were located at 16q12.1 (47178411Mb - 
51135038Mb) (n=12) and 16q23.1 (n=12). The first region encompassed many genes including Results 
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the tumour suppressor gene, CYLD (Cylindromatosis); patient 932 had entire loss of 16q and 
HD at 16q12.1, only involving CYLD and CARD15 (see Section 3.3.4.4). The second region of 
common loss encompassed the WWOX (WW domain containing oxidoreductase) gene; patient 
282 had a HD involving only this gene (77227769Mb – 77263523Mb) (Figure 3-12) as the cell-
line KMS-11 (76737934Mb – 77794243Mb). Among the pre-malignant patients, two MGUS 
and six SMM showed loss of 16q23.1; five patients showed loss of the entire 16q and in two of 
them the CNA appeared to be present in only a sub-population of PC. The three SMM patients 
(582, 1073 and 2198) with interstitial deletions encompassing 16q23.1 were positive for the 





   
   
 
Figure 3- 12  Diagram showing the megabase positions of 
copy number losses involving WWOX at 16q23.1 in six 
patients (four MM and two SMM)  
(patients from left to right: 551, 309, 2068, 282, 582 and 
2198) 
Patient  282  showed  the  presence  of  a  hemizygous  deletion 
involving the whole 16q and a HD at 16q23.1 (red bar with black 




Interestingly five of the six SMM with loss of 16q23.1 progressed to MM after 15, 15, 20, 31 
and 50 months from the time of analysis; the sixth SMM case (1073) remained stable after 55 
months. None of the two MGUS had shown evidence of disease evolution by the end of the 
study, after 72 and 78 months. 
 
3.3.4.3.8  Chromosome 17 abnormalities 
Ten MM cases showed 17p deletions, of which nine encompassed the TP53 gene at 17p13.1. 
The common minimally deleted region at 17p13.1 was defined by the positions 7290085Mb and 
7495207Mb. There was no specific association of this CNA with any particular genetic groups. Results 
  117
Five patients also shared a common minimally deleted region at 17p11.2 (19378373Mb – 
20160056Mb). Only one MGUS patient (3318) showed loss of almost the entire chromosome 
including the 17p13.1 region. As previously stated in Table 3-9, despite the fact that the patient 
did not receive treatment for MM before her death (17 months after diagnosis), her paraprotein 
was steadily rising at that time. 
 
3.3.4.3.9  Chromosome 18 abnormalities 
Loss of 18p was found in six MM patients (one of them showed entire monosomy). 
Interestingly the five cases with interstitial losses were t(4;14) cases (P=0.002). The common 
minimally deleted region was defined by the chromosomal bands 18p11.2 and 18p11.32. 
Among the pre-malignant cases, one MGUS (3318) and one SMM (1252), both had t(4;14), as 
well as loss of 18p. Both patients were stable at 17 and 24 months, respectively; however, the 
second patient was lost to follow-up after this time. 
 Results 
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3.3.4.4  CNA encompassing genes involved in the NF-ĸB pathway 
3.3.4.4.1  Array CGH 
Five of 27 (18%) HD identified in this patient cohort contained potential target genes associated 
with the regulation of the NF-κB signalling pathway (Table 3-8). Two recurrent HD were found 
at 11q22.1 (MM patients 309 and 1336, both with t(14;16)) and at 14q32.32 (SMM patient 582, 
with t(14;16); HRD MM patient 491). One HD was found at 16q12.1 (MM patient 932, with 
t(11;14)). The common minimally deleted region at 14q32.32 contains the genes TRAF3 (TNF-
receptor-associated factor 3), AMN (amnioless homolog, mouse) and CDC42BPB (CDC42-
binding protein kinase beta) (Figure 3-13A). The HD found at 11q22.1 was relatively large in 
patient 1336. However, in patient 309 the HD involved only BIRC2/cIAP1 (baculoviral IAP 
(inhibitor of apoptosis protein) repeat-containing protein 2) and BIRC3/cIAP2 genes (Figure 3-
14). Both CNA were confirmed by FISH. Given their small size, a combination of differently 
labelled fosmid and BAC probes was developed for their detection. The smallest HD were 
found in patient 582 for 14q32.32 and in patient 309 for 11q22.1; therefore the breakpoint 
positions characterizing these cases were used to design the probe combinations for iFISH. 
Figure 3-13B shows in detail the probe combination for the 14q32.32 deletion. The HD at 
16q12.1 involved the genes CYLD (cylindromatosis) and CARD15 (caspase recruitment 
domain-containing protein 15), as previously stated in Section 3.3.4.3.7.Results 
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Figure 3- 13  A) Patient 582: plot of calls for every oligonucleotide for the deleted region 
at 14q32.32; B) Screen shots from the Ensembl and UCSC browsers showing the locations 
of the BAC and fosmid probes selected for the 14q32.32 deletion; C) FISH confirmation of 
the deletion in patient 582: one nucleus with normal copy number for 14q32.32 (two 
red/green signals) and two nuclei with complete loss of the red signals and a diminished 






Fosmid probes labelled in Cy3












Figure 3- 14  G-banded idiograms of chromosomes 11 and the plot of ‘calls’ for every 
oligonucleotide for the selected chromosomal region are shown for patients 309 (on the 
left) and 1336 (on the right) 
 
TRAF3, BIRC2/3 and CYLD are negative regulators of the NF-ĸB signalling pathway and 
dysregulated expression of these genes has been detected in MM and HMCL carrying HD of 
these same chromosomal regions 
181,182.  
In the current study, hemizygous deletions encompassing these three regions were also found: 
14q32.32, MM (n=9), pre-malignant conditions (n=3); 11q22.1, MM (n=4), pre-malignant 
conditions (n=0); 16q12.1, MM (n=8), pre-malignant conditions (n=4).  
The array CGH profile of MM patient 2068 (t(14;16)) showed what appeared to be a 
hemizygous deletion at 14q32.32 including TRAF3 involving only a sub-clone of the PC 
population. iFISH revealed instead the presence of a HD involving this chromosomal region in 
25% of PC.  
The array CGH profile of MM patient 551 (t(14;16)) showed a deletion at 14q32.32 involving 
TRAF3 whose log2 ratio was intermediate between one indicating a hemizygous deletion and 
one indicating a HD. iFISH for this locus showed 30% of PC hemizygously deleted and 10% of 
PC carrying a HD, consistent with the array CGH results. This patient was initially diagnosed 
with MGUS and progressed to MM after a period of 76 months. Unfortunately the Database did 
not receive the BM sample taken at the time of MGUS diagnosis. However, a sample taken 6 
months before the time of MM diagnosis was available for FISH analysis. This showed 37% of 
PC to have a hemizygous deletion with no cells having HD at this locus. This result clearly 
indicates that the loss of the second allele was a very late event, possibly involved in the clinical 
manifestation of the disease. These two last cases confirm the importance of using iFISH to 
confirm ambiguous array CGH results as the biological significance of hemizygous or HD is 
very different.  
MM t(14;16)
dimx2(11)(101.06[11q22.1]-103.05[11q22.1])
MM t(14;16)      
dimx2(11)(101.69[11q22.1]-101.78[11q22.1])Results 
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Three other genes coding for members of the NF-κB pathway were found to be involved in 
CNA: 
 
1)  LTBR (lymphotoxin-beta receptor) at 12p13; CNA involving this gene were seen in two 
patients: 
i.  HRD MM patient (314) with interstitial gain (size of CNA: 0.9Mb). 
ii.  MM patient with a t(4;14) (665) showing hemizygous deletion immediately 
centromeric  of the LTBR gene suggesting the presence of a translocation at this locus 
leading to overexpression of this gene.  
 
2)  TACI (transmembrane activator and CAML interactor/TNFRSF13B) at 17p11.2-p12; CNA 
involving this gene were seen in two patients. This chromosomal region is characterized by 
a large number of low-copy repeats which are responsible for its instability. Fabris and 
colleagues firstly described an approximately 5Mb amplification at 17p11.2-p12 in the 
KMS-26 myeloma cell line by SNP microarray analysis and 12 genes included in this 
region were found to be significantly overexpressed, including TNFRSF13B/TACI, COPS3 
and NCOR1 
225. FISH analyses of 141 primary MM patients identified one MM carrying a 
3.8 Mb amplified region at 17p11.2 and two MM with gains specifically involving the TACI 
locus. 
i.  MM patient with t(14;16) (282) with amplification at 17p11.2-p12 (size of the CNA: 
1.3Mb) (Figure 3-15). The gene was located within the chromosomal region showing 










Figure 3- 15  G-banded idiogram (on the left) of chromosome 17 and the plot of ‘calls’ 






ii.  MM patient with an unidentified IgH rearrangement (1581) with interstitial gain at 
17p11.2 (size of the CNA: 1.4Mb). In this patient, the same CNA was found by array 
CGH in the sample collected when the patient was a SMM.  
 
3)  NF-κB-inducing kinase (MAP3K14/NIK) at 17q21.31; CNA involving this gene were seen 
in two patients: 
i.  MM case with a t(11;14) (504) with interstitial gain (size of the CNA: 0.17Mb). 
ii.  MM case with t(11;14) (2993) with hemizygous deletion immediately proximal to NIK 
gene (end position of the CNA: 41031250) suggestive of a translocation. This latter 
abnormality was confirmed by iFISH using a fusion probe strategy combining four 
different BAC probes labelled in Cy3 and Spectrum Green (see Appendix 3); break-
apart of the fusion probe was indicative of a structural rearrangement at this locus.  
 
All these abnormalities involving members of the NF-ĸB pathway were mutually exclusive and 
seemed to preferentially involve MM cases with a rearranged IgH (11/13). However, it has to be 
noted that the IgH rearrangements present in these patients not only included those associated 
with a poor prognosis in MM, but also t(11;14). Two of these CNA were found in pre-malignant 
patients: case 582 (SMM) positive for a HD at 14q32.32 and case 1581 (SMM) positive for an 
interstitial duplication at 17p11.2 and involving the TACI gene; both patients evolved to MM 
within 15 months. 
 
 
Interphase FISH was performed on the independent group of consecutive patients to search for 
abnormalities involving three of the NF-κB markers found to be recurrently involved in CNA 
by array CGH. 
 
1) BIRK2/3 (11q22.1). Homozygous and hemizygous deletions of BIRC2/3 were detected in 
seven (4%) and two (1%) of 163 MM patients, respectively. No abnormalities involving these 
genes were found in MGUS or SMM.  
In four of seven MM patients the HD was observed in the entire PC population; in the 
remaining three patients the HD was seen in a sub-clone of PC (14%;18%; 22%) with the 





Table 3- 12  Table of associations between BIRC2/3 deletions and other CA in MM 
(statistically significant associations are highlighted in blue) 
N, normal; T, translocated; Del, deletion; HD, homozygous deletion 
 
BIRC2/3 HD was associated with ∆13 (P=0.004), t(4;14) (P=0.006), ploidy (P=0.045), gain of 
1q (P=0.010) and 1p32.3 loss (P=0.03) (Table 3-12). 
 
2) TRAF3 (14q32.32). In MGUS and SMM, no HD at 14.32.32 were detected; five of 35 
MGUS and 3 of 11 SMM showed hemizygous deletions at this locus. In MM (n=168) 27 
hemizygous deletions (16%) and six HD (~4%) were detected; the HD involved the majority of 
PC in three cases; in the remaining cases, they were detected in 26%, 35% and 37% of PC with 




Table 3- 13  Table of associations between TRAF3 deletions and other CA in MM 
(statistically significant associations are highlighted in blue) 
N, normal; T, translocated; Del, deletion; HD, homozygous deletion 
 
TRAF3 loss (including both hemizygous and homozygous deletions) was significantly 
associated with ∆13 (P=0.006) and nonHRD (P=0.03). HD, despite being more frequent in 
cases with ∆13 and 1q gain, did not show any significant association (Table 3-13). 
 
The effect of TRAF3 loss on OS was calculated using both the time of diagnosis and the time of 
analysis (Figure 3-16). Patients with TRAF3 HD showed inferior OS compared with those with 
normal 14q32.32 and those with hemizygous deletions of this chromosomal region (P=0.012 
when survival time was calculated from time of diagnosis; P=0.002, when survival time was 
calculated from time of analysis). Interestingly, no difference was found between patients with 















Figure 3- 16  Kaplan-Meir curve for OS of MM patients calculated from time of 
cytogenetic analysis; patients were stratified for TRAF3 hemizygous and homozygous 
deletions 
 
3) MAP3K14/NIK (17q21.31). Abnormalities involving NIK were absent in MGUS and SMM, 
while they were found in three of 164 MM patients (~2%); all three patients were HRD. One 
MM patient (1192) showed amplification (>6 copies) of this locus: the number of signals was 
highly variable from cell to cell. Patient 1044 showed three fusion signals corresponding to non-
rearranged copies of the gene, but two of these signals appeared to be tandemly duplicated. 
Patient 963 was found with a break-apart of the fusion probe associated with deletion of the 
probe centromeric to NIK and duplication of NIK itself. This FISH pattern was indicative of an 
unbalanced structural rearrangement of the gene in 81% of PC. This patient was also positive 
for an IgH rearrangement whose partner gene was not one of the five primary ones discussed in 
Section 3.1. Translocations t(14;17)(q32;q21), involving IgH and NIK loci have been 
previously reported 
181,182; co-hybridization of probes for IgH and NIK, each labelled using a 
single fluorochrome, confirmed the presence of t(14;17) in this patient. The same patient also 
showed HD of TRAF3 in 26% of PC, indicating that the TRAF3 abnormalities followed the NIK 
rearrangement. In these three cases the CA involving NIK was present in the majority of PC.  
Two further MM patients showed a small percentage of PC (<10%) with what appeared to be a 
structural balanced rearrangement involving NIK; because of the low percentage of positive 
cells these cases were considered to be normal. No specific associations were found between 
NIK abnormalities and any other CA tested. 
 
The presence of any one of the three abnormalities (TRAF3 HD, BIRC2/3 HD and NIK 
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HD 6/6 8
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No Deletion 79/132 39
Hemizygous deletion 13/26 53
HD 6/6 8Results 
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independent cohort (median survival: 18 months vs 41 months, P=0.057). Although ten of the 
15 changes were found in nonHRD patients, this difference was not statistically significant 
(P=0.10). 
 
3.3.4.5  CNA involved in MGUS/SMM-MM transition of patients with t(11;14) 
Patient  Diagn  Losses  Gains  Amp  HD  Total  Specific CNA 
844  MGUS  0  1  0  0  1   
695  MGUS  3  0  0  0  3   
855  MGUS  1  1  0  0  2   
999  MGUS  1  1  0  0  2   
610  MGUS  1  1  0  0  2   
795  MGUS  0  1  0  0  1   
355  SMM  3  3  0  0  6   
  Average=2.1   
2906  MM  9  15  0  1  25  HD: 9p21.3, CDKN2A/2B 
3325  MM  15  15  1  0  31  Amp: 8q24, MYC 
932  MM  4  9  0  1  14  HD: 16q12, CYLD                
Hemizygous loss: 14q32.32, 
TRAF3 
1524  MM  22  10  1  0  33  Amp: 8q24, MYC 
504  MM  0  18  0  0  18  NIK duplication (17q21.31)  
1300  MM  6  1  0  0  7   
308  MM  10  8  0  0  18   
2993  MM  17  5  0  0  22  NIK rearr (17q21.31) 
  Average=21   
Table 3- 14  CNA in patients with t(6;14) or t(11;14) 
(Diagn, diagnosis; Amp, amplification; HD, homozygous deletion ; rearr, rearrangement) 
 
Table 3-14 and Figure 3-17 show that pre-malignant patients with t(11;14) had a relatively 
simple genome with an average of 2.1 CNA per case compared with 21 CNA observed in MM 
patients with the same translocation. In MM, recurrent CNA involved MYC and members of the 
NF-ĸB pathway, while in MGUS CNA were mainly represented by gains or losses of entire 
chromosomes. Such differences in the number of CNA between MGUS and MM was not seen 
in patients with t(4;16), t(14;16) or HRD (Table 3.7), in which the genome of the pre-malignant 
cases showed a relatively high level of complexity which often was not anticipated from the 
iFISH results. This observation might suggest that the acquisition of new CNA, associated with 
disease evolution, is a slower process in t(11;14) patients. Interestingly, none of the MGUS 
patients progressed to MM by the end of the study (follow-up range: 17-84 months; median, 72 Results 
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months). However, it has to be noted that within the Database many MM cases with t(11;14) 
and abnormal karyotype appeared to be very simple, with few CNA (data not shown). This 
observation suggested that, within the array CGH patient cohort, MM cases with t(11;14) were 
biased towards more complex cases. 
 
 
Figure 3- 17  Graphical representation of CNA in t(11;14) patients using snpview 
The bar at the top indicates the starting and the finishing positions of each chromosome. Every 
horizontal line corresponds to a patient: in black are regions with no CNA, in red regions of loss, in 
green regions of gain.  Regions where the red/green colour is less intense describe CNA only present 
in a sub-clone of PC. 
 
 
In patients with t(11;14), the CNA most common to all diagnostic groups was the duplication of 
11q13-qter with the breakpoint in 11q13 identical to the one characterizing the t(11;14). Loss of 
chromosome 13 was found in only one MGUS patient (999) in a sub-population of PC (48% of 
PC by iFISH, as described in Section 3.1), compared with six of eight MM cases. Array CGH 
confirmed that MGUS negative for ∆13 by iFISH, did not have other CNA of this chromosome, 
notably not involving the band 13q14 (where the iFISH probes map).  
By chance all patients with t(11;14) and array CGH results were female and loss of one copy of 
chromosome X was found in one of seven pre-malignant cases and in six of eight MM patients 
(P=0.040). 
The only SMM patient with t(6;14) (described in Section 3.1.4.4) progressed to MM after 20 
months from analysis and, compared with the MGUS group, had a higher number of CNA 
(n=7), including monosomy 13.  Results 
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3.3.4.6  Patients with array CGH on paired samples  
Within the Database, two patients had paired samples taken at the time of MGUS or SMM 
diagnosis and at the time of progression to MM, with good PC recovery at both stages. Array 
CGH was performed on both samples in order to determine whether disease evolution was 
associated with the acquisition of new CNA. 
 
3.3.4.6.1  MGUS-MM transition of a HRD patient  
Clinical data. Patient 989, a 67 year old caucasian male, was diagnosed with MGUS in July 
2003 due to the finding of an IgG paraprotein level of 18.81g/L. At this time his WBC, 
haemoglobin, calcium and β2M levels were normal. The BM aspirate showed BM elements to 
be adequately represented with a percentage of PC equal to 3%. His trephine was normal and no 
lytic lesions were observed by skeletal survey. The patient evolved to MM after a period of ~6.5 
years. During this follow-up period his paraprotein level showed a small but steady increase for 
the first 5 years, while it rapidly rose to 54 g/L in the last year and a half, as shown in Figure 3-
18. During his last year of follow-up the patient refused MRI, but in September 2009 he 
attended hospital with back pain. At this time his skeletal survey revealed multiple lesions in his 
long bones, a crushed vertebrae and the right hip at risk of fracture. At this time BM 

























































Figure 3- 18  Chart showing the variation of the serum M-protein (IgG) from the 
diagnosis of MGUS to diagnosis of symptomatic MM 
 
Genetic results. Two BM samples were sent to the Database: one taken when MGUS was 
diagnosed (sample 1) and one from the time of the MM diagnosis (sample 2). Sample 1 was Results 
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tested by iFISH for the presence of IgH and MYC rearrangements, ∆13 and ploidy status. 
Cytogenetic cultures were also set up. While metaphase analysis revealed only 33 normal 
metaphases (46,XY), iFISH showed the presence of multiple trisomies (chromosomes 3, 7, 9, 
11 and 15) in the absence of IgHt or ∆13, consistent with a relatively ‘simple’ HRD karyotype. 
On sample 2, iFISH was performed to test for IgHt and MYC rearrangements: no abnormalities 
were found.  
Array CGH was performed on purified PC from both samples (PC purity: 96% in sample 1; 
100% in sample 2). The array CGH profile of sample 1 showed a highly rearranged genome 
with 12 gains and 11 losses; most of the interstitial CNA detected could not be identified by 
routine iFISH tests. Sample 2 showed 20 regions of loss and 17 regions of gain; no HD or 
amplifications were detected in any of the samples (CNA of samples 1 and 2 are described in 
Table 3-15). Sample 1 showed the highest number of CNA when compared with the number of 
CNA of other HRD MGUS patients tested by array CGH and the second highest number of the 
entire MGUS group. All the CNA detected in sample 1 were confirmed in sample 2; the only 
exception was 8p loss: sample 1 showed loss of the entire arm, while sample 2 showed a smaller 
deletion (8p11.1-p22) where the degree of loss varied from region to region. Both CNA 
appeared to be present in a sub-clone of the PC population, while other changes involved all 
cells. Two alternative mechanisms may explain these findings: (i) within the sub-clone with 8p 
loss seen in sample 1, the remained allele further rearranged and partially duplicated; (ii) the 
CNA involving 8p in sample 2 arose in a distinct sub-clone with no 8p loss, while the clone 
with the 8p loss seen in sample 1 progressively disappeared during disease evolution. In sample 
2, most of the 8p loss showed a log2 ratio = -0.3 indicating a hemizygous deletion in a sub-clone 
of PC; within this region, two interstitial regions at 8p21.3 and 8p22 showed a log2 ratio = -1 
suggesting that, within the sub-clone, these two regions were homozygously deleted. 
Most interesting was the acquisition of monosomy 13 in sample 2 in almost all PC (this CA was 
completely absent in sample 1) (Figure 3-19 A), confirming that in HRD cases this CA may be 





 Table 3- 15  Presence and megabase position of CNA in paired samples of patient 989 
and associated genes 
* Loss of 8p was smaller in the second sample: 8p22-8p11.1 (17,652,178Mb- 41,739,024Mb) 










Type  Cytoband  Megabase position       
    Start  End       
Loss  1p36.13  16884678  17130584  √  √   
Loss  1p32.1-p31.3  59838544  62700901  √  √   
Loss  1p22.2-p22.1  88594706  94289803  √  √   
Loss  1p21.3-p13.2  95525023  113437396  √  √   
Loss  1p13.2-p11.1  114054012  120474160  √  √   
Loss  1q32.3  210638344  211099834  ─  √  HHAT, KCNH1 
Trisomy  3  39066  198858311  √  √   
Loss  4p16.1-p14  5237776  37140498  √  √   
Gain  4q24  103284326  103736367  ─  √  NFKB1, MANB, 
UBE2D3 
Gain  4q28.2  130561729  130984065  ─  √  No genes 
Trisomy  5  601072  180588699  √  √   
Loss  6q15-qter  88906931  170469193  √  √   
Gain  7pter-q21.13  140213  89079942  √  √   
Loss  7q21.13-q21.2  89110055  91396559  √  √   
Gain  7q21.2-q22.1  91403435  100536696  √  √   
Loss  7q22.1-q22.2  100549092  104379552  √  √   
Gain  7q22.2-qter  104399350  158568421  √  √   
Loss  8pter-p11.1  63810  47062180  √¤  √*  Many 
Gain  9pter-p11.1  153131  44167323  √  √   
Gain  9q11-qter  44167323  140036287  ─  √  Many 
Loss  10p12.32  20205581  21727776  ─  √  PLXDC2, TEM7R, 
NEBL, C10orf113 





Gain  11pter-11q14.2  182372  87080566  √  √   
Gain  11q14.3-qter  90041154  134352297  √  √   
Loss  12q23.1  98580482  98617562  √  √   
Monosomy  13  18065953  113562984  ─  √  Many 
Loss  14q13.1-q21.1  31820354  40521910  ─  √  Many 
Gain  14q31.1  78503451  80349809  ─  √  KIAA074, NRXN3 
Trisomy/ 
Tetrasomy 
15  18362555  100123384  √  √ 
 
Loss  16q12.1  47178411  51135038  ─  √  Many including 
CYLD 
Loss  17q21.2-21.31  36541969  38054342  ─  √  Many 
Loss  17q23.3-q24.2  59484545  61567907  ─  √  Many 
Trisomy/ 
Tetrasomy 
19  64418  63603518  √  √   
Loss  20q11.22-q13.2  31804568  50177871  √¤  √   
Trisomy   21  13334960  46846246  √  √   
Gain (x2)  Xq21.32-qter  92358622  154143903  √  √   Results 
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Interesting changes acquired in sample 2 were: gain of 4q24, which includes the NFKB1 gene 
and loss of 16q12.1, which includes CYLD (Figure 3-19 B). Both genes encode for members of 
the NF-ĸB pathway and CA involving these chromosomal regions have been reported to be 
altered in primary MM patients and cell-lines 
181,182 but not in stable MGUS (see Section 
3.3.4.4). 
 












Figure 3- 19  G-banded idiograms (on the left) and array CGH profiles (on the right) 
obtained with the Agilent software of chromosomes 13 (A) and 16 (B), for samples 1 and 2 
of patient 989. For chromosome 16 the plot of ‘calls’ for every oligonucleotide for 16q12.1 
(on the right) is shown 
 
3.3.4.6.2    SMM-MM transition of a nonHRD patient with unidentified 
IgH rearrangement  
Clinical data. The BM sample of patient 1581, a 55 year old caucasian male, was received in 
August 2004 (sample 1), 14 months after he was diagnosed with SMM. In November 2005 (15 
months after sample 1 and 29 months after diagnosis) a second BM sample (sample 2) was 
received; at this time the patient was diagnosed with MM and was entered into the Myeloma IX 
Trial. His paraprotein (IgAλ) level was: 19.35 g/L in July 2004; 21.7 g/L in May 2005; 26.4 g/L 
in August 2005; 27.1 g/L in October 2005; 41.04 g/L November 2005. At this time his WBC, 
calcium and β2M levels were normal, while the haemoglobin level was 117 g/L (reference 
range, 120 – 150 g/L).  
Chromosome 13 
Sample 1 Sample 2
Chromosome 13 
Sample 1 Sample 2
Sample 1 Sample 1 Sample 2 Sample 2
Chromosome 16










Type  Cytoband  Megabase position       
    Start  End       
Gain (x2)  1q12-qter  141465960  245433898  √  √  Many 
Gain  3q26.2  170637939  171652421  √  √  Many including 
MDS1, ARPM1, 
MYNN 
Gain  6pter-p21.2  97634  39021664  √  √  Many 
Loss  6q25.1-qter  151508818  170943147  √  √  Many 
Loss  7pter-p21.1  140213  16917680  √  √  Many 
Monosomy  13  18065953  114123908  √  √  Many 
Loss  14q24.1-q32.33  68331511  105760541  √  √  Many 
Gain (sub-
clonal) 
16p13.13  10614700  11953884  √  √   
Loss  16q12.1-qter  45018886  88690615  √  √  Many 
Gain  17p12-p11.2  16117789  17556868  √  √  Many including 
TACI (see Section 
3.3.4.4) 
Gain  19p13.12  15790620  16485583  √  √   
Gain  Xq27.1-qter  137568878  154492983  √  √  Many 
 
Table 3- 16  Presence and megabase position of CNA in paired samples of patient 1581 
and associated genes  
 
Genetic results. Both samples 1 and 2 were tested by iFISH for the presence of IgH and MYC 
rearrangements, ∆13 and ploidy status; cytogenetic cultures were also set up on sample 2 but 
only two normal metaphases (46,XY) were detected. iFISH showed the presence of ∆13, 
deletion of 16q23 and the presence of an unbalanced IgH rearrangement with an unidentified 
partner associated with loss of the der(14). All CA were found to be present in both samples; 
∆13 and the IgH rearrangement were found in the majority of PC in both samples; 16q23 
deletion was found in 79% of PC in sample 1 and in 96% of PC in sample 2. Array CGH was 
performed on purified PC from both samples (PC purity: 98% in sample 1; 92% in sample 2) 
and showed the same profile of losses (n=5) and gains (n=8), with no acquisition of new CNA 
within the 15 months follow-up (Table 3-16). All the CNA detected by array CGH confirmed 
the iFISH results. Interestingly the patient showed tetrasomy of chromosome 1q, loss of 6q25.1-
qter, loss of 16q and gain of 17p12-p11.2 (including the TACI gene); the latter three CNA were 
found to be significantly more frequent in MM as compared with pre-malignant conditions (see 
Sections 3.3.4.3 and 3.3.4.4). As no new CNA were acquired after the first sample was taken, it 
can be hypothesised that the genetic changes characterizing the PC at the SMM stage were able 
to promote disease evolution; the SMM represented what may be called an ‘early MM’. 
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3.3.5  Overall summary of the results and discussion 
This study has shown that evolution of the genetic profiles from MGUS to SMM to MM is 
characterized by increasing complexity, which is evident from the significant increase in the 
mean number of CNA from asymptomatic conditions to overt disease. CNA were detected in all 
but one patient. In this MM case, characterized by t(14;20), the karyotype confirmed the 
presence of balanced structural rearrangements but no apparent copy-number changes.  
A number of CNA were detected in MGUS, SMM and MM at similar frequencies indicating 
that they are probably not involved in the transition from asymptomatic to overt disease (i.e 
trisomies of odd chromosomes, gain of Xq, gain of 11q). Other CNA were detected at a higher 
frequency in MM compared to MGUS/SMM, suggesting that these changes may be positively 
associated with disease progression (del(1p), del(6q), del(8p), 8q24 abnormalities, del(12p), 
del(16q), del(17p)). 
Interestingly, none of the MGUS patients with a low level of CNA (< 5) progressed to MM 
within the end of this study (P=0.003) (follow-up time: range, 17-125 months; median, 69 
months). The majority of cases with a low number of CNA had t(11;14) and t(14;20). However, 
patient 1189 (with t(14;16)) and patient 2326 (with deletion of 14q and no IgHt) also showed <5 
CNA with complete disease stability after 125 and 47 months from diagnosis, respectively. 
These observations suggested that the association between the level of CNA and disease 
evolution is independent of the specific primary translocation.  
As the difference in the number of CNA between MGUS and MM was much higher in t(11;14) 
cases compared to those with t(4;14), t(14;16) and HRD, it can be hypothesised that the genetic 
background associated with t(11;14) has reduced potential for rapid acquisition of new 
abnormalities and further complexity may only be acquired when specific secondary changes 
arise. In this study, the comparison between MGUS and MM with t(14;20) was less clear, as 
only two MM cases with this translocation had available material for array CGH of which one 
had no CNA, only balanced translocations. However, the second t(14;20) patient showed a total 
of 11 CNA and metaphase analysis of 18 MM patients with t(14;20) and abnormal cytogenetics 
showed highly complex karyotypes with multiple gains and losses of chromosomal material in 
the majority of cases which would correspond to high number of CNA.  
 
Among the abnormalities found to be rare in MGUS/SMM and more frequent in MM, some 
appeared to be exclusive to pre-malignant patients who then evolved to symptomatic disease. 
The same abnormalities were found in patients who, despite showing a continuous and rapid 
rise in their paraprotein level, either were never treated for MM because of premature death 
from MM-unrelated causes or no further follow-up was available. Examples of such 
abnormalities are 1p21-p22 loss, 6q25 loss, 8q24 abnormalities, 12p13.1 loss and TRAF3 HD Results 
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(Table 3-17) which are strongly associated with evolving disease. Other abnormalities, despite 
being less frequent in MGUS/SMM and detected in patients who eventually progressed, were 
also found in patients characterized by long-term stability and who remained completely 
asymptomatic at the end of the study (8p22-p21 loss, 9p21 loss and 16q23 loss; Table 3-17). 
Understanding the biological effect of these CNA is challenging. 
 
Gain of 1q has been reported to be absent from MGUS and has been associated with evolving 
disease by different groups 
162-164. However, in this patient cohort its frequency was not 
significantly different between diagnostic groups and its association with t(4;14), previously 
reported in MM 
162,165, was found to be already established in pre-malignant conditions. 
Moreover, no significant association was found between 1q gain and evolving disease either in 
MGUS or in SMM. As a result of these observations, the impact of this abnormality on 
progression has to be further investigated in a larger patient series (Section 3.4). 
Loss of 1p32.3, involving the CDKN2C/p18 and FAF1 genes, was found in MM but not in pre-
malignant disease. HD involving this locus was detected in three MM patients and in the KMS-
11 cell line, indicating that the presence of this CNA is associated with the clinical 
manifestation of MM. Deletions of this locus have been previously reported in MM using 50K 
SNP-based mapping and array CGH 
155,178. As all CNA involved both genes, it was impossible 
to ascertain which one was the target of this abnormality. However, HD affecting only 
CDKN2C/p18 have been detected in three MM cell lines. This gene has been associated with 
tumour progression, an increased proliferative index 
226 and its ectopic expression was found to 
inhibit growth and induce apoptosis 
227. Bergsagel and colleagues suggested that p18 
dysregulation is a late oncogenic event in MM, which occurs at a time when tumours become 
more proliferative and consequently more aggressive 
90. According to this model, the 
abnormality would not be associated with evolution from MGUS to MM.  
On chromosome 1p a second region of loss has been identified (1p21.3-p22.1), which appeared 
to be associated with progression to MM although progression was not immediate (74 and 75 
months in two MGUS patients). Interestingly, Chang et al. investigated the prevalence and 
prognostic significance of 1p21.2 loss in MM and MGUS by iFISH using a BAC probe 
immediately centromeric of the common minimally deleted region defined in the current study. 
The abnormality was detected in 18% of MM patients and those with 1p21 deletions were found 
to have significantly shorter progression-free survival and OS than those without such deletions. 
Of note was that the abnormality was absent from MGUS patients in support of the findings of 
the current study 
228. 
 
Combining array CGH and FISH, abnormalities involving the chromosomal band 8q24.21 
(where MYC is located) were found in 13 of 47 (28%) MM patients, with increased incidence in Results 
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HRD cases (P=0.025). This incidence was higher than that reported by Avet-Loiseau et al. 
(13%) 
111,143. The MYC abnormalities detected in the present study were highly variable and 
included small interstitial duplications, amplifications, deletions within the proximity of the 
gene, balanced and unbalanced rearrangements. The small duplications identified by array CGH 
were too small to be detected by the commercially available FISH probes or by the in-house 
probes described by Avet-Loiseau and colleagues. These observations suggested that a 
proportion of MYC abnormalities remain undetected when screened by FISH. This may explain 
why the frequency of MYC abnormalities varies between series, as it is dependent on the 
detection method used. All CNA involving MYC identified in the present study were confirmed 
using an in-house BAC probe for MYC, specifically grown and labelled for this purpose. 
However, given the multiple break-points and the variable nature of MYC abnormalities, an 
improved approach either using individual techniques (i.e. multiple iFISH probes, MLPA) or a 
combination needs to be developed in order to detect the majority of changes. MYC 
abnormalities were rare in pre-malignant conditions: only one MGUS and one SMM were found 
to be positive for abnormalities at 8q24.21. The rarity of these abnormalities in pre-malignant 
conditions and the fact that both cases progressed to MM (at 16 and 45 months) are strongly 
suggestive that MYC aberrations are involved in disease evolution of these cases. Interestingly, 
the patient who progressed after 45 months had the abnormality in only a sub-population of 
cells.  
 
In MM, array CGH defined two common minimally deleted regions on 12p. The most telomeric 
one, at 12p13.1, involved only three genes including CDKN1B. However, apart from two cases 
with small localized deletions which defined the two minimally deleted regions, 12p deletions 
were large with no common break-points, involving both common regions of loss. In the array 
CGH group, 12p deletions were absent from MGUS and SMM. In the iFISH group, 12p13.1 
deletions were found to be very rare in pre-malignant cases and, when present, they appeared to 
be associated with progression to MM. CDKN1B is a critical cell-cycle regulator which arrests 
cell division and inhibits G1-S transition. In MM, immunohistochemical studies have shown that 
patients with low CDKN1B expression had a significantly shorter OS, while patients with high 
CDKN1B expression experienced prolonged survival 
229. However, mutation or silencing of 
CDKN1B in human cancer is extremely rare 
230 while loss of CDKN1B protein is a common 
event resulting from enhanced proteolysis. This probably explains why, in the current study, 
12p13.1 deletion by iFISH was not associated with inferior OS in MM patients. As previously 
stated, the majority of 12p deletions were large, thus other genes within this chromosomal 
region may be associated with disease progression. In contrast, Avet-Loiseau and colleagues 
recently published a SNP array study in which they concluded that 12p13.31 loss represented a 
very powerful marker of inferior prognosis in MM 
167. However, preliminary FISH results Results 
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collected by the UK Myeloma Database on a similar number of patients did not confirm this 
finding (unpublished data). 
 
The initial array CGH results suggested a possible role of CDKN2A/2B loss at 9p21.3 in disease 
progression, in particular in t(14;16) cases. Surprisingly iFISH on the independent cohort 
showed a higher prevalence of this abnormality in MGUS as compared to MM (12% vs 6%). No 
9p21.3 losses were detected in SMM patients. In MM, the presence of this abnormality was 
associated with shorter OS (P=0.006). In MGUS, the biological effect of the abnormality was 
unclear as two patients progressed to MM, while another two remained stable after 38 and 79 




involved in the inhibition of G1 phase progression. Mutant or absent CDKN2A is a critical 
oncogenic factor in prestine-induced murine plasmacytomas, but the role of this gene in MM is 
less clear 
231. Surprisingly, Uchida et al. 
232 found no mutations or deletions of CDKN2A/2B in 
MM, but promoter methylation was reported at an incidence of 58%. Similarly, Gonzales-Paz et 
al. showed that methylation of CDKN2A was a common event in all PC disorders (including 
MGUS and SMM) and that its frequency increased with disease progression, although only in a 
modest fashion. In the same study gene methylation did not appear to affect gene expression 
levels; in addition no difference in OS was seen between patients with or without CDKN2A 
methylation, suggesting that the methylation of this gene may be a marker for overall epigenetic 
changes associated with disease progression with no obvious direct biological or clinical 
consequences 
233. However, a recent quantitative real-time PCR study by Sarasquete et al. 
showed that p15 expression was lower in symptomatic MM than in SMM with similar results 
for p14/p16. MM patients whose PC displayed high p15 and/or p14/p16 expression had a lower 
percentage of S-phase PC than the remaining cases, favourable prognostic factors and longer 
survival (P=0.007) 
234. These findings are in agreement with those reported in the current study.  
 
In this study a number of CNA were found to involve genes encoding for regulators of the NF-
κB pathway. Is has been suggested that activation of this pathway is important for the survival 
of healthy PC 
235 as well as MM tumours 
236-238. The NF-ĸB family of transcription factors 
consists of NFKB1 (p50 and its precursor p105), NFKB2 (p52 and its precursor p100), RelA 
(p65), RelB and c-Rel 
239. There are two general pathways of activation: classical and 
alternative (Figure 3-20). In the classical pathway activated IKKβ, which is part of an IKKα-
IKKβ-IKKγ complex, phosphorylates the inhibitory subunits IkBα, IĸBβ or IĸBε leading to 
their proteasomal degradation. As a result, NFKB homodimers and heterodimers comprised 
mainly of RelA, RelC and p50, accumulate in the nucleus. Many different stimuli activate the 
classical pathway 
239 which is required for a successful immune response and to amplify the Results 
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survival and proliferation of cells. In the alternative pathway, NIK activates IKKα, which 
phosphorylates NFKB2 resulting in proteasomal removal of an inhibitory C-terminal domain, 
generating the p52 subunit. This leads to accumulation of p52/RelB heterodimers in the nucleus. 
The alternative pathway, which is important in lymphoid development, is activated in response 
to a small subset of tumour necrosis factor (TNF) family members, including CD40L, LTαβ 
(lymphotoxin α or β), BAFF (B-cell-activating factor), RANKL (receptor activator of NF-ĸB 
ligand) and TWEAK (THF-related weak inducer of apoptosis). Several recent reports have 
indicated that the alternative NF-ĸB signalling is regulated mainly through the control of NIK 




Figure 3- 20  NF-ĸB signal transduction pathways  
Modified from Gilmore, 2006 
242 
 
Various cancer types utilize constitutive NF-ĸB signalling to block apoptosis 
243 and it has been 
shown that 50% of HMCL and most primary MM samples have a high level of NF-ĸB activity, 
which was based on a transcription signature of 11 genes 
182. It has also been reported that 
approximately 40% of HMCL and at least 17% of primary MM tumours have mutations in 
components of this pathway, and that the presence of these mutations is associated with a high 
level of NF-ĸB activity and possibly stromal cell independence 
181,182,244. Overall, these 
abnormalities involved loss of function of TRAF2, TRAF3, CYLD, BIRC2/3 and gain of function 
of NFKB1, NFKB2, CD40, LTBR, TACI and NIK. Some of these changes appear mainly to 
activate the classical pathway (CYLD, NFKB1, TACI) and one mainly the alternative pathway Results 
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(NFKB2), but most activate the alternative and to a lesser extend the classical pathway 
(BIRC2/3, NIK, TRAF2, TRAF3, CD40) 
245. 
In this array CGH study, 13% (2/15) of SMM and 26% (12/47) of MM patients, were found to 
have CNA involving members of this signalling pathway (one CNA was found in paired 
samples of the same patient at different stages of the disease). iFISH on the independent cohort 
of MM patients detected an overall incidence of abnormalities involving BIRC2/3, TRAF3 or 
NIK of 9%. In both patient cohorts, cases with hemizygous deletions of TRAF3, BIRC2/3 and 
CYLD were considered inconclusive, as no information was available on the status of the other 
allele. Inactivating mutations of TRAF3 and CYLD were found in 50% (8/16) and 20% (1/5) of 
MM patients with hemizygous deletions of these loci 
181. The lower frequency of NF-ĸB 
abnormalities in the independent cohort tested by iFISH may be explained by the fact that most 
MM patients from the array CGH cohort had a more aggressive disease. This hypothesis is in 
line with the fact that, because array CGH requires a relatively high quantity of good quality 
DNA, samples with high PC infiltration (often associated with high grade disease) are more 
likely to have been selected for this type of analysis. This observation also concurs with the 
hypothesis that changes involving this pathway are secondary events that occur late in the 
development of the disease. In agreement with this hypothesis, iFISH showed that in MM, these 
CA often involved only a proportion of neoplastic PC while other abnormalities, within the 
same patient, were found to be present in the entire PC population. Furthermore, a number of 
cases with HD of TRAF3 or BIRC2/3 showed that the loss of the second allele only involved a 
subclone of the population with the hemizygous deletion, indicating that the loss of the second 
allele occurred later on in tumour progression.  
In MM, the presence of TRAF3 HD was found to be significantly associated with an inferior 
outcome (P=0.002), while patients with hemizygous deletion showed a clinical course almost 
identical to patients with no abnormalities at this locus. This suggested that inactivation of both 
alleles is necessary to exert a biological effect.  
In the array CGH patient cohort, one SMM with t(14;16) was found to have a HD involving 
TRAF3; another SMM was found with an interstitial duplication at 17p12-p11.2 including 
TACI. Both evolved to MM within 15 months. Interestingly, the MGUS patient (989) with array 
CGH performed at the time of MGUS diagnosis and at the time of MM evolution showed 
acquisition of 4q24 gain (where NFKB1 is located) and 16q12.1 hemizygous deletion (where 
CYLD is located) only at the time of the second sample. In the iFISH patient cohort no HD of 
TRAF3, BIRC2/3 or NIK abnormalities (translocations or amplifications) were detected in 
MGUS or SMM patients. Overall, these findings suggested that abnormalities involving 
members of this pathway may play a role in the transition from MGUS/SMM to MM. 
Hemizygous deletions of TRAF3 were found in 14% and 27% of MGUS and SMM, 
respectively. It would have been interesting to perform mutational analysis on MGUS, SMM Results 
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and MM with TRAF3 hemizygous deletions in order to determine whether complete abrogation 
of the gene function was present in pre-malignant conditions or restricted to MM. Unfortunately 
the lack of material made this impossible. 
Interestingly, Annunziata et al. 
182 showed that not all molecular sub-groups of MM had 
equivalent expression of the NF-κB signature. It was high in tumours with c-MAF or MAFB 
dysregulation and those with low levels of bone disease. Expression was low in tumours with 
t(4;14) and MM with increased expression of proliferation-related genes. In our iFISH patient 
cohort, there was a significant association between these abnormalities and IgH rearranged 
cases, including tumours with t(4;14).  
 
Table 3-17 summarizes the various CNA found to be more frequent in MM than in MGUS and 
SMM. In MGUS and SMM, the presence of these CNA was correlated with the clinical course 
of the disease. Some of these CNA appeared strongly associated with progression to overt MM, 
while others were also found in cases characterized by long-term stability throughout the study. Results 
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CNA  CNA frequencies among diagnostic groups  Association with 
progression 
1q21-q23.2 gain  Increasing frequency from MGUS to SMM to MM 
However, difference not significant 
No
§ 
1p32.3 loss  Absent in MGUS/SMM; present in MM (also in form of 
HD) 
Unclear whether 
CNA involved in 
MGUS to MM 
progression or  only 
associated with late 
stage MM 
§ 
1p21.3-p22.1 loss  Increasing frequency from MGUS to SMM to MM  High 
6q25.1-q25.2 loss  Increasing frequency from MGUS to SMM to MM  High 
8p22-p21.2 loss  Increasing frequency from MGUS to SMM to MM  Ambiguous 
MYC abnormalities 
(8q24) 
Increasing frequency from MGUS to SMM to MM  High 
9p21.3 loss  • Array CGH cohort: absent in MGUS/SMM; present in 
MM (also in form of HD) 
• iFISH cohort: higher frequency in MGUS than in MM 
Ambiguous 
12p13.1-p12.3  loss  • Array CGH cohort: absent in MGUS/SMM; present in 
MM 
• iFISH cohort: higher frequency in MGUS than in MM 
High 
13q loss  Increasing frequency from MGUS to SMM to MM in 
t(11;14) patients 
High 
16q23.1 loss  Increasing frequency from MGUS to SMM to MM  Ambiguous 
17p13.1 loss  Increasing frequency from MGUS to SMM to MM  High 
NF-ĸB 
abnormalities 
Absent in MGUS; increasing frequency from SMM to 
MM in both the array CGH and iFISH patient cohort 
High 
 
Table 3- 17  Summary of the CNA with increasing frequency from MGUS to SMM to 
MM and their association with disease progression 
§  Confirmation of these findings was obtained on a larger patient cohort using array CGH and 
iFISH reported in Section 3.4. Results 
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3.4  Chromosome 1 abnormalities 
 
3.4.1  Introduction 
The array CGH results, described in Section 3.3.4.3.2, showed that 1q gain is present in the 
context of MGUS and SMM as well as in MM. The frequency of 1q gain was found to increase 
from MGUS to MM; however, the differences among the diagnostic groups were not 
statistically significant. More importantly, 1q gain did not appear to be significantly associated 
with disease evolution of pre-malignant patients.  
These results are in contrast with data that has been previously published. Hanamura and 
colleagues compared the frequency of 1q21 gain in different diagnostic groups. Such 
frequencies were 0% in MGUS (n=14), 45% in SMM (n=31), 43% in overt MM (n=479) and 
72% in relapsed cases (n=45) 
162. The same frequency of 1q21 gain in MGUS was reported by 
Chang et al. (n=23) 
163. In the paper by Hanamura et al., the abnormality was associated with a 
higher risk of transition of SMM to active MM, as 1q21 gain was detected in ten of 12 patients 
who evolved to MM compared to four of 19 patients who remained stable (P=0.001). In another 
study including 15 SMM patients studied by metaphase CGH, gain of 1q was also identified as 
one of the abnormalities which characterized the evolving-type of SMM (Section 1.5.2.2), 
together with ∆13 and deletions of 8p, 13q, 14q and 16q 
164. The pitfall of these studies was the 
fact that they all included relatively limited numbers of patients. Moreover, because of the high 
quantity of DNA required for metaphase- and array CGH, patient cohorts tested with these 
techniques may be biased towards patients with a higher degree of BM plasmacytosis. This is 
confirmed by the fact that abnormal metaphases were detected in 31 of the 39 (79%) MM 
patients tested by array CGH in Section 3.3, while the overall rate of MM patients with 
abnormal cytogenetics is ~38% 
87 (P=6.42 e-8). 
 
Array CGH showed that deletions of 1p are rare in pre-malignant conditions (Section 3.3.4.3.2). 
Within this chromosomal arm, two recurrently deleted regions were detected in the MM group. 
One was located at 1p32.3, where the common minimally deleted region encompassed the genes 
FAF1 and CDKN2C. No MGUS/SMM cases were found to be positive for this abnormality in 
line with the suggestion that it is predominantly a late change present in advanced MM 
90. 
However, the number of pre-malignant cases tested by array CGH was too small to conclude 
that 1p32.3 is exclusively associated with overt MM. Results 
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Here iFISH was used (i) to assess the incidence of 1q21 gain and 1p32.3 loss in a large cohort 
of patients with PC disorders; (ii) to look at the possible associations of these abnormalities with 
other changes tested by FISH; (iii) to clarify their prognostic significance in newly diagnosed 
MM patients; (iv) to assess whether 1q gain or 1p32.3 loss might be associated with disease 
progression.  
 
3.4.2  Patients 
A series of 924 patients with samples sent to the Myeloma Cytogenetic Database from multiple 
centres throughout the UK were evaluated. They comprised MGUS (n=100) (median age, 70 
years; range, 39-91 years), SMM (n=57) (median age, 65 years; range, 37-86 years) and MM 
patients (n=767) (median age, 65 years; range, 30-93 years).   
In the MGUS group, 16 patients had an IgA paraprotein isotype, 69 an IgG and two an IgM; for 
13 patients this information was not available. The paraprotein level at diagnosis was accessible 
for 75 cases: in 38 patients this was <15 g/L. Among the MM group, 445 patients were entered 
into the Myeloma IX Trial (median age, 64 years; range, 30-89 months); of the 322 non-trial 
patients, 82% were studied at diagnosis. OS was calculated for MM patients studied at diagnosis 
(trial patients: median follow-up, 21 months; range, 0-63 months; non-trial patients: median 
follow-up, 20 months; range, 0-78 months). In the MGUS series, follow-up data was available 
on 96 patients (median follow-up, 41 months; range, 3-86 months). Seven MGUS patients were 
not studied at diagnosis (the interval between diagnosis and cytogenetic analysis ranged from 8 
to 223 months); in these cases the follow-up was calculated from the time of analysis given the 
impossibility of knowing the time of acquisition of chromosome 1 abnormalities. In SMM, 
follow-up information was available for 47 patients (median follow-up, 35 months; range, 6-99 
months); in this group, one patient was not studied at diagnosis (patient 1581) and the only 
information available was that he had a long history of SMM. 
3.4.3  Methods 
3.4.3.1  Fluorescence in situ hybridization and array CGH 
Interphase FISH was performed on CD138
+ purified PC as described in Section 3.1.3.1. 
Patients were characterized for the presence of IgH rearrangements, ploidy status, ∆13 and 
deletions of TP53. To assess 1q status additional in-house probes were used: all patients were Results 
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tested for CKS1B (1q21.3); a proportion of patients were also tested for PDZK1 (1q21.1) (78% 
of MGUS, 54% of SMM and 28% of MM) and ASPM (1q31.3) (48% of MGUS, 26% of SMM 
and 28% of MM) (probes are described in Appendix 3). PDZK1 has been reported to be 
involved in organizing proteins at the cell membrane 
246 and in linking transmembrane proteins 
to the actin cytoskeleton 
247; the gene has been suggested to be one of the potential targets for 1q 
gain and its product has been associated with drug resistance 
156. The ASPM locus was tested in 
order to assess whether the abnormality involved only the proximal region of 1q or a more 
extended area.  
 
Deletions of 1p32.3 were assessed using a BAC mapping to the CDKN2C/p18 and FAF1 genes. 
Deletions of this locus can be particularly challenging to detect as they may be very small. 
Different probes were validated on cases known to be positive for a deletion at this locus by 
array CGH. The BAC clone RP11-116M11 (51364760Mb-51437772Mb; size: 73013bp) was 
the only one small enough to detect all deletions and was therefore applied to interphase cells of 
all samples. For 12 MGUS patients, 1q and 1p32.3 status was deduced from the array CGH 
results described in Section 3.3. 
 
3.4.4  Results  
3.4.4.1  Frequency and associations of 1q21 gain 
Within the MGUS group, 1q21 gain was found in 26 of 100 (26%) patients (detailed copy 
numbers for 1q21 are shown in Figure 3-21). In all positive cases detected by array CGH (five 
of 12), the gain involved the entire arm; in those tested by iFISH, when the three 1q probes were 
tested, all loci showed the same copy number in all but one patient (this case showed 5 copies of 
CKS1B/ASPM but normal PDZK1). By iFISH, 1q21 gain was found in a sub-population of PC 


















Figure 3- 21  Detailed copy number of 1q21 in MGUS, SMM and MM 
§ The MGUS cases assessed by array CGH showed 1q gain to be present in the majority of PC 
 
 
In SMM and MM, the frequency of 1q21 gain was found to be significantly higher compared to 
MGUS (MGUS vs MM, P=0.01): 21 of 57 (36.8%) SMM patients and 297 of 767 (38.7%) MM 
patients were positive for the abnormality. True amplification, defined as >6 copies, was absent 
in MGUS/SMM and rare in MM (n=6). In MGUS and MM, 1q21 gain was significantly 
associated with t(4;14), ∆13, and inversely associated with t(11;14) and t(6;14); in MM 1q21 
gain was also associated with t(14;16), t(14;20) and nonHRD; in SMM, 1q21 gain was 
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3 copies of 1q21  19%  28%  30% 
4 copies of 1q21  4%  9%  7% 
5 copies of 1q21  3%  0%  1% 
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MGUS (100) SMM (57) MM (767)Results 
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      t(4;14)  t(6;14) & 
t(11;14) 
∆13  t(14;16)  TP53 Del  t(14;20)  Ploidy  p18 Del 
      N  T  N  T  N  Del  N  T  N  Del  N  T  HRD  nonHRD  N  Del 
N  71  2  56  18  57  17  72  2  70  4  71  3  29  44  66  2 
MGUS 
Gain  22  4  26  0  12  14  23  3  22  2  23  2  8  16  21  2 
N  33  3  31  5  27  9  35  1  36  0  35  1  22  13  30  3 
SMM 
Gain  15  6  18  2  8  13  18  3  20  1  21  0  8  13  16  1 




Gain  239  56  266  28  114  181  280  14  265  26  283  10  152  127  223  41 
 
Table 3- 18  Associations between 1q21 gain and other chromosomal abnormalities in the three diagnostic groups 
(∆13, deletion/monosomy 13; N, normal; T, translocated; Del, deleted; HRD, hyperdiploid; nonHRD, non-hyperdiploid) 
Positive associations are highlighted in blue, negative ones in yellow 
 
Statistically significant associations: 
•  t(4;14) in MM (P<0.001) and MGUS (P=0.039) 
•   inverse association with t(6;14) and t(11;14) in MM (P<0.001) and MGUS (P=0.003)  
•   ∆13 in MM (P<0.001), SMM (P=0.010) and MGUS (P=0.006) 





3.4.4.2  Prognostic relevance of 1q21 gain in newly diagnosed MM and impact of 
this abnormality on the transition from MGUS and SMM to MM 
 
3.4.4.2.1  MM 
Among the MM patients studied at diagnosis (n=691), those with 1q21 gain showed 
significantly inferior OS compared with those with normal 1q (27 months vs 51 months, 
P=7.6e-6). Inferior OS was found for both trial and non-trial patients when analyzed separately 














Figure 3- 22  Kaplan-Meier analysis of OS in MM displayed in relation to the presence 




When MM patients with 1q21 gain were stratified on the basis of the presence or absence of 
other genetic markers of poor prognosis, gain of 1q21 remained an independent poor prognostic 
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P= 2.8 E-7 
Deaths/N      MS
No 1q21 gain                                         179/421     51
1q21 gain, no bad IgHt or TP53 Del      85/177       33
1q21 gain & bad IgHt or TP53 Del         67/92         21
Trial + non-Trial patients studied at 
diagnosis (N=691)
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Figure 3- 23  Kaplan-Meier analysis of OS in MM displayed in relation to the presence 
or absence of 1q21 gain and other chromosomal markers of inferior prognosis 
 
 
3.4.4.2.2  MGUS 
Within the MGUS group, follow-up information was available for 96 of 100 patients. Twenty-
four patients (25%) progressed to MM with a median time to progression of 33.5 months (range, 
4-79 months) (Table 3-19). In this study, there was no significant difference in the rate of 
progression between patients with a paraprotein level below or equal/greater than 15 g/L. Six of 
16 (38%) patients with an IgA subtype progressed to MM, compared with 16 of 66 (24%) 
patients with IgG. However, this difference was not statistically significant.  
 
Only five of 25 (20%) patients positive for 1q21 gain evolved to MM (median time to 
progression, 45 months) compared with 19 of 71 (27%) cases negative for the abnormality 














Table 3- 19  Association between progression and 1q21 gain in MGUS patients 
 
 
The median follow-up of the 20 patients with 1q21 gain and no evidence of progression was 42 
months (range, 3-78 months); six of these patients were completely stable after 5 years (Figure 
3-24) and their paraprotein level hardly changed from diagnosis. Interestingly two cases, stable 

















   
 
Figure 3- 24  Plot of MGUS patient follow-up versus progression and 1q21 status 
Median follow-up values for the different groups are indicated by black triangles (stable MGUS 
cases with 1q21 gain, 42 months; progressed MGUS cases with 1q21 gain, 45 months; stable MGUS 
cases with no 1q21 gain, 50 months; progressed MGUS cases with no 1q21 gain, 32 months). The 
three stable MGUS patients with 1q21 gain and less than 6 month follow-up died of MM-unrelated 
causes. 
 
P=0.60    Patient follow-up 
    Stable  Progressed  Total 
Normal  52  19     (27%)  71 
1q21 status 









































Cases without 1q21 gain
Stable Stable Progressed Progressed









































Cases without 1q21 gain
Stable Stable Progressed Progressed
















Figure 3- 25  Kaplan-Meier analysis of progression in MGUS displayed in relation to the 
presence or absence of 1q21 gain 
 
 
As shown in Figure 3-25, there was no evidence that the presence of 1q21 gain in MGUS 
results in a more rapid progression to MM (P=0.644). 
 
The five MGUS patients with 1q gain who progressed to MM were found to be positive for 
other abnormalities associated with a dismal prognosis in MM: t(4;14), t(14;16), ∆13, nonHRD 
and loss of p18. However, among the MGUS patients with 1q gain and stable disease for more 
than four years, similar abnormalities were detected: t(4;14), t(14;20), nonHRD, ∆13, deletions 
of chromosome 16, which have also been linked to an inferior prognosis 
248. 
 
3.4.4.2.3  SMM 
Within the SMM group, follow-up information was available for 47 of 57 patients. Eighteen 
patients (38%) progressed to MM with a median time to progression of 22 months (range, 11-56 
months). Eight of 18 (44%) patients positive for 1q21 gain evolved to MM (median time to 
progression, 22.5 months) compared with ten of 29 (34.5%) cases negative for the abnormality 
















Progressions/N         MP
No 1q21 gain             19/71                    79













Progressions/N         MP
No 1q21 gain             19/71                    79
1q21 gain                     5/25                    75
Progressions/N         MP
No 1q21 gain             19/71                    79








Table 3- 20  Association between progression and 1q21 gain in SMM patients 
 















Figure 3- 26  Plot of SMM patient follow-up versus progression and 1q21 status 
Median follow-up values for the different groups are indicated by black triangles (stable SMM 
cases with 1q21 gain, 41.5 months; progressed SMM cases with 1q21 gain, 22.5 months; stable 
SMM cases with no 1q21 gain, 42 months; progressed SMM cases with no 1q21 gain, 22 months) 
 
 
Interestingly none of the stable cases with the abnormality had more than one extra copy of 
1q21; in contrast four of the eight cases who progressed had two extra copies of 1q21 in all PC 
or in more than half of the PC population, with the remaining PC carrying three copies. 
As already observed in MGUS, 1q21 gain was found in association with other poor prognostic 
markers in both SMM cases who progressed and cases who remained stable. 
 
P=0.55    Patient follow-up 
    Stable  Progressed  Total 
Normal  19  10     (34.5%)  29 
1q21 status 
Gain  10  8       (44.4%)  18 
Cases without 1q21 gain
Stable Stable Progressed Progressed





























Cases without 1q21 gain
Stable Stable Progressed Progressed






























3.4.4.3  Frequency and associations of 1p32.3 loss 
Loss of 1p32.3 was found in four of 95 (4%) of MGUS, 4 of 50 (8%) of SMM and in 94 of 709 
(13%) of MM patients (MGUS vs MM, P=0.01). HD of this locus were only found in MM 
(9/709, 1%). One MGUS patient showed the deletion in 18% of PC and was considered 
negative for the abnormality (cut-off level: 20%). In two MGUS cases the abnormality was 
found in less than 50% of PC (40% and 45%); in the other two cases 1p32.3 loss was present in 
the majority of PC. All four positive SMM cases showed the abnormality to be present in less 
than 50% of PC; in MM the median percentage of PC with the deletion was 92% (range, 21-
100%). 
 
Within the MM group, 1p32.3 loss was positively associated with 17p13 deletions (P=0.045) 
and nonHRD (P=0.003) and inversely associated with the translocations t(6;14) and t(11;14) 
(P=0.01) (Table 3-21). No specific association was found between 1p32.3 loss and any of the 
other CA tested in both MGUS and SMM; this was probably due to the small number of 
patients in these diagnostic groups who were positive for the abnormality.  
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      t(4;14)  t(6;14) & 
t(11;14) 
∆13  t(14;16)  TP53 Del  t(14;20)  Ploidy  1q21 gain 
      N  T  N  T  N  Del  N  T  N  Del  N  T  HRD  nonHRD  N  Gain 
N  84  6  74  17  65  26  87  4  84  4  84  6  33  56  66  21 
MGUS 
Del  4  0  3  1  3  1  4  0  3  1  4  0  3  1  2  2 
N  40  6  38  7  29  17  42  4  46  0  45  1  24  20  30  16 
SMM 
Del  3  1  4  0  3  1  4  0  4  0  4  0  1  3  3  1 




Del  85  9  87  7  49  45  89  5  77  13  91  3  42  50  47  41 
 
Table 3- 21  Associations between 1p32.3 loss and other chromosomal abnormalities in the three diagnostic groups 
(∆13, deletion/monosomy 13; N, normal; T, translocated; Del, deleted; HRD, hyperdiploid; nonHRD, non-hyperdiploid) 
Positive associations are highlighted in blue, negative ones in yellow 
 
Statistically significant associations: 
•  TP53 deletion in MM (P=0.045) 
•  nonHRD in MM (P=0.003) 
•   inverse association with t(6;14) and t(11;14) in MM (P=0.01)Results 
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3.4.4.4  Prognostic relevance of 1p32.3 loss in newly diagnosed MM and impact of 
this abnormality on the transition from MGUS and SMM to MM 
Among the four MGUS patients with the deletion: for one case, the follow-up was lost 
immediately after diagnosis; one patient died of MM-unrelated causes 3 months after diagnosis, 
while the remaining two patients progressed to MM after 40 and 68 months. 
Among the four SMM patients: two patients remained stable after 9 and 81 months; one patient 
progressed to MM after 22 months and subsequently died of refractory disease; whilst the last 















Figure 3- 27  Kaplan-Meier curve for OS in newly diagnosed MM patients for 1p32.3 
deletions 
 
In newly diagnosed MM, patients with 1p32.3 loss (either loss of one or two copies) showed a 
significantly inferior OS compared to patients without the abnormality (median survival, 23 
months vs 46 months, P=0.003) (Figure 3-27). Among the nine patients with HD at this locus, 
seven (78%) died (median time to death = 17 months). When MM patients with 1p32.3 loss 
were stratified on the basis of the presence or absence of TP53 deletion (given the association 
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Normal 253/553         46
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Deaths/N        MS
Normal 253/553         46
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Trial + non-Trial patients studied at 
diagnosis (N=633)Results 
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3.4.5  Overall summary of the results and discussion 
This study shows for the first time that 1q21 gain may be present in MGUS (26%); 
disagreement with other reports is probably due to the limited number of cases enrolled in those 
studies 
162,163. The frequencies of 1q21 gain in SMM and MM were in agreement with published 
data 
162,163,165. However, when the specific copy number of CKS1B was considered in cases 
positive for the abnormality, MM patients from our cohort only showed ~9% of cases with 
more/equal four copies, while Hanamura and colleagues 
162 reported 18% of their MM patients 
with high level gains. 
Despite being considered as a secondary change, only two of 26 (8%) MGUS cases with the 
abnormality showed 1q21 in a PC sub-clone, suggesting that the acquisition of this CA is often 
an early event.  
The same associations as found in MM between 1q21 gain and other CA were confirmed in 
MGUS and SMM; lack of significant associations for some of the markers in SMM was 
probably a consequence of the fact that fewer patients were included in this group. In MM, 1q21 
gain was associated with inferior OS in both the trial and the non-trial groups (P=1.02e-4 and 
P=0.025, respectively) and despite its coexistance with other markers of poor prognosis (i.e. 
adverse IgH translocations), 1q21 gain appeared to be independent of these factors.  
 
In MGUS, 1q21 status was correlated with time to progression using the Kaplan-Meier analysis: 
no evidence was found that the presence of 1q21 gain was responsible for very rapid 
progression, as there was no difference in the time to progression between patients with and 
without 1q gain. Interestingly, six patients with the abnormality were completely stable for more 
than 5 years and two patients, stable at 57 and 74 months, clearly showed five copies of 1q21 in 
their clonal PC. It was hypothesized that the specific association with other chromosomal 
abnormalities might modulate the biological effect of 1q21 gain in MGUS. In this study, no 
difference in the association of 1q21 with other chromosomal markers was detected between 
patients with 1q21 gain who progressed and patients with 1q21 gain whose disease remained 
stable. However, this needs to be explored further in a larger series as the disease is genetically 
highly heterogeneous and some changes are relatively rare.  
 
A risk stratification system for MGUS patients based on clinical parameters was defined by the 
Mayo Clinic; this combines paraprotein isotype, paraprotein level and free light chain ratio 
48. 
Unfortunately MGUS patients from this cohort were not assessed for free light chain ratio. 
However, both the paraprotein isotype and the paraprotein level could be correlated with time to 
progression: no significant association between these markers and progression was found. 
Interestingly, similar results have been reported by Weiss et al. 
75: in their patient cohort there Results 
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were no patients who satisfied the criteria for high-risk MGUS defined by the Mayo clinic 
model, in fact patients who rapidly progressed were classified as low risk by this same model. 
In SMM the effect of 1q21 gain on progression was more difficult to assess as the follow-up 
was only available on 47 patients: 44% of patients with 1q21 gain progressed to MM compared 
with 35% without the abnormality. This difference was not statistically significant (P=0.55) and 
no difference in median follow-up time was found between stable cases with and without the 
abnormality (41.5 months vs 42 months, respectively). However, it should be noted that none of 
the stable patients with 1q21 gain had more than three copies of 1q while half of the patients 
who progressed had at least two extra copies of the chromosomal arm. This observation may 
suggest that, in SMM, either acquisition of extra copies of 1q affects disease evolution or it 
might be that those cases (with more than one extra copy of 1q) achieved a high level of 
genomic complexity. Maybe this complexity was responsible for their evolution, with tetrasomy 
1q being only a manifestation of this complexity and not the cause of progression.   
 
Loss of 1p32.3 was found to be rare in MGUS (4%) confirming the array CGH results. In six of 
eight pre-malignant cases positive for the abnormality, this was found to involve only a sub-
clone of PC suggesting that the abnormality is a secondary event in most cases. 
In MM loss of 1p32.3 was associated with an inferior OS (P=0.003). In MGUS and SMM a 
clear understanding of the effect of 1p32.3 loss was hampered by the limited number of patients 
with the abnormality and by the lack of follow-up information for three of the eight. However, it 
is of interest that of the five patients with this information, two MGUS and one SMM patient 
progressed to MM after 40, 68 and 22 months, respectively. As noticed for other abnormalities, 
in those patients with 1p32.3 loss who progressed to MM time to progression was variable 
suggesting that other factors might have played a role in their transformation. Results 
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3.5  Sequential analysis of a SMM case 
 
3.5.1  Introduction 
The course of MGUS and SMM patients is usually monitored by the continuous observation of 
clinical parameters, while BM samples are only taken at diagnosis or when progression is 
suspected. This practice makes it difficult to perform longitudinal genetic studies on those rare 
cases who transform to frank MM.  
 
Patient 259 was initially diagnosed as SMM and was followed for a period of 4.5 years until 
progression to symptomatic MM. Five serial BM samples, taken every year following diagnosis 
of SMM, were sent to the Myeloma Cytogenetic Database with detailed information of the BM 
morphology and the clinical parameters. Conventional cytogenetics, iFISH and array CGH were 
carried out on the five serial samples in order to associate the time of appearance of the different 
abnormalities detected in the neoplastic clone with the clinical course of the disease.  
 
3.5.2  Case Report 
Patient 259, a 30 year old caucasian woman, was incidentally found to have protein in her urine 
in September 2001, in the absence of urinary symptoms or infections of the urinary tract. 
Laboratory findings included WBC count of 6.4 x 10
9/L (reference range, 4.0–11.0 x 10
9/L); 
haemoglobin level of 125 g/L (reference range, 120–150 g/L); calcium corrected of 2.32nmol/L 
(reference range, 2.15–2.55 nmol/L). Her BM aspirate (sample 1) showed BM elements 
adequately represented, with normal differentiation and maturation; 9% PC with atypical 
morphology was observed (Figure 3-28A). The trephine displayed a degree of architectural 
disorganization, with low level increase in the number of PC, and occasional focal aggregations.  
There was an IgAk paraprotein of 32.4 g/L (reference range, 0.8–2.8 g/L) and kappa light chain 
in the urine, with no evidence of end organ damage, although β2M was 3.4 mg/L (reference 
range, 1.2–2.4 mg/L) and renal function was slightly impaired (creatinine 132 µmol/L; reference 
range, 60–125 µmol/L). A renal biopsy showed minor glomerular abnormalities, but no changes 
that are typically associated with MM related renal damage. She was diagnosed with SMM and Results 
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no treatment was given. Laboratory examination in 2002 indicated stable disease, with no raise 
in paraprotein or in creatinine levels; WBC count, haemoglobin, electrolytes and calcium levels 
were also normal. Subsequent BM investigations were performed in June 2003 (sample 2), June 
2004 (sample 3) and May 2005 (sample 4). PC levels were 13%, 3% (haemodilute) and 28%, 
respectively, with trephines indicating low level PC infiltration in normocellular marrows. 
Paraprotein levels fluctuated between 25.5 and 33.2 (Figure 3-29). Creatinine did not increase, 
and was 113 µmol/L in 2005, but β2M increased to 5.6 mg/L at that time. Repeat MRI scans 










Figure 3- 28  A) Bone marrow aspirate (2001 sample); B) Binucleated PC in 2006 sample 
(Hematoxylin and eosin stain) 
 
In January 2006 the patient remained asymptomatic, despite a slight increase in paraprotein 
(35.7 g/L) and a marginal decrease in platelet count (116 x 10
9/L). In March 2006 she was 
urgently re-assessed and treated, due to bone pain in her left clavicle, subsequently shown to be 
due to a lytic lesion. The BM aspirate (sample 5) showed ~30% PC with binucleated forms 
present (Figure 3-28B), while the biopsy revealed sheets of atypical PC in some areas. The 
patient was found to be anemic and trombocytopenic with a haemoglobin level of 106 g/L and 
platelet count of 97 x 10
9/L. She was entered into the MRC Myeloma IX Trial and treated with 
cyclophosphamide, thalidomide, and dexamethasone, followed by autologous stem cell 
transplantation in September 2006. She had an initial good response achieving partial remission, 
but relapsed with rising paraprotein in September 2008. 
 
3.5.3  Methods 
PC were isolated from all five samples described above as described in Section 2.2.6. All 





adequate for cytogenetic analysis (Section 2.3). Sample 2 had sufficient material to extract 
DNA for array CGH analysis. For array CGH, genomic DNA (1.9µg) was extracted from 
purified PC stored in Carnoy’s fixative and hybridized to the 244k microarray and processed as 
described in Section 2.6. Duplicated, amplified and deleted regions were defined using a 500 kb 
weighted moving-average window and the ADM-2 algorithm of the CGH Analytics software 
with a threshold of 6.0 (Section 2.6.6).  
 
3.5.4  Results  
3.5.4.1  Clinical data 
The paraprotein level, monitored for the 4.5 years, did not show a progressive increase as 
depicted in Figure 3.29.  
The pattern of BM infiltration by PC, except for a slight increase, did not change significantly 










































































Figure 3- 29  Chart showing the variation of the serum M-protein (IgA) from the 
diagnosis of asymptomatic SMM to diagnosis of symptomatic MM 
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3.5.4.2  Genetic data 
The main iFISH results are shown in Table 3-22. FISH indicated a hypodiploid karyotype for 
all samples (confirmed in sample 2 by array CGH and in sample 5 by cytogenetic analysis).  At 
presentation all PC had a t(4;14) with loss of the der(14). It is not clear whether loss of der(14) 
occurred at the time of t(4;14) formation or was a secondary change, although no FISH signal 
patterns indicative of the balanced form were observed. No other abnormalities were detected 
by iFISH at this time apart from ∆13 in 18% PC. This is below the European Myeloma 
Network–agreed cut-off of 20%, but well above our laboratory false positive rate, indicating the 
presence of a low level population with this abnormality. As a confirmation, the proportion of 
PC with this abnormality progressively increased throughout the years: sample 2, <20%; sample 
3, 40%; sample 4, 74%; sample 5 (diagnosis of MM), 100%. Conventional cytogenetic analysis 
of the second sample revealed only 26 normal metaphases. The 16q23 status was tested for the 
first time on the second sample; at this time a deletion of this locus was found in 69% of PC; 
similar to ∆13, the proportion of PC with this CA increased to 97% in the 2005 sample. 
 
 
   Results 





Table 3- 22  Summary of the critical iFISH results for the five samples 
N indicates normal/negative result; IgHr, IgH rearrangement; unb, unbalanced; der(14), derivative (14) from an IgHt; nt, not tested 
16q status was deduced from loss of the c-MAF part of the Abbott IgH/MAF probe combination 
* Result confirmed by array CGH 
† The MYC split was detected with the Abbott MYC break apart probe combination; the t(8;14)(q24;32) was tested with the IgH/MYC, CEP 8 probe 
combination
Sample 
number         
(date) 
diagnosis 











t(8;14) &  
MYC split  CC 
1 (09/2001) 
SMM 
iFISH   (18%)   (98%)  Unbalanced 







 (<20%)    (100%)  Unbalanced* 




N  N *   N *  N  Normal: 
46,XX[26] 
 3 (06/2004) 
SMM 
iFISH   (40%)   (100%)  Unbalanced 
(100%)  N  16q23 deletion 
(89%)  N  nt  N  N  Not set up 
 4 (05/2005) 
SMM 
iFISH   (74%)   (100%)  Unbalanced 
(100%)  N  16q23 deletion 
(97%)  N  N  deletion 
(42%) 
MYC split (40%)†; 
t(8;14) negative  Not set up 





 (100%)   (100%)  Unbalanced 
(100%)  N  nt  N  N  deletion 
(82%)  MYC split (100%)  Abnormal 
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The array performed on sample 2 (2003) showed several CNA. All were losses, involving 
chromosomal regions 2p, 4p, 12q, 16p, 16q, 19q and monosomies of chromosomes 13 and 14; 
all chromosomal regions apart from chromosome 13 (log2 ratio = −0.18) (Figure 3-30) showed 
loss of one copy in the majority of tumour cells, consistent with the iFISH results exhibiting 










Dim (2)(11.19[2p25.1]-26.43[2p23.3])     Dim (4)(0.04[4pter]-1.85[4p16.3])         Monosomy(13)(18.07-114.12) 
 
Figure 3- 30  Array CGH analysis for chromosomes 2, 4 and 13 with the G-banded 
idiograms  
G-banded idiograms (on the left) with the size of the abnormalities are shown for every 
chromosome; for the chromosomal regions 2p23-p25, 4p16 and 13q14 the plot of ‘calls’ for every 
nucleotide is shown in detail. Gains are labelled in red, losses in green 
 
Array results: Dim(1)(145.82[1q21.1/.2]-146.47[1q21.1/.2]); DimX2(1)(165.96[1q24.2]-
165.99[1q24.2]); Dim (2)(11.19[2p25.1]-26.43[2p23.3]); Dim(2)(89.0[2p11.2]-89.31[2p11.2]); Dim 
(4)(0.04[4pter]-1.85[4p16.3]); Enh(5)(37.49[5p13.2]-37.5[5p13.2]); Dim (5)(172.59[5q35.1/.2]-
172.6[5q35.1/.2]); Dim (6)(32.57[6p21.32]-32.63[6p21.32]); Dim (8)(6.93[8p23.1]-7.79[8p23.1]); Enh 
(8)(39.36[8p11.23]-39.51[8p11.23]); Dim (12)(34.42[12CEP]-132.39[12qter]); Dim(13)(18.07-114.12); 
Dim(14)(18.15-105.99); Enh(15)(18.68[15q11.2]-20.25[15q11.2]); Dim(16)(0.03[16pter]-
10.97[16p13.13]); Dim(16)(34.06[16p11.2]-34.61[16p11.2]); Dim(16)(45.03[16q12.1]-88.69[16qter]); 
Dim(19)(47.99[19q13.13]-48.45[19q13.13]); Enh(22)(22.69[22q11.23]-22.73[22q11.23]); 
Dim(22)(37.68[22q13.1]-37.71[22q13.1]) (CNV are written in italics). 
 
FISH for the three markers on 1q showed no numerical changes in any of the samples; array 
CGH on sample 2 did not show CNA involving any region of chromosome 1.  
However, the abnormal karyotype found at the time of diagnosis of MM showed an interstitial 
deletion on 1p, defined as 1p13 to 1p3?2 (Figure 3-31). FISH analysis performed with probes in 
1p12 and 1p32.2 confirmed the involvement of 1p32.3 within the deletion, encompassing the 
CDKN2C/p18 and FAF1 genes. The preceding samples were then retrospectively tested for this 
CA. As shown in Table 3-21, the first three were negative as confirmed by array CGH on 
sample 2, but samples 4 and 5 showed 42% and 82% of PC, respectively, with the deletion. The 
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deletion observed in this patient appeared to be larger than this specific locus, therefore the 


















The karyotype also showed a rearrangement involving 8q24, as an unbalanced translocation 
t(8;13). FISH confirmed that this rearrangement involved MYC, as shown in Figure 3-32, but 
not the IgH locus. Although the IgLλ locus was not tested in this case, it has been reported that 
in the majority of MM patients MYC rearrangements occur through translocations with other, 





Figure 3- 32  Interphase FISH 
patterns from sample 5 (2006) 
hybridized with LSI MYC dual colour 
break-apart MYC probe (Vysis) 
 
 
The one orange (119kb upstream of the 5′ end of MYC), one green (1.5Mb 3′ of MYC), and one 
fusion pattern represents a breakpoint within the gap between the hybridization targets of the 
probe combination resulting in a MYC rearrangement 
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Similar to the 1p deletion, the MYC rearrangement was observed for the first time in sample 4 
and at this time it involved only a sub-population of cells (40%). This rapidly increased to 100% 
in sample 5.  
 
3.5.5  Overall summary of the results and discussion 
This female patient was incidentally diagnosed with SMM at the unusually young age of 30 
years; less than 3% of SMM patients are younger than 40 years of age 
39. Serial annual genetic 
analyses were carried out over a period of 4.5 years, at which time evolution to symptomatic 
MM had occurred. This gave a rare opportunity to compare the clinical course of the disease at 
the same time points as the characterization of the genetic profile of her clonal PC at different 
stages of her follow-up.  
As described in Section 1.5.2.2, a number of diagnostic clinical parameters have been defined 
as predictive for disease progression to MM in patients with SMM. Despite having evidence of 
an IgA paraprotein, the patient had <10% PC in the BM and a paraprotein level >30g/L. These 
parameters have been associated with the lowest median rate and longest median time to 
progression 
39. According to the definition of ‘evolving’ and ‘non-evolving’ type of SMM 
defined by Rosinol et al.
54 and described in Section 1.5.2.2, this patient conformed to the ‘non-
evolving’ type as her paraprotein did not show a progressive increase during the follow-up time.  
An unbalanced t(4;14) was found in all PC from the time of the first sample. The balanced and 
the unbalanced forms of this translocation are associated with a poor outcome in MM 
123,218 but, 
as shown in Section 3.2 and in agreement with other reports 
44,138, its presence does not 
necessarily lead to disease evolution in the context of pre-malignant cases. In this patient at 
diagnosis the translocation was not associated with an aggressive phenotype. The appearance of 
∆13 was clearly secondary to the IgH translocation and the increase in proportion of cells with 
this abnormality was slow, particularly in the first three years. Array CGH suggested that 
monosomy 13 was the latest numerical change to have been acquired by the time of the second 
sample. Although the abnormality might have conferred a proliferative advantage to the cell, it 
did not represent the cause of malignant transformation.  
As described in Sections 3.3.4.3.4 and 3.4.4.3, chromosomal rearrangements involving MYC 
and loss of 1p32.3 are very rare in MGUS and SMM; in MM they have been associated with 
advance stage disease 
90. However, in this patient, both abnormalities seemed to be associated 
with the establishment of symptomatic MM. Results 
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3.6  Comparison between genetic abnormalities detected in 
MM and those detected in PCL  
 
3.6.1  Introduction 
Due to the rarity of PCL, only sporadic cytogenetic studies have been published; these have 
shown complex karyotypes, mainly hypodiploid, with multiple marker chromosomes involving 
unidentified chromosomal regions. Although unable to detect cryptic and balanced alterations, 
metaphase CGH has provided additional information 
151,153 while FISH revealed the presence of 
specific changes in patients with failed, normal and highly rearranged karyotypes 
97,151,153,249-252.  
Many of the chromosomal abnormalities reported in PCL have also been described in MM and 
the other plasma cell dyscrasias. However, the incidence of such abnormalities appeared to 
differ between the specific disease subtypes. The translocation t(11;14)(q13;q32), involving the 
CCND1 and IgH genes, is such an example. Although not exclusive to pPCL, it represents the 
most frequent IgH translocation, suggesting a potential role of this rearrangement in the etiology 
of this disease 
97,252.  
 
In this section, array CGH was used to define the genomic profile of 12 PCL patients in 
combination with conventional cytogenetic and FISH. These results were then compared with 
those obtained from MM patients described in Sections 3.1 and 3.3. 
 
3.6.2  Patients 
BM samples from 12 PCL patients were evaluated using multiple techniques; ten were 
classified as pPCL, the remaining two were sPCL. Their median age was 72.5 years (range: 23-
83 years). The most relevant clinical features of the 12 patients are presented in Appendix 11. 
OS was extremely poor (median: 3 months; range: 1–20 months) following heterogeneous 
treatment regimens. Five of 11 patients died within the first month from diagnosis and four 
within the first year. FISH data from these patients were compared with those from the cohort of 
400 newly diagnosed MM patients described in Section 3.1.2. Array CGH profiles of PCL Results 
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patients were compared with those obtained from the group of 47 MM patients described in 
Section 3.3. 
 
3.6.3  Methods 
3.6.3.1  Metaphase analysis 
Cytogenetic studies were performed on BM from all PCL patients following density gradient 
separation (Section 2.2.3). PC percentage was assessed on Leishman’s-stained slides from 
cytospin preparations (Section 2.2.4). Cells were cultured for 24 hours, 3 days and/or 6 days, 
depending on the quantity of cells available as described in Section 2.3.  
 
3.6.3.2  iFISH studies 
All samples were tested by iFISH as described in Section 2.4. The probes used were those 
described in Section 3.1.3.1. Additional probes were used for MYC status (the t(8;14)(q24;q32) 
fusion probe combination, MYC break apart probe combination; PAC RP1-80K22 covering only 
MYC). BAC RP11-473K22 was used to test for deletion at 5q32; BAC probes RP11-142D17 
and RP11-395I14 were used to confirm deletion at 8p21.2 (probes are listed in Appendix 3). 
 
3.6.3.3  Array CGH studies 
Eleven of the 12 PCL patients were tested by array CGH. Genomic DNA was extracted from 
purified PC stored as a dried pellet (patients 325, 3210 and 3342), purified PC stored in 
Carnoy’s fixative (patients 3272, 3125, 3343, 2359 and165) or non-purified fixed cells derived 
from 24 hour (patients 742 and 1188) and 3 day (patient 1576) cytogenetic cultures with a 
percentage of abnormal cells (tested by iFISH for known abnormalities) greater than 70% 
(Section 2.5). Genomic DNA was hybridized to the 244k microarray and processed as described 
in Section 2.6. Duplicated, amplified and deleted regions were defined using a 500 kb weighted 
moving-average window and the ADM-2 algorithm of the CGH Analytics software with a 
threshold of 6.0 (Section 2.6.6).  Results 
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3.6.3.4  mRNA identification of genes mapping at 5q33.1 
At 5q33.1, a common minimally deleted region was identified and included eight genes: 
SPINK5L2 (Kazal type serine protease inhibitor 5-like 2), SPINK6 (serine peptidase inhibitor, 
Kazal type 6) SPINKL5L3, SPINK7, SPINK9, FBXO38 (F-BOX only protein 38), HTR4 (5-
ydroxytryptamine (serotonin) receptor 4) and ADRB2 (β-2-adrenergic receptor). Based on the 
NCBI Unigene EST Profile Viewer (URL in Appendix 1), only FBXO38 is expressed in the 
BM, lymph nodes and also in BM samples from patients with leukaemia. However, despite 
being ubiquitously expressed, no certain information was available on its expression in PC. In 
order to ascertain that only FBXO38 is expressed in PC, total RNA was extracted from purified 
PC from four randomly selected MM patients (374, 665, 1037, 1148) and two patients with 
myelodysplastic syndrome whose PC were isolated from total BM as described in Section 2.2.5 
(final PC purity: 70% and 80%). The total RNA was converted into cDNA (Section 2.7) and 
checked for quality (Section 2.7.1). Specific sequences covering two or more exons were 
selected for each gene product (primers are listed in Appendix 12). The PCR mix contained: 
5µl of 10x Buffer, 2µl MgCl2, 1µl dNTP mix (25 nM each nucleotide), 2µl primer (forward and 
reverse), 0.5µl HotStar Taq polymerase (Qiagen, UK), 1µl of template and 37.5µl of water. PCR 
was performed with an initial denaturation at 95˚C for 15 min, followed by 30 cycles of 95˚C 
for 30 seconds, the annealing temperature for 30 seconds and 72˚C for 30 seconds. A final 
extension of 72˚C for 10 min concluded the PCR. PCR products were run for 40 min on a 1.2% 
Agarose gel.  
 
3.6.3.5  Mutational analysis of TP53, CDCA2, PPP2R2A and FBXO38 
Exons 5 to10 of the TP53 gene were amplified from genomic DNA of nine PCL patients (325, 
3210, 3342, 1188, 3272, 742, 1576, 165, 3343): exons 5-6 (with 5F, 5'-
CTTTGCCGTCTTCCAGTTG-3'; 6R, 5'-ACGCCATTCTCCTTCCTCAGC-3'),  exons 7-10 
(with 7F, 5'GCCTCATCTTGGGCCTGTGT-3'; 10R, 5'-GCAGGCTAGGCTAAGCTATGAT-
3'; 8F, 5'-CTGATTTCCTTACTGCCTCTTG-3'); alternative (a) exon 10 (with 10aF, 5'-
CAGCCAAGATTGCACCATTGC-3'; 10aR, 5'-TTGACCATGAAGGCAGGATGA-3').  
All exons (n=22) of the FBXO38 (F-box only protein 38) gene also known as MoKA were 
amplified from genomic DNA of four MM patients (282, 665, 1776, 2993) and the KMS-11 cell 
line (primers are listed in Appendix 13). 
All exons (n=10) of the gene PPP2R2A (protein phosphatase 2 (formerly 2A) regulatory subunit 
B, alpha isoform) were amplified from genomic DNA of three PCL (165, 3210, 3343) and 
seven MM (309, 1798, 1037, 1776, 342, 374, 114, 2993) patients; all exons (n=15) of the gene Results 
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CDCA2 (cell division cycle associated 2) were amplified from four patients (two PCL; 165, 
3210) and two MM (1798, 1037) (primers for the two genes are described in Appendix 14).  
The PCR mix contained: 5µl of 10x Buffer, 2µl MgCl2, 1µl dNTP mix (25 nM each nucleotide), 
2µl primer (forward and reverse), 0.5µl HotStar Taq polymerase (Qiagen, UK), 1µl of template 
and 37.5µl of water. PCR was performed with an initial denaturation at 94˚C for 15 min, 
followed by 30 cycles of 94˚C for 30 seconds, the primer specific annealing temperature for 30 
seconds and 72˚C for 30 seconds. A final extension of 72˚C for 10 min concluded the PCR. The 
PCR products were purified using Exo-SAP reaction (Section 2.9.1). Products were sequenced 
directly using BigDye v1.1 or v3.1 (Applied Biosystems, UK) as described in Section 2.9.2 and 
purified using the montage SEQ96 sequencing reaction clean up kit (Section 2.9.3). DNA from 
the purified sequencing reaction was resuspended in deionised formamide and loaded onto an 
ABI 3100 sequencer Genetic Analyser (Applied Biosystems, UK). 
 
3.6.3.6  Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
RNA was extracted from purified PC from seven PCL (325, 3210, 1576, 742, 2359, 1188 and 
3342) and 19 randomly selected MM patients as described in Section 2.7. The qRT-PCR was 
performed as described in Section 2.8. 
 
3.6.3.7  MLPA 
MLPA, using the modified MRC-Holland kit ‘SALSA MLPA kit P088 Glioma 1’, was 
performed on genomic DNA of the PCL patient 3210 as described in Section 2.10.1; genomic 
DNA from two healthy individuals was used as control.  
 
3.6.4  Results 
3.6.4.1  Metaphase analysis and iFISH results 
Eleven of 12 patients (92%) showed an abnormal karyotype and eight were classified as highly 
complex (Table 3-21). Five were hypodiploid (<45 or >75 chromosomes in tetraploid cases), 
two were pseudodiploid (46-47 chromosomes) and four were HRD (>48 and <75 Results 
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chromosomes). The case without cytogenetic information appeared to have a nonHRD 
karyotype by iFISH and array CGH.  
Specific IgHt at 14q32 were detected in nine cases (75%) (Table 3-23): five (four pPCL and 
one sPCL) had t(11;14)(q13;q32), three had t(14;16)(q32;q23), the remaining sPCL case had 
t(4;14)(p16.3;q32). Eight of the nine (89%) 14q32 translocations were found in nonHRD 
karyotypes. Interestingly three of the four pPCL patients with t(11;14) translocation showed a 
duplication of the LSI IgH 3' flanking probe, corresponding to a duplication of the fusion signal 
with CCND1 on the der(14). In these cases, array CGH showed gain of part of 11q, 
commencing at the chromosomal position corresponding to the breakpoint involved in the 
translocation and including CCND1, confirming the iFISH results. 
∆13 was found in seven patients (58%), involving the majority of the cells (range: 85%-100% 
PC). Deletions of chromosome 16 at 16q23 were found in six patients (50%). A deletion at 
17p13.1 was detected in three of 12 (25%) tumours, two pPCL and one sPCL.  Compared with 
the MM group, several abnormalities were more frequent in PCL: deletion of 16q (50% vs 21%; 
P=0.025), deletion of TP53 (25% vs 10%) although non statistically significant (P=0.114), 
t(11;14) (41.7% vs 14%; P=0.020), t(14;16) (25% vs 4%; P=0.015) and nonHRD (75% vs 43%; 
P=0.036) (Table 3-24). FISH for the t(8;14) showed only one case (3343) with an unbalanced 
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Table 3- 23  iFISH and metaphase analysis results for the twelve PCL: pPCL were 
ordered by the IgH translocation partner; the last two patients correspond to the two 
sPCL  
(Del, deletion; der, derivative chromosome; Unb, unbalanced; N, normal; ps, pseudodiploid; HOD, 
hypodiploid; DM, double minutes) 
In the description of the karyotype, the karyotype of the normal cell population has been omitted.  
Abnormal FISH signal patterns for MYC status have been described. For t(8;14) probe, B = 8CEP, 
R = 8q24, G = IgH; for MYC break apart probe, F = fusion signal, R = centromeric probe at 8q24, 
G = telomeric probe at 8q24 
a Patients with interstitial abnormalities involving or in close proximity to MYC detected by array 
CGH. 
b MYC duplication confirmed with PAC RP1-80K22.  
c FISH showed three copies of MYC 
due to an extra-copy of 8q, array CGH showed a further extra-copy of MYC, not detectable by 
FISH. Results 
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  iFISH results  Metaphase analysis  iFISH for 8q24 
Pt  13 
%PC 
IgH Locus 
(%PC)  IgHt  TP53 
(%PC)  Ploidy  Karyotype  MYC status 
325
a 
  N  Split (100%), 
+der(14) (30%) 
Unb 




t(8;14): 2B-3G-3R (90%); 2B-3G-[2-100]R (10%)   











(86%)  HOD 
40,X,-X,del(1)(p12p3?3),add(3)(q1?),add(4)(q2),add(6)(q2),add(8)(p1),-9,                             




MYC break apart: 1G-1R-1F (90%)  















t(8;14): 2B-(3-4)G-2R (1R signal of bigger size, 
shown to be doubled up by smaller probe
 b
) 
MYC duplication at 8q24 
128  N  Split (100%)  t(11;14)  N  Ps  46,XY,t(6;20)(q21;p11),der(9)t(9;16)(p11;q13)del(16)(q13q24),der(14)t(11;14)(q13;q32),add(22)(q13) 
t(8;14): 2B-3G-2R (15%); 2B-3G-3R (85%) 
MYC  break apart: 2R-1F  (90%) 









t(8;14): negative  
MYC break apart: negative 
742
a





t(8;14):  negative  
MYC break apart: 3 F (90%) 
c
 
165  Del 





t(8;14): negative  
MYC break apart: negative  









t(8;14): 2B 2G 2R (43%); 1B 3G 1F (57%)  
MYC break apart: 2F (60%); 1F (40%) 
Unbalanced t(8;14), insertion of IgH in 8q24 
2359  Del 





(iFISH)  Failed  t(8;14): 2B-3G-3R (88%) 
MYC break apart: 3F (83%); 4F (16%) 
1188
a
  N  Split x 2 (98%)  t(11;14)  N  HRD  50,XX,add(8)(q11),+11,t(11;14)(q13;q32),+13,+18,+18[9]  t(8;14): negative 
3342  Del 
(100%)  Split (90%)  t(4;14)  Del 


















Table 3- 24  Prevalence of CA detected by iFISH in MM and PCL 
(Statistically significant P values are in red) 
3.6.4.2  Array CGH results: overall abnormalities 
Good quality DNA for array CGH analysis was available from 11 PCL patients and CNA were 
detected in all samples. Overall, a total of 322 CNA, defined as discrete segments showing copy 
number variation consistent with loss or gain, were detected with a median of 26 per case 
(range, 15–48) (array CGH results for each patient are described in Appendix 8; a graphical 
representation of CNA for all chromosomes of all patients is shown in Appendix 9). Patients 
3210 and 2359 harboured the highest number of CNA (48 and 42, respectively). Interestingly 
the three patients who remained alive throughout the study (at 3, 13 and 20 months from 
diagnosis) had fewer than the median value of CNA (23, 15 and 22). Ten HD were detected 
(Table 3-25) in five patients, with four of them occurring in the same patient, corresponding to 
the most complex karyotype in the series. Notably, all HD (apart from 13q14.2) were observed 
only once. The only amplified region (defined as more than/equal to six copies) was found at 
8q24.13-q24.21 (124.98Mb - 129.42Mb) in one case (Table 3-23). Chromosomes 1, 8, 13 and 
16 showed the highest number of CNA (Figure 3-33). 
CA 
MM cases (%) 
n=400 
PCL cases (%) 
n=12 
P-value 
∆13  186/395 (47)  7/12 (58.3)  0.561 
Deletion 16q23  75/365 (21)  6/12 (50)  0.025 
Deletion TP53  38/388 (10)  3/12 (25)  0.114 
Any IgHt  183/398 (46)  9/12 (75)  0.075 
t(4;14)  49/400 (12)  1/12 (8.3)  1 
t(6;14)  6/393 (2)  0/12  - 
t(11;14)  55/399 (14)  5/12 (41.7)  0.020 
t(14;16)  15/396 (4)  3/12 (25)  0.015 
t(14;20)  9/394 (2)  0/12  - 




Table 3- 25  HD revealed by array CGH in PCL with their chromosomal location and 
genes involved (recurrent HD are highlighted in blue) 
 
3.6.4.3  Chromosome 1 abnormalities 
All patients showed abnormalities of chromosome 1. Deletions of 1p were detected in four 
patients: two had a single interstitial deletion while the other two had multiple interstitial 
deletions. In two patients the deletion included 1p32.3: the first (patient 3125) showed a mono-
allelic deletion (50.64Mb - 51.18Mb, size of the CNA: 546kb) involving the genes FAF1 and 
CDKN2C (confirmed by iFISH); the second (patient 3210) showed three different interstitial 
deletions on 1p, of which the largest (1p35.1-p21.3; 33.33Mb - 97.02Mb), had a small region 
deleted from both alleles, involving only CDKN2C (51.13Mb - 51.15Mb). This CNA was 
confirmed by MLPA which showed the two probe binding sites on p18, the one between FAF1 
and p18 and the one centromeric of p18 to be involved in the HD, while the two probe binding 
sites selected for the FAF1 gene were found to be hemizygously deleted (Appendix 15).  
Patient  Chr  Chromosomal 
position  Start (Mb)  End (Mb)  Size of 
CNA (Mb)  Genes involved 
3210  1  1p32.3  51,139,615  51,157,731  0.018  CDKN2C 
2359  1  1q31.3-q32.1  194,597,222  196,876,612  2.279  C1orf53, LHX9, NEK7, 
ATP6V1G3, DENND1B 






FBX038, SPINK9, HTR4, 
ADRB2 
3342  6  6q27  165,695,958  165,701,090  5.132  PDE10A 





742  8  8p21.2  25,205,684  26,224,281  1.018 
DOCK5, AC103779.5,  
GNRH1, KCTD9,  CDCA2, 
EBF2,  AC090103.4, 
PPP2R2A 
2359  13  13q14.2  47,797,577  47,896,834  0.099  RB1, P2RY5 
3342  13  13q14.2  47,851,735  47,948,983  0.097  RB1, P2RY5  
3210  14  14q22.1  51,967,480  52,064,804  0.097  TXNDC16 
3210  14  14q22.3  54,932,376  54,960,676  0.028  KIAA0831, TBPL2  Results 
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Abnormalities involving 1q were highly complex: the region from 1q12 to 1q22 (141.52Mb - 
145.64Mb) was gained in seven of the 11 patients; four patients had one extra copy of the 





Figure 3- 33  Graphical representation of CNA for chromosomes 1, 8 and 16 in PCL 
The 850-band idiograms of the G-banding patterns are shown on the left. Vertical blue lines 
correspond to each patient; red bars = gains, thicker red bars = gain of two extra copies; green 
bars = mono-allelic losses; black areas circled in red = HD; dark blue areas = amplifications; 
yellow and light blue areas = CNV, respectively losses and gains Results 
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3.6.4.4  Chromosome 8 abnormalities and mutational analysis of CDCA2 and 
PPP2R2A 
Combining array CGH and FISH, abnormalities of chromosome 8 were seen in eleven of the 12 
patients (92%): five (45%) showed deletions of 8p, which were relatively large and involved the 
whole arm in three cases. The common minimally deleted region was defined by the bands 
8p21.2 (26.06Mb) and 8p21.3 (19.02Mb). Within this region, one case (742) with hemizygous 
loss of the entire arm showed HD at 8p21.2 (25.20Mb - 26.22Mb) involving the genes DOCK5, 
AC103779.5, GNRH1, KCTD9, CDCA2, EBF2, AC090103.4 and PPP2R2A. The deletion was 
confirmed by iFISH (probes for PPP2R2A are described in Appendix 3): a normal copy 
number was detected in cells other than PC and complete loss of the region was observed in the 
PC; this was proof that the deletions of both alleles were somatically acquired. This HD has not 
been previously reported in PC disorders. As described in Section 3.3.4.3.4, deletions of 8p 
were present in 32% of MM patients; in these patients the common minimally deleted region 
was defined as 8p22-p21.2, which included the HD found in the PCL patient. After 
investigating the literature for the possible functional importance of the genes included in this 
HD, mutational analysis of PPP2R2A (on ten patients) and CDCA2 (on four patients) was 
carried out on cases found to be hemizygously deleted at 8p21. No mutations were found in any 
of the genes. 
 
A number of abnormalities involving 8q were found, including gain of the whole arm in three 
cases (27%). One case (patient 325) showed a high level gain at 8q24.13-q24.21 (124.98Mb - 
129.42Mb). The level of gain did not indicate a genomic amplification, while metaphase-FISH 
for MYC showed a highly variable degree of amplification in the form of DM (2 - 100 copies), 
which were present in only approximately 10% of the malignant clone. This finding clarified the 
apparent discrepancy between the level of amplification found by FISH and the level of gain by 
array CGH. Two cases (patients 3272 and 1188) showed two small deletions at 8q24.21 not 
directly involving MYC: the first (128.82Mb - 128.97Mb) between MYC and TMEM75; the 
second (129.09Mb - 129.21Mb) telomeric of TMEM75. Cytogenetic and FISH analysis failed to 
detect these small deletions. Patient 1576 displayed an interstitial duplication involving MYC 
and TMEM75 (8q24.21; 128.45Mb - 129.38Mb) which corresponded to a tandem duplication of 
8q as indicated by FISH. One case (patient 742) showed gain of the whole 8q and a further gain 
involving only MYC and TMEM75 (128.64Mb - 129.13Mb). Patient 3343 with monosomy of 
the entire chromosome 8 showed a small region with a normal ratio by array CGH at 8q24.21 
(128.81Mb - 129.7Mb), which iFISH showed to be involved in a t(8;14) translocation. 
Interphase FISH revealed a split of MYC arising from a translocation with an unknown partner 
other than IgH in patients 3210 and 128, who showed a normal copy number ratio at 8q24.21 by Results 
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array CGH. Interestingly patient 3210 also showed gain of the chromosomal region 2pter to 
2p24.3 with the breakpoint at the position 15.95Mb, immediately distal to the N-MYC locus 
(15.99Mb – 16.00Mb).  
 
3.6.4.5  Chromosome 13 abnormalities 
Losses of chromosome 13 were detected in seven patients (64%) of which five showed 
complete monosomy, while the remaining two patients had large deletions.  The common 
minimally deleted region was defined by the bands 13q13.1 (33.0Mb) and 13q31.1 (80.53Mb). 
Within this region of hemizygous loss, two patients showed a homozygous deletion at 13q14.2 
including only the genes RB1 and P2RY5 (Table 3-24). Interestingly HD of the same 
chromosomal region was found in two MM patients (Table 3-8).  
 
3.6.4.6  Chromosome 16 abnormalities 
Seven (64%) patients showed loss of 16q with three areas most frequently affected: 16q22.1 
(65.39Mb - 68.09Mb) in six patients (55%); 16q22.2 -q23.1 (69.76Mb - 73.52Mb) in six 
patients (55%), and 16q23.1 (77.64Mb - 77.84Mb) including only the WWOX gene in six 
patients (55%). 
 
3.6.4.7  Chromosome 5 abnormalities and mutational analysis for FBXO38  
The very young pPCL patient (3125; 23 years old) was found to have a HD at 5q33.1 
(146702762Mb – 148240825Mb) (Figure 3-34 A) within a relatively simple karyotype. The 
HD was confirmed to be restricted to the neoplastic PC clone by iFISH (probe described in 
Appendix 3). The array CGH profiles for chromosome 5 in MM patients (Section 3.3) showed 
the presence of a number of losses on chromosome 5q in nonHRD cases; these losses were 
characterized by different break-points and shared two minimally deleted regions at 5q31.1 
(132267368Mb – 132912148Mb; n=5) and 5q33.1-q33.2 (147507861Mb – 150556320Mb; 
n=5); the array CGH profile of the KMS-11 cell-line also showed a hemizygous deletion 





















Figure 3- 34  A) Patient 3125: G-banded idiogram of chromosome 5 (on the left) with the 
CNA for the p and the q arms. For the chromosomal region 5q33.1, the plot of ‘calls’ for 
every nucleotide is shown in detail; B) Graphical representation of chromosome 5 losses in 
PCL (n=1, patient 3125), MM (n=5) and the cell line KMS-11 (light blue bars = individual 
patients; green bars = losses; red bars: gains; black areas circled in red = HD)  
 
Among the genes included in the common minimal deleted region, mRNA identification of 
genes mapping to 5q33.1 showed a PCR product for mRNA only for FBXO38 (two bands of 
850bp and 150bp corresponding to two isoforms: variant 2 missed exon 15) and ADRB2 
(product of 380bp). However, ADRB2 has only one exon therefore it is likely that the detected 
band was derived from contamination with genomic DNA. None of the other six genes showed 
a band suggesting that they are not expressed in PC. Mutational analysis of FBXO38 in four 
MM patients and the KMS-11 cell line with hemizygous deletions of 5q33.1 detected by array 





KMS-11 PCL MMResults 
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3.6.4.8  Mutational analysis for TP53 
Functionally relevant TP53 coding mutations were found in three patients: two pPCL (patient 
325 and 3210) and one sPCL (patient 3342). Patients 325 and 3210 (this patient was also 
positive for a hemizygous deletion) were both found to have a missense mutation in the DNA 
binding domain, in exon 8 (c.839G>A) and exon 6 (c.653T>A) (Figure 3-35 A-B), 
respectively, resulting in non-functional proteins. Patient 3342 had a hemizygous deletion at 
17p13 and was found to be positive for a missense mutation in exon 5 (c.536A>C) also 





















Figure 3- 35  DNA sequences showing the mutation at exon 6 (A) and exon 8 (B) of the 
TP53 gene in patients 3210 and 325, respectively. Patient 3210 showed the presence of only 
one allele as the other was found to be deleted by iFISH 
Patient 325, Exon 8 (c.839G>A)
Patient 3210, Exon 6 (c.653T>A)  Patient 3210, Exon 6 (c.653T>A) Results 
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3.6.4.9  Correlation between CNA at 8q24 and MYC expression 
Array CGH and iFISH detected a number of different CNA involving chromosomal band 8q24 
(Figure 3-36). These different alterations directly involved MYC or were in close proximity (i.e. 
within 400kb) of the gene. MYC mRNA expression levels were analyzed in seven PCL and 19 
randomly selected MM patients by qRT-PCR (the individual levels of MYC expression relative 
to BCR and GUSB and the FISH and/or array CGH results for 8q24 are described for every 
patient in Appendix 16 and Figures 3-37 and 3-38). Five PCL (patients 325, 3210, 1576, 742 
and 1188) and six MM patients had evidence of 8q24 rearrangements by array CGH (including 
small interstitial deletions within the proximity of MYC) or by iFISH. All patients with 
abnormalities at 8q24, including the one with the small interstitial deletion telomeric of 
TMEM75 detected by array CGH, showed increased levels of MYC expression. Those cases 
with gain of the entire 8q arm were not considered to be abnormal for MYC. In fact one pPCL 
(2359) with gain of the entire 8q did not show increased level of MYC mRNA. The three MM 
cases with t(8;14) showed comparable levels of MYC expression; in these cases the level of 
expression was lower than those observed in cases with gene amplification in the form of DM, 
or with multiple copies of MYC in marker or ring chromosomes (patients 1247 and 1524). The 
two latter cases were also tested for MYC/Igλ rearrangements and were both found to be 
negative. The difference in MYC expression levels between cases (MM and PCL) with and 
without evidence of structural or numerical abnormalities at 8q24 was highly significant (Mann-
Whitney test, P<0.001 for BCR; P=0.005 for GUSB) (Figure 3-37). When only MM patients 
were considered, the difference was significant for BCR but not for GUSB (Mann-Whitney test, 
P=0.02 for BCR; P=0.10 for GUSB). Four of 13 MM patients, with no apparent MYC 
abnormalities by iFISH, showed levels of MYC mRNA comparable to those detected in cases 
with t(8;14) (Figure 3-38). The sPCL patient 3342, also showed increased level of MYC mRNA 
in the absence of 8q24 abnormalities by FISH or by array CGH, resulting in both sPCL cases 






































































































Figure 3- 36  Diagram showing the different CNA 
identified in nine PCL patients by iFISH and array CGH in 
a region of 2.5Mb centred on MYC at 8q24 (patient order 
from left to right: 1576, 325, 3343, 3272, 1188, 742, 2359, 
128 and 3210) 
 
Vertical black lines correspond to regions with no CNA or 
structural aberrations detected; red bars = gains; green bars = 
mono-allelic losses; blue bar = amplification; dotted lines = 


















Figure 3- 37  Box plot of natural log values of MYC mRNA levels relative to GUSB and 
BCR as determined by qRT-PCR in 15 MM and PCL patients with no apparent 
rearrangements at 8q24 (8q24 normal) and 11 MM and PCL patients with different 
alterations at 8q24 (8q24 rearr) (Mann-Whitney test) 
Asterisk symbol corresponds to outlier value, open boxes indicate the interquartile range, and the 

















Figure 3- 38  Natural log values of MYC mRNA levels relative to BCR for all patients  
The specific genetic abnormalities at 8q24 are described for the MM group with extra copies of MYC in 
marker or ring chromosomes and for PCL patients positive for 8q24 abnormalities (amp, amplification; chr, 
chromosome; del, deletion; DM, double minutes; dup, duplication; rear, rearrangement) 
 
3.6.5  Overall summary of the results and discussion 
In this study, a series of 12 PCL, ten primary and two secondary, were genetically characterized 
using cytogenetic analysis, iFISH, and array CGH. As previously reported in other series, the 
prognosis of these patients, particularly those with pPCL, was very poor: 50% of the pPCL 
patients died within the first month. 
 
The percentage of PCL patients with an abnormal clone by cytogenetic analysis was 92%, 
significantly higher than MM (30%-50%) 
83,87. These data suggest that clonal PC from PCL 
display a higher proliferative capacity in vitro compared to PC from MM patients, characterized 
by a slow cell turnover comparable to non-malignant BM cells. The majority of pPCL (75%) 
were nonHRD, although two pPCL and one sPCL displayed a HRD karyotype. This contrasts 
with the recent series reported by Tiedeman at al. 
252 in which all pPCL were exclusively 
nonHRD and HRD was found only in sPCL. However, it should be noted that patient 1188 
(sPCL), despite having a karyotype with 50 chromosomes, also had a t(11;14) which is rarely 
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in HRD cases, only chromosome 11 was gained in this patient. Therefore it is unclear whether, 
biologically, this patient should be considered as HRD or nonHRD. 
 
Translocations of the IgH locus were present in 75% of cases (seven of ten pPCL and both 
sPCL), with t(11;14) (four cases) and t(14;16) (three cases) only being found in these pPCL, 
confirming the specific association of these two translocations with this disease 
65,97. The t(4;14) 
was not seen in this series of pPCL. The prevalence of t(11;14) in our cohort (41%) was similar 
to that reported by Avet-Loiseau et al. (33%) 
97. Interestingly, 80% of pPCL with t(11;14) 
showed duplication of the fusion signal on the der(14) with an associated interstitial gain of 11q 
(minimally gained region: 11q13.3-q13.4). This was shown to be a secondary event as it was 
found in only a subpopulation of the neoplastic cells. This same 11q duplication has been 
observed in MM and pre-malignant patients (Figure 3-17), thus it is not exclusive to PCL. 
However, in MGUS and MM no duplication of the fusion signal deriving from the translocation 
was observed, suggesting that the two mechanisms are different. Using a survival end-point of 
12 months, t(11;14) has been associated with significantly longer OS 
97. This was not so in our 
series. However, an association between longer survival and low genomic complexity as 
assessed by array CGH was observed. Similar findings have been described in chronic 




Translocations t(11;14) and t(14;16), as well as 16q23 deletion and nonHRD, were significantly 
more common in PCL than in MM, suggesting that, despite the presence of overlapping 
chromosomal abnormalities, the two diseases involve different genetic pathways which may 
explain their different clinical behaviour. In this study ∆13 was more frequent in PCL than in 
MM (58% vs 47%). However, this difference was not statistically significant (P=0.561), which 
was in contrast to other reports 
65,71,97,252. A HD at 13q14.2 was found in 18% of PCL (one pPCL 
and one sPCL), involving only the genes RB1 and P2RY5. These HD were too small to be 
detected by the probes routinely used to assess chromosome 13 status by iFISH. HD at the same 
chromosomal position were found in two of 47 MM patients (4%) (Table 3-8). These findings 
suggest that RB1 is one of the targeted genes of ∆13. Deletions of 17p13.1 were found in only 
20% of pPCL patients, at an incidence significantly lower than those reported in other series 
71,97,252. TP53 loss was complemented by functionally relevant TP53 coding mutations in two 
other pPCL cases (325 and 3210). Patient 3210 was also positive for the deletion, leading to a 
bi-allelic TP53 inactivation.  
 
Array CGH detected CNA in all cases tested. Cytogenetic analysis and array CGH showed that 
the karyotype and the genomic profile of the majority of these patients was complex. Other Results 
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studies had reported that cytogenetic changes were more frequent in PCL than in MM 
153,254,255. 
Our data confirms that although some PCL cases are extremely complex, others have relatively 
simple changes.  
 
CNA on chromosome 1 were frequent. A recent iFISH study which included 41 cases of PCL 
found deletions of 1p21 in 37% of cases and the abnormality was associated with a shorter OS 
by univariate analysis 
256.  Deletions of 1p were found in 36% of PCL in our series, including 
one heterozygous deletion and one HD both at 1p32.3. The heterozygous deletion involved the 
FAF1 and CDKN2C genes, while the HD encompassed only CDKN2C suggesting that this gene 
is the target of deletions occurring at this locus. This HD was confirmed using MLPA as the 
CNA by array CGH included only three consecutive aberrant calls, while a called aberration 
requires a minimum of five consecutive aberrant oligonucleotides.   
 
Gain of 1q was found in 39% of MM patients and in this group it was associated with an 
inferior prognosis (Section 3.4.4.1). The PCL patients showed multiple CNA of 1q, including 
interstitial gains and deletions, sometimes within the same patient. The region 1q12-q22 was 
gained in 64% of patients, with three patients having two extra copies. No amplifications of >6 
copies were found.  
 
Chromosome 5 is one of the chromosomes usually gained in MM, particularly in those cases 
with a HRD karyotype. The gain of this chromosome is routinely used with chromosomes 9 and 
15 to define the ploidy status by iFISH 
216. In this PCL cohort, only one HRD case (patient 165), 
with no IgHt, had a partial gain of chromosome 5. One young pPCL patient (3125) with a 
relatively simple karyotype showed a large heterozygous deletion of 5q (5q14.3-q33.1) with an 
associated small HD at 5q33.1 (146702762Mb – 148240825Mb). FISH confirmed that the small 
HD was confined to the PC population. Fourteen genes were included in the HD. This novel 
deletion has not been previously reported although 5q deletions were observed in four of 24 
cases (17%) 
97 and eight of 27 cases (30%) 
252. In both series, these large deletions encompassed 
the whole or part of 5q and all included 5q33.1. Comparing array CGH results from PCL with 
those from MM described in Section 3.3, six further cases (including the KMS-11 cell line) 
were found to be hemizygously deleted at this locus. Among the genes included in the common 
minimal deleted region, FBXO38 (MoKA) was found to be expressed in PC from both MM 
patients and individuals without PC dyscrasias, thus it was postulated to be involved in 
myelomagenesis. FBXO38 codifies for an F-Box Protein that modulates and enhances the 
Krüppel-like transcription factor 7 (KLF7) activity 
257,258. KLF7 is a member of the mammalian 
Kruppel-like family of zinc finger proteins which can modulate cell cycle regulators. Its induced 
overexpression results in a decrease in DNA synthesis, induction of p21
WAF1/Cip1 (cyclin-Results 
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dependendent kinase inhibitor 1A) protein, inhibition of cyclin D1 and G1 arrest 
259. Despite 
representing a plausible target gene of these deletions, no mutations were detected in four 
patients with loss of one allele. However, it can be hypothesised that other mechanisms control 
FBXO38 expression. 
 
Loss of 8p was frequent in PCL. As mentioned above, few studies have reported the prognostic 
significance of this abnormality in MM. Bryant et al. 
260 found 8p loss to be associated with 
shorter survival in MM, regardless of treatment. In MM patients, we found that 8p deletions 
were usually large; thus it was difficult to determine the targeted genes. Within the PCL cohort, 
array CGH defined a common minimally deleted region at 8p21.2-p21.3 (26.06Mb - 19.02Mb). 
Within this region a HD at 8p21.2 (25.20Mb - 26.22Mb) involving the genes DOCK5, 
AC103779.5, GNRH1, KCTD9, CDCA2, EBF2, AC090103.4 and PPP2R2A was found. In the 
paper by Carrasco et al. 
178 among the high-confidence minimal common regions of loss, they 
listed the region at 8p21.3-p12 including the genes TNFRSF10B and PPP2R2A. PPP2R2A 
belongs to the phosphatase 2 regulatory subunit B family. Protein phosphatase 2 is one of four 
major Ser/Thr phosphatases and is implicated in the negative control of cell growth and 
division. Studying the fusion of CHEK2 and PPP2R2A in childhood teratoma, Jin et al. 
261 
reported that deregulation of CHEK2 and/or PPP2R2A is of pathogenetic importance in at least 
a subset of germ cell tumors. HD of PPP2R2A have also been found in prostate cancer cell lines 
262. Interestingly, combined SNP array and GEP data on 259 newly diagnosed MM patients 
analyzed at the Section of Haemato-Oncology, The Institute of Cancer Research, London, 
Walker et al. found that among the 237 genes mapping within common 8p deletions the most 
under-expressed genes were ZDHHC2, FDFT1, CNOT7, PPP2R2A and PPP2CB (unpublished 
data). CDCA2 is a regulator of chromosome structure during mitosis, required for condensin-
depleted chromosomes to retain their compact architecture through anaphase. The protein has 
been found to be overexpressed together with other cell cycle and proliferation-related genes 
124. 
Unfortunately in this study, sequencing analysis of both genes did not show the presence of 
mutations suggesting that if one of these genes is important in MM and PCL pathogenesis the 
mechanism leading to its dysregulation does not involve mutations at the genomic level. 
 
Avet-Loiseau and colleagues showed that MYC translocations at 8q24 were rare in primary 
PCL. This was a surprising result given the high prevalence in advanced primary tumours and 
HMCL that are derived from primary and secondary PCL 
111,263,264. In a series of 43 HMCL, Dib 
et al. showed MYC overexpression in 93% of cases; two cell lines expressed N-MYC and one L-
MYC 
263. Consistent with these results, N-MYC expression was found in eight of 559 primary 
MM tumours whereas none of these tumours expressed L-MYC 
124. In this study, the 
chromosomal region most frequently involved in structural and numerical abnormalities, apart Results 
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from 14q23, was 8q24 (including seven of ten pPCL and one of two sPCL); the other sPCL 
patient, despite lacking evidence of 8q24 abnormalities by iFISH or array CGH showed MYC 
upregulation by qRT-PCR. The nature of such abnormalities was highly variable (as previously 
observed in MM patients described in Section 3.3.4.3.4) including amplification, tandem 
duplication, small interstitial deletions, balanced and unbalanced translocations. The detection 
of these alterations could only be achieved combining FISH and array CGH. The MYC 
amplification in the form of DM, observed in patient 325, was present in only a subset of 
tumour cells, providing evidence for a secondary event in this case. Quantitative RT-PCR 
confirmed that these different alterations led to increased levels of MYC mRNA. The level of 
MYC overexpression seemed to vary depending on the type of genomic abnormality involved. 
Such variation was not dependent on the proportion of PC carrying the abnormality as, apart 
from the pPCL patient 325, all cases showed the MYC abnormality in all malignant cells.  
There was no evidence from array CGH or metaphase analysis of abnormalities specifically 
involving L- or N-MYC in any of the PCL patients. Among the PCL cases with MYC 
abnormalities, only patient 3343 showed involvement of the IgH locus. In newly diagnosed 
MM, the IgH and Igλ loci were found to be involved in 17% and 10%, respectively, of cases 
with a MYC rearrangement; Igκ was rarely involved 
111. In our series there was no indication 
from metaphase analysis of rearrangements involving Igλ or Igκ. However, because these loci 
were not tested by FISH, their involvement in cryptic rearrangements cannot be excluded (e.g. 
small insertion of Igλ enhancers in proximity to MYC). Potentially, cryptic alterations that are 
not detectable by FISH with commercial probes or by array CGH could account for cases such 
as patient 3342, who showed increased MYC expression in the absence of apparent MYC 
abnormalities. Alternatively, MYC may be upregulated by the activity of mutant, activated 
proteins (e.g. β-catenin) 
265. Overall, these findings confirm the complex and unpredictable 
nature of the mechanisms leading to MYC overexpression in PC disorders and suggest that MYC 
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The PC dyscrasias, MGUS, SMM, MM and PCL, are conditions diagnosed on the basis of 
clinical parameters such as the M-protein level, the percentage of PC within the BM or the 
peripheral blood (for PCL) and the presence or absence of clinical manifestations. Biologically, 
these conditions likely represent a continuum with MGUS and SMM characterized by a limited 
clonal PC expansion, while MM and PCL are characterized by an increasing clonal PC 
expansion in the presence of symptoms. The gradual progression of the disease makes the 
distinction between the different entities very difficult, particularly between early MM and 
advanced stage SMM or MGUS. Moreover, the pattern and the timing of evolution of pre-
malignant patients seem to differ between individuals. Some patients are in the process of 
evolution at the beginning of their follow-up and are characterized by constant and progressive 
increase of their paraprotein level and the level of BM plasmacytosis. Other pre-malignant 
patients, in particular within the MGUS group, may remain completely stable for long periods 
from their recognition and, if progression occurs, it seems to happen relatively rapidly.  
This extensive overlap between the different conditions is also observed at a genetic level. In 
Section 3.1, using a panel of probes to investigate 13 different loci, iFISH showed that 90% of 
MGUS and 98% of SMM patients had cytogenetic changes which are usually found in MM. 
Furthermore, none of the chromosomal abnormalities tested were exclusive to a specific stage of 
the disease, confirming that common chromosomal markers, usually investigated in MM, 
cannot be used to discriminate between asymptomatic and symptomatic stages. However, 
statistically significant differences were observed in the incidence of specific abnormalities 
between the three conditions. In particular the incidences of ∆13, 16q23 deletion and TP53 
deletion were found to progressively increase from MGUS to SMM to MM. In MGUS, these 
abnormalities were often detected in a sub-clone of the malignant PC population while, in the 
same cases, other abnormalities were present in all PC. These observations confirm that the 
acquisition of these changes often represents a secondary event.  
The rarity of ∆13 in MGUS, as compared to MM, was not common to all genetic groups. It 
applied to cases with t(11;14) (one of 28 MGUS patients; MGUS vs MM, P<0.001) and those 
with t(6;14) (although this translocation is too rare to draw significant conclusions). In SMM 
patients with t(11;14), ∆13 was also rare (two of 13). In contrast, the ∆13 was present in 40% of 
MM and in 60% of pPCL patients with this translocation. Such striking difference in the 
incidence of ∆13 in t(11;14) cases, depending on the diagnostic class, has not been previously 
described. However, other published studies reported lower overall incidences of ∆13 in MGUS 
as compared with MM 
85,109. These findings suggest that in patients with t(11;14) the ∆13 is a 
secondary event occurring a long time after the acquisition of the IgH translocation. In these 
patients ∆13 might be involved in driving disease evolution, as two of the three pre-malignant 
patients belonging to this genetic group with available follow-up information progressed to 
MM. Despite the fact that ∆13 was found to be highly associated with t(4;14), t(14;16) and Discussion 
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t(14;20) in all diagnostic groups, there was evidence that the temporal appearance of ∆13 is 
related to the presence of specific concomitant abnormalities: early when t(4;14) or t(14;16) is 
present, later with t(14;20), and even later with t(11;14) (and probably with t(6;14), although the 
incidence of this latter abnormality is too low to find significant associations). The ∆13 was 
tested for by iFISH with two probes located to 13q14, therefore there was concern that cases 
considered to be normal by iFISH may carry chromosome 13 deletions not involving this 
chromosomal region. However, array CGH profiles of patients from all diagnostic groups 
showed that only three of 67 (4%) cases with chromosome 13 deletions did not involve the loci 
investigated by iFISH. Moreover, the only recurrent HD detected on this chromosome involved 
the RB1 gene, reinforcing its role as one of the targeted genes of ∆13. 
 
Overall, the presence of IgH rearrangements was found at similar frequencies in the three 
diagnostic groups and, in cases positive for these translocations, the rearrangement involved the 
majority of cells in the PC clone. These findings confirm the theory that these translocations are 
early events in MM pathogenesis. These changes lead to the overexpression of a cyclin D gene 
which then enables PC to autonomously overcome the early G0G1 checkpoint, contributing to 
the limited clonal PC expansion characterizing the MGUS and the SMM stages.  
However, a lower incidence of t(4;14) was observed in MGUS compared with SMM and MM 
patients (3% vs 13% vs 12%, respectively). The t(4;14), as well as t(14;16) and t(14;20), are 
associated with a very poor prognosis in MM 
46,87,89,143 and the survival curves obtained from 
over 1800 MM patients studied at the Myeloma Database confirmed these findings (Section 
3.2.2). The observation that t(4;14) was less frequent in MGUS has been previously 
demonstrated 
40,44,109,137,138. Reports have implied that, because of the biological impact of this 
translocation on PC, the MGUS phase quickly evolves to overt MM in those patients. However, 
the t(14;16) was found at similar frequencies in MGUS and MM, and t(14;20), which was 
associated with the worst outcome and the shortest median survival in MM, was present in 5% 
of MGUS but in only 2% of MM patients. Therefore, by comparing the incidence of the IgH 
translocations in MGUS, SMM and MM, the assumption that IgH translocations associated to a 
poor prognosis in MM induce MGUS patients to progress more rapidly applied only to t(4;14) 
MGUS patients. In order to evaluate the biological effect of these three translocations in pre-
malignant cases, as described in detail in Section 3.2, the disease course of a total of 45 MGUS 
and SMM patients with one of these three rearrangements was followed until the end of this 
study. In MGUS, the presence of any one of these translocations, including t(4;14), was not 
found to be associated with immediate progression to MM, in fact long-term stability was 
experienced by many patients. This was particularly true for patients with t(14;20), as none of 
them became symptomatic within a median follow-up period of 5 years. Since the rate of 
progression of SMM patients is normally higher than that seen in MGUS, the effect of these Discussion 
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translocations on patients in the SMM group was more difficult to assess. Notably, some SMM 
patients remained completely stable up to 5 years from diagnosis. Interestingly, for both MGUS 
and SMM, the presence of ∆13 associated with any of these three translocations did not appear 
to influence the disease course.  
The reasons why translocations that are high-risk features in MM are associated with long 
periods of stability in the absence of symptoms in pre-malignant conditions is not clear. One 
possible explanation is that, to exert the effect seen in MM, they have to be associated with 
other factors, genetic or otherwise. A similar explanation probably accounts for the high 
prevalence of t(11;14) in PCL (42%), as described in Section 3.6 and previously reported in 
other studies 
97,252. In MM, this translocation is associated with an intermediate prognosis, while 
it is the most frequent IgH rearrangement in the most aggressive of the PC dyscrasias. However, 
PCL karyotypes were found to be extremely complex with multiple structural and numerical 
changes coexisting with the IgH translocation. Interestingly, all t(11;14) PCL included in the 
current study were found to have associated abnormalities involving MYC at 8q24 and MYC 
abnormalities appear to be ubiquitous molecular events in the pathogenesis of PCL. 
 
Together with the translocations t(4;14), t(14;16) and t(14;20), deletion of 17p13.1, the location 
of the tumour suppressor gene TP53, is a high risk feature in MM and it is considered to be the 
most significant molecular cytogenetic factor for prognostication 
266. Unlike the translocations, 
this abnormality has been described as a secondary/late genetic event in MM and in fact, for 
accurate prognostic determination, testing for 17p13.1 loss should be repeated at later time-
points after the initial diagnosis 
266. Deletions of 17p13.1 have been reported to be uncommon in 
pre-malignant conditions, in accordance with the findings described in Section 3.1 (3% in 
MGUS; ~1% in SMM). The incidence of this abnormality was found to be higher in patients 
with extramedullary disease: Tiedeman et al. reported that most cases of PCL (primary and 
secondary) have abnormalities in the TP53 gene 
71,97,252. In Section 3.6, combining FISH for 
17p13.1 and mutational analysis of TP53, deletions and coding mutations were found in only 
30% of pPCL cases with one patient being positive for both changes. However, as inactivation 
of p53 can also occur through overexpression of the regulatory protein Mdm2 or by p14ARF 
inactivation 
267,268, it is possible that other mechanisms inhibiting p53 activity might be present 
in cases negative for TP53 deletions or mutations. 
All pre-malignant patients with 17p13.1 deletion progressed to MM suggesting that, unlike the 
IgH translocations, the presence of this abnormality is responsible for the more aggressive 
behaviour in these conditions. All patients except one progressed to MM within two years from 
diagnosis, with SMM patients showing the most rapid evolution. The variation in time to 
progression seen in these patients was not dependent on the percentage of PC positive for the 
abnormality, as the MGUS patient who progressed after 32 months had 17p13.1 deletion in 87% Discussion 
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of PC. These observations indicated that other factors must be modulating the biological effect 
of 17p13.1 loss in MGUS and SMM. It should be noted that, despite its strong association with 
progression, this abnormality is very rare in all diagnostic groups, including MM; thus 17p13.1 
loss cannot represent a ubiquitous mechanism of disease evolution from MGUS to MM.    
 
In contrast to 17p13.1 deletion, gain of 1q21 is a secondary change which is highly prevalent in 
MM as well as in SMM patients (40%-45%) 
162,163,165,269. In Sections 3.3 and 3.4, the incidence 
of this abnormality was evaluated by array CGH and iFISH (with the same BAC probe used in 
previously published studies) in a large patient cohort: the frequencies of 1q21 gain in MM and 
SMM were found to be similar to those reported by other groups (MM, 39%; SMM, 37%). In 
PCL (Section 3.6), 1q gain was detected in 58% of patients. In the literature 1q21 gain has been 
reported to be absent from MGUS 
162,163, while in the present study (the largest so far) 26% of 
MGUS patients were found with extra copies of 1q21, indicating that although the abnormality 
is rarer in MGUS as compared with MM or SMM (MGUS vs MM, P=0.01), it does occur in all 
diagnostic groups. Among all three groups, the size and the chromosomal position of these 
gains appeared to be the same. Moreover, similar associations between 1q21 gain and other 
chromosomal abnormalities were found in MGUS, SMM and MM.  
In MM, gain of 1q21 was found to be associated with a dismal prognosis in different studies 
154,165. This finding, together with the rarity of the abnormality in MGUS, highlighted 1q21 gain 
as a possible marker of progression 
48,162,164. The current study confirmed 1q21 gain as an 
independent marker of poor prognosis in MM. However, there was no evidence that the 
presence of the abnormality in MGUS resulted in rapid evolution to symptomatic disease, an 
effect that was observed in MGUS patients with 17p13.1 deletion. Within the MGUS group, 
80% of patients with the 1q21 gain remained completely stable up to the end of the study within 
a maximum follow-up period of 78 months; 30% of patients with the abnormality were totally 
asymptomatic 5 years from diagnosis. It should be noted that in this study the number of 
transformations within the MGUS group was high (25% of patients transformed) compared to 
the rate of malignant progression of ~1% per year which has been reported for this condition 
40,42. There is no obvious explanation to account for this difference, particularly because samples 
were collected from many different centres. It may be hypothesized that the cohort was biased 
towards high-risk MGUS cases. However, if high-grade patients are defined by their M-protein 
level and paraprotein type, no over-representation of this patient category was found in this 
cohort. In relation to this bias, because the purpose of this study was to better understand the 
biological role of 1q21 gain in MGUS, having a representative number of transformations was 
highly informative. As MGUS, SMM patients with 1q21 gain did not seem to preferentially 
evolve to MM, as a similar proportion of patients with and without 1q21 gain progressed to MM 
with the same median time to progression. In addition, 30% of patients with the abnormality Discussion 
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remained totally stable 5 years from diagnosis. However, the number of patients within this 
group was relatively small. 
One limitation of this analysis was that the median follow-up of the MGUS and the SMM 
groups were only 41 and 22 months, respectively. MGUS in particular is a slowly evolving 
disease and a longer follow-up is required to fully understand the effects of genetic changes in 
asymptomatic patients. Therefore the study remains as work in progress. Another aspect that 
needs to be considered is that, although there was no suggestion that the different effects of 
1q21 gain might depend on its specific association with other genetic markers either in MGUS 
or in SMM, these diseases are genetically highly heterogeneous and some changes are relatively 
rare, thus larger sample sizes are required. 
Regarding chromosome 1, it has been reported that in MM 1q gain is closely related to 1p loss 
152,178,270. Array CGH results for the total patient cohort, described in Section 3.3, showed that 
all the abnormalities involving 1p were chromosomal losses. However, there was no association 
between these abnormalities and 1q gain (P=0.76). These losses, which were highly variable in 
size and break-points, were rare in pre-malignant cases, while they accounted for 36% of MM 
cases. Two common minimal deleted regions were identified at 1p21.3-p22.1 and at 1p32.3. 
Loss of 1p21.3-p22.1 appeared to be strongly related to progression to MM in the array CGH 
group. However, this finding has to be confirmed on a larger patient cohort and genomic results 
have to be correlated with expression data in order to identify the possible gene(s) targeted by 
this deletion. The second region of loss on 1p was particularly interesting as it was 
hemizygously deleted in three MM and one PCL patients and homozygously deleted in another 
three MM, the cell-line KMS-11 and a second pPCL case. More importantly, within the array 
CGH patient cohort, no pre-malignant cases showed deletion of this region. In MM and in the 
cell-line, HD involved both the CDKN2C/p18 and the FAF1 genes as they are situated in close 
proximity to one another. However, in the PCL case only CDKN2C/p18 seemed to be included 
in the HD, reinforcing the potential role of CDKN2C as the targeted gene of this abnormality. 
The analysis of this region was extended to a larger patient cohort by iFISH which confirmed 
that 1p32.3 is very rare in MGUS (4%) and that it occurred in 8% and 13% of SMM and MM 
patients, respectively. In MM, 1% of these deletions were HD while those found in pre-
malignant cases were hemizygous. In MM, hemizygous and homozygous deletions of 1p32.3 
were found to be associated with an inferior OS (P=0.003).  
In the SMM case described in Section 3.5, a large deletion on chromosome 1p was detected by 
metaphase analysis at the time of progression to MM. FISH confirmed the involvement of 
1p32.3 but not of 1p21.3-p22.1 in the deletion and revealed that while this change involved the 
entire PC population at the time of MM diagnosis, it was present in only a sub-clone of PC a 
year before progression and was completely absent in the three previous samples, taken each 
year during the follow-up period. This finding from the iFISH results confirms that 1p losses are Discussion 
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likely to be secondary changes associated with the clinical manifestation of MM and suggests 
that 1p loss may have been directly involved in disease transformation of this specific case. 
However, the karyotype showed a large deletion of 1p, therefore the importance of other genes 
within the region of loss cannot be excluded. Moreover, together with 1p loss the patient was 
found to have acquired a MYC rearrangement within the year prior to progression, making it 
difficult to decipher the effect of the individual abnormalities on progression. From examination 
of the disease course of those MGUS and SMM patients found to be positive for 1p32.3 loss 
within the large cohort tested by iFISH, no definite conclusions could be drawn. Among the 
four MGUS patients, two had informative follow-up information and both progressed to MM, 
although evolution was not immediate (at 40 and 68 months from diagnosis). Among the SMM 
patients with the abnormality, although one progressed to MM after 22 months, two remained 
stable until the end of the study, 9 and 81 months from diagnosis. Nine months represents a very 
short follow-up period, therefore the first of the two SMM cases who did not progress by the 
end of the study was not highly informative. However, in the other patient the abnormality 
clearly was not enough to promote disease evolution within a period of more than 6.5 years. 
These inconsistent results may reflect the data reported by Leone et al. 
271. In MM, CDKN2C 
losses were found to be rarely HD and frequently hemizygous. Leone and colleagues found no 
mutations or methylation within the locus involving the residual allele in hemizygously deleted 
cases, suggesting that the main mechanism of loss of function of CDKN2C is by deletion. 
Moreover, they demonstrated that cases with HD not only lacked CDKN2C expression but, 
using an expression-based proliferation index, they were the most proliferative MM, consistent 
with the biological function of the gene as a cyclin-dependent kinase inhibitor. However, in 
hemizygously deleted cases, no direct correlation was found between CDKN2C mRNA levels 
and DNA copy number of the locus and only 78% of these cases showed a high proliferation 
index 
271. Therefore it may be hypothesized that in cases with hemizygous loss of CDKN2C 
there is a gene dosage effect, but this needs the additive effect of other dysregulated elements 
involved in the G1-S transition. 
 
In addition to 1p loss, array CGH detected a number of other chromosomal regions which 
appeared to be more frequently involved in copy number abnormalities in MM compared to 
MGUS or SMM. As expected, the overall number of CNA increased from MGUS to SMM to 
MM in all genetic groups. However, apart from MGUS and SMM patients with t(11;14) and 
t(14;20), the other pre-malignant patients already showed a high level of genomic complexity. 
In MGUS, this level of genomic complexity, expressed as the number of CNA per case, was 
found to be associated with progression, independently from the primary IgH rearrangement or 
ploidy class (P=0.003). However, because the majority of cases with a low level of CNA were 
represented by MGUS patients with t(11;14) or t(14;20), it can be hypothesized that MGUS Discussion 
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cases in which these two IgH translocations represented the primary genetic events, are 
characterized by a genetic background which does not promote rapid acquisition of additional 
abnormalities. As progression seems to originate from the acquisition of specific secondary 
genetic events, in these pre-malignant cases the genetic hit leading to MM has a reduced chance 
of occurring. In contrast, in MGUS cases where the primary genetic event is represented for 
example by t(4;14) or t(14;16), the genetic background established by these initiating changes 
tends to promote a more rapid acquisition of secondary abnormalities with an associated higher 
probability that changes responsible for progression will occur. This model is in agreement with 
the observations regarding the timing of acquisition of ∆13 within the different genetic classes.  
The integration of array CGH results with information about the disease course of pre-malignant 
cases has shown that the rarity of a specific abnormality in MGUS or SMM compared to MM is 
insufficient to consider that this abnormality is responsible for progression, as clearly shown for 
1q21 gain. Changes such as losses of 1p32.3, 8p21-p22, 9p21 and 16q23 were also significantly 
more frequent in MM. However, they were also found in MGUS/SMM patients who 
experienced long periods of stability despite the presence of the abnormality. A detailed 
example is shown by the acquisition of 16q23 loss in the SMM patient described in Section 3.5. 
In MM, 16q23 loss is a secondary event whose presence has been associated with an inferior OS 
248. However, in the SMM patient with serial genetic analysis, the abnormality was detected in a 
high proportion of PC more than 3 years before progression to MM. This suggested that, 
although it’s role in disease transformation cannot be excluded, 16q23 loss was not the critical 
factor responsible. The ambiguous role of these abnormalities can be explained through 
different mechanisms: (i) these changes do not affect progression but simply reflect a higher 
degree of genomic complexity established at the time of disease evolution; (ii) they have an 
impact on progression which can only be exerted in co-operation with other factors; (iii) they do 
influence disease evolution but act in a slow, gradual manner consistent with the fact that 
MGUS is a slowly evolving condition. Therefore for some patients within this study their effect 
has not become apparent. 
Other abnormalities such as 1p22.3-p23 loss, 6q25 loss, 8q24 changes (where MYC is located), 
12p13 loss, ∆13 in t(11;14)/t(6;14) patients, changes involving members of the NF-ĸB pathway 
and 17p13 loss were exclusively found in patients who had progressed before the end of this 
study. However, also among patients with these abnormalities, time to progression varied 
considerably, with some cases experiencing rapid evolution to MM and others only progressing 
after some years. Such variation in time to progression was observed among patients carrying 
the same abnormality, suggesting that these changes are probably not the only factors which 
determine disease progression.  
Among the patients with multiple samples taken at different stages of their disease course two 
different patterns of evolution were noted. Two patients (MGUS patient 355, Section 3.1.4.4; Discussion 
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SMM 1581 patient, Section 3.3.4.6.2) showed no differences in the abnormalities of their clonal 
PC before and at the time of progression, suggesting that those abnormalities were sufficient to 
drive disease evolution in these patients. The PC of both patients had changes associated with 
progression: patient 355 (with t(6;14)) had loss of 16q, and monosomy 13; patient 1581 had loss 
of 6q25, loss of 16q and gain of 17p12-p11.2, where TACI is located. Interestingly, in both 
patients the paraprotein level did not remain stable but steadily increased from diagnosis. In 
another two patients, the CNA detected at the time of diagnosis did not appear to be sufficient to 
drive disease progression and these patients experienced long-term stability with no fluctuation 
in paraprotein level. Progression to symptomatic MM coincided with the acquisition of new 
abnormalities which seemed to be strongly associated with progression. Patient 989 (MGUS, 
Section 3.3.4.6.1) and patient 259 (SMM, Section 3.5) represent two examples of this pattern of 
evolution: the first patient (HRD) acquired monosomy 13 and abnormalities involving the NF-
ĸB pathway; the second (t(4;14)) acquired loss of 1p (including 1p32.3) and a MYC 
rearrangement. However, it should be noted that in both samples at the time of MGUS or SMM 
diagnosis, FISH and array CGH had already detected a high number of abnormalities which 
were suggestive of a genetic background prone to acquiring new changes.  
 
Increased levels of MYC protein are found in many types of human cancer because the control 
mechanisms of MYC are inactivated during malignant transformation 
141,142,272. MYC is the 
oncogene dysregulated by Ig translocations in Burkitt lymphoma 
273, mouse plasmacytoma 
274 
and rat immunocytomas 
275. In these tumours MYC dysregulation represents the primary event 
driving malignant transformation. In MM, MYC abnormalities are not initiating events and can 
occur through a number of different mechanisms (i.e. reciprocal and non-reciprocal 
translocations, insertions, inversions, deletions, duplications or amplifications). In the present 
study, the only recurrent amplified chromosomal region identified among the different 
diagnostic groups was 8q24 and combination of array CGH and FISH detected MYC 
abnormalities in 23% of MM (Section 3.3) and 67% of PCL (Section 3.6). In PCL, MYC 
overexpression seemed to represent a preferred mechanism of oncogenesis. These incidences 
are considerably higher than those reported in other series 
97,111,143, suggesting that more 
comprehensive and detailed analysis of the MYC locus can reveal a higher incidence of MYC 
abnormalities. Interestingly, MYC abnormalities appeared to occur in all genetic classes, with a 
particular association with HRD. However, in the present study qRT-PCR also detected MYC 
overexpression in cases with no apparent 8q24.21 abnormalities, suggesting that a variety of 
mechanisms give rise to MYC dysregulation. Some may occur by dysregulated trans-activation 
through the transcriptional activity of presently uncharacterized factors. Thus, gene expression 
studies are more accurate for the identification of MYC-related tumours.  Discussion 
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In pre-malignant patients, MYC abnormalities were detected in only one MGUS and two SMM 
patients; all three progressed to MM. One of the two SMM patients was followed for 4.5 years 
before progression to MM (Section 3.5). She was found to have acquired a MYC rearrangement 
in 40% of PC 10 months prior to transformation. By the time of MM diagnosis, the aberration 
was present in all cells. It should be noted that, although in both SMM cases progression 
occurred relatively rapidly (10 and 16 months from the detection of the abnormality), in the 
MGUS patient, clinical symptoms did not appear until 45 months from diagnosis. This 
difference in time to progression indicates that, as in cases with 17p13.1 deletion, the biological 
effect exerted by abnormalities which are strongly associated with evolving disease varies in 
different individuals; probably highly dependent on the influence of other factors. 
     
Chesi and colleagues reported the generation of a transgenic mouse model, Vk*MYC, from 
C57BL/6 oocytes 
276. In these mice, sporadic MYC activation in the germinal centre is 
Activation-Induced Deaminase (AID) 
277 dependent and mediated by the process of somatic 
hypermutation. In this study, whereas C57BL/6 mice developed benign monoclonal 
gammopathy with age 
278, all of Vk*MYC mice developed indolent MM associated with 
biological and clinical features highly characteristic of the human disease. The fact that in the 
Vk*MYC mice, MYC activation led to MM in a mouse prone to MGUS, suggested that MYC is 
capable of driving the same progression in man. Consistent with these findings, recent reports of 
differential gene expression in MGUS and MM suggested that MYC overexpression or 
alterations in the MYC pathway in MM are not as rare as initial iFISH studies suggested. 
Elevated levels of MYC mRNA and MYC target genes distinguished patients with MM from 
those with MGUS, implicating a causal role for MYC in the progression of MGUS to MM. A 
gene expression profiling study performed on MGUS and MM patients from the Mayo Clinic, 
using gene-set enrichment analysis, reported over 300 gene-sets significantly enriched for genes 
overexpressed in MM compared to MGUS, representing potential activated pathways mediating 
transformation 
173,276,279,280. Gene-set enrichment analysis is a method that determines whether an 
a priori defined set of genes (group of genes that share common biological function, pathway, 
chromosomal location or regulation; information, which is extracted from published 
experimental data or curated databases) shows statistically significant differences between two 
biological states (i.e. MGUS and MM). After the clustering of the 313 gene-sets, three groups 
emerged: one including cell cycle related gene-sets, one proliferation related gene-sets and one 
MYC activation related gene-sets. These findings were validated in an independent cohort of 50 
MGUS and 351 MM patients 
279,280. From these findings, a MYC-signature was derived which 
included targets under the direct control of MYC in a B cell specific transcriptional network 
281. 
The highest MYC expression was seen in samples with a strong MYC signature. Both MYC 
signature and MYC expression were absent from normal PC, peripheral blood B cells, chronic Discussion 
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lymphocytic leukemia and Waldenstrom macroglobulinemia, rarely weakly present in MGUS, 
strongly expressed in Burkitt lymphoma and in the majority (60%) of MM. Similar results were 
described by Anguiano et al. using gene expression from 877 PC dyscrasia patients with 
differential diagnoses 
174. RAS mutations have been identified only rarely in MGUS, but are 
present in 30% of newly diagnosed MM, with an increasing frequency in advanced disease 
282. 
Interestingly, tumours with RAS mutations were found to consistently express the MYC 
signature and cases with RAS mutations together with samples with very high expression of 
MYC mRNA deriving from MYC translocations accounted for 67% of cases with MYC 
activation 
280. Overall, these results suggest that the MYC pathway is central in the evolution of 
MGUS to MM. However, other gene-sets not related to the MYC pathway were found to be 
differentially expressed between MGUS and MM, suggesting that MYC dysregulation is not the 
only mechanism responsible for MM development. 
 
In many haematological malignancies such as Hodgkin lymphoma, mucosa-associated 
lymphatic tissue lymphoma and diffuse large B cell lymphoma, NF-ĸB is constitutively 
activated 
283. Most primary MM (80%) and nearly 50% of HMCL have been shown to have 
elevated NF-κB transcriptional index defined by the transcription signature of eleven genes 
182. 
High expression of this signature was also found in PC isolated from BM of MGUS patients (in 
virtually 100% of cases) and of healthy individuals 
182. Normal and most neoplastic PC are 
strongly dependent on the BM microenvironment and part of the increased NF-κB signature 
activation is likely to be related to signals that PC receive within this microenvironment. Given 
the multiple recurrent abnormalities involving various regulators of this signalling which have 
been reported in HMCL and primary MM tumours 
181,182, it has been proposed that the 
acquisition of mutations in genes coding for these regulators result in constitutive and ligand-
independent activation of the signalling. As a confirmation, it was observed that in virtually all 
HMCL their high NF-ĸB index was a consequence of inactivation of suppressors (by either HD 
or deletion/mutation combinations) or by hyperactivation of pathway inducers as a consequence 
of gain/amplification or chromosomal translocation.  
The present study confirmed the presence of changes involving various members of the NF-ĸB 
pathway (BIRC2/3, TRAF3, TACI, NKB1, LTBR, CYLD) with TRAF3 and BIRC2/3 losses being 
the predominant ones. The high incidence of TRAF3 loss might be partly explained by the fact 
that TRAF3 deletion is significantly more frequent in nonHRD MM (P=0.03) and the gene is 
located on chromosome 14, which is frequently lost in tumours in this ploidy category. BIRC2/3 
loss was also found to be associated with nonHRD. However, the high frequency of this 
abnormality cannot be similarly explained, as chromosome 11 (where BIRC2/3 are located) is 
rarely lost in MM. Interestingly, such abnormalities were only found in MM and in two SMM Discussion 
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patients who evolved to MM after 6 and 15 months, respectively. Moreover, in one MGUS case 
with available material from both the time of MGUS diagnosis and the time of progression to 
MM, CNA involving NF-ĸB members (gain of NFKB1 and loss of CYLD) were found to be 
present only in the MM sample. These findings suggested that changes dysregulating members 
of this pathway are only associated with overt MM and that they may promote the evolution of 
pre-malignant conditions by the constitutive activation of the pathway.  
Interestingly, none of the PCL patients showed HD or amplification of any of the genes 
encoding for members of the pathway. This is in line with the fact that, while more than 80% of 
MM patients were found to have high NF-ĸB expression, only half of HMCL showed over-
activation of the pathway. In most of these HMCL, mutations involving the signalling members 
were detected 
181. The majority of HMCL are derived from BM PC of PCL patients; therefore it 
is possible that NF-ĸB dysregulation does not play a major role in the etiology of PCL.  
A number of reports have shown that in MYC-driven lymphomas, NF-ĸB is not involved in 
tumour promotion. In the EµMyc-mouse model, which has a transgene expressing the MYC 
oncogene under the control of the enhancer (µ) in the IgH locus, NF-ĸB activity was found to be 
dispensable for lymphomagenesis 
284. Another two studies reported that low expression of NF-
ĸB target genes were hallmarks of Burkitt lymphoma 
285,286. Klapport et al. 
287, investigating the 
role of NF-ĸB in mouse and human MYC-transformed lymphomas, reported that the NF-ĸB 
canonical pathway is extinguished in murine lymphoma cells and that extrinsic stimuli, typically 
inducing NF-ĸB activity, failed to activate this pathway. In these cells, genetic activation of the 
NF-ĸB signalling induced apoptosis, whereas inhibition of NF-ĸB provided a selective 
advantage in vitro. The activation of NF-ĸB was also found to induce apoptosis in human 
Burkitt lymphoma cells.  
In the present study, it was evident that the majority of PCL patients were characterized by MYC 
abnormalities (eight of 12 patients) associated with MYC overexpression. Moreover, of the 
patients tested by qRT-PCR, MYC overexpression was observed in one patient lacking any 
abnormality at 8q24, confirming that MYC overexpression can be activated by a number of 
different mechanisms. This finding together with the fact that no abnormalities involving NF-ĸB 
members were detected in PCL, may suggest that in these patients the NF-ĸB pathway is not 
essential. Interestingly, within the group of MGUS, SMM and MM patients analyzed by array 
CGH, abnormalities involving MYC and abnormalities involving members of the NF-ĸB 
pathway were found to be mutually exclusive. However, it has to be noted that in MYC-driven 
lymphomas, MYC dysregulation has been implicated as a primary event, while in MM it is 
responsible for progression, meaning that the biology of these tumours may be different with 
regard to the inter-relation between the MYC and the NF-ĸB pathways. Moreover, the 
comparison between MYC expression 
263and the NF-ĸB index 
245 for a number of recently 
published HMCL showed that some cell lines with high MYC expression also have high NF-ĸB Discussion 
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index. However, these suggestions need to be investigated further as NF-ĸB inhibitors are 
widely used in the treatment of MM patients and such responses may have negative 
implications for therapy in MYC-positive tumours. 
 
Concluding remarks 
The main aim of this study was to identify molecular cytogenetic markers responsible for 
disease evolution from MGUS and SMM to MM and PCL. The findings presented in the 
preceding chapters have yielded novel insights into the role of different chromosomal 
abnormalities in the development of MM. Despite the high level of genetic complexity which 
characterizes PC disorders, it has been possible to discern an underlying order of events 
characterizing various abnormalities and to better understand their biological impact in the 
context of different stages of the disease.  
The first main observation from this study was the increasing genomic complexity from MGUS 
to SMM to MM to PCL, a pattern which was common to all genetic groups. In MGUS, a high 
level of complexity, defined as the number of chromosomal gains and losses per case, was 
found to be associated with progression, independent of the underlying IgH translocation or 
ploidy category. None of the primary IgH translocations, regardless of their biological impact in 
MM, seemed to have an effect on progression in either MGUS or SMM patients. The 
comparison of copy number and structural aberrations among the different classes did not 
identify one common chromosomal aberration associated with progression but instead 
uncovered various secondary changes, which were rare or absent in pre-malignant cases and 
recurrent in MM and PCL. In addition, within the same genetic group, there did not appear to be 
a common event associated with progression, apart from possibly ∆13 in most pre-malignant 
cases with t(6;14) and t(11;14) and dysregulation of members of the NF-ĸB pathway in IgH-
translocated cases. These findings suggested that either (i) many different mechanisms can 
induce MGUS or SMM patients towards progression or that (ii) there are common pathways 
which are crucial for progression to MM, but these same pathways can be dysregulated through 
a number of different members and mechanisms. In either scenario, identification of the 
mechanism is difficult when attempted exclusively from the genetic point of view, given the 
karyotypic chaos characterizing many cases. These observations strongly suggested that an 
approach where genomic studies are integrated with gene expression data is required. Another 
main finding of this study was that changes found to be significantly rare in MGUS and SMM 
compared to MM were not necessarily associated with disease progression. For some of these 
changes, it is unknown whether they are directly involved in disease progression or whether 
they simply reflect the increased genomic complexity typical of overt MM. This was also true in 
the context of those abnormalities which in MM have been confirmed to be associated with 
inferior prognosis. Thus, the biological significance of chromosomal changes in pre-malignant Discussion 
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conditions cannot be assumed from the effect they exert in patients receiving treatment. High-
risk chromosomal changes do not automatically lead to overt disease when present in MGUS or 
SMM; gain of 1q21 is one such example. Other changes seem to be directly responsible for 
progression (i.e. 17p13.1 loss, 1p21.3-p22.1 loss and MYC abnormalities). However, time to 
progression in patients positive for these abnormalities seemed to vary considerably suggesting 
that other modulating factors, which might be represented by co-existent genetic abnormalities, 
may play a role. In order to investigate possible interactions between different chromosomal 
changes, studies must be conducted over long follow-up periods, given the slow disease 
evolution of most MGUS cases. In addition they have to involve large numbers of patients 
considering the high level of genetic heterogeneity (e.g. previous studies failed to detect 1q21 
gain in MGUS because the number of cases investigated was too small 
162,163). For these 
reasons, this study should be continued by: (i) following the sample patients in order to re-
evaluate the effect of the different abnormalities in the context of longer-term follow-up and (ii) 
studying increased numbers of new patients in order to confirm or disprove the role of those 
abnormalities found to be associated with disease progression in the current study. Particular 
effort should be made to collect and genetically characterize sequential patient samples at 
different stages of the disease, as these provide the unique opportunity to determine how and 
when specific abnormalities arise and how these changes correlate with the clinical evolution of 
the disease. 
Although this study has advanced the understanding of the genetics of PC dyscrasia, much more 
work still needs to be done. In particular with consideration of novel technologies including 
deep sequencing and other complex technologies, such as chromatin immunoprecipitation and 
DNA methylation methodologies in order to identify epigenetic changes in addition to genomic 
abnormalities. These new approaches may uncover previously unidentified 
changes/mechanisms responsible for MGUS and SMM progression to MM, which may be 
applicable as potential novel molecular targets for therapy, either to prevent progression or, at 
least, to prolong the pre-malignant stage. In addition, the early detection of abnormalities known 
to drive disease evolution (i.e. changes of  MYC, TP53 and NF-ĸB) in MGUS and SMM 
patients may provide the opportunity to use increasingly effective treatments on patients fit 
enough to benefit from them as they do not suffer from irreversible lytic bone disease, renal 






















Appendix 1: URL 
 
 
•  Children’s Hospital Oakland Research Institute (BACPAC Resources): 
http://bacpac.chori.org/order.php 
 
•  Database of Genomic Variants: http://projects.tcag.ca/variation/ 
 
•  Department of Genetics and Microbiology, University of Bari (Prof. Rocchi): 
http://www.biologia.uniba.it/rmc/ 
 
•  Ensembl Human Genome Browser: http://www.ensembl.org/Homo_sapiens/ 
 
•  GeneCards: http://www.genecards.org/ 
 
•  OMIM: http://www.ncbi.nlm.nih.gov/Omin 
 
•  Primer3 program: http://primer3.sourceforge.net/ 
 
•  University of California Santa Cruz Human Genome browser: http://genome.ucsc.edu/ 
 
•  Mitelman Database of Chromosomes in Cancer: 
http://cgap.nci.nih.gov/Chromosomes/Mitelman/ 
 
•  MRC-Holland biotechnology company: http://www.mrc-holland.com/ 
 
•  IARC p53 website: http://www-p53.iarc.fr/index.html 
 




Appendix 2: Buffers and Reagents 
•  Zap-o-globin  
Stock solution was kept at 4˚C; working solution (1:1; Zap-o-globin:sterile water) was kept at room 
temperature 
•  Red Cell Lysis (RCL) buffer  
155mM NH4Cl 
10mM KHCO3 
0.1mM EDTA  
RCL buffer kept at room temperature; the dispenser bottle in use kept at 37
oC 
•  RPMI culture medium 
RPMI 1640 Dutch modification medium (Gibco) 
20% Fetal calf serum (Sigma-Aldrich) 
1% penicillin/streptomycin (Sigma-Aldrich) 
2% L-Glutammine (Sigma-Aldrich) 
The constituents were filtered using a syringe with attached a Sarsted filter. Culture medium 
was kept at 4˚C and warmed up at 37˚C before used 
•  Wash medium 
This was either be outdated full RPMI culture medium or freshly made up RPMI culture 
medium but containing only 12.5% of fetal calf serum. Wash medium was kept at 4˚C and 
warmed up at 37˚C before used 
•  Phosphate buffered saline
+ (PBS
+) buffer  
For 200ml solution:  1 tablet of PBS (Sigma-Aldrich)  
      0.5% BSA (albumin from bovin serum; Sigma-Aldrich) 
      2mM EDTA 
The solution was filtered into sterile 100ml bottles and left 24 hours in the fridge at 4˚C with the 
lids partially unscrewed to allow the degassing Appendices 
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•  IL-6 (First Link) 
IL-6 stock solution: 1µg/ml (stored at -20˚C). For the working solution (100ng/ml), the stock 
solution was diluted in wash medium; this solution was viable for one week if kept at 4˚C. 
Concentration used for cytogenetic cultures: 10µl per ml of culture medium (1ml culture 
medium = 1x10
6 cells) 
•  FdU (Sigma-Aldrich; working solution: 1x10
-5M in PBS, kept at 4˚C) 
•  Uridine (Sigma-Aldrich; working solution: 4x10
-4M in PBS, kept at 4˚C) 
•  Thymidine (Sigma-Aldrich; working solution: 1x10
-3M in PBS, kept at 4˚C) 
•  Colcemid (Gibco; working solution: 10µg/ml, kept at 4˚C)  
•  Hypotonic solution: 0.075M KCl (Sigma-Aldrich; 5.56g KCl was added to a 1 
litre of sterile water and kept at room temperature. The dispenser in use was kept at 
37
oC) 
•  Carnoy’s fixative (3:1; methanol:acetic acid; methanol and glacial acetic acid were 
dispensed immediately before use)  
•  Wright’s buffer (10ml of commercial Sorensen’s phosphate buffer (Mercia 
Diagnostics) were added to 100ml of sterile water) 
•  Wright’s stain (1.5g of Wright’s stain (Sigma-Aldrich) was dissolved in 500ml of 
methanol) 
•  LB Broth (GibcoBRL)  
20g per litre dH20 (autoclaved and then stored at room temperature) 
•  Agar (Dibco)     
2g/100ml LB Broth (autoclaved and kept at 50
˚C until ready) 
The desired concentration of antibiotic was added when cool 
Plates were poured and stored at 4
˚C Appendices 
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•  Antibiotics   
Kanamycin Sulphate (GibcoBRL)  10mg/ml 
Ampicillin (Hospital Pharmacy)   10mg/ml 
Tetracycline (Hospital Pharmacy)  10mg/ml 
Chloramphenicol (Sigma-Aldrich)  10mg/ml 
•  P 1 solution        
15mM Tris Base pH8.0  
10mM EDTA  
100µg/ml RNase A (Sigma-Aldrich) added just before use  
•  P 2 solution     
4ml NaOH (Sigma-Aldrich; 4g NaOH Anhydrous pellets in 100ml dH20) 
2ml 10% SDS (20% SDS + equal vol. dH20) 
    14ml dH20 
•  P 3 solution   
60ml 5M KAC  
11.5ml Glacial Acetic Acid 
28.5ml dH20 
•  TE (pH8.0) 
10ml 1M Tris (pH8.0) 
2ml 0.5M EDTA (pH 8.0) 
•  0.8% Agarose Gel 
1.2g Agarose (Bioline) 
150ml 1x TBE  
•  5x TBE Buffer (Sigma-Aldrich) 




•  Standard DNA Assay  
100µl Calf Thymus DNA (1mg/ml, Pharmacia Biotec) 
100µl 10xTNE Buffer                      
800µl dH20 filtered 
•  Loading Buffer (for gels)   
8g Sucrose (Sigma-Aldrich) 
1ml 5% Orange G (Sigma-Aldrich) 
40µl 0.5M EDTA 
Made up to final volume of 20ml with dH20 
•  Stock DNase I (1mg; Sigma-Aldrich) 
Enzyme Diluent   400µl sterile dH2o 
100µl 10x Nick Translation Buffer 
500µl Sterile Glycerol 
DNase I Working Solution (1µg/ml): 1µl of Stock Dnase I in 1ml of Enzyme Diluent 
•  10x Nick Translation Buffer 
0.5M Tris.Cl pH7.5    
0.1M MgS04    
1mM Dithiothreitol (Mw 154.25)    
500µg/ml Bovine Serum Albumin  
All reagents stored at -20
˚C 
•  0.5 mM dNTPs (Pharmacia, 100mM)  
2µl each of dATP, dCTP, dGTP, and 1194µl of sterile dH20 
•  Spectrum Green dUTP (Vysis)  
50µl TE (pH7.5) added to powder 
•  3M Sodium Acetate (pH 7.0)   
24.61g dissolved in 200ml sterile dH20 Appendices 
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•  Human Cot - 1 DNA (500mg; GibcoBRL )  
50µl aliquots (2µl in 18µl dH20) 
•  Complete Hybridization Mix   
5ml de-ionised formamide + dextron sulphate 
∗ ∗ ∗ ∗  
2ml 10x SSC
∗ ∗ ∗ ∗∗ ∗ ∗ ∗ 
3ml dH20 
∗ De- ionised formamide: 5g (monobed) resin in 150ml formamide, stirred for 45 min at room 
temperature and filtered. 20% dextron sulphate (Polysciences Inc.) and dissolve overnight. 
∗ ∗ ∗ ∗∗ ∗ ∗ ∗
 10x SSCP - equal Vol. of 20x SSC and dH20. 
•  RNase A (Sigma-Aldrich)  
1mg/ml of RNase buffer (stored at -20˚C) 
RNase buffer (10mM Tris; 15mM NaCl (pH 7.5)) 
Boiled for 30 minutes to destroy DNase and stored in 50µl aliquots at -20˚C 
•  Pepsin (Sigma-Aldrich)  
50mg/ml in 0.01M HCl  
Stored in 50µl aliquots at -20
˚C 
•  20x SSC       
175.3g NaCl (Sigma-Aldrich) 
88.2g NaCit (Sigma-Aldrich) 
Made up to 1 litre dH20 (stirred for a couple of hours to ensure complete dissolvement) 
•  2x SSC        
450mls dH20 
50mls 20 x SSC 
•  0.4x SSC/0.3% NP40 (Igepal, Sigma-Aldrich) 
4ml 20xSSC       
      196ml dH2O           
      600µl NP40           Appendices 
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•  2x SSC/0.1%NP40 
      100ml 20xSSC       
      900ml dH2O           
      1000µl NP40             
•  4x SSC/0.05%NP40    
100ml 20xSSC       
      400ml dH2O           
      250µl NP40           
•  RSB (Resuspension Buffer) 
                                        0.075M NaCl 
                                        0.024M EDTA 
                                        In 1L dH2O (pH=8.0) 
•  Proteinase K (Sigma-Aldrich) 
                                       50mg/ml in dH2O Appendices 
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•  BCR-ABL Multiplex Mix   
                         2.4ml PCR buffer (Invitrogen) 
                         0.9ml MgCl2 (Invitrogen) 
                        192µl dNTPs at 25 mM* 
                       120µl of each of the primers (CA3-, C5e-, B2B, BCR-C)** 
                       16ml dH2O 
* dNTPs was made by combining equal volumes of each of the 4 dNTPs 
** All primers were at 100µM 
250µl aliquots were stored at -70C 
 
•  Control Gene Multiplex PCR Primers 
 
Frag.  Gene  Exon  Forward primer  Reverse primer 
100 bp  TBXAS1  9 
5′-GCC CGA CAT TCT GCA 
AGT CC-3′ 
5′-GGT GTT GCC GGG AAG 
GGT T-3′ 
200 bp  RAG1  2 
5′-TGT TGA CTC GAT CCA 
CCC CA-3′ 
5′-TGA GCT GCA AGT TTG 
GCT GAA-3′ 
300 bp  PLZF  1 
5′-TGC GAT GTG GTC ATC 
ATG GTG-3′ 
5′-CGT GTC ATT GTC GTC 
TGA GGC-3′ 
400 bp  AF4  11 
5′-CCG CAG CAA GCA ACG 
AAC C-3′ 
5′-GCT TTC CTC TGG CGG 
CTC C-3′ 
600 bp  AF4  3 
5′-GGA GCA GCA TTC CAT 
CCA GC-3′ 
5′-CAT CCA TGG GCC GGA 
CAT AA-3′ 
 
Primer mix A: 
25µl of each 10pmol/µl stock:    100bpF, 100bpR 
          200bpF, 200bpR 
          300bpF, 300bpR 
          400bpF, 400bpR 
Primer mix B: 






Appendix 3: List of in-house FISH probes  
 
 
Fish probes are listed with their chromosomal position, name of the gene involved and 
fluorochrome used (Chr, chromosome; Sp, spectrum) 
 
*   Fosmid probe 
**   Cosmid probe 
Source: Sanger Institute, Hinxton, UK (except for RB1 which was sent by Prof. Rocchi, Resources 
for Molecular Cytogenetics, University of Bari, Italy) Appendices 
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List of commercial FISH probes from Vysis (Abbott) 
 
 
Chromosome  Probe  Vysis code 
3  CEP3 (D3Z1) Spectrum Orange  32-130003 
4/14 
LSI IGH/FGFR3 Dual Colour (Spectrum Orange & Green), Dual Fusion 
Translocation Probe  N/A 
5/9/15 
LSI D5S23/D5S721/CEP 9/ CEP 15 Multi-colour Probe Set 
§ (Spectrum 
Aqua, Green & Orange)  32-231021 
8 
LSI MYC Dual Color (Spectrum Orange & Green), Break Apart 
Rearrangement Probe  32-191096 
 
LSI IGH/MYC, CEP 8 Tri-Colour Translocation Probe (Spectrum Aqua, 
Green & Orange)  32-191020 
7  CEP7 (D7Z1) Spectrum Aqua  32-131007 
9  CEP9 Spectrum Aqua  32-131009 
11/14 
LSI IGH/CCND1 XT Dual Colour (Spectrum Orange & Green), Dual Fusion 
Translocation Probe  N/A 
13  LSI D13S319 (13q14.3) Spectrum Orange Probe  32-190045 
14 
LSI IGH Dual Color (Spectrum Orange & Green), Break Apart 
Rearrangement Probe  32-191019 
16/14 
LSI IGH/MAF t(14;16)(q32;q23) Dual Colour (Spectrum Orange & Green), 
Dual Fusion Translocation Probe  32-231014 
17  CEP17 (D17Z1) Spectrum Green  32-132017 
  LSI p53 (17p13.1) Spectrum Orange  32-190008 
22  LSI 22 (BCR) Spectrum Green  32-192024 Appendices 
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Appendix 4: Custom probes added to the ‘Salsa MLPA kit 
P088 Glioma 1’ (MRC-Holland) for the detection of copy 





band & Mb 
position 
Gene involved 
Probe sequence (in bold, 48bp) & stuffer 




51,096,769Mb     







51,197,809Mb     
 








51,204,960Mb     
 









51,207,953Mb     
 





























Appendix 5: Karyotype description of the cytogenetically 
abnormal MGUS and SMM cases studied in Section 3.1; for 
each patient the ploidy status determined by iFISH is shown 
 
RegID  Diag  Ploidy  Karyotype 
355  MGUS  HRD  47,XX,+X,t(6;14)(p21;q32),+9,+11,-13,-14,-16,+19[1]/46,XX[47] 




911  MGUS  HRD  52,X,-X,+3,+5,+7,+add(9)(q22),-13,+15,+15,+19,+21[1]/46,XX[52] 
949  MGUS  nonHRD  85<4n>XX,-Y,-Y,dic(8;15)(q24;p11)x2,t(11;14)x2,+15,-16,-16,-17,-19,-20,-
22,+2mar[1]/46,XY[16] 
1494  MGUS  nonHRD  46,XX,del(13)(q12q22),t(14;16)(q32;q24),add(16)(q24)[1]/46,XX[73]  
1870  MGUS  HRD  52,X,-X,+5,+9,+11,+15,+18,+19,+19[1]/46,XX[76]  
1889  MGUS  HRD  57,X,-X,+3,+4,+5,+7,+9,+9,+11,+15,+18,+19,+21,+21[1]/46,XX[131] 
2136  SMM  nonHRD  46,XY,del(1)(p13p?31),del(14)(q22)[4]/46,idem,der(15)t(1;15)(q11;q26)[1]/46,XY[65] 










1516  SMM  HRD  50,X,-Y,t(1;8)(p13;q24),+3,+3,+7,+9,der(13)t(1;13)(q21;q12),+15[4]/46,XY[48] 
1717  SMM  HRD  57,XY,+3,+8,+9,+9,+11,+add(14)(q32),+15,+15,?+19,+2mar[2]/46,XY[59]  
2178  SMM  nonHRD  46,XY,t(11;14)(q13;q32)[1]/46,XY,der(16)t(1;16)(q11;q23)/46,XY[50] 
276  SMM  HRD  50,X,-X,+3,+6,+7,der(7)t(1;7)(q12;p22),+9,-13,+15,+19[10]/46,XX[80] 
2033  SMM  HRD  52,XY,del(1)(p?21p32),+3+5,+9,+11,add(12)(q24),+15,+19[2]/52,idem,add(18)(q23)[2]/46,
XY[45] 
616  SMM  HRD  48,X,-X,+3,+4,der(6)t(6;?7)(q2?3;q1?1),add(7)(p1),-8,+9,add(10)(q26),+11,add(12)(q24),-
13,add(16)(p1),add(18)(p1),+20,add(20)(q11)x2,-22,+mar[1]/46,XX[49] 
331  SMM  HRD  48,XX,+3,+del(6)(?q21q23),add(7)(p22),+8,+9,-13,-14,der(15)t(?3;15)(p11;p11),-
16,+add(17)(p11),der(20)t(1;20)(q12;p13),inc[1]/46,XX[78] 
2035  SMM  nonHRD  46,XX,t(11;14)(q13;q32)[cp2]/46,XX[177] 





1925  SMM  nonHRD  45,X,t(X;11)(q13;q23),der(11)t(1;11)(q12;p15),-
13,?del(14)(q2?4q32),?rdel(20)(p11q12),del(20)(p1),+mar[3]/46,XX[168]   
1873  SMM  nonHRD  48,X,-Y,?dup(1)(q21q32),+?der(1)add(1)(p12)?dup(1)(q21q32),+9,+19[1]/46,XY[78]  
231  SMM  HRD  54,XY,+3,+5,+7,dic(8;12)(p23;p11),+9,+9,+11,?psudic(11;18)(q25;p11),+15,+15,+19,+20[
3]/46,XY[50] 
508  SMM  HRD  54,XX,+3,t(6;16)(p21;p13),+7,+9,+11,+15,+18,+19[1]/46,XX[14] 
2213  SMM  HRD  57,XY,del(1)(p11),+t(1;3)(p3?6;p1?3),t(2;8)(p12;q24),+5,+5,+7,+7,+9,+9,+11,+15,+19[1]/5
7,idem,+2,+8,-t(2;8),add(14)(q32)[1]/46,XY[13] 
Cases where FISH and karyotype were discrepant for ploidy status are in red 
(Reg ID, patient ID; diagn, diagnosis) Appendices 
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Appendix 6: Characteristics of MGUS and SMM patients 
with array CGH results 
 
 
(RegID, patient identification; CC, conventional cytogenetics; Diagn, diagnosis; PP, paraprotein 
type; Progr, progression; FU, follow-up time; F, female; M, male) 
* Patient not studied at diagnosisAppendices 
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Appendix 7: Characteristics of MM patients with array CGH results 
 
Genetic 




t(4;14)                   
  719  77  M  Abnormal  44,X,-Y,der(3)t(1;3)(q12;q29),der(4)t(4;?7)(p16;q22),add(6)(q2?7),t(8;13)(q24;q14),-
13,add(16)(p13)add(17)(p13)[13]/46,XY[4]  IgAk  Dead  4  4 
  604  55  M  NSU    IgGl  Dead  21  21 




IgGl  Dead  40  40 




k only  Dead  3  3 




IgGl  Dead  2  92 
  1875  51  F  Abnormal  43,X,-X,+1,dic(1;19)(p10;q13.43),dic(8;20)(p10;q10),-13,rea(14)/46,XX[102]  IgAl  Alive  34  34 
  52  66  M  Abnormal  >>46,XX,?del(13)(q14q22),?del(11)(q13),inc[3]/46,XX[87]  IgAk  Dead  3  3 





IgG  Dead  15  15 
  1172  67  M  Abnormal  42,X,-Y,add(5)(q1?3),der(7)t(7;12)(p22;q15),-12,-13,add(16)(p13),-18,-
22,+mar[2]/42,idem,t(1;10)(p2;q24),del(8)(q21q24)[1]/46,XY[62]  IgAk  Dead  41  41 




IgGk  Dead  4  4 






IgG  Dead  9  9 Appendices 
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Genetic 




t(14;16)                   




IgGk  Dead  19  19 




IgAl  Dead  6  6 
  309  49  F  Normal    IgA  Dead  12  12 
  2068  67  M  NSU    IgGl  Dead  25  25 
  954  75  F  NSU    IgGl  Dead  6  67 
  1798  70  F  NSU    Unknown  Unknown     
  2125  61  F  Abnormal  44,X,-X,del(1)(p13p22),-
13,del(14)(q22q32),t(14;16)(q32;q23)[16]/44,idem,?t(15;16)(q22;p13)[2]/46,XX[55]  IgAl  Alive  37  37 





l only  Alive  84  84 
HRD                   
  297  67  M  Normal    IgA  Alive  56  56 
  506  59  F  Abnormal  55,XX,+5,+7,+7,+9,+9,+11,-13,+15,-16,+19,+21,+21,+mar[7][ab11]/46,XX[11]  IgG  Alive  59  59 




IgGk  Dead  2  2 
  824  80  M  Abnormal  55,XY,+3,+5,+7,+9,+11,+15,+15,dic(15;17)(q26;p11),dic(15;17)(q26;p11)del(17)(q12q
21),+19,+19,+?21,+mar[cp3]/46,XY[7]  IgGk  Dead  21  21 
  1512  74  F  NSU    k only  Dead  34  34 
  491  48  M  NSU    IgGk  Dead  20  29 





IgA  Dead  18  18 
  830  55  F  Normal    IgGk  Alive  63  63 
  883  60  M  Normal    IgGk  Alive  61  61 
 Appendices 
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Genetic 




  2218  44  M  Abnormal  55,XY,+3,+5,+7,+8,+9,+11,+15,+19,+21[4]/46,XY[123]  IgGl  Alive  36  36 
  989  67  M  NSU    IgG  Alive  4  4 
  1776  75  M  Abnormal  48~50,X,-Y,+3,del(5)(q2?3q2?5),del(8)(p1?2),del(9)(p13p21),+11,add(13)(p11),-
14,+15,+18,+19[cp3]/46,XY[41]  IgAl  Dead  4  62 
  1213  65  M  Abnormal 
48,XY,der(2)t(2 ;6)(q3 ?3 ;?q25),+5,del(5)(q11q31),der(5)t(5 ;9)(q31 ;?),der(6)t(X ;6)( ?
q22 ;q ?15)x2,der(8)t(8 ;16)(q24 ;?p12),der(12)t(1 ;12)(q12 ;p13),-
13,der(14)t(8 ;14)(q24 ;q32),+15,der(16)t(6 ;16)( ?q11 ;p11),+19,der(21)t(6 ;21)(p21 ;q2
2)[44]/46,XY[43] 
IgAk  Dead  0  0 
t(11;14)                   




Unknown  Dead  Unknown  Unknown 
  1524  73  F  Abnormal 
41,-X,der(X)t(X ;1)(q13 ;q12),+1,dic(1 ;13)(p12 ;p11), ?i(4)(p12) or 
add(4)(p ?),der(5 ;15)(p10 ;q10),der(6)t(6 ;11)(q12 ;q13),+der(6)t(6 ;17)(q13 ;q11),t(11 ;
14)(q13 ;q32),-12,-13,add(16)(q12),-17,-22[9]/44,idem,+ ?20,+ ?21,+22[1] 
/46,XX[57] 
IgAl  Dead  20  20 
  1300  61  F  Normal      Dead  12  12 
  504  47  F  NSU    IgGk + 
free k  Dead  6  6 
  308  57  F  Abnormal  44,X,-X,add(1)(p13),der(5)t(5 ;12)(q31 ;q13),t(11 ;14)(q13 ;q32),-
12, ?der(13)t(1 ;13)(p13 ;q14)[9]  k only  Alive  57  57 




IgGl  Dead  13   
  932*  62  F  Normal    IgA  Alive  4  4 
  2906  65  M  Failed    IgGk  Alive  26  26 
t(14;20)                   




IgGl  Dead  26  26 
  1890  59  F  Abnormal  46,XX,t(2;8)(p11;q24),t(14;20)(q32;q12)[13]  IgGk  Dead  45  45 
 Appendices 
  214 
Genetic 








                 
  3004  76  M  Abnormal  43~45,XY,t(2;16)(p13;q1),add(3)(p25),t(4;?10)(q3?1;q11),del(5)(q3?3;q3?5),der(12;17)
(q10;q10),add(14)(q32),?del(14)(q1q2?4),del(20)(q11),-22,+mar[cp2]/46,XY[57]  IgAk  Alive  29  28 
  1581  55  M  Normal    IgAl  Alive  43  43 
  619  86  F  Abnormal  43,X,-X,+1,add(1)(q21),dic(1;21)(p13;p11),dic(1;22)(p13;p11),add(2)(q37),+9,-
13,der(16)t(1;16)(q21;q13),add(17)(q25),-22[3]/46,XX[102]  IgGk  Dead  25  25 






IgGk  Alive  35  35 
  666  68  M  Abnormal  47,XY,add(5)(q35),+6,?del(6)(q23q25),+9,+11,-13,idic(15)(p13),+19,-20,-
22[cp6]/46,XY[53]  IgGl  Alive  43  43 
 
(RegID, patient identification; CC, conventional cytogenetics; PP, paraprotein level; FU, follow-up; NSU, not set up; nonHRD, non-hyperdiploid; unid, 
unidentified partner; IgHr, IgH rearrangement) Appendices 
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Diagnosis  Genetic 
group 
CNA by array CGH 
‘Dim’ and ‘Enh’ describe loss and gain respectively, with the genomic position of the abnormality shown in brackets after the 
chromosome; Dim X2 = HD. Trisomy, tetrasomy and monosomy have additional breakpoint information. CNV are in blue. 
3318  MGUS  t(4;14)  Dim(1)(82.91[1p31.1]-142.72[1p11.1]); Enh(1)(142.72[1q12]-246.84[1qter]); Dim(2)(0.02[2pter]-13.86[2p24.3]); Dim(2)(14.98[2p24.3]-
15.18[2p24.3]); Dim(2)(16.43[2p24.3]-20.15[2p24.1]); Enh(2)(20.71[2p24.1]-20.74[2p24.1]); Enh(2)(42.84[2p21]-42.87[2p21]); Dim 
X2(2)(88.93[2p11.2]-89.15[2p11.2]); Dim(2)(141.52[2q22.1]-141.91[2q22.1]); Dim(3)(23.31[3p24.3]-23.52[3p24.3]); Enh(3)(48.58[3p21.31]-
48.68[3p21.31]); Dim(4)(0.04[4pter]-38.43[4p14]); Dim(4)(69.06[4q13.2]-69.17[4q13.2]); Dim(4)(124.96[4q28.1]-125.09[4q28.1]); 
Enh(5)(0.08[5pter]-24.27[5p14.2]); Enh(6)(0.1[6pter]-7.94[6p24.3]); Dim(6)(142.42[6q24.1]-170.17[6qter]); Dim(7)(38.28[7p14.1]-38.32[7p14.1]); 
Dim(8)(0.06[8pter]-34.8[8p12]); Enh(10)(0.12[10pter]-24.36[10p12.1]); Enh(10)(46.37[10q11.21]-46.57[10q11.22]); Dim X2(12)(9.53[12p13.31]-
9.55[12p13.31]); Dim(12)(99.38[12q23.1]-132.13[12qter]); Monosomy(13)(18.07-113.58); Dim(14)(60.57[14q23.1]-81.18[14q31.1]); 
Enh(14)(105.08[14q32.33]-105.28[14q32.33]); Dim(14)(105.33[14q32.33]-106.16[41q32.33]); Dim(15)(54.18[15q21.3]-54.31[15q21.3]); 
Dim(15)(68.92[15q23]-68.97[15q23]); Dim(16)(33.88[16p11.2]-45.02[16p11.2]); Dim(17)(0.03[17pter]-40.53[17q21.31]); Dim(17)(54.65[17q22]-
78.65[17qter]); Dim(18)(0.0[18pter]-10.69[18p11.22]); Dim(18)(62.7[18q22.1]-75.59[18qter]); Enh(19)(0.06[19pter]-19.72[19p12]); Dim 
X2(22)(21.39[22q11.22]-21.58[22q11.22]); Enh(22)(22.61[22q11.23]-22.73[22q11.23]); Enh(X)(127.81[Xq25]-154.49[Xqter]) 
2664  MGUS  t(4;14)  Enh(1)(142.72[1q12]-245.59[1qter]); Dim X2(1)(150.82[1q21.3]-150.85[1q21.3]); Dim X2(1)(246.79[1q44]-246.86[1q44]); Dim(2)(88.94[2p11.2]-
89.03[2p11.2]); Dim(3)(164.0[3q26.1]-164.1[3q26.1]); Dim X2(4)(69.06[4q13.2]-69.17[4q13.2]); Dim X2(6)(32.6[6p21.32]-32.63[6p21.32]); Dim 
X2(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(9)(70.17[9q12]-140.04[9qter]); Dim X2(12)(9.53[12p13.31]-9.55[12p13.31]); Monosomy(13)(18.07-
113.96); Dim(14)(19.27[14q11.2]-19.49[14q11.2]); Dim(14)(105.31[14q32.33]-105.62[14q32.33]); Dim(18)(67.67[18q22.3]-75.9[18qter]); 
Enh(19)(0.06[19pter]-32.55[19p12]) 
2715  MGUS  t(4;14)  Dim(1)(16.77[1p36.13]-17.03[1p36.13]); Enh(1)(141.47[1q12]-245.43[1qter]); Dim(2)(89.0[2p11.2]-89.32[2p11.2]); Dim(4)(1.85[4p16.3]-
1.87[4p16.3]); Dim(4)(70.35[4q13.2]-70.44[4q13.2]); Dim(5)(172.24[5q35.1]-172.42[5q35.2]); Dim(8)(7.04[8p23.1]-8.14[8p23.1]); 
Enh(8)(39.36[8p11.22]-39.5[8p11.22]); Dim(9)(79.37[9q21.13]-79.52[9q21.13]); Monosomy(13)(18.07-114.12); Dim X2(13)(66.24[13q21.32]-
66.37[13q21.32]); Enh(14)(21.44[14q11.2]-22.03[14q11.2]); Dim(14)(105.34[14q32.33]-105.85[14q32.33]); Enh(15)(18.74[15q11.2]-
20.22[15q11.2]); Dim(17)(41.55[17q21.31]-42.05[17q21.31]); Monosomy(21)(9.9-46.91); Monosomy(22)(14.5-49.51); Monosomy(X)(2.69-154.49) 
2849  SMM  t(4;14)  Enh(1)(141.47[1q12]-245.43[1qter]); Dim(2)(89.01[2p11.2]-91.04[2p11.2]); Dim(6)(89.88[6q15]-89.93[6q15]); Dim(7)(3.03[7p22.2]-12.47[7p21.3]); 
Dim(8)(0.06[8pter]-39.33[8p11.22]); Monosomy(13)(18.07-114.12); Enh(14)(105.35[14q32.33]-105.42[14q32.33]); Monosomy(22)(14.5-48.91); 
Enh(X)(136.99[Xq26.3]-154.49[Xqter]) 
508  SMM  t(4;14)  Dim(1)(145.82[1q21.1]-146.01[1q21.1]); Dim(2)(88.99[2p11.2]-89.27[2p11.2]); Dim(2)(242.64[2q37.3]-242.74[2q37.3]); Trisomy(3)(0.04-199.38); 
Dim(4)(0.06[4pter]-1.85[4p16.3]); Enh(4)(1.9[4p16.3]-2.06[4p16.3]); Dim(4)(91.53[4q22.1]-91.62[4q22.1]); Dim(6)(162.67[6q26]-162.9[6q26]); 
Trisomy(6)(0.1-170.86); Trisomy(7)(0.14-158.62); Dim(8)(39.36[8p11.21]-39.51[8p11.21]); Trisomy(9)(0.15-138.4); Dim(9)(1.41[9p24.3]-
1.56[9p24.3]); Dim(10)(67.77[10q21.3]-68.03[10q21.3]); Trisomy(11)(0.18-134.43); Enh(14)(105.57[14q32.33]-106.35[14q32.33]) 
Enh(15)(18.36-100.28); Trisomy(18)(0.0-76.11); Trisomy(19)(0.06-63.78); Enh(22)(22.65[22q11.23]-22.73[2q11.23]) 
259  SMM  t(4;14)  Dim(1)(145.82[1q21.1/.2]-146.47[1q21.1/.2]); Dim X2(1)(165.96[1q24.2]-165.99[1q24.2]); Dim(2)(11.19[2p25.1]-26.43[2p23.3]); 
Dim(2)(89.0[2p11.2]-89.31[2p11.2]); Dim(4)(0.04[4pter]-1.85[4p16.3]); Enh(5)(37.49[5p13.2]-37.5[5p13.2]); Dim(5)(172.59[5q35.1/.2]-
172.6[5q35.1/.2]); Dim(6)(32.57[6p21.32]-32.63[6p21.32]); Dim(8)(6.93[8p23.1]-7.79[8p23.1]); Enh(8)(39.36[8p11.23]-39.51[8p11.23]); Dim Appendices 
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X2(10)(134.26[10q26.3]-134.28[10q26.3]); Dim(12)(34.42[12CEP]-132.39[12qter]); Monosomy(13)(18.07-114.12); Monosomy(14)(18.15-105.99); 
Enh(15)(18.68[15q11.2]-20.25[15q11.2]); Dim(16)(0.03[16pter]-10.97[16p13.13]); Dim(16)(34.06[16p11.2]-34.61[16p11.2]); 
Dim(16)(45.03[16q12.1]-88.69[16qter]); Dim(19)(47.99[19q13.13]-48.45[19q13.13]); Enh(22)(22.69[22q11.23]-22.73[22q11.23]); 
Dim(22)(37.68[22q13.1]-37.71[22q13.1]) 
1836  SMM  t(4;14)  Enh(1)(141.47[1q12]-245.43[1qter]); Dim(1)(145.82[1q21.1]-146.47[1q21.2]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); DimX2(2)(89.0[2p11.2]-
89.2[2p11.2]); Dim(3)(11.73[3p25.3]-12.18[3p25.2]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Dim(6)(32.56[6q21.32]-32.66[6p21.32]); Enh(6)(121.24[6q22.31]-123.33[6q22.31]); Dim(6)(123.33[6q22.31]-170.94[6qter;); Dim(8)(7.26[8p23.1]-
8.12[8p23.1]); Dim X2(8)(39.36[8p11.23]-39.51[8p11.22]); Enh(12)(11.4[12p13.2]-11.44[12p13.2]); Enh(12)(19.27[12p12.3]-19.54[12p12.3]); 
Enh(12)(50.97[12q13.13]-51.07[12q13.13]); Monosomy(13)(18.07-114.12); Dim X2(14)(105.31[14q32.33]-106.11[14q32.33]); Trisomy(15)(18.36-
100.28); Enh(16)(33.21[16p11.2]-33.54[16p11.2]); Dim(16)(54.35[16q12.2]-54.39[16q12.2]); Enh(17)(41.52[17q21.31]-41.71[17q21.31]); 
Enh(17)(77.42[17q25.3]-77.5[17q25.3]); Trisomy(19)(0.06-63.78); Trisomy(21)(13.33-46.91); Monosomy(22)(14.5-49.51); Monosomy(X)(2.69-
154.49) 
331  SMM  t(4;14)  Enh(1)(44.92[1p34.2]-45.0[1p34.2]); Enh(1)(141.47[1q12]-245.33[1qter]); Enh(2)(0.02[2pter]-91.23[2p11.2]); Dim(2)(88.99[2p11.2]-89.32[2p11.2]); 
Trisomy(3)(0.04[3pter]-199.21[3qter]); Dim(4)(0.06[4pter]-1.85[1p16.3]); Enh(4)(153.93[4q31.3]-153.99[4q31.3]); Dim(4)(91.68[4q22.1]-
91.95[4q22.1]); Dim(4)(171.36[4q33]-171.48[4q33]); Dim(1)(39.36[8p11.2]-39.51[8p11.2]); Trisomy(9)(0.15-138.4); Trisomy(10)(0.12-135.4); 
Enh(11)(64.36[11q13.1]-64.46[11q13.1]); Enh(12)(101.34[12q23.2]-101.4[12q23.2]); Monosomy(13)(18.07-114.12); Monosomy(14)(18.15-106.35); 
Dim(15)(19.81[15q11.2]-20.08[15q11.2]); Enh(16)(69.41[16q22.2]-69.75[16q22.2]); Enh(17)(9.27[17p13.1]-78.65[17qter]); Enh(19)(2.02[19p13.3]-
2.07[19p13.3]); Enh(22)(22.67[22q11.23]-22.72[22q11.23]); Dim(22)(44.87[22q13.31]-44.90[22q13.31]) 
105  SMM  t(4;14)  Dim(1)(16.99[1p36.13]-17.02[1p36.13]); Enh(1)(141.47[1q12]-146.01[1qter]); Dim(1)(145.82[1q21.1]-146.01[1q21.1]); Dim(2)(88.99[2p11.2]-
89.2[2p11.2]); Dim(4)(91.75[4q22.1]-92.2[4q22.1]); Enh(5)(37.48[5p13.2]-37.52[5p13.2]); Dim(6)(32.56[6p21.32]-32.65[6p21.32]); 
Enh(7)(38.07[7p14.1]-38.08[7p14.1]); Dim X2(7)(141.41[7q34]-141.44[7q34]); Dim(8)(39.36[8p11.22]-39.49[8p11.22]); Dim(9)(8.99[9p24.1]-
9.17[9p24.1]); Dim(11)(99.28[11q22.1]-99.52[11q22.1]); Monosomy(13)(18.07-114.12); Dim(14)(105.31[14q32.33]-105.93[14q32.33]); 
Dim(15)(32.51[15q14]-32.63[15q14]); Dim(16)(31.86[16p11.2]-34.1[16p11.2]); Enh(16)(69.41[16q22.1/.2]-69.74); Enh(17)(77.44[17q25.3]-77.52); 
Dim(19)(3.48[19p13.3]-3.49); Dim(19)(47.99[19q13.31]-48.24[19q13.31]); Dim(22)(39.27[22q13.2]-49.47[22qter]); Dim(X)(88.16[Xq21.31]-
92.1[Xq21.31]); Enh(X)(141.59[Xq27.2]-154.49[Xqter]) 
1525  SMM  t(4;14)  Dim(1)(35.11[1p35.1]-35.48[1p35.1]); Dim(1)(70.29[1p31.1]-93.76[1p21.3]); Dim(2)(88.98[2p11.2]-89.31[2p11.2]); Dim(7)(106.53[7q22.3]-
106.59[7q22.3]); Dim(8)(0.06[8pter]-32.99[8p12]); Dim(8)(39.36[8p11.22]-39.48[8p11.22]); Dim(12)(11.4[12p13.2]-11.4[12p13.2]); 
Dim(13)(18.07[13pter]-110.63[13q33.4]); Dim(14)(19.27[14q11.2]-19.49[14q11.2]); Dim(14)(56.74[14q23.1]-87.19[14q31.1]); 
Dim(14)(105.33[14q32.33]-106.14[14q32.33]); Enh(15)(19.82[15q11.2]-20.31[15q11.2]); Dim(15)(32.51[15q14]-32.61[15q14]); 
Dim(18)(0.0[18pter]-14.79[18p11.1]); Dimx2(22)(21.09[22q11.22]-21.57[22q11.22]); Enh(22)(22.68[22q11.23]-22.73[22q11.23]); 
Dim(22)(27.43[22q12.1]-28.01[22q12.2]); Ampl(22)(35.16[22q12.3]-38.95[22q13.2]); Enh(X)(71.27[Xq13.1]-154.49[Xqter]) 
837  MGUS  t(14;16)  Enh(1)(141.47[1q12]-245.33[1qter]); Dim(2)(88.98[2p11.2]-89.2[2p11.2]); Enh(2)(173.25[2q31.1]-173.48[2q31.1]); Enh(3)(164.0[3q26.1]-
164.1[3q26.1]); Enh(4)(38.57[4p14]-38.78[4p14]); Enh(6)(7.84[6p24.3]-8.07[6p24.3]); Enh(6)(109.19[6q21]-109.3[6q21]); Enh(6)(168.16[6q27]-
168.39[6q27]); Enh(8)(39.36[8p11.21]-39.51[8p11.21]); Dim(9)(0.15[9pter]-301.34[9p21.1]); Enh(9)(32.24[9p21.1]-38.61[9p13.2]); 
Dim(10)(45.49[10q11.21]-47.16[10q11.21]); Monosomy(13)(18.07-114.12); Trisomy(14)(18.15-106.35); Dim(14)(105.34[14q32.33]-
105.43[14q32.33]); Enh(15)(18.66[15q11.2]-19.43[15q11.2]); Enh(15)(63.8[15q22.31]-64.01[15q22.31]); Enh(16)(55.43[16q12.2]-55.58[16q12.2]); 
Enh(17)(41.52[17q21.31]-41.71[17q21.31]); Dim(22)(15.43[22q11]-35.1[22q12.3]); Dim X2(22)(21.43[22q11.2]-21.57[22q11.2]); Dim 
X2(22)(23.99[22q11.23]-24.23[22q11.23]); Enh(X)(98.65[Xq22.1]-154.35[Xqter]) 
582  SMM  t(14;16)  Enh(1)(16.78[1p36.13]-17.02[1p36.13]); Dim(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(2)(89.0[2p11.2]-89.15[2p11.2]); Trisomy(3)(0.04-199.38); 
Enh(4)(0.04-191.31); Enh(6)(32.56[6p21.32]-32.65[6p21.32]); Trisomy(7)(0.01-158.62); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Appendices 
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Dim(8)(140.84[8q24.3]-141.02[8q24.3]); Trisomy(9)(0.15-138.4); Dim(10)(46.4[10q11.22]-47.74[10q11.22]); Trisomy(11)(0.18-134.43); 
Trisomy(13)(18.07-114.12); Enh(14)(18.54[14q11]-34.94[14q13.2]); Dim(14)(93.51[14q32.13]-94.26[14q32.13]); Dim(14)(102.3[14q32.32]-
102.63[14q32.32]); Dim X2(14)(102.4[14q32.32]-102.52[14q32.32]); Dim(14)(1051.14[14q32.33]-105.46[14q32.33]); Enh(14)(105.97[14q32.33]-
106.31[14q32.33]); Enh(15)(18.66[15q11.2]-20.22[15q11.2]); Dim(16)(0.51[16p13.3]-0.54[16p13.3]); Enh(16)(28.49[16p11.2]-30.85[16p11.2]); 
Enh(16)(32.11[16p11.2]-33.54[16p11.2]); Dim(16)(54.35[16q12.2]-54.39[16q12.2]); Dim(16)(77.34[16q23.1]-77.52[16q23.1]); Trisomy(17)(0.03-
78.65); Trisomy(19)(0.06-63.78); Enh(22)(17.27[22q11.21]-17.33[22q11.21]); Dim(22)(20.6[22q11.22]-20.92[22q11.22]); Monosomy(X)(2.69-
154.49) 
2198  SMM  t(14;16)  Dim(2)(88.99[2p11.2]-89.14[2p11.2]); Enh(2)(96.35[2q11.2]-97.03[2q11.2]); Dim(4)(69.04[4q13.2]-70.53[4q13.2]); Enh(8)(39.36[8p11.21]-
39.51[8p11.21]); Enh(9)(68.15[9q12]-138.4[9qter]); Monosomy(13)(18.07-114.12); Enh(14)(105.02[14q32.33]-105.33[14q32.33]); 
Dim(14)(105.34[14q32.33]-105.41[14q32.33]); Dim(14)(105.96[14q32.33]-106.0[14q32.33]); Enh(14)(106.13[14q32.33]-106.35[14q32.33]); 
Dim(16)(77.19[16q23.1]-86.1[16q24.2]); Enh(19)(0.06[19pter]-19.75[19p11]); Monosomy(22)(14.5-48.87); Monosomy(X)(2.69-154.49) 
1494  MGUS  t(14;16)  Enh(1)(16.07[1p36.13]-16.14[1p36.13]); Enh(1)(103.82[1p21.1]-103.88[1p21.1]); Dim(2)(88.98[2p11.2]-89.31[2p11.2]); Dim(2)(230.92[2q37.1]-
231.93[2q37.1]); Dim(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(5)(44.22[5p12]-46.01[5p12]); Dim(5)(68.37[5q13.1]-70.78[5q13.1]); 
Dim(7)(75.86[7q11.23]-76.23[7q11.23]); Dim(7)(117.45[7q31.2]-147.29[7q36.1]); Enh(8)(142.3[8q24.3]-145.91[8q24.3]); Dim(12)(110.8[12q24.12]-
111.04[12q24.12]); Monosomy(13)(18.07-114.12); Enh(14)(18.86[14q11.2]-19.49[14q11.2]); Enh(14)(21.53[14q11.2]-22.11[14q11.2]); 
Dim(14)(30.23[14q12]-31.15[14q12]); Enh(14)(100.07[14q32.13]-101.31[14q32.13]); Enh(14)(103.62[14q32.33]-105.31[14q32.33]); 
Dim(14)(105.34[14q32.33]-105.9[14q32.33]); Dim(15)(18.84[15q11.2]-20.08[15q11.2]); Enh(15)(76.84[15q25.1]-76.89[15q25.1]); 
Enh(16)(31.96[16p11.2]-33.54[16p11.2]); Enh(22)(18.08[22q11.21]-19.03[22q11.21]); Dim(22)(21.08[22q11.22]-21.56[22q11.22]); 
Enh(X)(6.31[Xp22.31]-7.95[Xp22.31]); Enh(X)(152.07[Xq28]-153.48[Xq28]) 
1189  MGUS  t(14;16)  Dim(2)(89.01[2p11.2]-89.2[2p11.2]); Enh(11)(99.39[11q22.1]-131.77[11q25]); Dim(14)(105.52[14q32.33]-106.28[14q32.33]);  
Monosomy(X)(3.26-154.49) 
1073  SMM  t(14;16)  Enh(1)(142.61[1q12]-245.43[1qter]); Dim(2)(88.98[2p11.2]-89.11[2p11.2]); Enh(3)(185.44[3q27.2]-186.0[3q27.2]); Dim(5)(69.27[5q13.2]-
70.72[5q13.2]); Dim(5)(171.28[5q35.1]-171.4[5q35.1]); Dim(6)(109.37[6q21]-170.94[6qter]); Dim(8)(0.06[8pter]-37.6[8p12]); 
Enh(8)(39.36[8p11.22]-39.5[8p11.22]); Dim(11)(132.82[11q25]-133.38[11q25]); Monosomy(13)(18.07-114.12); Enh(14)(18.54[14q11.2]-
19.52[14q11.2]); Dim(14)(23.99[14q12]-91.7[14q32.12]); Dim(14)(105.35[14q32.33]-105.74[14q32.33]); Enh(15)(18.66[15q11.2]-20.06[15q11.2]); 
Dim(16)(69.74[16q22.2]-88.69[16qter]); Dim(17)(41.55[17q21.31]-41.98[17q21.31]); Trisomy(19)(0.06-63.78); Dim(22)(15.68[22q11.21]-
35.88[22q13.1]); Dim X2(22)(22.7[22q11.23]-22.71[22q11.23]); Monosomy(X)(2.69-154.49) 
417  MGUS  t(14;20)  Dim(1)(153.85[1q22]-153.99[1q22]); Enh(3)(164.05[3q26.1]-164.11[3q26.1]); Dim(8)(39.36[8p11.22]-39.51[8p11.22]); Monosomy(13)(18.07-
114.12); Dim(14)(18.19[14q11.2]-19.5[14q11.2]); Dim(14)(105.35[14q32.33]-106.35[14qter]); DimX2(14)(105.54[14q32.33]-105.58[14q32.33]); 
Dim(15)(19.39[15q11.2]-20.25[15q11.2]); Dim(20)(0.01[20pter]-38.01[20q12]); Monosomy(22)(14.5-49.51) 
866  SMM  t(14;20)  Dim(1)(12.8[1p36.21]-12.85[1p36.21]); Dim(1)(16.79[1p36.13]-17.02[1p36.13]); Dim(2)(88.99[2p11.2]-89.28[2p11.2]); Dim(2)(213.49[2q34]-
213.56[2q34]); Dim(2)(242.64[2q37.3]-242.67[2q37.3]); Enh(4)(69.2[4q13.2]-69.31[4q13.2]); Dim X2(5)(140.2[5q31.2]-140.22[5q31.3]); 
Dim(6)(37.92[6p21.2]-38.56[6p21.2]); Dim(8)(7.26[8p23.1]-8.12[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(10)(1.16[10p15.3]-
1.26[10p15.3]); Dim(10)(46.4[10q11.22]-47.13[10q11.22]); Monosomy(13)(18.07-114.12); Dim X2(14)(105.34[14q32.33]-105.79[14q32.33]); 
Enh(15)(18.43[15q11.2]-19.28[15q11.2]); Enh(16)(28.74[16p11.2]-29.5[16p11.2]); Monosomy(22)(14.5-18.08) 
976  MGUS  t(14;20)  Dim(1)(193.44[1q31.3]-193.53[1q31.3]); Dim(2)(89.0[2p11.2]-89.15[2p11.2]); Dim(2)(242.44[2q37.3]-242.73[2q37.3]); Enh(3)(164.0[3q26.1]-
164.1[3q26.1]); Dim(3)(193.48[3q29]-193.57[3q29]); Dim(4)(70.03[4q13.2]-70.38[4q13.2]); Enh(6)(29.96[6p21.33]-30.01[6p21.33]); 
Enh(7)(38.07[7p14.1]-38.08[7p14.1]); Dim(8)(39.36[8p11.22]-39.49[8p11.23]); Dim X2(12)(9.53[12p13.31]-9.59[12p13.31]); Monosomy(13)(18.07-
114.12); Dim X2(14)(105.33[14q32.33]-106.12[14q32.33]); Dim(15)(18.72[15q11.2]-20.22[15q11.2]); Enh(22)(22.68[22q11.23]-22.72[22q11.23]) 
367  MGUS  t(14;20)  Enh(1)(142.72[1q12]-246.36[1qter]); Dim X2(1)(193.47[1q31.3]-193.53[1q31.3]); Dim(2)(88.96[2p11.2]-89.31[2p11.2]); Dim(4)(145.18[4q31.21]-Appendices 
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145.42[4q31.21]); Enh(5)(0.74[5p15.33]-0.86[5p15.33]); Dim(6)(32.61[6p21.32]-32.63[6p21.32]); Dim(8)(7.04[8p23.1]-8.13[8p23.1]); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(12)(82.97[12q21.31]-92.99[12q22]); Dim(12)(98.65[12q23.1]-100.93[12q23.2]); 
Dim(12)(105.02[12q23.3]-107.47[12q23.3]); Dim(12)(122.65[12q24.31]-123.23[12q24.31]); Dim(12)(126.64[12q24.32]-132.2[12q24.33]); 
Dim(13)(18.07[13q11]-110.27[13q34]); Enh(14)(21.5[14q11.2]-22.2[14q11.2]); Dim X2(14)(105.4[14q32.33]-106.12[14q32.33]); 
Dim(16)(45.06[16q11.2]-88.69[16qter]); Enh(20)(1.49[20p13]-1.59[20p13]); Dim(21)(13.38[21q11.2]-13.6[21q11.2]); Dim(22)(21.5[22q11.22]-
21.57[22q11.22]) 
698  MGUS  nonHRD  Dim(1)(72.49[1p31.1]-102.25[1p21.1]); Enh(1)(141.47[1q12]-145.43[1qter]); Enh(2)(29.21[2p23.2]-81.69[2p12]); Dim(2)(89.01[2p11.2]-
89.14[2p11.2]); Enh(3)(101.83[3q12.2]-101.92[3q12.2]); Enh(3)(102.08[3q12.2]-199.38[3qter]); Dim(3)(164.02[3q26.1]-164.11[3q26.1]); 
Enh(5)(172.97[5q35.1]-173.04[5q35.2]); Dim(6)(32.56[6p21.32]-32.74[6p21.32]); Dim(7)(141.22[7q34]-141.25[7q34]); Dim(7)(143.32[7q35]-
143.51[7q35]); Dim(8)(6.93[8p23.1]-8.14[8p23.1]); Dim(8)(39.36[8p11.23]-39.51[8p11.22]); Dim(11)(7.77[11p15.4]-7.78[11p15.4]); 
Enh(12)(7.88[12p13.31]-8.06[12p13.31]); Monosomy(13)(18.07-114.12); Enh(14)(60.45[14q23.1]-64.26[14q23.2]); Dim(14)(64.27[14q23.3]-
106.35[14qter]); Dim X2(14)(105.33[14q32.33]-105.63[14q32.33]); Dim(15)(18.81[15q11.2]-20.08[15q11.2]); Dim(20)(13.4[20p12.1]-
13.54[20p12.1]); Dim(Y)(2.69-57.37) 
1581  SMM  nonHRD, 
unid IgH 
rearr 
Enh(1)(141.47[1q12]-245.43[1qter]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(2)(88.98[2p11.2]-89.11[2p11.2]); Enh(2)(91.06[2p11.2]-
91.45[2p11.2]); Enh(3)(166.18[3q26.2]-167.91[3q26.2]); Enh(6)(0.1[6pter]-38.96[6p21.2]); Dim X2(6)(32.59[6p21.32]-32.73[6p21.32]); 
Dim(6)(151.52[6q25.1]-170.94[6qter]); Dim(7)(0.14[7pter]-16.94[7p21.1]); Dim(8)(7.04[8p23.1]-8.14[8p23.1]); Dim(8)(39.36[8p11.22]-
39.51[8p11.22]); Dim X2(11)(5.74[11p15.4]-5.76[11p15.4]); Monosomy(13)(18.07[13pter]-114.12[13qter]); Dim(14)(68.33[14q24.1]-
105.76[14q32.33]); Dim(15)(32.52[15q14]-32.65[15q14]); Enh(16)(10.61[16p13.13]-11.95[16p13.13]); Enh(16)(32.21[16p11.2]-33.53[16p11.2]); 
Dim(16)(45.02[16q11.2]-88.69[16qter]); Enh(16)(69.41[16q22.1]-69.75[16q22.2]); Enh(17)(16.12[17p12]-17.56[17p11.2]); 
Dim(17)(41.52[17q21.31]-41.84[17q21.31]); Enh(17)(41.84[17q21.31]-42.14[17q21.31]); Enh(19)(15.81[19p13.12]-16.89[19p13.11]); 
Dim(22)(21.06[22q11.22]-21.58[22q11.22]); Dim(22)(37.68[22q13.1]-37.71[22q13.1]); Enh(X)(137.57[Xq27.1]-154.49[Xqter]); Dim(Y)(2.69-57.37) 
2326  MGUS  nonHRD  Dim(4)(69.07[4q13.2]-69.64[4q13.2]); Dim(9)(22.2[9p22.1]-22.42[9p22.1]); Dim(14)(77.62[14q24.3]-87.26[14q31.3]); Dim(14)(105.32[14q32.33]-
105.32[14q32.33]); Enh(16)(55.22[16q13]-55.28[16q13]) 
844  MGUS  t(11;14)  Dim(1)(16.79[1p36.13]-17.0[1p36.13]); Dim X2(2)(34.61[2p22.3]-34.64[2p22.3]); Dim(2)(88.99[2p11.2]-89.11[2p11.2]); Enh(3)(35.78[3p22.3]-
35.9[3p23]); Enh(5)(32.15[5p13.3]-32.2[5p13.3]); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); Enh(6)(168.16[6q27]-168.4[6q27]); Dim 
X2(8)(39.36[8p11.22]-39.51[8p11.22]); Dim X2(13)(56.66[13q21.1]-56.67[13q21.1]); Dim(14)(73.08[14q24.3]-73.12[14q24.3]); 
Dim(14)(105.35[14q32.33]-105.42[14q32.33]); Dim X2(14)(105.6[14q32.33]-105.63[14q32.33]) 
355  SMM  t(6;14)  Enh(1)(1.14[1p36.33]-1.18[1p36.33]); Dim(1)(16.8[1p36.13]-16.99[1p36.13]); Dim(2)(34.61[2p22.3]-34.64[2p22.3]); Dim(2)(89.0[2p11.2]-
89.2[2p11.2]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Enh(5)(0.74[5p15.33]-0.9[5p15.33]); 
Dim(6)(29.96[6p22.1]-30.01[6p21.33]); Dim X2(6)(32.57[6p21.32]-32.67[6p21.32]); Dim(8)(7.26[8p23.1]-7.79[8p23.1]); Enh(8)(39.36[8p11.22]-
39.51[8p11.22]); Trisomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); Enh(12)(11.4[12p13.2]-11.43[12p13.2]); Monosomy(13)(18.07-114.12); 
Enh(14)(18.19[14q11.1]-19.4[14q11.2]); Monosomy(14)( 18.15-106.35); Dim X2(14)(105.31[14q32.33]-106.16[14q32.33]); Enh(16)(31.86[16p11.2]-
33.54[16p11.2]); Dim(16)(34.69[16q11.2]-88.09[16q24.3]); Dim X2(16)(54.35[16q12.2]-54.38[16q12.2]); Enh(17)(76.89[17q25.3]-76.95[17q25.3]); 
Enh(17)(77.42[17q25.3]-77.5[17q25.3]); Trisomy(X)(2.69-154.49) 
999  MGUS  t(11;14)  Dim(1)(246.79[1q44]-246.88[1q44]); Dim(4)(69.06[4q13.2]-246.88[4q13.2]); Dim X2(6)(32.56[6p21.32]-32.61[6p21.32]); Dim 
X2(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(11)(68.8[11q13.2]-133.98[11qter]); Dim X2(12)(9.53[12p13.31]-9.63[12p13.31]); Monosomy(13)(18.07-
113.76); Enh(14)(18.62[14q11.1]-19.51[14q11.1]); Enh(15)(18.44[15q11.2]-19.99[15q11.2]) 
Enh(16)(31.84[16p11.2]-34.61[16p11.2]); Dim(17)(41.58[17q21.31]-41.71[17q21.31]); Enh(22)(22.68[22q11.23]-22.73[22q11.23]) 
855  MGUS  t(11;14)  Dim X2(1)(88.94[2p11.2]-89.22[2p11.2]); Enh(5)(0.74[5p15.33]-0.86[5p15.33]); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); Enh(8)(39.37[8p11.22]-
39.54[8p11.22]); Enh(10)(46.47[10q11.22]-46.57[10q11.22]); Enh(11)(68.91[11q13.2]-134.32[11qter]); Enh(14)(18.62[14q11.1]-19.54[14q11.2]); Appendices 
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Dim X2(14)(105.33[14q32.33]-105.82[14q32.33]); Enh(15)(18.72[15q11.2]-20.08[15q11.2]); Dim(22)(20.85[22q11.22]-21.57[22q11.22]); 
Monosomy(X)(2.71-154.39) 
795  MGUS  t(11;14)  Dim(1)(12.76[1p36.21]-12.84[1p36.21]); Dim(1)(187.6[1q31.1]-187.81[1q31.1]); Dim(2)(35.38[2p22.3]-35.54[2p22.3]); Dim(2)(88.93[2p11.2]-
89.09[2p11.2]); Dim X2(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(4)(69.06[4q13.2]-69.17[4q13.2]); Dim X2(7)(141.41[7q34]-141.45[7q34]); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(11)(0.18[11pter]-77.82[11q14.1]); Dim X2(14)(73.07[14q24.3]-73.09[14q24.3]); 
Dim(14)(105.33[14q32.33]-105.41[14q32.33]); Enh(15)(18.66[15q11.2]-19.99[15q11.2]); Enh(16)(31.86[16p11.2]-34.06[16p11.2]); Dim 
X2(22)(22.68[22q11.23]-22.73[22q11.23] 
610  MGUS  t(11;14)  Dim X2(2)(88.92[2p11.2]-89.1[2p11.2]); Enh(5)(32.15[5p13.3]-32.22[5p13.3]); Enh(11)(68.97[11q13.3]-134.2[11qter]); Dim(14)(105.28[14q32.33]-
106.06[14q32.33]); Enh(22)(41.23[22q13.2]-41.28[22q13.2]); Monosomy(X)(2.71-154.39) 
695  MGUS  t(11;14)  Dim(4)(69.06[4q13.2]-69.17[4q13.2]); Enh(6)(32.56[6p21.32]-32.67[6p21.32]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(11)(5.74[11p15.4]-
5.76[11p15.4]); Dim(12)(10.46[12p13.31]-10.49[12p13.31]); Dim(14)(105.25[14q32.33]-105.9[14q32.33]); Dim(16)(0.03[16pter]-10.93[16p13.13]); 
Dim(16)(45.02[16q11.2]-88.67[16qter]); Dim(20)(19.71[20p11.23]-19.82[20p11.23]); Dim(22)(21.07[22q11.22]-21.58[22q11.22]) 
1822  SMM  HRD  Enh(1)(181.83[1q31.1]-195.8[1q32.1]); Enh(1)(245.05[1q44]-245.13[1q44]); Dim(2)(242.63[2q37.3]-242.68[2q37.3]); Trisomy(3)(0.04-199.38); 
Trisomy(5)(0.01-180.64); Dim(8)(0.53[8p23.3]-0.63[8p23.3]); Enh(8)(2.31[8p23.2]-2.6[8p23.3]); Enh(8)(39.36[8p11.23]-39.51[8p11.23]); 
Trisomy(9)(0.15-138.4); Dim(10)(46.4[10q11.22]-46.56[10q11.22]); Trisomy(11)(0.18-134.43); Monosomy(13)(18.07-114.12); 
Monosomy(14)(18.15-106.35); Dim X2(14)(105.34[14q32.33]-105.96[14q32.33]); Tetrasomy(15)(18.36-100.28); Trisomy(19)(0.06-63.78); 
Trisomy(21)(9.9-46.91); Dim X2(22)(22.68[22q11.23]-22.72[22q11.23]); Monosomy(X)(2.69-154.49) 
865  MGUS  HRD  Enh(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(2)(88.99[2p11.2]-89.27[2p11.2]); Trisomy(3)(0.04-199.29); Dim X2(3)(46.77[3p21.31]-46.83[3p21.31]); 
Dim X2(4)(69.2[4q13.2]-69.31[4q13.3]); Trisomy(5)(0.08-180.64); Trisomy(6)(0.1-170.94); Trisomy(7)(0.14-158.62); Enh(8)(39.36[8p11.22]-
39.51[8p11.22]); Enh(9)(21.16[9p21.3]-21.21[9p21.3]); Trisomy(11)(0.18-134.43); Dim(11)(5.74[11p15.4]-5.76[11p15.4]); Dim(11)(7.77[11p15.4]-
7.78[11p15.4]); Monosomy(13)(18.07-1141.12); Dim X2(13)(56.66[13q21.1]-56.67[13q21.1]); Dim(14)(105.34[14q32.33]-105.88[14q32.33]); 
Trisomy(15)(18.36-100.28); Trisomy(17)(0.03-78.65); Trisomy(19)(0.06-63.78); Enh(X)(152.21[Xq28]-152.62[Xq28]) 
528  MGUS  HRD  Dim X2(1)(25.35[1p36.11]-25.41[1p36.11]); Enh(1)(142.57[1q12]-245.43[1qter]); Dim(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(1)(245.05[1q44]-
245.13[1q44]); Dim(2)(89.0[2p11.2]-89.11[2p11.2]); Dim(4)(69.2[4q13.2]-69.82[4q13.2]); Dim(4)(70.33[4q13.2]-70.53[4q13.2]); Trisomy(5)(0.08-
180.64); Trisomy(6)(0.1-170.94); Trisomy(7)(0.14-158.62); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(8)(125.79[8q24.13]-128.61[8q24.13]); 
Trisomy(9)(0.15-138.4); Monosomy(13)(18.07-114.12); Dim(14)(18.54[14q11.1]-18.62[14q11.1]); Dim(14)(105.14[14q32.33]-105.58[14q32.33]); 
Trisomy(15)(20.31-100.28); Trisomy(19)(0.06-63.78); Trisomy(21)(14.31-46.91); Enh(22)(36.38[22q13.1]-36.43[22q13.1]); Monosomy(X)(2.69-
154.49) 
911  MGUS  HRD  Dim(1)(145.82[1q21.1]-145.99[1q21.1]); Dim(2)(88.99[2p11.2]-89.94[2p11.2]); Trisomy(3)(0.04-199.38); Dimx2(3)(164.0[3q26.1]-164.1[3q26.1]); 
Trisomy(5)(0.08-180.64); Dim(6)(32.6[6p21.32]-32.63[6p21.32]); Dim X2(6)(79.04[6q14.1]-79.08[6q14.1]); Trisomy(7)(0.14-158.62); 
Dim(8)(3.91[8p23.2]-6.66[8p23.1]); Dim(8)(39.36[8p11.23]-39.51[8p11.22]); Trisomy(9)(0.15-138.4); Monosomy(13)(18.07-114.12); 
Enh(14)(18.64[14q11.1]-19.48[14q11.1]); Dim(14)(73.08[14q24.3]-73.11[14q24.3]); Dim(14)(105.34[14q32.33]-105.42[14q32.33]); 
Dim(14)(105.6[14q32.33]-105.63[14q32.33]); Dim(14)(105.67[14q32.33]-106.35[14q32.33]); Tetrasomy(15)(18.36-100.28); Enh(16)(33.21[16p11.2]-
33.54[16p11.2]); Dim(17)(41.53[17q21.31]-42.05[17q21.31]); Tetrasomy(19)(0.06-63.78); Trisomy(21)(14.49-46.91); Dim(22)(20.72[22q11.22]-
21.56[22q11.22]); Dim(22)(22.67[22q11.23]-22.72[22q11.23]); Monosomy(X)(2.7-154.49) 
403  SMM  HRD  Trisomy(3)(0.04-199.38); Trisomy(5)(0.08-180.64); Trisomy(7)(0.14-158.62); Trisomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); 
Dim(14)(19.27[14q11.2]-19.5[14q11.2]); Dim(14)(103.61[14q32.33]-105.33[14q32.33]); Trisomy(15)(18.36-100.28); Enh(17)(77.39[17q25.3]-
77.61[17q25.3]); Trisomy(19)(0.21-63.78); Trisomy(21)(14.31-46.91); Enh(22)(17.27[22q11.21]-17.34[22q11.21]); Dim(22)(21.08[22q11.22]-
21.58[22q11.22]); Enh(22)(44.82[22q13.31]-44.87[22q13.31]); Dim(X)(43.9[Xp11.3]-43.91[Xp11.3]); Enh(X)(151.82[Xq28]-153.47[Xq28]) 
1473  MGUS  HRD  Dim(2)(88.99[2p11.2]-89.14[2p11.2]); Trisomy(3)(0.04-199.38); Trisomy(5)(0.08-180.64); Dim(6)(79.04[6q14.1]-79.08[6q14.1]); Appendices 
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Dim(8)(7.04[8p23.1]-8.15[8p23.1]); Dim(8)(39.36[8p11.23]-39.47[8p11.23]); Trisomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); 
Enh(12)(56.43[12q13.3]-56.46[12q13.3]); Dim(14)(105.34[14q32.33]-105.42[14q32.33]); Trisomy(15)(19.14-100.28); Dim(17)(41.53[17q21.31]-
41.65[17q21.31]); Trisomy(19)(0.06-63.78); Enh(X)(3.31[Xp22.33]-3.59[Xp22.33]);  
121  MGUS  HRD  Dim X2(1)(72.49[1p31.1]-72.51[1p31.1]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(1)(158.32[1q23.3]-158.37[1q23.3]); 
Dim(1)(244.97[1q44]-245.43[1qter]); Dim(2)(15.29[2p24.3]-15.43[2p24.3]); Dim(2)(88.98[2p11.2]-89.2[2p11.2]); Enh(3)(164.0[3q26.1]-
164.1[3q26.1]); Trisomy(5)(0.08-180.64); Dim(5)(140.2[5q31.2]-140.22[5q31.3]); Dim(6)(32.6[6p21.32]-32.63[6p21.32]); Trisomy(7)(0.14-158.62); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Trisomy(9)(0.15-138.4); Dim(13)(73.26[13q22.1]-73.34[13q22.1]); Dim(14)(105.14[14q32.33]-
105.45[14q32.33]); Trisomy(15)(18.36-100.28); Trisomy(18)(0.0-76.11); Trisomy(19)(0.06-63.78); Dim(22)(21.03[22q11.22]-21.58[22q11.22]); 
Monosomy(X)(2.7-154.49) 
396  MGUS  HRD  Dim(1)(83.33[1p31.1]-83.58[1p31.1]); Dim(2)(89.01[2p11.2]-91.04[2p11.2]); Trisomy(3)(0.04-199.38); Trisomy(5)(0.08-180.64); 
Dim(5)(69.77[5q13.2]-70.7[5q13.2]); Dim(6)(29.96[6p22.1]-30.02[6p22.1]); Dim(6)(32.6[6p21.32]-32.63[6p21.32]); Dim(8)(7.26[8p23.1]-
8.12[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Trisomy(9)(0.15-138.4); Dim(10)(46.38[10q11.22]-47.03[10q11.22]); Trisomy(11)(0.18-
134.43); Dim(12)(7.92[12p13.31]-8.01[12p13.31]); Dim X2(13)(56.66[13q21.1]-56.67[13q21.1]); Dim X2(14)(105.33[14q32.33]-105.42[14q32.33]); 
Enh(15)(20.8[15q11.2]-100.28[15qter]); Dim(17)(41.53[17q21.31]-41.71[17q21.31]); Enh(18)(0.32[18p11.32]-0.7[18p11.32]); Trisomy(19)(0.06-
63.78); Dim(20)(30.39[20q11.21]-30.47[20q11.21]); Trisomy(21)(13.33-46.91); Dim(X)(88.11[Xq21.31]-91.69[Xq21.32]) 
989  MGUS  HRD  Dim(1)(16.88[1p36.13]-17.13[1p36.13]); Dim(1)(59.84[1p32.1]-62.70[1p31.3]); Dim(1)(88.59[1p22.2]-94.29[1p22.1]); Dim(1)(95.53[1p21.3]-
113.44[1p13.2]); Dim(1)(114.05[1p13.2]-120.47[1p11.1]); Enh(1)(159.78[1q23.3]-159.91[1q23.3]); Dim(2)(88.96[2p11.2]-89.03[2p11.2]); 
Trisomy(3)(0.04-199.38); Dim(4)(5.24[4p16.1]-37.14[4p14]); Dim(4)(70.18[4q13.2]-70.30[4q13.3]); Trisomy(5)(0.08-180.64); 
Enh(6)(35.57[6p21.32]-32.67[6p21.32]); Dim(6)(88.91[6q15]-170.47[6qter]); Enh(7)(0.14[7pter]-89.08[7q21.13]); Dim(7)(89.11[7q21.13]-
91.40[7q21.2]); Enh(7)(91.40[7q21.2]-100.54[7q22.1]); Dim(7)(100.55[7q22.1]-104.38[7q22.2]); Enh(7)(104.40[7q22.2]-158.57[7qter]); 
Dim(8)(0.63[8pter]-47.06[8p11.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(9)(0.15[9pter]-44.17[9p11.1]); Enh(10)(45.48[10q11.21]-
46.57[10q11.21]); Enh(11)(0.18[11pter]-87.08[11q14.2]); Dim(11)(55.12[11q11.2]-55.20[11q11.1]); Enh(11)(90.04[11q14.3]-134.35[11qter]); 
Enh(12)(9.53[12p13.31]-9.63[12p13.31]); Dim(12)(18.36[12q23.1]-98.62[12q23.1]); Dim(14)(19.27[14q11.2]-19.48[14q11.2]); 
Dim(14)(105.35[14q32.33]-105.45[14q32.33]); Dim X2(14)(105.60[14q32.33]-105.63[14q32.33]); Dim X2(14)(105.96[14q32.33]-106.00[14q32.33]); 
Trisomy(15); Enh(16)(31.81[16p11.2]-32.75[16p11.2]); Enh(17)(77.41[17q25.3]-77.56[17q25.3]); Trisomy(19); Dim(20)(31.80[20q11.22]-
50.18[20q13.2]); Trisomy(21); Enh X2(X)(92.36[Xq21.32]-154.14[Xqter]) 
2879  MGUS  HRD  Trisomy(3)(0.04-199.19); Dim(4)(69.07[4q13.2]-69.17[4q13.2]); Trisomy(5)(0.08-180.44); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); 
Enh(6)(150.2[6q25.1]-150.39[6q25.1]); Trisomy(7)(0.14-158.81); Enh(8)(37.85[8p12]-38.28[8p12]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); 
Enh(8)(145.06[8q24.3]-145.09[8q24.3]); Tetrasomy(9)(0.15-140.02); Trisomy(11)(0.18-134.36); Enh(14)(42.8[14q21.3]-43.29[14q21.3]); 
Dim(14)(105.31[14q32.33]-105.43[14q32.33]); Tetrasomy(15)(18.36-100.16); Trisomy(17)(0.03-78.65); Tetrasomy(19)(0.06-63.78) 
719  MM  t(4;14)  Enh (1)(141.47[1q12]-245.43[1qter]); Enh(1)(141.47[1q21]-181.76[1q31.3]); Enh(1)(197.82[1q32.1]-209.02[1q41]); Enh(1)(232.14[1q42.3]-
245.43[1qter]); Dim(2)(89.0[2p11.2]-8.11[2p11.2]); Dim(4)(0.04[4pter]-37.68[4p14]); Dim(5)(68.85[5q13.2]-70.69[5q13.2]); Dim(5)(118.33[5q23.1]-
118.63[5q23.1]); Dim(6)(32.56[6p21.32]-32.73[6p21.32]); Dim(6)(124.2[6q22.31]-124.96[6q22.31]); Dim(6)(149.16[6q25.1]-155.54[6q25.3]); 
Dim(6)(167.09[6q27]-170.94[6q27]); Enh(7)(81.85[7q21.11]-158.62[7qter]); Dim(8)(39.34[8p11.22]-39.48[8p11.22]); Dim(9)(8.71[9p23]-
17.75[9p22.2]); Enh(10)(46.37[10q11.22]-47.99[10q11.22]); Dim(11)(79.86[11q14.1]-104.4[11q22.3]); Monosomy(13)(18.07-114.12); Dim 
X2(13)(47.79[13q14.2]-48.0[13q14.2]); Dim(14)(105.32[14q32.33]-105.95[14q32.33]); Dim(15)(18.86[15q11.2]-19.79[15q11.2]); 
Dim(15)(32.51[15q14]-32.59[15q14]); Dim(16)(3.18[16p13.3]-9.13[16p13.2]); Enh(17)(0.07[17pter]-10.04[17p13.1]); Enh(17)(14.94[17p12]-
28.88[17q11.2]); Enh(17)(38.26[17q21.31]-78.65[17qtel]); Dim(20)(14.63[20p12.1]-14.71[20p12.1]); Dim X2(X)(21.34[Xp22.11]-21.37[Xp22.11]); 
Dim(X)(88.46[Xq21.31]-92.1[Xq21.32]); Dim(Y)(2.69-57.37) 
604  MM  t(4;14)  Enh X2(1)(141.47[1q12.1]-245.43[1qter]); Dim(2)(88.98[2p11.2]-89.16[2p11.2]); Dim(2)(180.3[2q31.2]-180.35[2q31.2]); Dim(4)(69.2[4q13.2]-Appendices 
  221 
69.79[4q13.2]); Dim(4)(81.79[4q21.21]-81.91[4q21.21]); Dim(5)(163.28[5q34]-163.52[5q34]); Dim(6)(32.59[6p21.32]-32.72[6p21.32]); 
Dim(7)(138.83[7q34]-139.12[7q34]); Dim(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(8)(67.65[8q13.1]-68.11[8q13.1]); Dim(9)(116.58[9q33.1]-
116.68[9q33.1]); Enh(10)(46.37[10q11.22]-47.99[10q11.22]); Dim (10)(64.74[10q21.3]-64.83[10q21.3]); Monosomy(13)(18.07-114.12); 
Dim(14)(19.27[14q11.2]-19.49[14q11.2]); Enh(14)(21.53[14q11.2]-22.26[14q11.2]); Dim(14)(105.31[14q32.33]-106.28[14q32.33]); 
Dim(16)(5.35[16p13.3]-9.96[16p13.2]); Trisomy(19)(0.06-63.78); Dim(22)(21.38[22q11.22]-21.6[22q11.22]); Dim(X)(90.19[Xq21.31]-
91.69[Xq21.31]); Dim(Y)(3.43[Yp11.31]-6.82[Yp11.2]) 
1148  MM  t(4;14)  Dim(1)(185.86[1q31.1]-186.57[1q31.1]); Dim(1)(215.11[1q41]-238.02[1q43]); Dim(2)(233.86[2q37.2]-234.0[2q37.2]); Enh(3)(0.04[3pter]-
68.9[3p14.1]); Enh(3)(85.53[3p12.1]-199.38[3qter]); Dim(4)(26.26[4p15.2]-26.37[4p15.2]); Dim(4)(70.28[4q13.3]-70.5[4q13.3]);  
Dim(4)(103.15[4q24]-103.38[4q24]); Dim(4)(168.26[4q32.3]-168.95[4q32.3]); Dim(4)(175.67[4q34.1]-177.2[4q34.1]); Dim(4)(188.78[4q35.2]-
188.88[4q35.2]); Dim(5)(90.6[5q14.3]-91.12[5q14.3]); Dim(5)(94.04[5q15]-94.07[5q15]); Dim(5)(94.35[5q15]-94.81[5q15]); Enh X2(6)(0.1[6pter]-
90.01[6q15]); Enh X2(6)(91.13[6q15]-97.13[6q16.1]); Dim(7)(76.77[7q21.11]-76.94[7q21.11]); Dim(7)(109.96[7q31.1]-110.05[7q31.1]); 
Dim(8)(84.02[8q21.13]-84.16[8q21.13]); Dim(8)(134.48[8q24.22]-134.65[8q24.22]); Dim(10)(0.12[1opter]-7.81[10p14]); Dim(10)(20.36[10p12.31]-
21.14[10p12.31]); Enh(12)(50.98[12q13.13]-51.09[12q13.13]); Dim(13)(18.07[13q12.11]-20.3[13q12.11]); Dim(13)(26.49[13q12.2]-33.95[13q13.2]); 
Dim(13)(51.06[13q14.3]-51.18[13q14.3]); Dim(13)(56.31[13q21.1]-76.92[13q22.3]); Dim X2(13)(63.16[13q21.31]-63.24[13q21.31]); 
Dim(13)(110.24[13q34]-110.58[13q34]); Dim(14)(49.28[14q21.3]-49.33[14q21.3]); Dim(14)(49.46[14q21.3]-99.33[14q32.2]); 
Dim(14)(105.31[14q32.33]-106.29[14q32.33]); Enh(15)(18.41[15q11.2]-33.31[15q14]); Enh(15)(39.2[15q15.1]-42.93[15q15.3]); 
Enh(15)(47.06[15q21.1]-50.96[15q21.3]); Enh(15)(85.81[15q25.3]-88.62[15q26.1]); Dim(15)(88.74[15q26.1]-88.8[15q26.1]); 
Enh(15)(95.37[15q25.2]-98.14[15q26.3]); Enh(16)(4.32[16p13.3]-4.38[16p13.3]); Dim(17)(0.12[17pter]-1.01[17p13.3]); Enh(17)(1.11[17p13.3]-
2.08[17p13.3]); Dim(17)(2.09[17p13.3]-2.84[17p13.3]); Dim(17)(3.04[17p13.2]-3.07[17p13.2]); Enh(17)(3.14[17p13.2]-5.82[17p13.2]); 
Amplified(17)(4.74[17p13.2]-5.68[17p13.2]); Dim(17)(5.87[17p13.2]-9.17[17p13.1]); Enh(17)(9.17[17p13.1]-9.27[17p13.1]); 
Dim(17)(9.27[17p13.1]-9.42[17p13.1]); Enh(17)(9.42[17p13.1]-10.21[17p13.1]); Dim(17)(10.22[17p13.1]-13.04[17p12]); Enh(17)(13.55[17p12]-
14.13[17p12]); Dim(17)(14.14[17p12]-15.28[17p12]); Dim(17)(19.65[17p11.2]-21.21[17p11.2]); Enh(17)(22.34[17p11.1]-24.41[17q11.2]); 
Dim(17)(24.45[17q11.2]-24.71[17q11.2]); Enh(17)(26.76[17q11.2]-26.93[17q11.2]); Dim(17)(27.55[17q11.2]-28.25[17q11.2]); 
Dim(18)(1.08[18p11.32]-6.36[18p11.31]); Dim(18)(6.4[18p11.31]-9.82[18p11.22]); Enh(18)(9.83[18p11.22]-20.5[18q11.2]); 
Dim(18)(20.52[18q11.2]-31.27[18q12.1]); Enh(18)(31.28[18q12.2]-32.06[18q12.2]); Dim(18)(32.07[18q12.2]-36.2[18q12.3]); Dim(18)(72.39[18q23]-
72.52[18q23]); Trisomy(19)(0.06-63.78); Dim(22)(14.88[22q11.11]-30.19[22q12.3]); Enh(X)(113.86[Xq23]-115.42[Xq23]); Dim(X)(115.44[Xq23]-
115.9[Xq23]); Enh(X)(115.94[Xq23]-154.49[Xqter]); Dim(Y)(2.77[Yp11.31]-6.78[Yp11.2]) ; Dim(Y)(2.69-57.37) 
342  MM  t(4;14)  Dim(1)(77.99[1p31.1]-78.18[1p31.1]); Enh(1)(141.47[1q21.1]-245.43[1qter]); Enh(1)(141.47[1q21.1]-183.00[1q31.1]); Enh(2)(0.02[2pter]-
91.57[2p11.1]); Dim(2)(89.0[2p11.2]-89.32[2p11.2]); Dim(2)(183.12[2q31.3]-183.22[2q32.1]); Enh(3)(48.55[3p21.31]-48.67[3p21.31]); 
Dim(3)(79.08[3p12.3]-79.15[3p12.3]); Dim(3)(85.71[3p12.1]-85.92[3p12.1]); Dim(3)(164.0[3q36.1]-164.1[3q36.1]); Dim(4)(40.81[4p13]-
41.01[4p13]); Dim(4)(69.2[4q13.2]-69.82[4q13.2]); Dim(4)(190.86[4q35.2]-191.05[4q35.2]); Dim(5)(0.08[5pter]-33.32[5p13.2]); 
Dim(6)(26.26[6p22.1]-26.34[6p22.1]); Dim(6)(74.42[6q13]-170.74[6qter]); Dim(7)(3.61[7p22.2]-3.77[7p22.2]); Dim(7)(151.38[7q36.2]-
151.55[7q36.2]); Dim(8)(0.06[8pter]-112.27[8q23.3]); Dim(11)(34.04[11p13]-34.17[11p13]); Dim(11)(72.44[11q13.4]-72.55[11q14.3]); 
Dim(11)(76.93[11q13.5]-77.7[11q13.5]); Dim(12)(12.72[12p13.1]-12.78[12p13.1]); Monosomy(13)(18.07-114.12); Monosomy(14)(18.15-106.35); 
Dim(15)(68.68[15q23]-68.88[15q23]); Dim(16)(10.69[16p13.3]-10.82[16p13.13]); Enh(16)(69.41[16q22.2]-69.74[16q22.2]); Dim(18)(0.0[18pter]-
15.32[18p11]); Dim(20)(34.75[20q11.23]-35.58[20q11.23]); Dim X2(20)(34.84[20q11.23]-34.97[20q11.23]); Dim(20)(40.65[20q12]-40.65[20q12]); 
Dim(X)(87.81[Xq21.31]-92.1[Xq21.32]); Dim(Y)(2.69-57.37) 
374  MM  t(4;14)  Dim(1)(25.52[1p36.11]-25.81[1p36.11]); Dim(1)(50.62[1p32.3]-51.3[1p32.3]); Dim X2(1)(51.12[1p32.3]-51.25[1p32.3]); Dim(1)(85.84[1p22.3]-
95.16[1p21.3]); Enh(1)(141.47[1q21.1]-245.43[1qter]); Enh(1)(141.47[1q21.1]-179.25[1q25.3]); Dim(2)(88.99[2p11.2]-89.47[2p11.2]); 
Dim(2)(97.15[2q11.2]-97.71[2q11.2]); Dim(2)(108.66[2q13]-111.61[2q13]); Dim(2)(122.08[2q14.3]-122.7[2q14.3]); Dim(2)(123.41[2q14.3]-Appendices 
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124.99[2q14.3]); Enh(2)(185.51[2q32.1]-198.45[2q33.1]); Dim(3)(75.47[3p12.3]-76.02[3p12.3]); Enh(3)(164.02[3q26.1]-164.11[3q26.1]); 
Dim(3)(173.33[3q26.31]-173.59[3q26.31]); Dim(4)(0.04[4pter]-1.24[4p16]); Enh(5)(1.05[5p15.33]-1.2[5p15.33]); Dim(5)(85.37[5q14.3]-
85.63[5q14.3]); Enh(6)(0.33[6pter]-43.72[6p21.1]); Trisomy(7)(0.14-158.62); Dim(8)(0.06[8pter]-35.59[8p12]); Dim(8)(39.36[8p11.22]-
39.54[8p11.22]); Dim(9)(9.68[9p23]-10.01[9p23]); Enh(9)(68.13[9q12]-138.40[9qter]); Dim(10)(0.12[10pter]-8.23[10p14]); Dim(10)(15.12[10p13]-
18.77[10p12.31]); Dim(10)(22.99[10p12.2]-23.99[10p12.2]); Enh(10)(41.93[10q11.21]-135.4[10qter]); Monosomy(13)(18.07-114.12); 
Dim(14)(18.15[14pter]-105.99[14q32.33]); Dim (15)(18.45[15q11.2]-20.25[15q11.2]); Dim(18)(0.0[18pter]-15.32[18p11.21]); Monosomy(22)(14.5-
49.51); Monosomy(X)(2.69-154.49) 
1875  MM  t(4;14)  Enh(1)(141.47[1q12]-245.43[1qter]); Dim(2)(88.98[2p11.2]-89.11[2p11.2]); Enh(4)(40.54[4p14]-40.62[4p14]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Dim(5)(69.74[5q13.2]-70.34[5q13.2]); Dim(6)(16.51[6p22.3]-17.01[6p22.3]); Dim(8)(0.06[8pter]-35.52[8p12]); Dim(8)(39.36[8p11.23]-
39.51[8p11.22]); Dim(9)(11.81[9p23]-12.19[9p23]); Enh(10)(46.38[10q11.22]-47.74[10q11.22]); Dim(10)(116.86[10q25.3]-117.7[10q25.3]); 
Dim(11)(55.12[11q11]-55.21[11q11]); Monosomy(13)(18.07-114.12); Dim X2(13)(54.75[13q21.1]-55.07[13q21.1]); Enh(14)(18.86[14q11.2]-
19.49[14q11.2]); Dim(14)(44.6[14q21.2]-44.77[14q21.2]); Dim(14)(4619[14q21.3]-46.27[14q21.3]); Dim(14)(57.54[14q23.1]-86.96[14q31.3]); 
Dim(14)(105.28[14q32.33]-1059.99[14q32.33]); Enh(15)(18.43[15q11]-20.08[15q11]); Dim(17)(42.86[17q21.32]-43.02[17q21.32]); 
Dim(20)(0.01[20pter]-26.16[20p11]); Dim X2(22)(20.88[22q11.22]-21.57[22q11.22]); Dim(22)(22.7[22q11.23]-22.71[22q11.23]); 
Monosomy(X)(2.69-154.49) 
52  MM  t(4;14)  Dim(1)(91.68[1p22.1]-98.86[1p21.3]); Dim(1)(99.82[1p21.2]-105.54[1p21.1]); Dim(2)(88.99[2p11.2]-89.27[2p11.2]); Enh(3)(12.31[3p25.2]-
19.01[3p24.3]); Enh(4)(1.83[4p16.3]-26.51[4p15.2]); Dim(4)(95.11[4q22.3]-124.36[4q28.1]); Dim(6)(136.12[6q23.3]-168.98[6q27]); 
Dim(8)(0.06[8pter]-43.65[8p11.1]); Dim(12)(0.03[12pter]-30.39[12p11.22]); Dim(12)(49.02[12q13.12]-49.1[12q13.12]); Monosomy(13)(18.07-
114.12); Dim(14)(30.54[14q12]-105.42[14q32.3]); Enh(14)(105.42[14q32.33]-106.35[14qter]); Dim(15)(33.58[15q14]-38.39[15q14]); 
Dim(17)(0.03[17pter]-13.39[17p12]); Dim(17)(17.73[17p11.2]-22.32[17p11.2]); Dim(17)(77.42[17q25.3]-77.69[17q25.3]); Dim(20)(0.01[20pter]-
25.47[20p11.1]); Dim(20)(596.55[20q13.33]-62.38[20qter]); Monosomy(22)(15.45-49.51); Dim(X)(2.72[Xpter]-125.55[Xq25]); Dim(Y)(2.69-57.37) 
665  MM  t(4;14)  Dim(1)(45.89[1p34.1]-117.9[1p12]); Dim X2(1)(50.13[1p331]-51.88[1p32.3]); Dim X2(1)(89.28[1p22.2]-90.85[1p22.2]); Enh(2)(0.02[2pter]-
81.03[2p12]); Dim(2)(81.15[2p12]-84.24[2p12]); Dim X2(2)(88.98[2p11.2]-89.33[2p11.2]); Enh(3)(0.04[3pter]-54.2[3p14.3]); 
Dim(3)(176.92[3q26.32]-177.29[3q26.32]); Enh(5)(0.08[5pter]-28.09[5p14.1]); Dim(5)(58.37[5q11.2]-180.64[5qter]); Dim X2(6)(32.56[6p21.32]-
32.6[6p21.32]); Dim(6)(115.34[6q22.1]-170.94[6qter]); Enh(7)(69.51[7q11.22]-158.62[7qter]); Dim(8)(2.21[8p23.2]-5.97[8p23.2]); 
Dim(8)(85.39[8q21.2]-85.57[8q21.2]); Dim(9)(0.15[9pter]-32.16[9p21.1]); Enh(9)(32.93[9p13.3]-43.95[9p11.2]); Dim(10)(46.41[10q11.22]-
46.57[10q11.22]); Enh(11)(88.05[11q14.3]-134.43[11qter]); Dim(12)(6.37[12p13.31]-20.57[12p12.1]); Monosomy(13)(18.07-114.12); 
Dim(14)(19.27[14q11.2]-19.5[14q11.2]); Dim(14)(28.13[14q12]-29.03[14q12]); Enh(14)(30.04[14q12]-31.57[14q12]); Dim(14)(31.59[14q12]-
95.37[14q32.2]); Dim(14)(98.84[14q32.2]-106.35[14qter]); Dim X2(14)(105.41[14q32.33]-106.12[14q32.33]); Dim(17)(0.03[17pter]-22.13[17p11.2]); 
Dim(18)(0.0[18pter]-15.11[18p11.21]); Trisomy(19)(0.06-63.78); Dim(20)(0.01[20pter]-16.07[20p12.1]); Enh(20)(29.39[20q11.21]-63.03[20qter]); 
Monosomy(22); Dim X2(22)(21.43[22q11.22]-21.57[22q11.22]) 
1172  MM  t(4;14)  Dim X2(1)(145.82[1q21.1]-146.01[1q21.1]); Dim(1)(199.09[1q32.1]-199.29[1q32.1]); Dim(1)(245.05[1q44]-245.13[1q44]); Dim X2(2)(89.0[2p11.2]-
89.34[2p11.2]); Dim(3)(59.61[3p14.2]-59.8[3p14.2]); Dim(3)(70.0[3p13]-78.56[3p12.3]); Dim(3)(133.82[3q22.1]-133.86[3q22.1]); 
Dim(3)(167.47[3q26.1]-168.5[3q26.2]); Dim(4)(108.1[4q24]-109.28[4q25]); Dim(4)(131.3[4q28.3]-132.24[4q28.3]); Enh(5)(32.09[5p13.3]-
32.2[5p13.3]); Dim(5)(58.72[5q11.2]-58.93[5q11.2]); Dim(5)(98.04[5q21.1]-138.09[5q31.2]); Dim(6)(97.12[6q16.1]-97.21[6q16.1]); 
Dim(7)(0.14[7pter]-16.44[7p21.1]); Dim(12)(0.03[12pter]-56.43[12q14.1]); Monosomy(13)(18.07-114.12); Dim(16)(0.03[16pter]-8.52[16p13.12]); 
Enh(16)(27.2[16p11.2]-31.41[16p11.2]); Dim(18)(0.0[18pter]-18.86[18q11.2]); Dim(18)(20.21[18q11.2]-20.93[18q11.2]); Dim(22)(14.79[22q11.1]-
34.36[22q12.3]); Dim X2(X)(75.92[Xq21.1]-75.99[Xq21.1]); Enh(X)(114.95[Xq23]-154.49[Xqter]); Dim(Y)(2.69-57.37) 
2458  MM  t(4;14)  Enh X2(1)(141.47[1q12]-245.43[1qter]); Dim X2(2)(89.0[2p11.2]-89.27[2p11.2]); Dim(3)(85.91[3p12.1]-85.97[3p12.1]); Dim(4)(69.2[4q13.2]-
69.79[4q13.2]); Dim(5)(21.85[5p14.3]-22.08[5p14.3]); Dim(5)(79.94[5q14.1]-80.01[5q14.1]); Dim(6)(32.57[6p21.32]-32.6[6p21.32]); Appendices 
  223 
Dim(6)(35.61[6p21.31]-35.78[6p21.31]); Dim(6)(102.29[6q16.3]-102.49[6q16.3]); Enh(7)(14.66[7p21.1]-15.39[7p21.1]); Enh(7)(128.03[7q31.32]-
128.16[7q31.32]); Dim(7)(151.38[7q36.1]-151.55[7q36.2]); Dim(8)(0.06[8p23.3]-0.96[8p23.3]); Dim(8)(6.43[8p23.1]-41.8[8p11.21]); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(8)(55.7[8q12.1]-129.55[8q24.21]); Enh(8)(142.08[8q24.3]-145.79[8q24.3]); Enh(12)(56.43[12q14.1]-
56.47[12q14.1]); Monosomy(13)(18.07-114.12); Dim X2(14)(105.41[14q32.33]-106.23[14q32.33]); Enh(18)(37.32[18q12.3]-62.79[18q22.1]); 
Enh(22)(18.08[22q11.21]-19.11[22q11.21]); Monosomy(X)(2.69-154.49) 
756  MM  t(4;14)  Dim(1)(72.84[1p31.1]-76.02[1p31.1]); Dim(1)(83.99[1p31.1]-14.47[1p11.1]); Enh(1)(141.47[1q12]-245.43[1qter]); Dim X2(1)(195.02[1q31.3]-
195.06[1q31.3]); Dim(2)(88.99[2p11.2]-89.33[2p11.2]); Dim(3)(122.31[3q13.33]-122.4[3q13.33]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); 
Dim(4)(0.04[4pter]-1.83[4p16.3]); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); Dim(8)(0.06[8pter]-39.64[8p11.22]); Enh(8)(39.36[8p11.22]-
39.51[8p11.22]); Enh(8)(122.52[8q24.13]-128.84[8q24.21]); Enh(8)(138.31[8q24.23]-140.0[8q24.23]); Monosomy(12)(0.03-132.39); 
Monosomy(14)(18.15[14pter]-105.45[14q32.33]); Enh(15)(18.66[15q11.2]-20.08[15q11.2]); Enh(16)(31.96[16p11.2]-33.54[16p11.2]); 
Dim(17)(7.26[17p13.1]-7.75[17p13.1]); Dim(18)(25.63[18q12.1]-27.3[18q12.1]); Enh(19)(0.6[19p13.3]-0.63[19p13.3]); Dim(X)(2.69[Xp22.33]-
127.44[Xq25]); Enh(X)(128.0[Xq25]-154.49[Xqter]) 
KMS-11  Cell-line  t(4;14)  Dim(1)(27.4[1p35.3]-47.31[1p33]); Dim X2(1)(47.93[1p33]-51.95[1p32.3]); Enh(1)(51.98[1p32.3]-52.64[1p32.3]); Dim(1)(54.88[1p32.2]-
59.66[1p32.1]); Enh(1)(59.71[1p32.1]-60.15[1p32.1]); Dim(1)(60.15[1p32.1]-97.99[1p21.3]); Enh(1)(98.0[1p21.2]-98.73[1p21.2]); 
Dim(1)(98.73[1p21.2]-109.29[1p13.3]); Enh(1)(109.31[1p13.3]-110.41[1p13.3]); Dim(1)(110.42[1p13.2]-120.22[1p11.2]); Enh(1)(141.47[1q21.1]-
164.81[1q24.2]); Enh(1)(171.5[1q24.2]-214.95[1q41]); Dim(2)(0.02[2pter]-28.96[2p23.2]); Dim(2)(52.4[2p16.3]-53.95[2p16.2]); 
Dim(2)(88.99[2p11.2]-91.12[2p11.2]); Enh(2)(91.18[2p11.2]-91.32[2p11.2]); Dim(2)(94.77[2q11.2]-151.8[2q23.3]); Enh(2)(151.8[2q23.3]-
153.96[2q24.1]); Dim(2)(153.96[2q24.1]-154.34[2q24.1]); Enh(2)(154.36[2q24.1]-159.84[2q24.2]); Dim(2)(159.84[2q24.2]-171.7[2q31.1]); 
Dim(2)(187.8[2q32.1]-242.78[2qter]); Dim(3)(0.04[3pter]-113.32[3q13.2]); Dim(4)(0.04[4pter]-49.42[4p12]); Dim(4)(69.2[4q13.2]-69.79[4q13.2]); 
Dim(5)(21.07[5p14.3]-49.6[5p12]); Enh(5)(98.92[5q21.1]-102.11[5q21.1]); Dim(5)(102.21[5q21.1]-180.64[5qter]); Monosomy(6)(0.1-170.94); 
Dim(7)(17.57[7p21.1]-18.44[7p21.1]); Enh(7)(71.45[7q11.23]-71.74[7q11.23]); Enh(7)(111.98[7q31.1]-158.62[7qter]); Dim(8)(0.06[8pter]-
59.58[8q12.1]); Enh(8)(73.54[8q13.3]-75.0[8q21.11]); Dim(8)(76.96[8q21.11]-87.64[8q21.3]); Enh(8)(91.39[8q21.3]-101.72[8q22.3]); 
Dim(8)(112.65[8q23.3]-116.44[8q23.3]); Dim(8)(129.62[8q24.21]-137.66[8q24.23]); Enh(8)(137.66[8q24.23]-138.59[8q24.23]); 
Dim(8)(138.61[8q24.23]-146.0[8qter]); Dim(9)(0.15[9pter]-64.14[9p11.1]); Dim(9)(123.98[9q33.3]-125.83[9q33.3]); Dim(10)(41.93[10q11.21]-
135.4[10qter]); Dim(11)(0.18[11pter]-74.99[11q13.5]); Enh(11)(85.28[11q14.2]-86.53[11q14.2]); Dim(11)(86.56[11q14.3]-134.43[11qter]); 
Dim(12)(1.61[12p13.33]-29.72[12p11.22]); Enh(12)(51.8[12q13.13]-81.8[12q21.31]); Dim(12)(81.81[12q21.31]-132.39[12qter]); Dim 
X2(12)(117.07[12q24.23]-117.19[12q24.23]); Monosomy(13)(18.07-114.12); Dim(14)(18.15[14q11.2]-104.98[14q32.33]); 
Dim(14)(105.22[14q32.33]-106.35[14q32.33]); Monosomy(15)(19.81-100.28); Dim(16)(45.07[16q12.1]-88.69[16qter]); Enh(16)(69.41[16q22.1]-
69.74[16q22.1]); Dim X2(16)(76.74[16q23.1]-77.79[16q23.1]); Dim(17)(0.03[17pter]-22.13[17p11.1]); Dim(17)(30.09[17q12]-32.43[17q12]); 
Dim(17)(38.33[17q21.31]-38.58[17q21.31]); Dim(17)(41.52[17q21.33]-44.06[17q22]); Dim(18)(0.0[18pter]-17.95[18q11.2]); 
Enh(18)(39.32[18q12.3]-76.11[18qter]); Dim(19)(0.06[19pter]-32.55[19p12]); Dim(19)(51.09[19q13.32]-63.78[19q13.43]); Dim(20)(0.01[20pter]-
29.3[20q11.21]); Enh(20)(47.33[20q13.13]-62.38[20qter]); Monosomy(22)(14.5-49.51); Monosomy(X)(2.69-154.49) 
551  MM  t(14;16)  Enh(1)(21.34[1p36.12]-22.9[1p36.12]); Enh(1) X2(141.47[1q12]-245.43[1qter]); Dim(2)(88.98[2p11.2]-89.34[2p11.2]); Dim(3)(163.98[3q26.1]-
164.25[3q26.1]); Enh(3)(170.54[3q26.2]-172.25[3q26.2]); Dim(6)(34.56[6p21.31]-35.29[6p21.31]); Enh(8)(39.36[8p11.22]-39.5[8p11.22]); 
Dim(9)(21.85[9p21.3]-22.02[9p21.3]); Enh(12)(46.99[12q13.11]-48.59[12q13.11]); Dim(12)(48.65[12q13.12]-50.04[12q13.12]); 
Dim(12)(74.69[12q21.2]-132.26[12qter]); Monosomy(13)(18.07-114.12); Enh(14)(21.37[14q11.2]-22.02[14q11.2]); Dim(14)(22.15[14q11.2]-
22.49[14q11.2]); Dim(14)(72.31[14q24.2]-74.96[14q24.2]); Dim(14)(90.28[14q32.12]-90.88[14q32.12]); Dim(14)(102.09[14q32.32]-
102.86[14q32.32]); Dim(14)(105.34[14q32.33]-106.35[14q32.33]); Enh(15)(18.72[15q11.2]-20.22[15q11.2]); Dim(15)(91.31[15q26.1]-
91.34[15q26.1]); Dim(16)(45.06[16q11.2]-77.62[16q23.1]); Enh(16)(69.41[16q22.1]-69.75[16q22.3]); Enh(19)(1.81[19p13.3]-2.77[19p13.3]); 
Dim(22)(16.0[22q11.1]-30.45[22q12.3]) Appendices 
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1336  MM  t(14;16)  Dim(1)(16.99[1p36.13]-24.24[1p36.11]); Dim(1)(45.59[1p34.1]-52.2[1p32.3]); Dim X2(1)(49.91[1p33]-51.76[1p32.3]); Enh(1)(117.3[1p12]-
117.69[1p12]); Enh(1) X2(141.47[1q12]-245.43[1qter]); Dim(2)(88.98[2p11.2]-89.32[2p11.2]); Dim(3)(25.93[3p24.2]-4.77[3p21.31]); 
Enh(5)(61.63[5q12.1]-70.34[5q13.2]); Dim(5)(70.69[5q13.2]-83.62[5q14.3]); Enh(6)(14.7[6p22.3]-57.13[6p12.1]); Dim(6)(90.07[6q15]-
117.81[6q22.31]); Dim(8)(39.36[8p11.21]-39.51[8p11.21]); Dim(9)(20.92[9p21.3]-22.45[9p21.3]); Enh(11)(60.24[11q12.2]-65.87[11q13.2]); 
Dim(11)(65.88[11q13.2]-72.95[11q13.4]); Dim(11)(94.78[11q21]-106.14[11q22.3]); Dim X2(11)(101.06[11q22.1]-103.02[11q22.3]); 
Monosomy(13)(18.07-114.12); Dim(14)(19.27[14q11.2]-19.49[14q11.2]); Enh(14)(70.19[14q24.2]-70.24[14q24.2]); Dim(14)(105.34[14q32.33]-
105.62[14q32.33]); Enh(16)(55.45[16q13]-55.52[16q13]); Enh(16)(69.41[16q22.1]-69.74[16q22.1]); Monosomy(22)(14.5-49.51); Dim 
X2(22)(21.09[22q11.22]-21.56[22q11.22]); Dim(X)(88.11[Xq21.31]-92.21[Xq21.31]); Dim(Y)(2.69-57.37) 
309  MM  t(14;16)  Dim(1)(83.29[1p31.1]-83.38[1p31.1]); Dim(1)(93.28[1p22.1]-118.36[1p12]); Dim(1)(193.47[1q31.3]-193.56[1q31.3]); Dim(1)(210.93[1q41]-
239.34[1q43]); Enh(3)(164.02[3q26.1]-164.10[3q26.1]); Dim(4)(5.95[4p16.2]-6.95[4p16.2]); Enh(4)(7.1[4p16.1]-7.2[4p16.1]); Enh(4)(7.5[4p16.1]-
7.72[4p16.1]); Enh(4)(7.95[4p16.1]-8.37[4p16.1]); Dim(4)(8.38[4p16.1]-8.83[4p16.1]); Dim(4)(15.83[4p15.33]-15.89[4p15.33]); 
Dim(4)(16.72[4p15.32]-22.07[4p15.31]); Dim(4)(22.21[1p15.31]-25.64[1p15.2]); Dim(4)(33.02[4p15.1]-34.41[4p15.1]); Enh(4)(35.52[4p14]-
37.63[4p14]); Dim(6)(84.01[6q14.2]-106.95[6q21]); Dim(8)(0.17[8pter]-41.03[8p11.21]); Dim(9)(0.15[9pter]-4.84[9p24.1]); Dim(9)(20.62[9p21.3]-
30.96[9p21.1]); Dim(11)(66.28[11q13.2]-67.74[11q13.2]); Dim(11)(71.74[11q13.4]-73.71[11q13.4]); Dim(11)(82.83[11q14.1]-87.32[11q14.2]); 
Dim(11)(92.28[11q21]-110.37[11q23.1]); Dim X2(11)(97.01[11q22.1]-103.61[11q22.3]); Dim(11)(133.71[11q25]-134.43[11q25]); 
Dim(16)(2.42[16p13.3]-8.89[16p13.13]); Dim(16)(23.96[16p12.2]-26.58[16p12.1]); Dim(16)(34.13[16p11.2]-35.01[16p11.2]); 
Enh(16)(45.47[16q12.1]-62.07[16q21]); Dim(16)(77.55[16q23.1]-88.69[16qter]); Enh(17)(41.52[17q21.31]-41.7[17q21.31]); 
Dim(21)(13.46[21q11.2]-16.05[21q21.1]); Dim(22)(21.4[22q11.22]-21.55[22q11.22]); Monosomy(X)(2.69-154.49) 
2068  MM  t(14;16)  Dim(1)(35.39[1p34.3]-35.43[1p34.3]); Enh(1)(141.47[1q12]-167.53[1q24.3]); Dim(1)(167.59[1q24.3]-200.42[1q32.1]); Enh(1)(200.45[1q32.1]-
245.43[1qter]); Dim(2)(89.05[2p11.2]-89.94[2p11.2]); Dim(4)(70.33[4q13.2]-70.47[4q13.3]); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); 
Enh(9)(68.15[9q13]-138.21[9qter]); Dim(12)(101.72[12q23.1]-104.29[12q23.1]); Monosomy(13)(18.07-114.03); Enh(14)(18.86[14q11.2]-
19.48[14q11.2]); Enh(14)(105.02[14q32.33]-105.24[14q32.33]); Dim(14)(105.34[14q32.33]-105.95[41q32.33]); Dim(15)(19.54[15q11.2]-
20.39[15q11.2]); Dim(16)(3.09[16p13.3]-10.23[16p13.12]); Enh(16)(31.96[16p11.2]-33.53[16p11.2]); Dim(16)(45.06[16q12.1]-64.72[16q22.1]); 
Enh(16)(69.42[16q22.2]-69.74[16q22.2]); Dim(16)(77.26[16q23.1]-77.48[16q23.1]); Dim(17)(41.53[17q21.31]-42.18[17q21.31]); 
Dim(22)(21.38[22q11.22]-21.51[22q11.22]); Dim(22)(27.43[22q12.1]-27.58[22q12.1]) 
954  MM  t(14;16)  Dim(1)(3.6[1p36.32]-19.88[1p36.12]); Dim(1)(51.41[1p32.3]-101.06[1p21.1]); Dim(1)(105.01[1p21.1]-141.47[1p11.2]); Enh(1)(141.47[1q12]-
245.33[1qter]); Dim(2)(111.72[2q13]-126.6[2q14.3]); Dim(2)(143.48[2q22.3]-150.49[2q23.2]); Dim(2)(171.64[2q31.1]-175.87[2q31.1]); 
Dim(2)(178.5[2q31.2]-183.73[2q32.1]); Dim(2)(220.26[2q35]-225.54[2q36.3]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(3)(146.09[3q24]-
149.68[3q24]); Dim(6)(32.59[6p21.32]-32.65[6p21.32]); Dim(7)(1.83[7p22.3]-1.91[7p22.3]); Dim(7)(21.16[7p15.3]-26.98[7p15.2]); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(10)(134.9[10q26.3]-135.05[10q26.3]); Dim(11)(77.46[11q14.1]-107.56[11q22.3]); 
Dim(13)(18.69[13q11]-45.53[13q14.13]); Dim(13)(105.28[13q33.2]-107.26[13q33.3]); Dim(14)(105.34[14q32.33]-106.28[14q32.33]); 
Enh(16)(31.96[16p11.2]-33.76[16p11.2]); Dim(16)(77.21[16q23.1]-77.32[16q23.1]); Enh(17)(77.44[17q25.3]-77.5[17q25.3]); 
Dim(22)(21.0[22q11.22]-21.53[22q11.22]); Dim(X)(2.69[Xpter]-96.87[Xq21.33]) 
1798  MM  t(14;16)  Dim(1)(35.13[1p34.3]-36.16[1p34.3]); Dim(1)(91.02[1p22.2]-93.79[1p22.1]); Enh(1)(146.97[1q21.2]-148.25[1q21.2]); Enh(1)(149.99[1q21.3]-
150.75[1q21.3]); Dim(1)(15.21[1q22]-152.4[1q22]); Enh(1)(152.75[1q22]-153.34[1q22]); Enh(1)(170.41[1q24.3]-171.32[1q25.1]); 
Enh(1)(180.02[1q25.3]-180.82[1q25.3]); Enh(1)(205.95[1q32.2]-206.72[1q32.2]); Dim(2)(32.03[2p22.3]-32.92[2p22.3]); Dim(2)(60.75[2p15]-
62.32[2p15]); Dim(2)(88.98[2p11.2]-89.11[2p11.2]); Enh(2)(113.51[2q14.1]-113.88[2q14.1]); Dim(3)(47.07[3p21.31]-48.35[3p21.31]); 
Enh(4)(153.22[4q31.3]-154.33[4q31.3]); Dim(5)(133.98[5q31.1]-134.25[5q31.1]); Dim(5)(68.36[5q13.2]-70.86[5q13.2]); Dim(6)(62.04[6q11.2]-
170.94[6qter]); Dim(7)(4.72[7p22.1]-5.03[7p22.1]); Dim(7)(5.53[7p22.1]-6.64[7p22.1]); Dim(8)(0.17[8pter]-43.52[8p11.21]); Enh(8)(39.36[8p11.22]-
39.5[8p11.22]); Dim(9)(0.15[9pter]-14.77[9p22.3]); Dim(9)(20.14[9p21.3]-26.59[9p21.2]); Dim(9)(31.63[9p21.1]-32.61[9p21.1]); Appendices 
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Dim(9)(129.74[9q34.11]-129.98[9q34.11]); Dim(12)(52.04[12q13.13]-52.12[12q13.13]); Dim(12)(78.54[12q21.31]-78.6[12q21.31]); 
Dim(12)(97.32[12q23.1]-97.55[12q23.1]); Enh(14)(21.53[14q11.2]-22.15[14q11.2]); Dim(15)(18.74[15q11.2]-20.08[15q11.2]); 
Dim(15)(56.8[15q21.3]-57.14[15q21.3]); Enh(19)(15.99[19p13.11]-16.66[19p13.11]); Dim(19)(19.6[19p12]-22.21[19p12]); 
Dim(19)(37.84[19q13.11]-38.31[19q13.11]); Dim(19)(39.28[19q13.11]-39.71[19q13.11]); Dim(19)(41.9[19q13.12]-42.21[19q13.12]); 
Enh(22)(24.8[22q12.1]-25.79[22q12.1]); Dim(X)(142.27[Xq27.2]-142.61[Xq27.2]) 
2125  MM  t(14;16)  Dim(1)(83.38[1p31.1]-83.57[1p31.1]); Dim(1)(91.42[1p22.1]-115.39[1p13.1]); Dim(2)(89.05[2p11.2]-89.32[2p11.2]); Dim(2)(230.93[2q37.1]-
231.44[2q37.1]); Enh(3)(164.04[3q26.1]-164.11[3q26.1]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Dim X2(4)(70.33[4q13.2]-70.53[4q13.2]); 
Dim(5)(68.84[5q13.2]-70.7[5q13.2]); Dim(6)(57.34[6p11.2]-57.6[6p11.2]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Monosomy(13)(18.07-114.12); 
Dim(14)(29.87[14q12]-95.37[14q32.2]); Dim(14)(105.41[14q32.33]-105.9[14q32.33]); Enh(17)(77.27[17q25.3]-77.65[17q25.3]); 
Dim(22)(21.0[22q11.22]-21.54[22q11.22]); Monosomy(X)(2.69-154.49) 
282  MM  t(14;16)  Dim(1)(0.6[1pter]-101.92[1p21.1]); Dim(1)(105.89[1p21.1]-120.96[1p11.1]); Enh(1) X2(141.47[1q12]-245.33[1qter]); Monosomy(2)(0.02-242.78); 
Deeper Dim(2)(0.02[2pter]-5.06[2p25.2]); Dim X2(2)(88.98[2p11.2]-89.95[2p11.2]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(3)(196.93[3q29]-
196.97[3q29]); Dim(5)(142.99[5q31.3]-156.11[5q33.3]); Dim(6)(32.56[6p21.32]-32.74[6p21.32]); Dim(6)(62.04[6q11.1]-170.94[6qter]); 
Dim(7)(0.14[7pter]-16.37[7p21.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(8)(137.76[8q24.23]-137.92[8q24.23]); Dim(9)(92.09[9q22.31]-
92.12[9q22.31]); Enh(10)(46.57[10q11.22]-47.17[10q11.22]); Monosomy(11)(0.18-134.43); Dim(12)(0.03[12pter]-25.63[12p12.1]); 
Dim(12)(26.65[12p12.1]-52.52[12q13.13]); Dim(12)(53.66[12q13.2]-54.07[12q13.2]); Dim(12)(56.61[12q13.2]-58.02[12q14.1]); 
Dim(12)(58.96[12q14.1]-132.39[12qter]); Dim(13)(18.07[13q11]-64.57[13q21.31]); Dim(13)(66.51[13q21.32]-66.86[13q21.32]); 
Enh(14)(21.37[14q11.2]-22.02[14q11.2]); Dim(14)(105.33[14q32.33]-105.96[14q32.33]); Enh(15)(18.68[15q11.2]-20.22[15q11.2]); 
Dim(15)(76.47[15q25.1]-100.28[15qter]); Dim(16)(0.03[16pter]-11.71[16p13.13]); Dim(16)(14.96[16p13.11]-15.02[16p13.11]); 
Dim(16)(32.38[16p11.2]-88.69[16qter]); Dim X2(16)(77.23[16q23.1]-77.26[16q23.1]); Dim(17)(0.03[17pter]-13.88[17p12]); Enh(17)(14.03[17p12]-
17.45[17p11.2]); Amplified(17)(15.8[17p12]-17.11[17p11.2]); Dim(17)(18.7[17p11.2]-19.65[17p11.2]); Dim(21)(9.9[21p11.2]-32.74[21p22.11]); 
Dim(22)(14.5[22q11.1]-32.33[22q12.3]); Dim X2(22)(21.0[22q11.22]-21.56[22q11.22]) 
2314  MM  t(14;20)  Enh(1)(16.68[1p36.13]-16.98[1p36.13]); Dim(1)(25.32[1p36.11]-25.41[1p36.11]); Dim(1)(72.54[1p31.1]-120.23[1p11.2]); Enh(1)(158.27[1q23.3]-
158.38[1q23.3]); Dim(1)(245.05[1q44]-245.13[1q44]); Dim(2)(88.99[2p11.2]-89.33[2p11.2]); Dim(3)(58.99[3p14.2]-119.55[3q13.32]); 
Enh(3)(120.09[3q13.33]-199.38[3qter]); Dim(4)(69.2[4q13.2]-69.79[4q13.2]); Enh(6)(32.57[6p21.32]-32.6[6p21.32]); Dim(6)(81.89[6q14.1]-
170.94[6qter]); Dim X2(8)(39.36[8p11.23]-39.51[8p11.22]); Monosomy(13)(18.07-114.12); Dim(15)(19.79[15q11.2]-20.08[15q11.2]); 
Enh(16)(0.76[16p13.3]-0.83[16p13.3]); Dim(16)(45.02[16q11.2]-88.69[16qter]); Enh(17)(31.46[17q12]-31.5[17q12]); Dim(22)(21.38[22q11.22]-
21.58[22q11.22]); Dim(X)(2.69[Xp22.33]-99.34[Xq22.1]); Enh(X)(138.76[Xq27.1]-139.03[Xq27.1]) 
1890  MM  t(14;20)  Dim(8)(7.26[8p23.1]-7.79[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(15)(32.54[15q14]-32.68[15q14]) 
3004  MM  nonHRD, 
unid IgH 
rearr 
Dim(1)(108.73[1p13.3]-120.96[1p11.1]); Enh(1)(141.47[1q12]-245.43[1qter]); Dim(1)(142.47[1q21.1]-142.52[1q21.1]); Dim(1)(145.73[1q21.2]-
146.51[1q21.2]); Dim(1)(245.08[1q44]-245.13[1q44]); Dim X2(2)(89.0[2p11.2]-91.06[2p11.2]); Enh(5)(0.73[5p15.33]-0.92[5p15.33]); 
Enh(6)(32.52[6p21.32]-32.74[6p21.32]); Dim(8)(7.26[8p23.1]-8.12[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(12)(59.75[12q14.1]-
105.31[12q23.3]); Enh(12)(122.42[12q24.31]-122.58[12q24.31]); Dim(13)(18.07[13q12.11]-19.86[13q12.11]); Enh(13)(19.86[13q12.11]-
20.2[13q12.11]); Dim(13)(20.2[13q12.11]-27.1[13q12.2]); Enh(13)(27.1[13q12.2]-28.06[13q12.3]); Dim(13)(28.06[13q12.3]-94.14[13q32.1]); 
Enh(13)(94.15[13q32.1]-101.41[13q33.1]); Dim(13)(101.42[13q33.1]-103.37[13q33.2]); Enh(13)(103.37[13q33.2]-103.73[13q33.2]); 
Dim(13)(103.77[13q33.2]-113.05[13q34]); Enh(13)(113.05[13q34]-113.66[13q34]); Dim(13)(113.77[13q34]-114.12[13q34]); 
Dim(14)(35.97[14q13.2]-38.12[14q13.3]); Dim(14)(60.05[14q23.1]-63.44[14q23.2]); Dim(14)(66.61[14q23.3]-96.32[14q32.2]); 
Dim(14)(105.33[14q32.33]-105.9[14q32.33]); Dim(16)(31.96[16p11.2]-34.1[16p11.2]); Dim(16)(71.02[16q22.2]-71.33[16q22.2]); 
Dim(16)(73.3[16q23.1]-74.02[16q23.1]); Dim(16)(74.17[16q23.1]-74.19[16q23.1]); Monosomy(22)(14.5-49.51) 
1581  MM  nonHRD,  Enh(1)(141.47[1q12]-245.43[1qter]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(2)(88.98[2p11.2]-89.11[2p11.2]); Enh(2)(91.06[2p11.2]-Appendices 
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unid IgH 
rearr 
91.45[2p11.2]); Enh(3)(166.18[3q26.2]-167.91[3q26.2]); Enh(6)(0.1[6pter]-38.96[6p21.2]); Dim X2(6)(32.59[6p21.32]-32.73[6p21.32]); 
Dim(6)(151.52[6q25.1]-170.94[6qter]); Dim(7)(0.14[7pter]-16.94[7p21.1]); Dim(8)(7.04[8p23.1]-8.14[8p23.1]); Dim(8)(39.36[8p11.22]-
39.51[8p11.22]); Dim X2(11)(5.74[11p15.4]-5.76[11p15.4]); Monosomy(13)(18.07[13pter]-114.12[13qter]); Dim(14)(68.33[14q24.1]-
105.76[14q32.33]); Dim(15)(32.52[15q14]-32.65[15q14]); Enh(16)(10.61[16p13.13]-11.95[16p13.13]); Enh(16)(32.21[16p11.2]-33.53[16p11.2]); 
Dim(16)(45.02[16q11.2]-88.69[16qter]); Enh(16)(69.41[16q22.1]-69.75[16q22.2]); Enh(17)(16.12[17p12]-17.56[17p11.2]); 
Dim(17)(41.52[17q21.31]-41.84[17q21.31]); Enh(17)(41.84[17q21.31]-42.14[17q21.31]); Enh(19)(15.81[19p13.12]-16.89[19p13.11]); 
Dim(22)(21.06[22q11.22]-21.58[22q11.22]); Dim(22)(37.68[22q13.1]-37.71[22q13.1]); Enh(X)(137.57[Xq27.1]-154.49[Xqter]); Dim(Y)(2.69-57.37) 
619  MM  nonHRD, 
unid IgH 
rearr 
Dim(1)(0.6[1pter]-141.47[1p11.1]); Enh(1)(141.47[1q12]-245.43[1qter]); Dim X2(2)(89.0[2p11.2]-89.32[2p11.2]); Enh(2)(91.12[2p11.2]-
91.45[2p11.2]); Dim(2)(225.23[2q36.2]-225.31[2q36.2]); Dim(2)(236.48[2q37.2]-242.78[2qter]); Dim(3)(77.74[3[12.3]-77.78[3p12.3]); 
Enh(3)(164.02[3q26.1]-164.11[3q26.1]); Dim X2(5)(68.87[5q13.2]-70.69[5q13.2]); Dim X2(6)(32.56[6p21.32]-32.73[6p21.32]); 
Dim(7)(69.28[7q11.22]-69.68[7q11.22]); Dim(7)(104.19[7q22.2]-104.27[7q22.2]); Dim(7)(110.57[7q31.1]-110.64[7q31.1]); Enh(8)(39.36[8p11.23]-
39.51[8p11.22]); Trisomy(9)(0.15-138.4); Enh(12)(9.53[12p13.31]-9.63[12p13.31]); Monosomy(13)(18.07-114.12); Dim X2(13)(47.82[13q14.2]-
47.93[13q14.2]); Dim(14)(93.97[14q32.13]-94.0[14q32.13]); Dim X2(14)(105.31[14q32.33]-105.9[14q32.33]); Enh(15)(18.66[15q11.2]-
20.08[15q11.2]); Enh(15)(35.53[15q14]-100.28[15qter]); Dim(16)(3.6[16p13.3]-3.88[16p13.3]); Dim(16)(45.02[16q11.2]-88.69[16qter]); Dim 
X2(16)(52.18[16q12.2]-52.5[16q12.2]); Dim(17)(1.65[17p13.3]-1.75[17p13.3]); Monosomy(22)(14.5-49.51); Dim X2(22)(37.68[22q13.1]-
37.71[22q13.1]); Dim(X)(2.69[Xp22.33]-138.72[Xq27.1]); Enh(X)(138.72[Xq27.1]-154.49[Xqter]) 
1037  MM  t(8;14), 
nonHRD 
Dim(1)(81.28[1p31.1]-106.95[1p13.3]); Enh(1)(153.02[1q21.3]-212.5[1q41]); Dim(1)(230.39[1q42.3]-244.87[1q44]); Enh(1)(245.09[1q44]-
245.43[1q44]); Dim(2)(89.0[2p11.2]-89.27[2p11.2]); Enh(3)(111.07[3q13.13]-128.23[3q21.3]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Enh(5)(0.08[5pter]-64.32[5q12.3]); Enh(5)(142.34[5q31.3]-180.64[5q35.3]); Enh(6)(0.1[6pter]-38.92[6p21.2]); Dim(6)(138.23[6q24.1]-
155.19[6q25.3]); Enh(7)(52.25[7p12.1]-131.85[7q33]); Dim(8)(0.06[8pter]-128.47[8q24.21]); Dim(10)(0.13[10pter]-9.35[10p14]); 
Dim(11)(35.33[11p15.4]-3.91[11p13]); Enh(11)(134.43[11q12.1]-59.32[11qter]); Dim(12)(8.13[12p13.31]-29.6[12p11.22]); Dim(12)(70.43[12q21.1]-
101.18[12q23.2]); Dim(13)(18.07[13q11]-75.53[13q22.2]); Dim(14)(44.76[14q21.2]-44.89[14q21.2]); Trisomy(15)(18.36-100.28); 
Dim(17)(70.79[17q25.1]-70.89[17q25.1]); Monosomy(18)(0.0-76.11); Enh(X)(102.99[Xq22.2]-103.14[Xq22.2]) 
666  MM  nonHRD  Dim(1)(59.72[1p32.1]-59.77[1p32.1]); Dim(1)(83.36[1p31.1]-83.58[1p31.1]); Enh(2)(73.77[2p13.2]-73.87[2p13.1]); Dim X2(2)(88.99[2p11.2]-
89.32[2p11.2]); Dim(2)(226.9[2q36.3]-242.78[2qter]); Enh(3)(48.58[3p21.31]-48.68[3p21.31]); Dim(3)(164.0[3q36.1]-164.11[3q36.1]); 
Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Enh(5)(131.75[5q31.1]-180.64[5qter]); Dim X2(5)(180.34[5q35.3]-180.37[5q35.3]); Enh(6)(0.1[6pter]-
149.34[6q25.1]); Dim X2(6)(32.56[6p21.32]-32.73[6p21.32]); Dim X2(6)(79.04[6q14.1]-79.08[6q14.1]); Dim(6)(149.34[6q25.1]-170.94[6qter]); 
Enh(7)(4.87[7p22.1]-4.97[7p22.1]); Enh(7)(7.92[7p21.3]-8.08[7p21.3]); Dim(7)(151.38[7q36.1]-151.58[7q36.1]); Enh(8)(39.37[8p11.22]-
39.51[8p11.22]); Enh(8)(128.81[8q24.21]-128.92[8q24.21]); Dim(8)(137.8[8q24.23]-137.92[8q24.23]); Dim(9)(107.84[9q31.2]-108.42[9q31.2]); 
Trisomy(11)(0.18-134.43); Dim(12)(11.4[12p13.2]-11.44[12p13.2]); Monosomy(13)(18.07-114.12); Dim X2(14)(105.24[14q32.33]-
106.23[14q32.33]); Enh(15)(19.81[15q11.2]-100.28[15qter]); Dim(15)(40.63[15q15.2]-40.71[15q15.2]); Dim(17)(41.53[17q21.31]-41.84[17q21.31]); 
Enh(17)(77.41[17q25.3]-77.52[17q25.3]); Enh(19)(0.06[19pter]-18.98[19p13.11]); Dim(20)(0.01[20pter]-59.39[20q13.33]); Enh(20)(59.43[20q13.33]-
60.48[20q13.33]); Amplified(20)(60.49[29q13.33]-61.93[20q13.33]); Enh(20)(61.94[20q13.33]-62.06[20q13.33]); Dim(20)(62.07[20q13.33]-
62.21[20q13.33]); Dim(22)(14.5[22q11.1]-16.42[22q11.1]); Dim(22)(21.5[22q11.22]-21.56[22q11.22]); Dim(22)(25.37[22q12.1]-30.31[22q12.2]); 
Enh(22)(49.0[22q13.33]-49.51[22q13.33]) 
1776  MM  HRD, 
unid IgH 
rearr 
Dim(1)(71.04[1p31.1]-120.12[1p11.1]); Dim(2)(88.99[2p11.2]-89.28[2p11.2]); Trisomy(3)(0.04-199.38); Dim(5)(122.33[5q23.2]-128.06[5q23.3]); 
Dim(5)(145.27[5q32]-159.93[5q34]); Dim(5)(178.19[5q35.3]-178.47[5q35.3]); Enh(7)(26.93[7p15.2]-26.99[7p15.2]); Enh(7)(97.12[7q21.3]-
102.06[7q22.1]); Dim(8)(0.98[8p23.3]-35.2[8p12]); Dim(8)(137.76[8q24.23]-137.92[8q24.23]); Dim(9)(15.75[9p22.3]-32.61[9p13.3]); 
Trisomy(11)(0.18-134.43); Dim(14)(24.4[14q12]-28.16[14q12]); Dim(14)(35.16[14q13.2]-48.7[14q21.3]); Dim(14)(55.12[14q22.3]-71.97[14q24.2]); 
Dim(14)(77.36[14q24.3]-90.58[14q23.12]); Dim(14)(96.51[14q32.2]-98.71[14q32.2]); Dim(14)(102.3[14q32.32]-102.43[14q32.32]); Appendices 
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Enh(14)(102.44[14q32.33]-102.48[14q32.33]); Enh(14)(104.39[14q32.33]-105.31[1432.33]); Trisomy(15)(20.39-100.28); Trisomy(19)(0.06-63.78) 
3325  MM  t(11;14)  Dim(1)(26.47[1p36.11]-102.18[1p21.1]); Dim X2(1)(45.91[1p34.1]-46.07[1p34.1]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); 
Dim(1)(210.75[1q32.3]-211.47[1q41]); Dim(2)(89.0[2p11.2]-89.11[2p11.2]); Enh(3)(0.04[3pter]-51.46[3p21.2]); Enh(3)(56.94[3p14.3]-66.4[3p14.1]); 
Dim(3)(77.71[3p12.3]-95.02[3p11.1]); Enh(3)(95.02[3q11.2]-199.38[3qter]); Dim X2(4)(69.2[4q13.2]-69.31[4q13.2]); Dim(5)(28.18[5p14.1]-
29.8[5p13.3]); Dim(5)(132.29[5q23.3]-132.92[5q31.1]); Dim(5)(147.51[5q32]-150.55[5q33.1]); Enh(6)(32.56[6p21.32]-32.66[6p21.32]); 
Dim(6)(64.68[6q12]-78.57[6q14.1]); Dim(6)(82.06[6q14.1]-116.32[6q22.1]); Dim(6)(119.6[6q22.31]-164.88[6q27]); Dim(1)(166.48[6q27]-
170.94[6q27]); Dim(7)(0.14[7pter]-10.45[7p21.3]); Dim(7)(108.27[7q31.1]-109.01[7q31.1]); Dim(8)(86.91[8q21.3]-87.49[8q21.3]); 
Dim(8)(105.21[8q22.3]-107.12[8q23.1]); Dim(8)(127.37[8q24.13]-127.95[8q24.13]); Amplified(8)(128.13[8q24.21]-130.34[8q24.21]); 
Enh(9)(0.15[9pter]-8.64[9p23]); Enh(9)(31.62[9p21.1]-138.4[9pter]); Enh(11)(0.18[11pter]-89.11[11q14.3]); Enh(11)(94.37[11q21]-95.8[11q22.1]); 
Enh(11)(102.66[11q22.3]-134.43[11qter]); Dim(12)(12.9[12p13.1]-17.19[12p12.3]); Dim(12)(128.23[12q24.32]-128.78[12q24.33]); 
Dim(13)(43.16[13q14.11]-76.65[13q31.1]); Enh(14)(75.93[14q24.3]-105.14[14q32.33]); Dim(14)(105.41[14q32.33]-105.88[14q32.33]); 
Enh(16)(31.96[16p11.2]-33.54[16p11.2]); Enh(18)(0.0[18pter]-27.4[18q12.1]); Enh(18)(58.06[18q21.33]-60.28[18q22.1]); Trisomy(19)(0.06-63.78); 
Enh(X)(123.77[Xq25]-154.49[Xqter]) 
1524  MM  t(11;14)  Enh(1)(141.47[1q21.1]-245.43[1qter]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(2)(88.98[2p11.2]-89.27[2p11.2]); Dim(2)(99.94[2q11.2]-
100.01[2q11.2]); Dim(2)(111.62[2q13]-111.84[2q13]); Dim(2)(112.54[2q13]-112.72[2q13]); Dim(2)(112.98[2q13]-113.21[2q13]); 
Enh(3)(164.02[3q26.1]-164.1[3q26.1]); Dim(4)(0.04[4pter]-34.81[4p15.1]); Enh(4)(35.92[4p15.1]-42.89[4p13]); Enh(4)(47.6[4p12]-48.16[4p12]); 
Dim(4)(52.69[4q11]-71.66[4q13.3]); Dim X2(4)(69.2[4q13.2]-69.79[4q13.2]); Enh(4)(71.94[4q13.3]-190.29[4q35.2]); Enh(5)(0.08[5pter]-
44.27[5p12]); Enh(5)(53.85[5q11.2]-55.54[5q11.2]); Dim(5)(55.97[5q11.2]-180.64[5q35.3]); Enh(6)(0.33[6p25.3]-28.65[6p22.1]); 
Dim(6)(77.53[6q14.1]-154.49[6q25.2]); Enh(6)(157.25[6q25.3]-170.94[6qter]); Dim(8)(0.06[8pter]-39.56[8p11.22]); Dim X2(8)(39.36[8p11.22]-
39.51[8p11.22]); Enh(8)(110.93[8q23.2]-138.61[8q24.23]); Enh(11)(58.51[11q12.1]-133.96[11qter]); Dim(12)(0.03[12pter]-36.98[12q12]); 
Dim(12)(65.89[12q14.3]-88.41[12q21.33]); Dim(12)(89.13[12q21.33]-90.95[12q22]); Dim(12)(92.52[12q22]-94.13[12q22]); 
Dim(12)(95.27[12q23.1]-110.24[12q24.12]); Dim(12)(123.62[12q24.31]-132.39[12qter]); Monosomy(13)(18.07-114.12); Dim(14)(105.31[14q32.33]-
105.59[14q32.33]); Enh(15)(18.81[15q11.2]-2.01[15q11.2]); Enh(15)(34.68[15q14]-100.28[15qter]); Dim(16)(0.03[16pter]-10.18[16p13.13]); 
Dim(16)(45.02[16q11.2]-88.69[16qter]); Dim(17)(0.03[17pter]-22.14[17p11.1]); Dim(18)(62.22[18q22.1]-76.11[18qter]); Dim(22)(20.72[22q11.22]-
21.05[22q11.22]); Dim X2(22)(21.06[22q11.22]-21.56[22q11.22]); Enh(22)(22.67[22q11.23]-22.73[22q11.23]); Dim(22)(42.74[22q13.31]-
42.86[22q13.31]); Monosomy(X)(2.69-154.49) 
1300  MM  t(11;14)  Enh(1)(8.36[1p36.23]-9.09[1p36.23]); Enh(1)(32.14[1p35.1]-32.63[1p35.1]); Enh(3)(170.95[3q26.2]-171.56[3q26.2]); Enh(4)(153.89[4q31.3]-
154.06[4q31.3]); Enh(6)(7.66[6p24.3]-8.24[6p24.3]); Enh(6)(31.62[6p21.33]-32.12[6p21.33]); Enh(6)(44.3[6p21.1]-44.34[6p21.1]); 
Enh(8)(33.26[8p12]-33.72[8p12]); Enh(8)(39.36[8p11.23]-39.51[8p11.22]); Enh(8)(66.81[8q13.1]-67.3[8q13.1]); Enh(8)(81.05[8q21.13]-
81.56[8q21.13]); Enh(9)(123.85[9q33.3]-124.26[9q33.3]); Enh(10)(111.86[10q25.2]-112.35[10q25.2]); Enh(10)(125.77[10q26.13]-126.31[10q26.13]); 
Enh(11)(68.82[11q13.3]-134.43[11qter]); Enh(12)(11.69[12p13.2]-12.23[12p13.2]); Enh(12)(26.6[12p11.23]-27.15[12p11.23]); 
Enh(14)(104.99[14q32.33]-105.25[14q32.33]); Dim(14)(105.31[14q32.33]-105.63[14q32.33]); Enh(14)(105.71[14q32.33]-105.86[14q32.33]); 
Dim(14)(105.87[14q32.33]-106.35[14qter]); Enh(17)(18.81[17p11.2]-19.23[17p11.2]); Enh(17)(27.95[17q11.2]-28.49[17q11.2]); 
Enh(17)(40.55[17q21.31]-40.72[17q21.31]); Dim(22)(22.67[22q11.23]-22.73[22q11.23]) 
504  MM  t(11;14)  Dim(1)(16.79[1p36.13]-16.84[1p36.13]); Dim X2(2)(89.0[2p11.2]-89.33[2p11.2]); Dim X2(2)(242.64[2q37.3]-242.74[2q37.3]); 
Dim(5)(22.54[5p14.3]-22.6[5p14.3]); Dim(6)(29.96[6p22.1]-30.01[6p21.33]); Dim(8)(0.06[8pter]-26.79[8p21.2]); Enh(8)(39.36[8p11.22]-
39.51[8p11.22]); Dim(9)(38.76[9p13.1]-43.09[9p13.1]); Enh(11)(69.13[11q13.3]-134.43[11qter]); Enh(12)(9.53[12p13.31]-9.61[12p13.31]); 
Enh(14)(21.56[14q11.2]-22.02[14q11.2]); Dim X2(14)(105.31[14q32.33]-105.93[14q32.33]); Dim(14)(105.95[14q32.33]-106.35[14qter]); 
Enh(15)(18.66[15q11.2]-20.08[15q11.2]); Dim(16)(58.03[16q21]-58.45[16q21]); Enh(17)(77.41[17q25.3]-77.5[17q25.3]); Dim 
X2(22)(22.67[22q11.23]-22.73[22q11.23]); Monosomy(X)(2.69-154.49) Appendices 
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308  MM  t(11;14)  Dim(1)(65.34[1p31.2]-66.72[1p31.2]); Dim(1)(93.11[1p22.1]-93.2[1p22.1]); Enh(1)(109.94[1p13.3]-109.97[1p13.3]); Dim(1)(117.73[1p12]-
118.17[1p12]); Enh(1)(118.18[1p12]-118.34[1p12]); Enh(1)(176.82[1q25.2]-176.97[1q25.3]); Dim X2(1)(193.47[1q31.3]-193.53[1q31.3]); 
Dim(1)(244.95[1q44]-245.01[1q44]); Dim(2)(88.99[2p11.2]-89.08[2p11.2]); Enh(2)(130.63[2q21.1]-130.67[2q21.1]); Enh(2)(233.02[2q37.1]-
233.13[2q37.1]); Enh(3)(170.95[3q26.2]-171.55[3q26.2]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Dim(4)(109.31[4q25]-109.44[4q25]); 
Enh(4)(185.44[4q35.1]-186.14[4q35.1]); Dim X2(5)(69.74[5q13.2]-69.74[5q13.2]); Dim(5)(150.17[5q33.1]-180.64[5qter]); Enh(6)(32.03[6p21.32]-
32.12[6p21.32]); Dim X2(6)(32.6[6p21.32]-32.63[6p21.32]); Dim(6)(35.61[6p21.31]-35.76[6p21.31]); Enh(7)(128.03[7q32.1]-128.15[7q32.1]); 
Dim(8)(7.26[8p23.1]-8.12[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(10)(134.89[10q26.3]-135.05[10q26.3]); Enh(11)(66.35[11q13.2]-
66.99[11q13.2]); Dim(12)(41.63[12q12]-50.68[12q13.13]); Enh(12)(51.47[12q13.13]-51.99[12q13.13]); Dim(12)(52.01[12q13.13]-52.17[12q13.13]); 
Dim(13)(42.35[13q14.11]-114.12[13qter]); Dim X2(14)(105.31[14q32.33]-105.45[14q32.33]); Dim(14)(105.86[14q32.33]-106.24[14q32.33]); 
Enh(15)(22.96[15q11.2]-23.05[15q11.2]); Dim(15)(75.27[15q24.3]-75.41[15q24.3]); Enh(16)(28.48[16p11.2]-31.15[16p11.2]); 
Enh(16)(31.38[16p11.2]-31.41[16p11.2]); Enh(16)(31.96[16p11.2]-33.43[16p11.2]); Enh(17)(77.28[17q25.3]-77.65[17q25.3]); 
Enh(22)(22.58[22q11.23]-22.73[22q11.23]); Monosomy(X)(2.69-154.49) 
2993  MM  t(11;14)  Dim(1)(149.37[1q21.3]-149.4[1q21.3]); Enh(2)(32.55[2p22.3]-33.23[2p22.3]); Dim(2)(88.99[2p11.2]-89.34[2p11.2]); Dim(3)(196.93[3q29]-
196.97[3q29]); Dim(4)(17.95[4p15.32]-37.93[4p14]); Dim X2(4)(69.2[4q13.2]-69.31[4q13.2]); Dim(5)(27.73[5p14.1]-27.87[5p14.1]); 
Dim(5)(69.74[5q13.2]-70.62[5q13.2]); Dim(5)(128.32[5q23.3]-163.91[5q34]); Dim(5)(180.35[5q35.3]-180.36[5q35.3]); Dim(6)(134.17[6q23.2]-
162.14[6q26]); Enh(8)(7.26[8p23.1]-7.79[8p23.1]); Dim(8)(12.63[8p22]-39.36[8p11.23]); Enh(8)(39.36[8p11.23]-39.51[8p11.23]); 
Dim(8)(113.96[8q23.3]-116.71[8q23.3]); Dim(9)(20.55[9p21.3]-23.56[9p21.3]); Enh(9)(127.23[9q34.11]-128.45[9q34.11]); Dim(11)(79.3[11q14.1]-
104.33[11q22.3]); Enh(11)(110.02[11q23.1]-111.34[11q23.1]); Dim(12)(2.78[12p13.33]-22.22[12p12.1]); Dim(13)(18.07[13q11]-36.15[13q13.3]); 
Enh(14)(18.62[14q11.2]-19.5[14q11.2]); Dim(14)(105.33[14q32.33]-105.64[14q32.33]); Enh(15)(18.66[15q11.2]-20.08[15q11.2]); 
Dim(15)(32.52[15q14]-32.63[15q14]); Enh(16)(32.21[16p11.2]-33.54[16p11.2]); Dim(17)(40.74[17q21.31]-41.03[17q21.31]); 
Enh(17)(41.58[17q21.31]-41.84[17q21.31]); Dim(17)(56.75[17q23.2]-61.91[17q24.2]); Dim(19)(2.17[19p13.3]-2.21[19p13.3]); 
Enh(19)(15.3[19p13.12]-17.31[19p13.11]); Dim(19)(57.72[19q13.41]-63.78[19qter]); Dim(22)(21.37[22q11.22]-21.58[22q11.22]); 
Monosomy(X)(2.69-154.49) 
932  MM  t(11;14)  Enh(1)(141.47[1q12]-157.11[1q23.2]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Enh(1)(175.56[1q25.1]-175.81[1q25.1]); Dim 
X2(2)(88.99[2p11.2]-89.06[2p11.2]); Enh(3)(53.08[3p11]-53.25[3p11]); Enh(3)(164.0[3q26.1]-164.11[3q26.1]); Dim(4)(69.05[4q13.2]-
69.84[4q13.2]); Dim(6)(29.96[6p22.1]-30.02[6p21.33]); Dim X2(6)(32.53[6p21.32]-32.73[6p21.32]); Enh(6)(150.25[6q25.1]-150.48[6q25.1]); 
Enh(7)(141.93[7q34]-141.98[7q34]); Enh(8)(39.51[8p11.23]-39.36[8p11.22]); Enh(8)(145.17[8q24.3]-145.77[8q24.3]); Enh(10)(7.44[10p14]-
7.7[10p14]); Enh(12)(11.4[12p13.2]-11.44[12p13.2]); Monosomy(13)(18.07-114.12); Dim(14)(19.52[14q11.2]-106.35[14qter]); Dim 
X2(14)(105.34[14q32.33]-106.35[14q32.33]); Dim(15)(19.38[15q11.2]-20.08[15q11.2]); Dim(16)(45.02[16q11.2]-88.69[16qter]); Dim 
X2(16)(49.3[16q12.1]-49.43[16q12.1]); Enh(20)(3.0[20p13]-3.04[20p13]); Dim(22)(21.06[22q11.22]-21.54[22q11.22]); Monosomy(X)(2.69-154.49) 
2906  MM  t(11;14)  Enh(1)(65.27[1p31.2]-67.22[1p31.2]); Dim(1)(83.45[1p31.1]-83.57[1p31.1]); Enh(1)(103.82[1p21.1]-103.88[1p21.1]); Dim(1)(151.8[1q22]-
151.83[1q22]); Dim(1)(154.71[1q23.2]-155.25[1q23.2]); Dim(2)(89.0[2p11.2]-89.11[2p11.2]); Dim(2)(132.09[2q21.2]-132.23[2q21.2]); 
Enh(4)(69.22[4q13.2]-69.31[4q13.2]); Enh(6)(18.22[6p22.3]-19.0[6p22.3]); Dim(6)(32.52[6p21.32]-32.63[6p21.32]); Enh(6)(105.9[6q21]-
106.79[6q21]); Enh(7)(24.66[7p15.2]-26.81[7p15.2]); Dim(7)(26.92[7p15.2]-26.99[7p15.2]); Enh(9)(36.81[9p13.2]-37.36[9p13.2]); 
Dim(9)(136.52[9p34.3]-136.54[9p34.3]); Dim(11)(65.07[11q13.2]-65.16[11q13.2]); Monosomy(13)(18.07-114.12); Dim(14)(19.27[14q11.2]-
19.49[14q11.2]); Enh(14)(102.04[14q32.32]-102.82[14q32.32]); Dim(14)(105.33[14q32.33]-105.63[14q32.33]); Enh(17)(72.51[17q25.2]-
72.81[17q25.2]); Enh(19)(10.18[19p13.2]-10.78[19p13.2]); Dim(21)(13.33[21q11.2]-14.44[21q11.2]); Enh(22)(17.26[22q11.21]-17.34[22q11.21]); 
Enh(22)(22.64[22q11.23]-23.63[22q11.23]); Enh(X)(48.43[Xp11.23]-48.51[Xp11.23]); Enh(X)(153.38[Xq28]-154.04[Xq28]) 
297  MM  HRD  Enh(1)(16.07[1p36.13]-16.13[1p36.13]); Enh(1)(149.36[1q21.3]-149.4[1q21.3]); Enh(1)(199.29[1q32.1]-199.35[1q32.1]); Trisomy(2)(0.02-242.78); 
Trisomy(3)(0.04-199.38); Dim(4)(135.3[4q28.3]-135.54[4q28.3]); Trisomy(5)(0.08-180.64); Enh(6)(0.1[6pter]-134.02[6q23.1]); Appendices 
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Dim(6)(32.59[6p21.32]-32.63[6p21.32]); Enh(6)(161.56[6q26]-170.94[6qter]); Trisomy(7)(0.14-158.62); Dim(8)(7.04[8p23.1]-8.15[8p23.1]); 
Dim(8)(39.36[8p11.23]-39.48[8p11.23]); Enh(8)(126.97[8q24.13]-146.26[8qter]); Tetrasomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); 
Enh(12)(56.43[12q14.1]-56.46[12q14.1]); Dim(14)(105.34[14q32.33]-106.0[14q32.33]); Tetrasomy(15)(18.36-100.28); Enh(16)(29.06[16p11.2]-
29.26[16p11.2]); Trisomy(19)(20.42-20.49); Enh(22)(17.04[22q11.21]-17.34[22q11.21]); Dim(22)(22.7[22q11.23]-22.72[22q11.23]); 
Enh(X)(52.78[Xp11.22]-52.83[Xp11.22]) 
506  MM  HRD  Enh(1)(0.97[1p36.33]-1.23[1p36.33]); Dim(1)(35.21[1p34.3]-35.69[1p34.3]); Dim(2)(233.36[2q37.1]-233.55[2q37.1]); Trisomy(5)(0.08-180.64); 
Enh(6)(45.63[6p21.1]-46.05[6p21.1]); Tetrasomy(7)(0.14-158.62); Dim(8)(7.04[8p23.1]-8.12[8p23.1]); Dim(8)(16.0[8p22]-16.06[8p22]); 
Enh(8)(126.62[8q24.13]-126.8[8q24.13]); Enh(8)(128.82[8q24.21]-128.87[8q24.21]); Tetrasomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); 
Monosomy(13)(18.07-114.12); Dim(14)(19.22[14q11.2]-19.5[14q11.2]); Dim X2(14)(105.32[14q32.33]-105.45[14q32.33]); Trisomy(15)(18.36-
100.28); Dim(16)(45.02[16q11.1]-85.85[16qter]); Trisomy(19)(0.06-63.78); Trisomy(21)(13.33-46.91); Dim(22)(23.97[22q11.23]-24.47[22q12.1]) 
375  MM  HRD  Dim(1)(52.85[1p32.3]-141.47[1p11.1]); Enh(3)(164.0[3q26.1]-164.1[3q26.1]); Trisomy(4)(0.04-191.31); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Trisomy(5)(0.08-180.64); Enh(5)(76.12[5q13.3]-76.18[5q13.3]); Enh(5)(78.53[5q14.1]-112.51[5q22.2]); Dim(6)(29.96[6p21.33]-30.02[6p21.33]); 
Enh(6)(168.16[6q27]-168.39[6q27]); Trisomy(7)(0.14-158.62); Dim(8)(7.26[8p23.1]-7.79[8p23.1]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); 
Enh(8)(128.82[8q24.21]-128.92[8q24.21]); Trisomy(9)(0.15-138.4); Dim(10)(46.38[10q11.22]-47.01[10q11.22]); Enh(10)(105.99[10q25.1]-
106.09[10q25.1]); Enh(11)(0.18[11pter]-34.89[11p13]); Enh(11)(54.79[11q11]-134.43[11qter]); Enh(12)(7.88[12p13.31]-8.01[12p13.31]); 
Dim(12)(26.6[12p11.23]-27.81[12p11.23]); Enh(14)(104.99[14q32.33]-105.28[14q32.33]); Dim(14)(105.33[14q32.33]-105.5[14q32.33]); 
Trisomy(15)(18.36-100.28); Amplified(16)(45.02[16q11.2]-46.08[16q12.1]); Enh(16)(50.65[16q12.1]-52.33[16q12.2]); 
Amplified(16)(65.24[16q22.1]-70.48[16q22.2]); Enh(16)(73.43[16q22.3]-79.37[16q23.2]); Enh(16)(46.08[16q12.1]-49.21[16q12.1]); 
Enh(17)(77.97[17q25.3]-78.11[17q25.3]); Trisomy(19)(0.06-63.78); Dim(20)(0.01[20pter]-19.63[20q11.23]); Enh(20)(19.63[20p11.23]-
62.38[20qter]); Trisomy(21)(9.9-46.91); Enh(X)(96.39[Xq21.33]-154.49[Xqter]) 
824  MM  HRD  Dim(1)(30.85[1p35.2]-31.01[1p35.2]); Dim(1)(145.73[1q21.2]-146.53[1q21.2]); Dim(2)(45.08[2p21]-45.15[2p21]); Enh(2)(70.17[2p13.3]-
70.38[2p13.3]); Dim(2)(89.0[2p11.2]-89.2[2p11.2]); Trisomy(3)(0.04-199.38); Enh(4)(185.56[4q35.1]-185.93[4q35.1]); Dim(4)(187.4[4q35.1]-
187.46[4q35.1]); Trisomy(5)(1.93-180.64); Trisomy(7)(2.93-158.62); Enh(8)(7.04[8p23.1]-7.79[8p23.1]); Trisomy(9)(0.15-132.9); 
Enh(11)(3.32[11p15.5]-133.69[11qter]); Dim(14)(105.33[14q32.33]-105.43[14q32.33]); Trisomy(15)(19.82-100.2); Enh(15)(31.38[15q14]-
73.29[15q23]); Dim(17)(0.03[17pter]-16.5[17p11.2]); Dim(17)(19.12[17p11.2]-20.55[17p11.2]); Enh(17)(20.57[17p11.2]-21.01[17p11.2]); 
Dim(17)(21.13[17p11.2]-21.72[17p11.2]); Enh(17)(21.84[17p11.2]-69.76[17q25.3]); Trisomy(19)(0.06-63.78); Dim(20)(59.18[20q13.33]-
62.38[20q13.33]); Enh(22)(20.34[22q11.22]-21.73[22q11.22]); Dim(22)(21.88[22q11.23]-22.91[22q11.23]) 
1512  MM  HRD  Dim(1)(193.47[1q31.3]-193.53[1q31.1]); Dim(1)(199.09[1q32.1]-199.29[1q32.1]); Enh(2)(0.02[2pter]-15.29[2p24.3]); Dim(2)(15.29[2p24.3]-
17.18[2p24.3]); Enh(2)(17.21[2p24.3]-44.52[2p21]); Enh(2)(45.85[2p21]-46.64[2p21]); Enh(2)(60.35[2p16.1]-62.42[2p15]); Enh(2)(64.15[2p14]-
64.15[2p14]); Dim(2)(104.83[2q12.1]-107.4[2q12.3]); Enh(2)(111.21[2q13]-116.4[2q14.1]); Enh(2)(119.85[2q14.2]-123.31[2q14.3]); 
Enh(2)(126.35[2q14.3]-131.53[2q21.1]); Enh(2)(132.43[2q21.2]-132.86[2q21.2]); Dim(2)(133.54[2q21.2]-135.06[2q21.2]); Dim(2)(136.32[2q21.3]-
137.44[2q21.3]); Enh(2)(137.86[2q22.1]-138.69[2q22.1]); Dim(2)(138.72[2q22.1]-139.09[2q22.1]); Enh(2)(139.1[2q22.1]-140.19[2q22.1]); 
Enh(2)(150.94[2q23.2]-242.78[2qter]); Trisomy(3)(0.04-199.38); Enh(4)(34.06[4p15.1]-34.44[4p15.1]); Enh(4)(43.2[4p13]-191.31[4qter]); 
Dim(4)(69.2[4q13.2]-69.79[4q13.2]); Enh(5)(0.08[5pter]-50.12[5q11.1]); Dim(6)(32.57[6p21.32]-32.63[6p21.32]); Enh(6)(95.64[6q16.1]-
97.13[6q16.1]); Enh(6)(104.41[6q16.3]-106.5[6q21]); Dim(6)(106.6[6q21]-170.94[6qter]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); 
Dim(8)(47.58[8q11.21]-50.06[8q11.21]); Enh(8)(53.74[8q11.23]-56.46[8q12.1]); Dim(8)(62.7[8q12.3]-74.91[8q21.11]); Enh(8)(75.01[8q21.11]-
87.87[8q21.3]); Amplified(8)(75.63[8q21.11]-76.19[8q21.11]); Amplified(8)(79.75[8q21.12]-81.16[8q21.13]); Amplified(8)(87.37[8q21.3]-
87.87[8q21.3]); Dim(8)(88.08[8q21.3]-128.43[8q24.21]); Enh(8)(128.45[8q24.21]-128.5[8q24.21]); Dim(8)(128.51[8q24.21]-128.67[8q24.21]); 
Amplified(8)(128.77[8q24.21]-129.99[8q24.21]); Enh(8)(130.03[8q24.21]-132.04[8q24.22]); Enh(8)(134.42[8q24.22]-135.32[8q24.22]); 
Enh(8)(143.1[8q24.3]-146.09[8q24.3]); Trisomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); Amplified(11)(60.45[11q12.2]-61.2[11q12.3]); Appendices 
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Amplified(11)(68.97[11q13.2]-70.44[11q13.4]); Dim(12)(61.14[12q14.1]-66.06[12q15]); Dim(12)(66.6[12q15]-82.48[12q21.31]); 
Monosomy(13)(18.07-114.12); Dim(14)(19.27[14q11.2]-19.5[14q11.2]); Dim(14)(105.34[14q32.33]-105.93[14q32.33]); Trisomy(15)(18.36-100.28); 
Enh(15)(33.58[15q14]-100.28[15qter]); Amplified(15)(62.78[15q22.31]-64.49[15q22.31]); Dim(17)(7.29[17p13.1]-8.76[17p13.1]); 
Dim(17)(19.38[17p11.2]-20.16[17p11.2]); Enh(17)(77.39[17q25.3]-77.65[17q25.3]); Enh(19)(0.06[19pter]-19.9[19p12]); Enh(19)(32.55[19q12]-
63.78[19qter]); Trisomy(21)(9.9-46.91); Amplified(21)(14.29[21q11.2]-14.49[21q11.2]); Enh(21)(14.67[21q11.2]-14.7[21q11.2]); 
Enh(X)(94.02[Xq21.32]-154.49[Xqter]) 
491  MM  HRD  Enh(1)(28.71[1p35.3]-28.77[1p35.3]); Dim(1)(83.31[1p31.1]-83.58[1p31.1]); Enh(1)(141.47[1q12]-245.43[1qter]); Trisomy(2)(0.02-242.78); 
Dim(2)(89.0[2p11.2]-89.33[2p11.2]); Trisomy(3)(0.04-199.38); Dim(3)(164.0[3q26.1]-164.1[3q26.1]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Enh(6)(0.1[6pter]-62.53[6p11.1]); Trisomy(7)(0.14-158.62); Dim(8)(7.04[8p23.1]-7.79[8p23.1]); Dim(8)(12.28[8p23.1]-12.51[8p23.1]); 
Dim(11)(49.11[11p11.12]-49.82[11p11.12]); Dim(11)(107.59[11q22.3]-107.92[11q22.3]); Monosomy(13)(18.07-114.12); Monosomy(14)(18.15-
106.35); Dim X2(14)(19.27[14q11.2]-19.5[14q11.2]); Dim X2(14)(102.41[14q32.32]-102.59[14q32.32]); Dim X2(14)(105.31[14q32.33]-
105.99[14q32.33]); Trisomy(15)(18.36-100.28); Trisomy(18)(0.0-76.11); Enh(19)(0.06[19pter]-32.55[19p12]); Enh(X)(52.78[Xp11.22]-
52.84[Xp11.22]); Dim(Y)(2.69-57.37) 
314  MM  HRD  Enh(1)(141.47[1q21.1]-181.66[1q25.3]); Enh(1)(194.46[1q31.3]-2455.43[1qter]); Dim(2)(89.0[2p11.2]-89.11[2p11.2]); Trisomy(5)(0.08-180.64); 
Trisomy(7)(0.14-158.62); Trisomy(9)(0.15-138.4); Trisomy(11)(0.18-134.43); Enh(12)(6.01[12p13.31]-6.94[12p13.31]); Monosomy(13)(18.07-
114.12); Enh(14)(64.13[14q23.3]-65.17[14q23.3]); Enh(14)(104.21[14q32.33]-105.31[14q32.33]); Dim(14)(105.6[14q32.33]-106.17[14q32.33]); 
Trisomy(15)(18.36-100.28); Dim(16)(45.02[16q11.2]-88.69[16qter]); Trisomy(18)(0.0-76.11); Trisomy(19)(0.06-63.78); Enh(20)(31.63[20q11.21]-
32.11[20q11.22]); Trisomy(21)(13.33-46.91); Monosomy(22)(14.5-49.51); Enh(X)(107.83[Xq23]-154.49[Xqter]) 
830  MM  HRD  Enh(1)(26.03[1p36.11]-26.25[1p36.11]); Enh(1)(116.86[1p12]-116.91[1p12]); Enh(1)(147.59[1q21.2]-147.69[1q21.2]); Dim(1)(193.47[1q31.3]-
193.53[1q31.3]); Enh(1)(204.26[1q32.2]-204.35[1q32.2]); Dim(2)(34.61[2p22.3]-34.64[2p22.3]); Dim(2)(88.99[2p11.2]-89.44[2p11.2]); 
Enh(3)(13.38[3p25.2]-13.53[3p25.2]); Enh(3)(52.21[3p21.2]-52.28[3p21.2]); Enh(3)(164.04[3q26.1]-164.1[3q26.1]); Dim(3)(196.91[3q29]-
196.95[3q29]); Trisomy(4)(0.04-191.31); Trisomy(5)(0.08-180.64); Enh(6)(7.82[6p24.3]-7.96[6p24.3]); Dim(6)(32.6[6p21.32]-32.66[6p21.32]); 
Enh(6)(167.58[6q27]-168.12[6q27]); Trisomy(7)(0.14-158.62); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(8)(128.82[8q24.21]-128.91[8q24.21]); 
Trisomy(9)(0.15-138.4); Dim(11)(5.74[11p15.4]-5.77[11p15.4]); Enh(11)(66.04[11q13.2]-66.18[11q13.2]); Enh(12)(11.4[12p13.2]-11.43[12p13.2]); 
Monosomy(13)(18.07-114.12); Dim(14)(105.29[14q32.33]-105.58[14q32.33]); Dim(14)(105.99[14q32.33]-106.35[14qter]); Trisomy(15)(18.36-
100.28); Enh(17)(41.55[17q21.31]-41.71[17q21.31]); Trisomy(19)(0.06-63.78); Enh(20)(31.88[20q11.22]-31.98[20q11.22]); 
Enh(22)(21.51[22q11.22]-21.7[22q11.22]); Dim(22)(37.68[22q13.1]-37.71[22q13.1]); Monosomy(X)(2.69-154.49) 
883  MM  HRD  Dim(1)(93.52[1p22.1]-141.47[1p11.1]); Dim(2)(88.99[2p11.2]-89.91[2p11.2]); Enh(2)(233.06[2q37.1]-233.13[2q37.1]); Trisomy(3)(0.04-199.38); 
Trisomy(5)(0.08-180.64); Enh(6)(43.04[6p21.1]-43.11[6p21.1]); Dim(6)(79.04[6q14.1]-79.08[6q14.1]); Trisomy(7)(0.14-158.62); Trisomy(9)(0.15-
138.4); Trisomy(11)(0.18-134.43); Dim(12)(31.66[12p11.21]-32.83[12p11.21]); Dim(12)(34.06[12p11.21]-34.32[12p11.21]); 
Enh(14)(103.61[14q32.33]-105.32[14q32.33]); Dim(14)(105.34[14q32.33]-105.38[14q32.33]); Trisomy(15)(18.36-100.28); Enh(16)(29.05[16p11.2]-
29.26[16p11.2]); Dim(16)(45.02[16q11.2]-88.69[16qter]); Dim(17)(4.84[17p13.2]-5.39[17p13.2]); Dim(17)(7.5[17p13.1]-16.66[17p11.2]); 
Dim(17)(41.53[17q21.31]-42.14[17q21.31]); Trisomy(19)(0.06-63.78); Enh(X)(95.84[Xq21.33]-154.49[Xqter]); Enh(Y)(2.69-57.37) 
2218  MM  HRD  Dim(2)(42.78[2p21]-44.76[2p21]); Trisomy(3)(0.04-199.38); Trisomy(5)(0.08-180.64); Enh(6)(168.16[6q27]-168.39[6q27]); Trisomy(7)(0.14-
158.62); Dim(7)(153.37[7q36.2]-153.43[7q36.2]); Dim(8)(7.04[8p23.1]-8.12[8p23.1]); Dim(8)(39.36[8p11.22]-39.47[8p11.22]); Tetrasomy(9)(0.15-
138.4); Trisomy(11)(0.18-134.43); Dim(11)(5.74[11p15.4]-5.76[11p15.4]); Dim(14)(105.34[14q32.33]-105.42[14q32.33]); 
Enh(14)(105.42[14q32.33]-105.47[14q32.33]); Dim(14)(105.48[14q32.33]-106.02[14q32.33]); Trisomy(15)(18.36-100.28); Trisomy(19)(0.06-63.78); 
Dim(22)(21.38[22q11.22]-21.54[22q11.22]); Enh(Y)(2.69-57.37) 
989  MM  HRD  Dim(1)(16.88[1p36.13]-17.13[1p36.13]); Dim(1)(59.84[1p32.1]-62.70[1p31.3]); Dim(1)(88.59[1p22.2]-94.29[1p22.1]); Dim(1)(95.53[1p21.3]-
113.44[1p13.2]); Dim(1)(114.05[1p13.2]-120.47[1p11.1]); Enh(1)(159.78[1q23.3]-159.91[1q23.3]); Dim(1)(210.64[1q32.3]-211.10[1q32.3]); Appendices 
  231 
Dim(2)(88.96[2p11.2]-89.03[2p11.2]); Trisomy(3)(0.04-199.38); Dim(4)(5.24[4p16.1]-37.14[4p14]); Dim(4)(70.18[4q13.2]-70.30[4q13.3]); 
Enh(4)(103.28[4q24]-103.74[4q24]); Enh(4)(130.56[4q28.2]-130.98[4q28.2]); Trisomy(5)(0.08-180.64); Enh(6)(35.57[6p21.32]-32.67[6p21.32]); 
Dim(6)(88.91[6q15]-170.47[6qter]); Enh(7)(0.14[7pter]-89.08[7q21.13]); Dim(7)(89.11[7q21.13]-91.40[7q21.2]); Enh(7)(91.40[7q21.2]-
100.54[7q22.1]); Dim(7)(100.55[7q22.1]-104.38[7q22.2]); Enh(7)(104.40[7q22.2]-158.57[7qter]); Dim(8)(0.63[8pter]-47.06[8p11.1]); 
Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(9)(0.15[9pter]-44.17[9p11.1]); Enh(9)(44.17[9q11]-140.04[9qter]); Dim(10)(20.21[10p12.32]-
21.73[10p12.32]); Enh(10)(45.48[10q11.21]-46.57[10q11.21]); Dim(10)(115.52[10q25.3]-115.68[10q25.3]); Enh(11)(0.18[11pter]-87.08[11q14.2]); 
Dim(11)(55.12[11q11.2]-55.20[11q11.1]); Enh(11)(90.04[11q14.3]-134.35[11qter]); Enh(12)(9.53[12p13.31]-9.63[12p13.31]); 
Dim(12)(18.36[12q23.1]-98.62[12q23.1]); Monosomy(13)(18.07-114.12); Dim(14)(31.82[14q13]-40.52[14q21.1]); Enh(14)(78.50[14q31.1]-
80.35[14q31.1]); Dim(14)(19.27[14q11.2]-19.48[14q11.2]); Dim(14)(105.35[14q32.33]-105.45[14q32.33]); Dim X2(14)(105.60[14q32.33]-
105.63[14q32.33]); Dim X2(14)(105.96[14q32.33]-106.00[14q32.33]); Trisomy(15); Enh(16)(31.81[16p11.2]-32.75[16p11.2]); 
Dim(16)(47.18[16q12.1]-51.13[16q12.1]); Dim(17)(36.54[17q21.2]-38.05[17q21.31]); Dim(17)(59.48[17q23.3]-61.57[17q24.2]); 
Enh(17)(77.41[17q25.3]-77.56[17q25.3]); Trisomy(19); Dim(20)(31.80[20q11.22]-50.18[20q13.2]); Trisomy(21); Enh X2(X)(92.36[Xq21.32]-
154.14[Xqter]) 
1213  MM  HRD  Enh(1)(141.47[1q21.1]-245.43[1qter]); Dim(2)(224.44[2q36.2]-242.78[2qter]); Dim(3)(68.0[3p14.1]-68.64[3p14.1]); Dim(3)(177.44[3q26.32]-
179.42[3q26.32]); Dim X2(3)(178.36[3q26.32]-178.40[3q26.32]); Enh(5)(0.08[5pter]-58.37[5q11.2]); Enh(5)(131.23[5q23.3]-142.17[5q31.3]); Enh 
X2(6)(0.1[6pter]-37.92[6p21.2]); Enh(6)(48.06[6p12.3]-103.2[6q16.3]); Dim(6)(103.63[6q16.3]-170.94[6qter]); Dim X2(6)(116.67[6q22.1]-
116.71[6q22.1]); Dim(7)(32.44[7p14.3]-32.89[7p14.3]); Enh(8)(39.37[8p11.22]-39.51[8p11.22]);  Enh(8)(128.27[8q24.21]-129.47[8q24.21]); 
Enh(9)(0.15[9pter]-15.56[9p22.3]); Dim(9)(120.57[9q33.2]-120.99[9q33.2]); Dim(12)(10.47[12p13.2]-10.49[12p13.2]); Dim(12)(85.45[12q21.32]-
85.55[12q21.32]); Dim(13)(18.07[13CEP]-22.37[13q12.12]); Dim(13)(23.79[13q12.12]-114.12[13qter]); Dim X2(13)(55.20[13q21.1]-
55.37[13q21.1]); Dim(14)(29.28[14q12]-29.46[14q12]); Dim(14)(38.78[14q21.1]-40.03[14q21.1]); Enh(14)(104.68[14q32.33]-105.31[14q32.33]); 
Dim X2(14)(105.33[14q32.33]-105.42[14q32.33]); Dim(14)(105.67[14q32.33]-106.35[14q32.33]); Trisomy(15)(18.36-100.28); Trisomy(19)(0.06-
63.78); Dim(21)(20.82[21q21.1]-21.5[21q21.1]); Dim(21)(43.84[21q22.3]-46.91[21qter]); Dim(22)(41.56[22q13.2]-48.87[22q13.33]); 
Dim(X)(2.69[Xpter]-113.68[Xq23]); Dim X2(X)(44.68[Xp11.3]-44.83[Xp11.3]); Dim X2(X)(79.72[Xq21.1]-79.88[Xq21.1]); Enh(X)(113.69[Xq33]-
154.49[Xqtel]); Dim(X)(122.16[Xq25]-122.96[Xq25]) 
325  pPCL  t(11;14)  Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim X2(1)(165.96[1q24.2]-165.99[1q24.2]); Dim X2(1)(245.06[1q44]-245.13[1q44]); 
Dim(2)(89.0[2p11.2]-89.33[2p11.2]); Dim(3)(60.36[3p14.2]-60.56[3p14.2]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Dim(5)(69.74[5q13.2]-
70.62[5q13.2]); Dim(6); Dim(7)(0.14[7pter]-20.19[7p21.1]); Dim(8)(7.26[8p23.1]-8.12[8p23.1]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); 
Enh(8)(96.83[8q22.1]-146.26[8qter]); Amplified(8)(124.98[8q24.13]-129.42[8q24.21]); Dim(10)(46.37[10q11.22]-46.57[10q11.22]); 
Enh(11)(69.1[11q13.3]-134.43[11qter]); Enh(14)(104.39[14q32.33]-105.28[14q32.33]); Dim(14)(105.31[14q32.33]-106.35[14qter]); 
Enh(15)(64.66[15q23]-67.15[15q23]) ; Enh(16)(32.11[16p11.2]-33.76[16p11.2]); Dim(17)(41.71[17q21.31]-42.18[17q21.31]); 
Enh(19)(1.59[19p13.3]-2.35[19p13.3]); Enh(19)(63.06[19q13.43]-63.78[19q13.43]); Enh(20)(43.97[20q13.12]-46.79[20q13.13]); 
Dim(X)(76.61[Xq21.1]-76.81[Xq21.1]); Enh(X)(114.29[Xq23]-154.49[Xqter]) 
1576  pPCL  t(11;14)  Enh(1)(142.58[1q21.1]-148.1[1q21.3]); Dim(2)(88.98[2p11.2]-91.12[2p11.2]); Enh(2)(99.3[2q11.2]-99.38[2q11.2]); Enh(3)(14.85[3p25.1]-
15.88[3p25.1]); Enh(4)(0.04[4pter]-154.56[4q31.3]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); Enh(6)(0.1[6pter]-31.71[6p21.32]); Dim 
X2(6)(32.57[6p21.32]-32.73[6p21.32]); Enh(6)(151.48[6q25.1]-152.74[6q25.2]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); 
Enh(8)(128.45[8q24.21]-129.38[8q24.21]); Trisomy(9)(0.15-138.4); Enh(10)(5.39[10p15.1]-6.38[10p15.1]); Enh(11)(68.74[11q13.3]-
73.19[11q13.4]); Enh(11)(94.87[11q21]-134.18[11q25]); Dim X2(12)(11.4[12p13.2]-11.43[12p13.2]); Dim(13)(33.0[13q13.1]-114.12[13qter]); 
Enh(14)(22.1[14q11.2]-23.17[14q11.2]); Enh(14)(104.79[14q32.33]-105.18[14q32.33]); Dim(14)(105.29[14q32.33]-105.8[14q32.33]); 
Dim(16)(0.03[16pter]-10.3[16p13.2]); Enh(16)(10.33[16p13.13]-31.25[16p11.2]); Dim(16)(34.1[16p11]-34.63[16p11]); Dim(16)(46.11[16q12.1]-
49.0[16q12.1]); Dim(16)(56.07[16q13]-88.69[16qter]); Enh(17)(41.52[17q21.31]-41.57[17q21.31]); Dim(20)(34.35[20q11.23]-62.38[20qter]); Appendices 
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Trisomy(21)(9.9-46.91); Enh(22)(17.26[22q11.21]-17.39[22q11.21]); Dim(22)(23.06[22q11.23]-34.64[22q12.3]) 
3210  pPCL  t(11;14)  Dim(1)(8.41[1p36.23]-8.55[1p36.23]); Dim(1)(33.33[1p35.1]-97.02[1p21.3]); Dim X2(1)(51.14[1p32.3]-51.16[1p32.3]); Dim(1)(106.05[1p21.1]-
141.47[1p11.1]); Dim(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(1)(159.29[1q23.3]-159.46[1q23.3]); Enh(2)(0.02[2pter]-15.95[2p24.3]); 
Dim(2)(35.44[2p22.3]-35.53[2p22.3]); Dim(2)(89.0[2p11.2]-89.34[2p11.2]); Dim(2)(114.33[2q14.1]-114.37[2q14.1]); Dim(2)(127.35[2q14.3]-
128.99[2q21.1]); Dim(2)(160.27[2q24.2]-163.04[2q24.2]); Dim(2)(196.31[2q32.3]-201.53[2q33.2]); Dim(3)(22.92[3p24.3]-23.36[3p24.3]); 
Dim(3)(161.42[3q25.33]-161.63[3q25.33]); Dim(4)(30.32[4p15.1]-30.54[4p15.1]); Dim(4)(43.81[4p13]-49.42[4p11]); Dim(4)(69.2[4q13.2]-
69.31[4q13.2]); Enh(4)(102.98[4q24]-105.96[4q24]); Dim(4)(135.3[4q28.3]-135.54[4q28.3]); Dim(4)(162.23[4q32.2]-166.33[4q32.3]); 
Enh(6)(79.04[6q14.1]-79.08[6q14.1]); Dim(6)(79.75[6q14.1]-79.82[6q14.1]); Dim(6)(85.77[6q14.3]-86.42[6q14.3]); Dim(6)(90.11[6q15]-
170.94[6qter]); Dim(7)(29.93[7p15.1]-30.57[7p14.3]); Dim(7)(110.16[7q31.1]-110.42[7q31.1]); Dim X2(8)(0.06[8pter]-1.12[8p23.3]); 
Dim(8)(3.05[8p23.2]-26.07[8p21.2]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(9)(0.15[9pter]-32.16[9p21.1]); Enh(9)(136.67[9q34.3]-
136.7[9q34.3]); Monosomy(10)(0.12-135.4); Enh(11)(69.08[11q13.1]-99.58[11q22.1]); Dim(12)(0.03[12pter]-20.8[12p12.2]); 
Dim(12)(31.27[12p11.21]-46.89[12q13.12]); Dim X2(12)(36.98[12q12]-37.2[12q12]); Enh(12)(48.7[12q13.12]-51.67[12q13.13]); 
Dim(12)(57.97[12q14.1]-110.06[12q24.12]); Monosomy(13)(18.07-114.12); Enh(14)(18.5[14q11.1]-19.54[14q11.2]); Dim(14)(25.91[14q12]-
27.99[14q12]); Dim X2(14)(51.97[14q22.1]-52.06[14q22.1]); Dim X2(14)(54.93[14q22.3]-54.96[14q22.3]); Enh(14)(86.41[14q31.3]-
105.4[14q32.33]); Dim(14)(105.41[14q32.33]-106.11[14q32.33]); Dim(15)(18.72[15q11.2]-20.22[15q11.2]); Dim(16)(33.21[16p11.2]-
33.4[16p11.2]); Dim(16)(45.06[16q12.1]-88.62[16qter]); Dim X2(16)(54.35[16q12.2]-54.38[16q12.2]); Dim(17)(0.03[17pter]-38.58[17q21.31]); 
Dim(18)(25.08[18q12.1]-25.46[18q12.1]); Enh(18)(47.96[18q21.1]-76.11[18qter]); Monosomy(22)(15.4-49.51); Dim X2(22)(21.49[22q11.22]-
21.56[22q11.22]); Dim X2(22)(22.7[22q11.23]-22.71[22q11.23]); Monosomy(X)(2.69-154.49) 
742  pPCL  HRD  Enh(1)(141.47[1q11]-245.43[1qter]); Dim(1)(145.82[1q21.1]-145.99[1q21.2]); Enh(1)(16.95[1p36.13]-1.7[1p36.13]); Enh(1)(117.41[1p12]-
117.49[1p12]); Trisomy(2)(0.02-242.78); Trisomy(3)(2.16-199.38); Dim(3)(85.93[3p12.1]-86.1[3p12.1]); Dim(4)(69.2[4q13.2]-69.31[4q13.2]); 
Enh(5)(133.89[5q31.1]-134.03[5q31.1]); Enh(5)(156.75[5q33.3]-157.25[5q33.3]); Enh(6)(0.1[6pter]-63.69[6q12]); Trisomy(7)(0.14-158.62); 
Dim(8)(0.06[8pter]-48.07[8q11.21]); Dim X2(8)(25.21[8p12.2]-26.22[8p12.2]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); Enh(8)(48.12[8q11.21]-
59.55[8q12.1]); Dim(8)(59.55[8q12.1]-65.84[8q12.3]); Enh(8)(65.85[8q12.3]-146.26[8qter]); Enh(9)(0.15[9pter]-94.03[9q22.31]); 
Enh(9)(94.84[9q22.32]-95.99[9q22.33]); Enh(9)(105.81[9q31.2]-106.88[9q31.2]); Enh(9)(113.62[9q32]-130.15[9q34.12]); Enh(9)(136.83[9q34.3]-
138.4[9qter]); Dim(10)(42.15[10q11.21]-69.39[10q21.3]); Enh(10)(70.82[10q22.1]-70.95[10q22.1]); Dim(10)(97.67[10q24.1]-97.91[10q24.1]); Dim 
X2(10)(100.68[10q24.2]-100.69[10q24.2]); Tetrasomy(11)(0.18-134.43); Dim(12)(81.94[12q21.31]-83.82[12q21.31]); Dim(14)(73.07[14q24.3]-
73.1[14q24.3]); Tetrasomy(15)(18.36[15pter]-100.28[15qter]); Enh(16)(55.26[16q131]-55.7[6q13]); Dim(16)(68.71[16q22.1]-68.75[16q22.1]); 
Dim(16)(69.76[16q22.2]-73.52[16q23.1]); Enh(17)(22.32[17q11.2]-25.61[17q11.2]); Enh(17)(37.83[17q21.2]-78.65[17qter]); Trisomy(18)(0.0-
76.11); Trisomy(19)(0.06-63.78); Trisomy(20)(0.01-62.38); Trisomy(21)(9.9-46.91); Enh(22)(21.57[22q11.22]-22.13[22q11.23]); 
Enh(22)(22.61[22q11.23]-22.67[22q11.23]); Monosomy(X)(2.69-154.49) 
165  pPCL  HRD  Enh(1)(12.79[1p36.21]-12.85[1p36.21]); Dim(1)(25.35[1p36.11]-25.41[1p36.11]); Dim(1)(97.55[1p21.3]-119.47[1p12]); Enh(1)(141.47[1q12]-
245.43[1qter]); Dim(1)(193.47[1q31.3]-193.56[1q31.3]); Dim X2(1)(245.05[1q44]-245.12[1q44]); Enh(2)(233.07[2q27.1]-233.13[2q27.1]); 
Trisomy(3)(0.04-199.38); Dim(4)(53.18[4q12]-54.45[4q12]); Dim X2(4)(69.2[4q13.2]-69.31[4q13.2]); Enh(4)(69.84[4q13.2]-70.9[4q13.3]); 
Dim(4)(189.59[4q35.2]-190.86[4q35.2]); Enh(5)(0.08[5pter]-103.98[5q21.3]); Enh(5)(161.34[5q34]-180.64[5qter]); Enh(6)(0.1[6pter]-66.67[6q12]); 
Dim(6)(52.78[6p12.2]-52.88[6p12.2]); Dim(6)(56.35[6p12.1]-56.43[6p12.1]); Dim(6)(66.67[6q12]-170.94[6qter]); Dim(7)(0.14[7pter]-
18.97[7p21.1]); Enh(7)(18.97[7p21.1]-140.37[7q34]); Enh(7)(142.42[7q35]-145.39[7q35]); Enh(7)(152.92[7q36.2]-157.93[7q36.3]); 
Dim(8)(19.02[8p21.3]-43.65[8p11.1]); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); Dim(9)(132.97[9q34.2]-132.99[9q34.2]); 
Dim(10)(96.5[10q23.33]-96.56[10q23.33]); Dim(11)(5.74[11p15.4]-5.76[11p15.4]); Enh(12)(6.34[12p13.31]-7.13[12p13.31]); 
Dim(12)(126.9[12q24.32]-128.09[12q24.32]); Monosomy(13)(18.07-114.12); Dim(14)(19.27[14q11.2]-19.49[14q11.2]); Enh(14)(104.21[14q32.33]-
105.31[14q32.33]); Dim(14)(105.41[14q32.33]-105.63[14q32.33]); Enh(14)(105.71[14q32.33]-105.9[14q32.33]); Dim(14)(105.96[14q32.33]-Appendices 
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106.06[14q32.33]); Dim(15)(18.36[15q11.2]-32.46[15q14]); Dim(15)(77.0[15q25.1]-77.52[15q25.1]); Dim(15)(77.95[15q25.1]-78.31[15q25.1]); 
Dim(15)(81.5[15q25.2]-100.28[15qter]); Dim(18)(10.58[18p11.22]-10.82[18p11.22]); Dim(18)(35.13[18p12.2]-35.45[18p12.2]); Trisomy(19)(0.06-
63.78); Dim(19)(23.42[19p12]-23.83[19p12]); Dim X2(20)(1.52[20p13]-1.53[20p13]); Dim(22)(21.37[22q11.22]-21.51[22q11.22]); 
Enh(22)(22.61[22q11.23]-22.75[22q11.23]); Enh(22)(41.22[22q13.2]-41.27[22q13.2]); Enh(X)(2.69[Xpter]-11.42[Xq22.2]); Enh(X)(140.46[Xq27.2]-
154.49[Xqter]) 
2359  pPCL  t(14;16)  Enh(1)(16.95[1p36.13]-17.02[1p36.13]); Enh(1)(25.36[1p36.11]-25.41[1p36.11]); Enh(1)(141.47[1q12]-156.56[1q23.2]); Dim(1)(156.57[1q23.2]-
158.29[1q23.3]); Enh(1)(158.31[1q23.3]-164.67[1q24.2]); Dim(1)(164.67[1q24.2]-196.88[1q25.2]); Enh(1)(175.52[1q25.2]-175.62[1q25.2]); 
Dim(1)(175.62[1q25.2]-187.41[1q31.2]); Dim(1)(188.03[1q31.2]-194.6[1q31.3]); Dim X2(1)(194.6[1q31.3]-196.88[1q32.1]); 
Dim(1)(199.19[1q32.1]-199.22[1q32.1]); Dim X2(2)(34.61[2p22.3]-34.67[2p22.3]); Dim(2)(88.98[2p11.2]-89.2[2p11.2]); Dim(3)(164.05[3q36.1]-
164.1[3q36.1]); Dim(3)(184.92[3q27.1]-199.38[3qter]); Dim(5)(119.26[5q23.1]-119.62[5q23.1]); Enh(5)(180.03[5q35.3]-180.15[5q35.3]); Dim 
X2(5)(180.35[5q35.3]-180.36[5q35.3]); Dim X2(6)(32.56[6p21.32]-32.75[6p21.32]); Dim(8)(0.06[8pter]-47.06[8p11.1]); Dim X2(8)(39.36[8p11.23]-
39.51[8p11.22]); Enh(8)(47.06[8q11.1]-146.26[8qter]); Dim(9)(136.9[9q34.3]-137.09[9q34.3]); Enh(10)(56.12[10q21.1]-56.16[10q21.1]); 
Enh(11)(72.02[11q13.4]-134.43[11qter]); Dim(12)(0.02[12pter]-4.41[12p13.32]); Dim(12)(5.19[12p13.32]-16.31[12p12.3]); Dim(12)(17.87[12p12.3]-
25.61[12p12.1]); Dim(12)(27.17[12p11.23]-28.47[12p11.22]); Dim(12)(32.84[12p11.1]-33.4[12p11.1]); Enh(12)(8.6[12q21.32]-126.61[12q24.32]); 
Dim(12)(126.64[12q24.32]-132.39[12qter]); Dim(13)(22.02[13q12.11]-80.53[13q31.1]); Dim X2(13)(47.8[13q14.2]-47.9[13q14.2]); 
Enh(13)(85.05[13q31.1]-114.12[13qter]); Dim(14)(19.27[14q11.2]-19.48[14q11.2]); Dim(14)(105.18[14q32.33]-106.35[14qter]); 
Enh(15)(18.66[15q11.2]-19.81[15q11.2]); Dim(15)(19.81[15q11.2]-20.22[15q11.2]); Dim(16)(0.51[16p13.3]-0.05[16p13.3]); 
Enh(16)(32.11[16p11.2]-33.53[16p11.2]); Dim(16)(45.02[16q11.2]-77.46[16q23.1]); Dim(17)(0.03[17pter]-1.63[17p13.3]); Dim(17)(7.19[17p13.1]-
7.22[17p13.1]); Dim(17)(7.33[17p13.1]-15.42[17p12]); Dim(17)(21.09[17p11.2]-21.63[17p11.2]); Enh(18)(0.0[18pter]-61.37[18q22.1]); 
Dim(18)(61.4[18q22.1]-76.11[18qter]); Enh(22)(17.04[22q11.21]-17.39[22q11.21]); Dim(22)(20.24[22q11.21]-32.79[22q12.3]); 
Dim(X)(90.84[Xq21.31]-92.1[Xq21.31]); Enh(X)(97.65[Xq21.33]-154.49[Xqter]) 
3125  pPCL  t(14;16)  Dim(1)(50.64[1p32.3]-51.19[1p32.3]); Dim(1)(83.33[1p31.1]-83.58[1p31.1]); Enh(1)(141.52[1q12]-145.65[1q23.3]); Dim(1)(145.65[1q21.2]-
146.01[1q21.2]); Dim(1)(193.49[1q31.1]-193.56[1q31.1]); Dim(2)(88.99[2p11.2]-8.91[2p11.2]); Enh(3)(185.32[3q27.2]-185.56[3q27.2]); 
Dim(4)(70.33[4q13.3]-70.41[4q13.3]); Dim(5)(87.79[5q14.3]-148.72[5q32]); Dim X2(5)(146.7[5q32]-148.21[5q32]); Dim(6)(32.56[6p21.32]-
32.73[6p21.32]); Dim(8)(7.36[8p23.1]-8.12[8p23.1]); Dim(10)(0.12[10p15.3]-38.6[10p11.1]); Dim(11)(111.42[11q23.1]-111.49[11q23.1]); 
Enh(12)(9.53[12p13.31]-9.61[12p13.31]); Dim(14)(19.27[14q11.2]-19.5[14q11.2]); Enh(14)(21.72[14q11.2]-22.02[14q11.2]); 
Dim(14)(105.31[14q32.33]-105.99[14q32.33]); Dim(16)(34.06[16p11.2]-45.02[16p11.2]); Dim(16)(65.39[16q22.1]-68.09[16q22.1]); 
Dim(16)(77.64[16q23.1]-77.84[16q23.1]); Enh(17)(44.02[17q21.32]-78.65[17qter]); Dim(X)(88.16[Xq21.31]-90.84[Xq21.31]) 
3343  pPCL  t(14;16) 
t(8;14) 
Dim(1)(82.13[1p31.1]-82.62[1p31.1]); Dim(1)(88.33[1p22.2]-144.83[1q21.1]); Dim(1)(149.37[1q21.3]-149.4[1q21.3]); Enh(1)(158.3[1q23.3]-
158.38[1q23.3]); Dim(1)(165.1[1q24.2]-168.72[1q25.1]); Dim(1)(173.88[1q25.2]-176.71[1q25.3]); Dim(1)(199.09[1q32.1]-199.25[1q32.1]); 
Dim(2)(89.0[2p11.2]-89.33[2p11.2]); Dim(4)(91.48[4q22.1]-91.65[4q22.1]); Dim(5q13.2); Dim(7)(0.14[7pter]-13.01[7p21.3]); 
Enh(7)(127.69[7q32.1]-158.62[7qter]); Monosomy(8)(0.06-146.26); Dim X2(8)(39.36[8p11.22]-39.51[8p11.22]); Normal(8)(128.81[8q24.21]-
129.7[8q24.21]); Enh(10)(46.37[10q11.22]-47.74[10q11.22]); Dim(12)(11.4[12p13.2]-11.44[12p13.2]); Monosomy(13)(18.07-114.12); 
Enh(14)(18.5[14q11.2]-19.49[14q11.2]); Dim(14)(42.54[14q21.2]-42.8[14q21.2]); Enh(14)(104.95[14q32.33]-105.29[14q32.33]); 
Dim(14)(105.41[14q32.33]-106.17[14q32.33]); Dim(15)(19.41[15q11.2]-20.08[15q11.2]); Enh(15)(75.28[15q24.3]-77.09[15q25.1]); 
Dim(16)(27.42[16p12.1]-27.55[16p12.1]); Dim(16)(45.06[16q11.2]-88.69[16qter]); Normal(16)(77.15[16q23.1]-77.37[16q23.1]); 
Enh(17)(21.25[17p11.2]-21.47[17p11.2]); Dim X2(22)(22.67[22q11.23]-22.71[22q11.23]) 
3272  pPCL  nonHRD  Enh(1)(141.47[1q12]-182.87[1q31.1]); Dim X2(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(1)(182.89[1q31.1]-186.42[1q31.1]); Enh(1)(186.59[1q31.1]-
188.86[1q31.2]); Dim(1)(188.96[1q31.2]-195.14[1q31.3]); Enh(1)(195.17[1q32.1]-208.32[1q32.3]); Dim(1)(208.34[1q32.3]-218.0[1q41]); 
Enh(1)(218.17[1q41]-227.09[1q42.2]); Dim(1)(227.12[1q42.2]-232.13[1q43]); Enh(1)(232.25[1q42.3]-245.43[1qter]); Dim X2(2)(88.98[2p11.2]-Appendices 
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89.33[2p11.2]); Dim(2)(116.05[2q14.1]-116.18[2q14.1]); Enh(3)(0.04[3pter]-83.81[3p12.1]); Dim(3)(164.04[3q26.1]-164.11[3q26.1]); 
Dim(3)(178.21[3q26.32]-178.41[3q26.32]); Dim(3)(181.62[3q26.33]-199.38[3qter]); Dim(4)(70.33[4q13.3]-70.41[4q13.3]); Dim(5)(140.2[5q31.2]-
140.21[5q31.2]); Trisomy(7)(0.14-158.62); Dim(8)(128.83[8q24.21]-128.97[8q24.21]); Dim(11)(83.76[11q14.1]-84.25[11q14.1]); 
Monosomy(12)(0.03-132.39); Monosomy(13)(18.07-114.12); Enh(14)(21.5[14q11.2]-22.07[14q11.2]); Dim(14)(105.28[14q32.33]-
105.79[14q32.33]); Dim(15)(18.75[15q11.2]-19.87[15q11.2]); Dim(16)(68.73[16q22.1]-68.75[16q22.1]); Dim(16)(72.93[16q22.3]-73.01[16q22.3]);  
Enh(19)(0.06[19pter]-23.4[19p12]); Dim(19)(52.33[19q13.32]-63.78[19qter]); Dim(20)(0.01[20pter]-13.75[20p12.1]); Dim(22)(20.88[22q11.22]-
21.57[22q11.22]); Dim(22)(37.68[22q13.1]-37.71[22q13.1]) 
3342  pPCL  t(4;14)  Enh(1)(141.47[1q12]-245.43[1qter]); Dim X2(2)(89.0[2p11.2]-89.16[2p11.2]); Dim(3)(196.91[3q29]-196.97[3q29]); Dim X2(4)(69.2[4q13.2]-
69.79[4q13.2]); Dim(4)(181.46[4q34.3]-181.72[4q34.3]); Enh(6)(32.57[6p21.32]-32.67[6p21.32]); Dim X2(6)(165.7[6q27]-165.7[6q27]); 
Dim(7)(41.78[7p14.1]-41.87[7p14.1]); Dim X2(7)(141.22[7q34]-141.25[7q34]); Dim(7)(151.56[7q36.1]-151.88[7q36.2]); Enh(8)(39.36[8p11.22]-
39.51[8p11.22]); Dim(9)(9.3[9p23]-9.47[9p23]); Dim X2(12)(9.53[12p13.31]-9.59[12p13.31]); Dim(12)(19.5[12p12.3]-19.54[12p12.3]); 
Dim(12)(95.14[12q23.1]-95.28[12q23.1]); Dim(12)(113.41[12q24.21]-132.39[12qter]); Monosomy(13)(18.07-114.12); Dim X2(13)(47.85[13q14.2]-
47.95[13q14.2]); Enh(14)(18.64[14q11.2]-19.5[14q11.2]); Dim(14)(105.31[14q32.33]-105.85[14q32.33]); Enh(15)(18.72[15q11.2]-20.08[15q11.2]); 
Enh(15)(54.5[15q21.3]-54.54[15q21.3]); Dim(16)(45.02[16q11.2]-88.69[16qter]); Enh(16)(69.41[16q22.2]-69.75[16q22.2]); Dim(17)(0.03[17pter]-
21.74[17p11.1]); Dim X2(19)(56.83[19q13.41]-56.84[19q13.41]); Enh(20)(48.72[20q13.13]-62.38[20qter]); Enh(22)(22.67[22q11.23]-
22.73[2q11.23]); Enh(22)(23.98[22q11.23]-24.23[22q11.23]); Dim(X)(81.84[Xq21.1]-124.15[Xq25]); Enh(X)(152.0[Xq28]-154.49[Xq28]) 
1188  sPCL  t(11;14)  Dim(1)(16.79[1p36.13]-16.84[1p36.13]); Enh(1)(16.95[1p36.13]-17.0[1p36.13]); Dim X2(1)(19.35[1p36.13]-19.36[1p36.13]); 
Enh(1)(149.37[1q21.3]-149.4[1q21.3]); Dim(1)(229.37[1q42.2]-237.78[1q43]); Enh(1)(244.16[1q44]-244.63[1q44]); Enh(2)(74.58[2p13.1]-
74.67[2p13.1]); Dim X2(2)(89.0[2p11.2]-89.11[2p11.2]); Dim X2(3)(164.0[3q26.1]-164.1[3q26.1]); Dim X2(4)(13.24[4p15.33]-13.26[4p15.33]); 
Dim(4)(145.2[3q31.21]-145.34[3q31.21]); Enh(6)(27.87[6p22.1]-27.98[6p22.1]); Enh(6)(30.63[6p22.1]-30.65[6p21.33]); Enh(6)(33.49[6p21.32]-
33.5[6p21.32]); Dim(7)(3.85[7p22.2]-3.86[7p22.2]); Enh(8)(2.34[8p23.2]-2.9[8p23.2]); Enh(8)(39.36[8p11.22]-39.51[8p11.22]); 
Dim(8)(52.77[8q11.22]-53.13[8q11.22]); Dim(8)(84.6[8q21.13]-85.33[8q21.2]); Dim(8)(108.35[8q23.1]-108.81[8q23.1]); Dim(8)(129.09[8q24.21]-
129.22[8q24.21]); Trisomy(11)(0.18-134.43); Trisomy(13)(18.07-114.12); Dim(14)(105.34[14q32.33]-106.22[14q32.33]); Enh(15)(19.81[15q11.2]-
20.08[15q11.2]); Dim(16)(68.73[16q22.1]-68.75[16q22.1]); Enh(17)(31.44[17q12]-31.5[17q12]); Dim(17)(36.76[17q21.2]-36.78[17q21.2]); 
Tetrasomy(18)(0.0-76.11); Dim(22)(21.47[22q11.22]-21.58[22q11.22]); Enh(22)(22.61[22q11.22]-22.73[22q11.22]); Enh(X)(134.53[Xq26.3]-
134.64[Xq26.3]) Appendices 
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Appendix 9: Graphical representation of array CGH results 
for all patient groups  
 
The 850-band idiogram of the G-banding pattern of the chromosome is shown on the left. 
Vertical light-blue lines correspond to each patient; red bars = gains; thicker red bars = 
gains of two extra copies or more; green bars = mono-allelic losses; black areas circled in 
red = HD; yellow and light blue areas = CNV, respectively losses and gains; dark blue 
areas circled in black = amplifications. Black vertical lines separate the different genetic 
groups. From left to right: pre-malignant patients, MM and PCL. Patients from the 
MGUS/SMM and MM groups were ordered as follow (from left to right): t(4;14), t(14;16), 
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Appendix 10: Karyotype description of the cytogenetically 
abnormal MM patients with t(14;20) 
 














































1849  ~90,XXY,t(2;22)(p11;q13),-13,t(14;20)(q32;q12)inc[1]/46,XY[117]  
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Appendix 11: Characteristics of PCL patients 
 
    Age  Sex 
Prior 
















mg/L        Months 
RegID                             
325    52  F  No  20.0  61.0  165  3.4  32.0  47.5  IgGk  89  Dead  1 
3210    78  F  No  33.2  86.0  18  4.3  36.0  1.9  IgGk  nr  Dead  5 
1576    79  M  No  11.8  82.0  168  2.7  28.0  7.4  IgA  85  Dead  6 
3272    59  M  No  64.0  12.5  112  3.0  ‘normal’  nr  nr  high  Dead  12 
742    84  F  No  5.7  94.0  340  2.2  26.0  8.0  IgAk  80  Dead  1 
165    73  F  No  38.0  nr  107  2.5  34.0  5.2  IgGλ  100  Dead  1 
3125    23  M  No  31.4  11.0  212  2.0  25.0  nr  IgGλ  42  Alive  13† 
3343    83  F  No  nr  71.0  nr  2.2  25.0  nr  IgGk  47  Alive  3† 
2359    50  M  No  14.6  61.0  23  3.4  19.0  9.6  IgAλ  55  Dead  0 
128    78  M  No  2.5  84.0  122  2.4  32.0  14.5  IgGk  nr  Dead  0 
1188    62  F  Yes  15.0  nr  221  3.5  27.0  2.8  IgGλ  98  Alive  20† 
3342    72  F  Yes  42.0  7.7  162  1.89  35.0  nr  IgGk  nr  Dead  1 
 
(RegID, patient identification; F, female; M, male; PP, paraprotein; MM, myeloma; OS, overall survival; nr, non reported; †, still alive at the time of the study)  Appendices 
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Appendix 12: Primers for the eight genes included in the 
common minimally deleted region at 5q33.1 
 
    Primers 
Gene  Primer location 
& product size 
Fwd  Rew 
SPINK5L2 
Primers in exons 2 










Primers in exons 1 










Primers in exons 3 










Primers in exons 1 









Primers in exons 1 











Primers in exons 14 
& 16; two PCR 











Primers in exons 6 





































Exon  Fwd  (5’ to 3’)  Rev (5’ to 3’) 
1  GGATGACAACACTCCGGAAATA  CCTAGAAGGCCAGGAACTACAAA 
2  ATGATACCTCTGCTTGTGTGTG  CCAGCCTACAAGGTGACTTAGATT 
3  GTATGACCGTATGTGTGGTAGCTT  GTGACCCAAGAAACATGTACTCAC 
4/5  GTGGAGTTTCTGACTCATTTCCTC  TTGTCCTATACACCGTGTCCACTA 
6  GTGGAGTTTCTGACTCATTTCCTC  AAGGGAGATTAAGGAAGCCAAC 
7  CAAGAACCTGATTTCAGAGAGC  GCTCATGGTTACTTACTGTCCATC 
8  CAGATGCCATCAGTGTCTTTGC  TGGAGACAATGGTCCTGAGAGG 
9  GTCAGCAGCATAGAAACGGACTAA  TCAAGACGTGAGAGCACCTAAGAT 
10  ACCTGAACCCAATGATAAGCAG  TACACTTCTAGGCAGAGAACGTCA 
11  CCAGGCCATTTAGTTCTCACA  AAGTCCGACTGTAACACCGTAAAG 
12  CAGATCTCTTCTCCTTGCATGACT  TCACCTACTCCCTCATGTTCCTTA 
13  AGGCCTAGTAATCAGCGGGACTG  CAGAATGATGAATGTGGGATGG 
14  GCATCTCTGTTGATTCCAGATCC  CCCAAGTTGTCATATTAAGGCCAAG 
15  TGAGGTTTGAAGGCATAGCTAAGGAG  GAAACAAGTTCATGCCTTTCTGC 
16  TGAATGTGCTTGAGGGAAAGA  GGAACTGGGCTAGACTGTGATAAAGG 
17  TCACAGTCTAGCCCAGTTCCTAA  GGCGGAACTAAAGATAACCCAACA 
18  CCAAAGATGATATGTACGGAGCTTAC  ACTGTAGGTTGGGCAAGTGAATGA 
19  CGGAGAGAGATTTCTAAGGCATTC  GAGTCCCTGCTATGAGAAATGA 
20  GATGGTTCCTTCCTACCCGACAC  CTACATTTGGGTTACTGCTTGCTG 
21  CCCACGCCAGTTAGCAATGTTAC  CACTGCACTGCTCCTAACTCACAA 
22  GGACCAGCTTATCAGTGATTTTCT  CTGGATGGCCCTACTTGCTTTCT 
 Appendices 
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Appendix 14: Primers for all exons of the PPP2R2A and 




Exon  Fwd (5’ to 3’)  Rev (5’ to 3’) 
1  CTGCCGGAGAAAGAGCACGA  ACCCTACTCCCTCAAACCCGA 
2  TGTGTGGGCAGAACTAGGCTG  TCGGCTTCAAGGAAATCCTCC 
3  GTTCTGAAACTAGTGAGTCGGG  TCCTCTGATGAGATTCTCCAGTGC 
4  TGCAGGGTCCTTTGGAATTG  CCTGCCCAAGATTACGAGACTG 
5  CATGGAATTTATGAGTGCCACC  GCTCTGCTCAGGATTTGGGCT 
6  GCTTGGCATGTCTTTCAAGC  ATGGGCACAACATGCCTTCTT 
7  GGCTGCAGTGAGCCGAGATTG  CAAGTGGCTCTGGACACACGGG 
8  GAAGCTTTCAGGAGAATTCTAGCC  GGTGAACAAACACCATACAGG 
9  GTACCTCCCTGAAGGGCTTGT  GACGAAGTTAGGACCTGGAATG 





Exon  Fwd (5’ to 3’)  Rev (5’ to 3’) 
1  CGGAGTTAAAGCGCTAAGAGAAG  GCCGAACAAAGTGCCTAGAAAT 
2  GATCGAATCACGTTCATCTTGC  TCCTGAAACGGACGACATATTG 
3  GCCTCCTTGTGAAGTTGAAGGT  GCAAGTTTGCAGAGTAGGCAAT 
4  CTCAGGCTGGTACATCACGAGT  GCTTCATTAACGGAATTCACGAC 
5  TTGGATTCAATGGCTGTAGGC  AACCATGCGGAAATGTAGGATT 
6  GCTGAAATCGCACCATTGTAC  CCAACAACTTCATTTTCCTATGC 
7  GAAGGTGACTGATTGAACATCAG  GGCAACTGGCCATGTACTAAGA 
8  GACGTTACTGCCCAATCAGGTT  CGGTAAGACGAGTAAGACATTTCC 
9  CTGCAGTTGACAGAGAATTTCA  ACCAATTCTGAGGCTCTCCAAG 
10  CTTGGAGAGCCTCAGAATTGGT  TTATTGCTCATGCAAAGCAGGT 
11  TGGGCACATTATGTATTCACTGC  AGCTTCATGTCAGCTTCCCAAT 
12  CACAGTGTTTCCAAAGGAAGATG  TACGTTGTGCCAAACACAAACA 
13  TTGCTTGTGCTTTACGGTATCC  TCTTGGTCCAAAGTCAACTGGA 
14  GTTGCAGTGAGCTGAGATTGTG  TGTCAGGATACCTGAACCCAG 
15  GAGGAGGAGGAGGATGACAGAA  AGCATTTACTCTCTGGCGGAAG 
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Appendix 15: Excel sheet describing MLPA results for the PCL patient 3210  
PEAK AREA
Probe location Control Sample 1 9 19 3 8 1 19 2 1 19 1 14 19 19 3 19 15 1 19 1 1 17 19 1 1 1 1 1 8 19 1 5 1 1 19 11 1 14 12 1 13 1
CDKN2C exon 2 108 554 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CDKN2C exon 3 111 253 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
centromeric of CDKN2C 114 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FAF1 intron 1-2 distal 117 517 735 1.121 0.621 0.561 0.721 0.543 1.079 0.617 0.699 0.59 0.485 0.622 0.555 0.637 0.496 0.615 0.62 0.647 1.098 0.538 1.102 0.958 0.94 0.537 0.558 0.592 0.505 0.99 0.604 0.64 0.42 0.549 0.428 0.644 0.435 0.567 0.615 0.679 0.974 0.545 1.043 0.975 0.927
FAF1 intron 1-2 prox 120 557 714 1.01 0.56 0.506 0.65 0.49 0.973 0.556 0.63 0.532 0.438 0.561 0.5 0.574 0.447 0.554 0.559 0.583 0.99 0.485 0.994 0.864 0.848 0.484 0.503 0.533 0.455 0.893 0.545 0.577 0.378 0.495 0.386 0.581 0.393 0.511 0.555 0.612 0.878 0.492 0.94 0.879 0.836
Between FAF1 & CDKN2C 124 363 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NOTCH2 1p11.2 130 748 949 1 0.554 0.501 0.643 0.485 0.963 0.55 0.624 0.527 0.433 0.555 0.495 0.568 0.442 0.548 0.553 0.577 0.98 0.48 0.983 0.855 0.839 0.479 0.498 0.528 0.45 0.883 0.539 0.571 0.375 0.49 0.382 0.575 0.389 0.506 0.549 0.606 0.869 0.487 0.93 0.87 0.827
con 9q21 136 442 1012 1.805 1 0.903 1.16 0.875 1.737 0.993 1.126 0.95 0.782 1.001 0.894 1.025 0.798 0.99 0.998 1.042 1.768 0.866 1.775 1.543 1.515 0.865 0.899 0.953 0.813 1.594 0.973 1.031 0.676 0.884 0.689 1.037 0.701 0.913 0.991 1.093 1.569 0.878 1.679 1.57 1.493
SMARCA4 19p13.3 142 550 1394 1.998 1.107 1 1.285 0.969 1.923 1.099 1.247 1.052 0.865 1.108 0.989 1.135 0.884 1.096 1.105 1.153 1.957 0.959 1.965 1.708 1.677 0.958 0.995 1.055 0.9 1.765 1.077 1.141 0.748 0.979 0.763 1.148 0.776 1.011 1.097 1.21 1.737 0.972 1.859 1.738 1.653
con 3q29 148 557 1099 1.555 0.862 0.778 1 0.754 1.497 0.856 0.97 0.819 0.674 0.863 0.77 0.884 0.688 0.853 0.86 0.898 1.523 0.747 1.529 1.33 1.305 0.745 0.775 0.821 0.7 1.374 0.839 0.889 0.582 0.762 0.594 0.894 0.604 0.787 0.854 0.942 1.352 0.757 1.447 1.353 1.286
con 8q24 154 396 1036 2.062 1.143 1.032 1.326 1 1.985 1.135 1.287 1.086 0.893 1.144 1.021 1.172 0.912 1.131 1.141 1.19 2.02 0.99 2.028 1.763 1.731 0.988 1.027 1.089 0.929 1.822 1.112 1.178 0.772 1.01 0.788 1.185 0.801 1.043 1.132 1.249 1.793 1.004 1.919 1.794 1.706
PPAP2B 1p32 160 456 601 1.039 0.576 0.52 0.668 0.504 1 0.572 0.648 0.547 0.45 0.576 0.514 0.59 0.46 0.57 0.575 0.6 1.018 0.499 1.022 0.888 0.872 0.498 0.517 0.548 0.468 0.918 0.56 0.594 0.389 0.509 0.397 0.597 0.404 0.525 0.57 0.629 0.903 0.506 0.967 0.904 0.859
CCNE1 19q12 166 471 1086 1.817 1.007 0.91 1.169 0.881 1.749 1 1.134 0.957 0.787 1.008 0.9 1.033 0.804 0.997 1.005 1.049 1.78 0.872 1.787 1.554 1.525 0.871 0.905 0.959 0.818 1.605 0.98 1.038 0.681 0.89 0.694 1.045 0.706 0.919 0.998 1.101 1.58 0.885 1.691 1.581 1.503
con 2p16 171 632 1285 1.603 0.888 0.802 1.03 0.777 1.543 0.882 1 0.844 0.694 0.889 0.794 0.911 0.709 0.879 0.887 0.925 1.57 0.769 1.576 1.37 1.345 0.768 0.798 0.846 0.722 1.416 0.864 0.916 0.6 0.785 0.612 0.921 0.623 0.811 0.88 0.971 1.393 0.78 1.491 1.394 1.326
GNB1 1p36.33 178 457 1101 1.899 1.052 0.951 1.221 0.921 1.828 1.045 1.185 1 0.822 1.053 0.94 1.079 0.84 1.042 1.051 1.096 1.86 0.912 1.867 1.624 1.594 0.91 0.946 1.002 0.855 1.677 1.024 1.085 0.711 0.93 0.725 1.091 0.738 0.961 1.042 1.151 1.651 0.924 1.767 1.652 1.571
PDCD5 19q13.12 184 368 1078 2.309 1.279 1.156 1.485 1.12 2.223 1.27 1.441 1.216 1 1.281 1.143 1.312 1.021 1.266 1.277 1.333 2.262 1.108 2.271 1.974 1.938 1.107 1.15 1.219 1.04 2.04 1.245 1.319 0.865 1.131 0.882 1.327 0.897 1.168 1.268 1.399 2.007 1.124 2.148 2.008 1.91
TNNT2 1q32.1 190 561 1283 1.803 0.999 0.902 1.159 0.874 1.735 0.992 1.125 0.949 0.781 1 0.893 1.024 0.797 0.989 0.997 1.04 1.766 0.865 1.773 1.541 1.513 0.864 0.898 0.952 0.812 1.592 0.972 1.03 0.675 0.883 0.688 1.036 0.701 0.912 0.99 1.092 1.567 0.877 1.677 1.568 1.491
con 14q24 202 265 679 2.02 1.119 1.011 1.299 0.979 1.944 1.111 1.26 1.064 0.875 1.12 1 1.147 0.893 1.108 1.117 1.166 1.978 0.969 1.986 1.727 1.695 0.968 1.006 1.066 0.909 1.784 1.089 1.154 0.756 0.989 0.771 1.161 0.785 1.022 1.109 1.224 1.756 0.983 1.879 1.757 1.671
LDLR 19p13.3 211 528 1179 1.76 0.975 0.881 1.132 0.854 1.694 0.968 1.098 0.927 0.762 0.976 0.871 1 0.779 0.965 0.974 1.016 1.724 0.845 1.731 1.505 1.477 0.844 0.877 0.929 0.793 1.555 0.949 1.006 0.659 0.862 0.672 1.012 0.684 0.89 0.966 1.066 1.53 0.857 1.638 1.531 1.456
PPP1R15A 19q13.2 220 455 1305 2.261 1.253 1.132 1.454 1.096 2.176 1.244 1.411 1.19 0.979 1.254 1.119 1.284 1 1.24 1.251 1.305 2.214 1.085 2.223 1.933 1.897 1.084 1.126 1.193 1.018 1.997 1.219 1.292 0.847 1.107 0.863 1.299 0.879 1.144 1.241 1.37 1.966 1.1 2.103 1.966 1.87
con 3p25 229 281 650 1.823 1.01 0.913 1.172 0.884 1.755 1.003 1.138 0.96 0.79 1.011 0.903 1.036 0.807 1 1.009 1.052 1.786 0.875 1.793 1.559 1.53 0.874 0.908 0.963 0.821 1.611 0.983 1.042 0.683 0.893 0.696 1.048 0.709 0.922 1.001 1.105 1.585 0.887 1.696 1.586 1.508
UPK1A 19q13.13 238 283 649 1.808 1.002 0.905 1.162 0.877 1.74 0.995 1.128 0.952 0.783 1.003 0.895 1.027 0.8 0.991 1 1.043 1.771 0.868 1.778 1.546 1.517 0.866 0.9 0.954 0.814 1.597 0.975 1.033 0.677 0.885 0.69 1.039 0.702 0.914 0.992 1.095 1.572 0.88 1.682 1.572 1.495
con 15q21 247 409 899 1.732 0.96 0.867 1.114 0.84 1.668 0.953 1.081 0.912 0.75 0.961 0.858 0.984 0.766 0.95 0.958 1 1.697 0.832 1.704 1.481 1.454 0.83 0.863 0.915 0.78 1.53 0.934 0.99 0.649 0.849 0.662 0.996 0.673 0.876 0.951 1.05 1.506 0.843 1.612 1.507 1.433
GTF2B 1p22.2 256 359 465 1.021 0.566 0.511 0.656 0.495 0.983 0.562 0.637 0.538 0.442 0.566 0.506 0.58 0.452 0.56 0.565 0.589 1 0.49 1.004 0.873 0.857 0.489 0.509 0.539 0.46 0.902 0.551 0.583 0.382 0.5 0.39 0.587 0.397 0.516 0.56 0.619 0.888 0.497 0.95 0.888 0.845
BC-2 19q13.4 266 367 970 2.083 1.154 1.043 1.34 1.01 2.005 1.146 1.3 1.097 0.902 1.156 1.032 1.184 0.922 1.143 1.153 1.202 2.041 1 2.049 1.781 1.748 0.999 1.038 1.1 0.938 1.84 1.123 1.19 0.78 1.02 0.796 1.197 0.81 1.054 1.144 1.262 1.811 1.014 1.938 1.812 1.723
LPHN2 1p31.1 274 293 378 1.017 0.563 0.509 0.654 0.493 0.979 0.56 0.635 0.535 0.44 0.564 0.504 0.578 0.45 0.558 0.563 0.587 0.996 0.488 1 0.869 0.853 0.487 0.507 0.537 0.458 0.898 0.548 0.581 0.381 0.498 0.388 0.584 0.395 0.514 0.558 0.616 0.884 0.495 0.946 0.884 0.841
FAF1 1p32.3 283 246 365 1.169 0.648 0.585 0.752 0.567 1.126 0.644 0.73 0.616 0.507 0.649 0.579 0.664 0.517 0.641 0.647 0.675 1.146 0.561 1.15 1 0.982 0.561 0.583 0.617 0.527 1.033 0.631 0.668 0.438 0.573 0.447 0.672 0.454 0.592 0.642 0.709 1.017 0.569 1.088 1.017 0.967
con 17q11 292 385 582 1.192 0.66 0.596 0.766 0.578 1.147 0.656 0.743 0.627 0.516 0.661 0.59 0.677 0.527 0.654 0.659 0.688 1.167 0.572 1.172 1.019 1 0.571 0.594 0.629 0.537 1.053 0.643 0.681 0.446 0.584 0.455 0.685 0.463 0.603 0.654 0.722 1.036 0.58 1.109 1.036 0.986
BAX 19q13.3 301 300 794 2.086 1.156 1.044 1.341 1.012 2.008 1.148 1.302 1.099 0.904 1.157 1.033 1.185 0.923 1.144 1.154 1.204 2.043 1.001 2.052 1.784 1.751 1 1.039 1.101 0.939 1.843 1.125 1.192 0.781 1.022 0.797 1.199 0.811 1.055 1.145 1.264 1.814 1.015 1.941 1.814 1.726
LMNA 1q21.2 310 298 759 2.008 1.112 1.005 1.291 0.974 1.932 1.105 1.253 1.057 0.869 1.114 0.994 1.141 0.888 1.101 1.111 1.159 1.966 0.964 1.974 1.717 1.685 0.962 1 1.06 0.904 1.773 1.083 1.147 0.752 0.983 0.767 1.154 0.78 1.016 1.102 1.216 1.745 0.977 1.868 1.746 1.661
PTAFR 1p35.3 320 310 745 1.894 1.05 0.948 1.218 0.919 1.823 1.042 1.182 0.998 0.82 1.051 0.938 1.076 0.838 1.039 1.048 1.093 1.855 0.909 1.863 1.62 1.59 0.908 0.944 1 0.853 1.673 1.021 1.082 0.709 0.928 0.723 1.089 0.736 0.958 1.04 1.148 1.647 0.922 1.762 1.648 1.567
TP73 1p36.3 328 312 879 2.221 1.23 1.112 1.428 1.077 2.138 1.222 1.386 1.169 0.962 1.232 1.1 1.262 0.982 1.218 1.229 1.282 2.175 1.066 2.184 1.899 1.864 1.064 1.106 1.172 1 1.962 1.197 1.269 0.832 1.088 0.848 1.276 0.863 1.123 1.219 1.345 1.931 1.081 2.066 1.931 1.837
CYP2J2 1p32.1 337 149 214 1.132 0.627 0.567 0.728 0.549 1.09 0.623 0.706 0.596 0.49 0.628 0.561 0.643 0.501 0.621 0.626 0.653 1.109 0.543 1.113 0.968 0.95 0.543 0.564 0.598 0.51 1 0.61 0.647 0.424 0.554 0.432 0.651 0.44 0.573 0.621 0.686 0.984 0.551 1.053 0.985 0.936
TNFRSF14 1p36.33 346 465 1094 1.854 1.028 0.928 1.192 0.899 1.785 1.02 1.157 0.977 0.803 1.029 0.918 1.054 0.82 1.017 1.026 1.07 1.816 0.89 1.824 1.586 1.556 0.889 0.924 0.979 0.835 1.638 1 1.06 0.694 0.908 0.708 1.066 0.721 0.938 1.018 1.124 1.612 0.903 1.725 1.613 1.534
con 8q13 355 467 1037 1.75 0.97 0.876 1.125 0.849 1.685 0.963 1.092 0.922 0.758 0.971 0.867 0.994 0.774 0.96 0.968 1.01 1.714 0.84 1.721 1.497 1.469 0.839 0.872 0.924 0.788 1.546 0.944 1 0.655 0.857 0.668 1.006 0.68 0.885 0.961 1.06 1.522 0.852 1.628 1.522 1.448
TGFB1 19q13.31 364 178 603 2.67 1.48 1.337 1.717 1.295 2.57 1.469 1.666 1.406 1.156 1.481 1.322 1.517 1.181 1.465 1.477 1.541 2.615 1.282 2.626 2.283 2.241 1.28 1.33 1.41 1.202 2.359 1.44 1.526 1 1.308 1.02 1.535 1.038 1.351 1.466 1.618 2.322 1.3 2.484 2.322 2.209
DPYD 1p21.3 373 183 474 2.042 1.131 1.022 1.313 0.99 1.965 1.123 1.274 1.075 0.884 1.133 1.011 1.16 0.903 1.12 1.129 1.178 2 0.98 2.008 1.746 1.713 0.979 1.017 1.078 0.919 1.803 1.101 1.166 0.765 1 0.78 1.173 0.793 1.033 1.121 1.237 1.775 0.994 1.899 1.776 1.689
con 5q22 382 115 382 2.618 1.451 1.311 1.684 1.27 2.52 1.441 1.634 1.379 1.134 1.452 1.296 1.488 1.158 1.436 1.448 1.511 2.565 1.257 2.575 2.239 2.197 1.255 1.304 1.382 1.179 2.313 1.412 1.496 0.981 1.282 1 1.505 1.017 1.324 1.437 1.586 2.276 1.274 2.436 2.277 2.166
TNFRSF4 1p36.33 391 188 415 1.74 0.964 0.871 1.119 0.844 1.675 0.957 1.086 0.916 0.754 0.965 0.862 0.989 0.77 0.954 0.963 1.004 1.704 0.835 1.711 1.488 1.46 0.834 0.867 0.919 0.784 1.537 0.938 0.994 0.652 0.852 0.665 1 0.676 0.88 0.955 1.054 1.513 0.847 1.619 1.513 1.439
MFN2 1p36.22 400 136 444 2.573 1.426 1.288 1.655 1.248 2.477 1.416 1.606 1.355 1.114 1.428 1.274 1.462 1.138 1.411 1.424 1.485 2.52 1.235 2.531 2.2 2.16 1.234 1.282 1.358 1.159 2.273 1.388 1.47 0.964 1.26 0.983 1.479 1 1.302 1.413 1.559 2.237 1.252 2.394 2.238 2.129
ZNF342 19q13.3 409 248 622 1.977 1.095 0.99 1.271 0.959 1.903 1.088 1.234 1.041 0.856 1.097 0.979 1.123 0.874 1.084 1.094 1.141 1.936 0.949 1.944 1.69 1.659 0.948 0.985 1.044 0.89 1.746 1.066 1.129 0.74 0.968 0.755 1.136 0.768 1 1.085 1.198 1.719 0.962 1.839 1.719 1.635
con 11q23 418 315 728 1.822 1.009 0.912 1.171 0.883 1.754 1.002 1.137 0.959 0.789 1.011 0.902 1.035 0.806 0.999 1.008 1.051 1.784 0.874 1.791 1.558 1.529 0.873 0.907 0.962 0.82 1.609 0.982 1.041 0.682 0.892 0.696 1.047 0.708 0.921 1 1.104 1.584 0.887 1.695 1.584 1.507
CRB1 1q31.3 427 245 513 1.65 0.915 0.826 1.061 0.8 1.589 0.908 1.03 0.869 0.715 0.916 0.817 0.938 0.73 0.905 0.913 0.953 1.617 0.792 1.623 1.411 1.385 0.791 0.822 0.871 0.743 1.458 0.89 0.943 0.618 0.808 0.63 0.949 0.641 0.835 0.906 1 1.435 0.803 1.536 1.435 1.365
con 14q22 436 233 340 1.15 0.637 0.576 0.74 0.558 1.107 0.633 0.718 0.606 0.498 0.638 0.57 0.653 0.509 0.631 0.636 0.664 1.127 0.552 1.131 0.983 0.965 0.551 0.573 0.607 0.518 1.016 0.62 0.657 0.431 0.563 0.439 0.661 0.447 0.582 0.631 0.697 1 0.56 1.07 1 0.951
con 12p13 445 211 550 2.055 1.138 1.028 1.321 0.996 1.978 1.131 1.282 1.082 0.89 1.14 1.017 1.167 0.909 1.127 1.137 1.186 2.012 0.986 2.02 1.757 1.724 0.985 1.023 1.085 0.925 1.815 1.108 1.174 0.769 1.006 0.785 1.181 0.798 1.039 1.128 1.245 1.786 1 1.912 1.787 1.7
PARK7 1p36.2 454 198 270 1.075 0.596 0.538 0.691 0.521 1.035 0.591 0.671 0.566 0.466 0.596 0.532 0.611 0.475 0.59 0.595 0.62 1.053 0.516 1.057 0.919 0.902 0.515 0.535 0.567 0.484 0.949 0.58 0.614 0.403 0.526 0.411 0.618 0.418 0.544 0.59 0.651 0.934 0.523 1 0.935 0.889
con 13q14 463 242 353 1.15 0.637 0.576 0.739 0.558 1.107 0.633 0.717 0.605 0.498 0.638 0.569 0.653 0.509 0.631 0.636 0.664 1.126 0.552 1.131 0.983 0.965 0.551 0.573 0.607 0.518 1.016 0.62 0.657 0.431 0.563 0.439 0.661 0.447 0.582 0.631 0.697 1 0.56 1.07 1 0.951
NRAS 1p13.2 472 163 250 1.209 0.67 0.605 0.777 0.586 1.164 0.665 0.754 0.637 0.524 0.671 0.599 0.687 0.535 0.663 0.669 0.698 1.184 0.58 1.189 1.034 1.015 0.579 0.602 0.638 0.544 1.068 0.652 0.691 0.453 0.592 0.462 0.695 0.47 0.612 0.664 0.732 1.051 0.588 1.125 1.051 1 
Peak height ratios below 0.7 or above 1.3 are regarded as indicative of a heterozygous deletion or duplication, respectively. Cells highlighted in yellow are those 
indicating probes on chromosome 1p. All MLPA results were compared with array CGH results and no discrepancies were found. Four probes on 1p showed a 
peak height ratio of ‘0’ indicative of a HD. These probes involved CDKN2C, the region between FAF1 and CDKN2C but not FAF1. Appendices 
  253
Appendix 16: Level of MYC expression in the seven PCL and 
19 MM patients relative to BCR and GUSB 
 
 
MDS, myelodisplastic; N, normal; Amp, amplification; DM, double minute 
a Ratio compared with the myelodisplastic sample 
b Amplification in form of DM was only present in 10% PC 
 
  Ratio compared                        











(control gene)  FISH  Array CGH 
Calibrator         
MDS case  1.00  1.00  N  - 
Cell line         
HL60  16.92  17.99  Amp (DM)  - 
PCL         
325  8.75  7.91  Amp (DM) 
b  High level gain 
3210  20.01  5.53  MYC split  N 
1576  9.02  10.43  Gain of one copy (tandem 
duplication) 
Interstitial gain 
involving MYC & TMEM75 
742  6.23  11.49  Gain of two copies  Gain of whole 8q, further gain 
involving MYC & TMEM75 
2359  1.11  0.84  N  Normal 
1188  19.48  24.25  N  Deletion telomeric to 
TMEM75 
3342  7.33  4.96  N  N 
MM         
1037  3.46  3.90  Unbalanced t(8;14)  Loss 8pter–q24.21 
(centromeric to MYC) 
1426  2.77  2.83  Unbalanced t(8;14)  - 
1247  17.70  5.13  Four intrachromosomal extra-
copies in ring chromosome  - 
1524  95.71  159.84 
Two to five intrachromosomal 
extra copies in marker 
chromosome 
High level gain 
290  2.66  3.01  Gain of one copy (tandem 
duplication)  - 
1213  5.69  1.80  t(8;14)  - 
1148  0.72  0.73  N  N 
2204  0.12  0.08  N  - 
296  0.57  0.75  N  - 
628  4.16  4.30  N  - 
2859  2.79  2.90  N  - 
832  1.19  0.85  N  - 
938  0.29  0.64  N  - 
1679  0.46  1.18  N  - 
993  1.73  4.54  N  - 
777  0.85  1.16  N  - 
1623  6.94  15.08  N  - 
571  1.98  4.28  N  - 
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